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ABSTRACT	
The	Genetics	of	Anti-Neutrophil	Cytoplasmic	Antibody	Associated	Vasculitis	(AAV)	
Limy	Wong	
Anti-neutrophil	cytoplasmic	antibody	(ANCA)-associated	vasculitis	(AAV)	is	a	multi-systemic	
autoimmune	 disorder	with	 evidence	 of	 circulating	 pathogenic	 ANCA.	 There	 are	 two	main	
antigenic	 targets:	 proteinase	 3	 (PR3)	 and	myeloperoxidase	 (MPO).	 Previous	 genome-wide	
association	 studies	 (GWAS)	 have	 provided	 evidence	 that	 PR3-AAV	 and	 MPO-AAV	 are	
genetically	distinct	autoimmune	syndromes,	though	only	three	loci	specific	to	PR3-AAV	and	
one	to	MPO-AAV	have	been	identified	to	date.	
	
With	the	European	Vasculitis	Genetics	Consortium,	we	conducted	a	larger	GWAS,	powered	
to	discover	additional	risk	loci	in	both	PR3-AAV	and	MPO-AAV	independently.	A	meta-analysis	
of	 two	European	cohorts	was	conducted,	 comprising	1,610	PR3-AAV	cases,	870	MPO-AAV	
cases	and	11,947	controls.	For	PTPN22	(rs6679677),	a	further	replication	cohort,	previously	
genotyped	using	 the	Sequenom	MassARRAY	platform,	and	comprising	1,122	PR3-AAV	and	
347	MPO-AAV	cases	and	1,531	controls	was	included	in	the	combined	analysis.	
	
This	is	the	largest	genome-wide	association	study	of	AAV	to	date	and	we	have	identified	a	
total	of	12	AAV	susceptibility	loci.	Previously	genome-wide	significant	loci	were	confirmed,	
including	HLA	class	II,	SERPINA1,	PRTN3	and	PTPN22.	Seven	new	genome-wide	significant	loci	
were	 identified:	 three	 associated	 with	 PR3-AAV	 (BCL2L11-MIR4435-2HG,	 EBF3-MGMT,	
IGHV1-69),	two	with	MPO-AAV	(BACH2,	ANKRD11-SPG7)	and	two	shared	by	both	(CTLA-4	and	
DGUOK-TET3).	 Further	 analyses	 based	 on	 common	 variants	 suggested	 that	 a	 substantial	
component	of	the	genetic	architecture	was	shared	between	PR3-AAV	and	MPO-AAV,	similar	
to	that	observed	between	ulcerative	colitis	and	Crohn’s	disease.		
	
In	 addition,	 Mendelian	 randomisation	 analysis	 confirmed	 that	 a	 higher	 eosinophil	 count	
increased	the	risk	of	PR3-AAV	but	not	MPO-AAV,	and	this	effect	might,	in	part,	be	modulated	
by	MIR4435-2HG	through	prolongation	of	eosinophil	survival.	MIR4435-2HG	encodes	a	long	
non-coding	RNA	that	plays	a	critical	role	 in	the	regulation	of	BCL2L11	 transcription	(a	Bcl2	
family	member	essential	for	controlling	apoptosis)	in	myeloid	cells	and	hence	their	lifespan.	
		
	 iv	
We	have	also	identified	a	missense	variant	in	IGHV1-69	(rs11845244)	that	leads	to	a	loss	in	
neutralising	function	of	antibodies	generated	against	the	NEAT2	domain	of	Staphylococcus	
aureus.	 This	 therefore	 provides	 a	 plausible	 host	 genetic	 factor	 in	 determining	 the	
susceptibility	to	infectious	disease	and	as	a	potential	driver	of	PR3-AAV.	Overall,	this	study	
provides	key	novel	insights	into	disease	biology	for	AAV	and	potential	therapeutic	targets.			
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1 Introduction	
1.1 The	history	of	systemic	vasculitis	
Although	 polyarteritis	 nodosa	 (PAN)	 was	 first	 described	 as	 a	 disease	 entity	 by	 Carl	 von	
Rokitansky	in	1852	(1),	the	first	description	of	necrotising	vasculitis	was	attributed	to	Adolf	
Kussmaul	and	Rudolf	Maier	in	1866,	who	reported	a	case	of	systemic	syndrome	affecting	the	
nervous	 system	 and	 kidneys	 of	 a	 young	man.	 They	 described	 the	 gross	 and	microscopic	
pathology	 of	 the	 disease	 which	 consisted	 of	 focal,	 inflammatory	 arterial	 nodules	 in	 the	
medium	and	small-sized	arteries	and	named	it	“periarteritis	nodosa”	(2).	It	was	not	until	1903	
that	 Ferrari	 in	 Trieste,	 Italy	 suggested	 the	 name	 “polyarteritis	 nodosa”	 to	 emphasise	 the	
transmural	inflammation	of	the	vessel	wall	that	characterises	this	vasculitis	(3),	which	remains	
in	 the	 revised	 nomenclature	 of	 systemic	 vasculitis	 today	 as	 the	 increasingly	 rare	 form	 of	
vasculitis	affecting	the	medium-sized	vessels	with	a	strong	association	with	hepatitis	B	virus	
(HBV).	Later,	two	further	reports,	one	from	F	J	Wohlwill	in	Hamburg	who	described	a	case	of	
what	is	now	known	as	microscopic	polyangiitis	(MPA)	in	1923	(4)	and	the	second	by	Heinz	
Klinger	(5),	who	reported	a	case	of	granulomatous	respiratory	inflammation	with	necrotising	
glomerulonephritis	in	1931,	both	preceded	the	first	case	series	of	Wegener’s	granulomatosis	
(WG)	by	Friedrich	Wegener	 in	1939,	under	the	name	“singular	rhinogenic	granulomatosis”	
(6).	In	fact,	it	was	Jacob	Churg	along	with	Gabriel	Godman	who	attributed	this	condition	to	
Wegener’s	 in	 1954	 (7),	 though	 the	 eponym	 has	 recently	 been	 dropped	 in	 the	 wake	 of	
emergence	of	evidence	linking	Wegener	to	the	Nazi	regime	during	World	War	II	(8).	Churg	
and	Godman	were	also	the	first	to	describe	that	microscopic	polyarteritis,	WG	and	allergic	
angiitis	 and	 granulomatosis	 (Churg-Strauss	 syndrome)	 were	 different	 from	 PAN	 based	
primarily	on	the	pathological	features	(7),	which	was	later	supported	by	the	findings	of	many	
groups	 that	 the	 former	 three	conditions	were	associated	with	anti-neutrophil	 cytoplasmic	
antibodies	(ANCA)	(9-14)	but	not	the	latter	one	(15),	further	endorsing	the	categorisation	of	
vasculitis	on	the	basis	of	biomarkers	(Figure	1.1).		
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Around	 the	 same	 time	 of	 the	 discovery	 of	 vasculitis	 affecting	 the	medium-sized	 arteries,	
Schönlein	 (16),	 Henoch	 (17,	 18)	 and	Osler	 (19,	 20)	 identified	 a	 form	 of	 purpura	 that	was	
accompanied	by	arthralgias,	abdominal	pain	and	nephritis.	The	histological	examination	of	
these	purpuric	 lesions	demonstrated	 inflammation	of	 small	 dermal	 vessels	with	extensive	
leukocytoclasia	 and	 IgA-dominant	 immune	 deposits	 in	 the	 vessel	 wall	 (21),	 which	 is	 now	
termed	 IgA	 vasculitis.	 As	most	 of	 the	 clinical	 and	 pathological	manifestations	 of	 systemic	
vasculitides	were	identified	before	the	end	of	twentieth	century,	our	understanding	of	the	
aetiology	 and	 pathogenesis	 of	 these	 diseases	 have	 improved	 considerably	 in	 the	 recent	
decades,	so	as	the	classification	and	nomenclature	systems	which	have	undergone	numerous	
revisions	since.	
	
	
Figure	1.1:	The	historical	evolution	of	the	nomenclature	of	necrotising	systemic	vasculitis.	
The	upper	panel	depicts	the	investigators	who	made	significant	contributions	to	the	description	of	clinical	and	
pathological	 patterns	 of	 vasculitis.	 The	 middle	 panel	 shows	 the	 discovery	 of	 biomarkers	 that	 demonstrate	
different	pathogenic	categories	of	vasculitis.	Lastly,	the	bottom	panels	provide	the	diagnostic	names	proposed	
by	the	1994	and	2012	Chapel	Hill	Consensus	Conference	(CHCC)	on	Nomenclature	of	Vasculitides.	This	diagram	
was	adapted	and	modified	from	Jennette	JC,	Presse	Med	2013	(22).	ANCA,	anti-neutrophil	cytoplasmic	antibody;	
SVV,	small-vessel	vasculitis.	
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1.2 The	classification	and	nomenclature	of	systemic	vasculitis	
Classification	 of	 disease	 is	 the	 process	 of	 categorising	 illnesses	 in	 a	 larger	 framework	 of	
medical	 conditions	 to	 facilitate	 compilation	 of	 mortality	 and	 morbidity	 statistics	 for	
epidemiological	purposes,	highlighting	the	associations	between	diseases	as	well	as	creating	
a	framework	for	diagnosis	and	management.	It	can	be	based	on	topology	(bodily	region	or	
system),	anatomy,	aetiology,	histology,	physiology,	clinical	characteristics	or	a	combination	
of	these	features.	 It	differs	from	nomenclature	which	is	essentially	a	system	of	names	and	
descriptions	of	diseases.	Both	the	classification	and	nomenclature	of	systemic	vasculitis	have	
undergone	numerous	revisions	over	the	years	which	reflect	the	complex	and	heterogeneous	
nature	of	the	illnesses.	
	
1.2.1 American	College	of	Rheumatology	(ACR)	criteria	
In	1990,	the	ACR	published	criteria	for	the	classification	of	seven	types	of	systemic	vasculitis	
which	 include	giant	cell	arteritis	 (GCA),	Takayasu	arteritis	 (TAK),	eosinophil	granulomatosis	
with	 polyangiitis	 (EGPA,	 a.k.a	 Churg-Strauss	 Syndrome),	 granulomatosis	 with	 polyangiitis	
(GPA,	a.k.a	Wegener’s	granulomatosis),	PAN,	IgA	vasculitis	and	hypersensitivity	vasculitis	(23).	
This	represents	the	first	most	comprehensive	set	of	classification	criteria	though	it	has	several	
limitations.	Firstly,	MPA	was	not	included	as	one	of	the	named	conditions	as	it	was	not	widely	
recognised	in	the	1980s.	Secondly,	the	criteria	were	developed	before	the	use	of	ANCA	testing	
which	 is	now	readily	available	and	has	become	a	fundamental	aspect	 in	the	diagnosis	and	
classification	 of	 ANCA-associated	 vasculitis	 (AAV).	 Furthermore,	 the	 introduction	 of	 new	
radiological	 diagnostic	 techniques	 (e.g.	 computed	 tomography	 and	 magnetic	 resonance	
imaging)	 has	 contributed	 to	 a	 better	 distinction	 between	 different	 types	 of	 vasculitis.	
Interestingly,	a	recent	evaluation	of	the	classification	criteria	by	Seeliger	et	al	showed	that	
while	the	sensitivity	of	the	1990	ACR	Criteria	for	vasculitis	at	diagnosis	was	67.1%,	but	the	
specificity	has	remained	high	(24).	
	
1.2.2 Chapel	Hill	Consensus	Conference	(CHCC)	on	the	Nomenclature	of	Vasculitides	
The	CHCC	in	1994	was	aimed	to	construct	the	names	and	definitions	of	the	most	common	
forms	of	vasculitides	including	MPA,	but	not	for	the	intention	of	classification	or	diagnosis.	A	
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revision	was	made	in	2012	and	it	retained	the	primary	reliance	on	the	calibre	of	the	vessels	
involved,	 but	 added	 several	 important	 categories	 comprising	 of	 variable	 vessel	 vasculitis.	
These	 include	 Behcet’s	 disease	 and	 Cogan’s	 syndrome,	 single	 organ	 vasculitis,	 vasculitis	
associated	with	systemic	disease	and	vasculitis	associated	with	a	probable	aetiology	as	well	
as	subcategories	which	include	division	of	SVV	into	immune	complex,	ANCA-associated,	anti-
glomerular	 basement	 membrane	 and	 hypocomplementemic	 urticarial	 vasculitis.	 It	 also	
recommended	 that	 the	 ANCA	 reactivity	 should	 be	 specified,	 i.e.	myeloperoxidase	 (MPO)-
ANCA,	proteinase	3	(PR3)-ANCA	or	ANCA-negative	AAV	(25).	
	
1.2.3 European	Medicines	Agency	(EMEA)	Algorithm	
Given	the	overlapping	and	conflicting	classifications	from	the	existing	schemes	such	as	ACR,	
CHCC	definitions	as	well	as	Lanham	Criteria	for	EGPA,	the	EMEA	algorithm	was	developed	for	
the	purpose	of	classification	in	epidemiological	studies	(26).	All	patients	must	fulfil	the	criteria	
for	a	clinical	diagnosis	of	AAV	or	PAN	prior	entering	the	algorithm,	which	is	optimally	used	for	
classification	rather	than	diagnosis	of	acute	cases	and	patients	should	ideally	be	followed	up	
for	at	least	3	months	where	possible.	It	includes	a	list	of	surrogate	markers	for	the	diagnosis	
of	GPA	consisting	of	 laboratory,	 radiological,	histological	and	clinical	manifestations	of	 the	
upper	 and	 lower	 respiratory	 tracts.	 The	major	 advantage	of	 this	 algorithm	 is	 its	 ability	 to	
unequivocally	classify	the	patients	within	the	subcategory	of	AAV	down	to	a	single	diagnosis	
and	it	has	been	independently	validated	on	a	large	cohort	of	Chinese	patients	(27).		
	
The	 existing	 classification	 criteria	 are	 useful	 but	 there	 is	 no	 doubt	 that	 there	 are	 some	
shortcomings	 given	 the	 evolving	 diagnostic	 tools,	 discovery	 of	 novel	 biomarkers,	 better	
understanding	of	the	disease	pathogenesis	and	recent	genetic	studies	which	have	highlighted	
the	 difference	 between	 GPA	 and	 MPA.	 Interestingly,	 Mahr	 and	 colleagues	 employed	 an	
unsupervised	 machine	 learning	 algorithm	 -	 cluster	 analysis	 to	 identify	 subgroups	 of	 AAV	
patients.	They	have	successfully	defined	five	clusters	with	distinct	mortality	and	relapse	rates	
using	 four	 variables	 consisting	 of	 ANCA	 specificity,	 renal,	 cardiac	 and	 gastrointestinal	
involvement	 (28),	 suggesting	 this	 subgrouping	might	 be	 aetiologically	 and	 therapeutically	
relevant	and	 requires	 further	validation.	A	global	 study	 -	The	Diagnostic	and	Classification	
Criteria	for	Vasculitis	Study	(DCVAS)	which	began	in	2010,	is	currently	underway	to	develop	
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and	 improve	 the	 diagnostic	 criteria	 for	 systemic	 vasculitides.	 Over	 100	 sites	 across	 30	
countries	in	Asia,	Australasia,	Europe,	North	America,	South	America	and	the	UK	are	involved	
and	the	results	of	this	study	will	be	much	anticipated	(29).	
	
1.3 Epidemiology	of	ANCA-associated	vasculitis	
The	incidence	of	AAV	across	different	populations	is	approximately	20	per	million	with	a	peak	
age	 of	 diagnosis	 between	 65	 to	 74	 years.	 The	 differences	 in	 the	 geographical	 and	 ethnic	
distributions	 in	the	clinical	 features	of	patients	with	primary	systemic	vasculitis	have	been	
well	reported.	In	Europe,	GPA	appears	to	be	more	common	at	high	latitudes	(Norway,	United	
Kingdom	and	Germany),	whereas	MPA	shows	the	reverse	pattern,	being	encountered	more	
frequently	 in	 southern	 Europe	 (Lugo,	 Spain),	 Kuwait	 and	 other	 Asian	 countries	 including	
Japan,	Korea	and	China	(30-35).	The	annual	incidence	of	AAV	was	previously	reported	to	be	
similar	between	Japan	and	the	UK,	but	the	clinical	phenotypes	were	different.	Among	patients	
with	AAV,	MPA	was	the	predominant	subtype	accounting	for	about	83%	of	the	patients	 in	
Japan	while	in	the	UK,	more	than	half	of	the	patients	were	of	the	GPA	subtype.	As	for	the	
pattern	of	ANCA	positivity,	more	than	80%	of	the	Japanese	patients	were	perinuclear	ANCA	
(p-ANCA)	or	MPO-ANCA	positive,	whereas	two-thirds	of	UK	patients	were	cytoplasmic	ANCA	
(c-ANCA)	or	PR3-ANCA	positive	(36).		
	
In	 New	 Zealand,	 GPA	 was	 twice	 as	 common	 in	 Europeans	 than	 those	 of	Maori	 or	 Asian	
background.	A	latitude-dependent	incidence	gradient	was	observed	(37).	Similarly	in	a	French	
multi-ethnic	population	study,	the	prevalence	of	AAV	was	twice	as	common	in	individuals	of	
European	as	compared	to	those	of	non-European	ancestry	(38).	GPA	is	relatively	uncommon	
in	African	Americans	(39).	The	occurrence	of	different	phenotypes	is	likely	to	be	influenced	
by	both	the	environmental	factors	and	different	genetic	susceptibility	in	the	diverse	ethnicity	
groups	 (40).	 Some	 of	 the	 environmental	 risk	 factors	 that	 have	 been	 previously	 reported	
include	low	vitamin	D	levels	as	a	results	of	decreased	sun	exposure	(41),	infection	-	particularly	
chronic	nasal	carriage	of	Staphylococcus	aureus	(S.	aureus)	which	is	related	to	an	increased	
risk	of	relapse	in	GPA	(42)	and	fimbriated	pathogens	which	have	been	identified	as	potential	
triggers	of	autoimmunity	to	lysosomal	associated	membrane	protein-2	(LAMP-2)	(43),	silica	
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and	high	occupational	 solvent	exposure	 (44),	asbestos	exposure	 (45),	medications	such	as	
propylthiouracil	(46,	47),	hydralazine	(48),	anti-tumour	necrosis	factor	agents	(49)	and	more	
recently,	levamisole-adulterated	cocaine	(50).	
	
1.4 The	genetics	of	ANCA-associated	vasculitis	
The	most	obvious	challenge	to	conducting	a	rigorous	genetic	study	in	AAV	is	the	small	number	
of	eligible	patients	due	to	the	rarity	of	the	condition	and	therefore,	limited	study	power.	There	
are	several	pointers	towards	a	genetic	component,	mainly	from	studies	of	familial	occurrence	
(51-55),	human	leukocyte	antigen	(HLA)	type	of	patients	and	differences	in	the	incidence	of	
AAV	 in	 various	 ethnic	 groups.	 A	 number	 of	 candidate	 gene	 approach	 studies	 have	 been	
performed	over	the	years	but	the	success	of	this	approach	depends	 largely	on	the	chosen	
genes	 or	 pathways	 studied.	 The	 understanding	 of	 genetics	 in	 AAV	 has	 only	 substantially	
improved	following	the	genome-wide	association	studies	(GWAS)	conducted	by	the	European	
Vasculitis	Genetics	 Consortium	 (EVGC)	 and	 the	US	Vasculitis	 Clinical	 Research	Consortium	
(VCRC)	which	have	thus	far	been	limited	to	individuals	of	European	ancestry.	
	
1.4.1 Human	leukocyte	antigen	region	associations	
The	 HLA	 region	 or	 major	 histocompatibility	 complex	 is	 located	 in	 the	 short	 arm	 of	
chromosome	6p21.3	and	spans	over	4	Mb	containing	the	highly	polymorphic	classical	HLA	
class	I	and	II	loci,	as	well	as	other	genes	that	are	involved	in	the	immunological	function.	This	
region	has	been	rigorously	studied	due	to	its	pivotal	role	in	immune	response	in	the	setting	
of	 transplantation,	 strong	 association	 to	 various	 autoimmune	 disorders	 (56)	 as	 well	 as	
susceptibility	and	resistance	to	a	range	of	bacterial	and	viral	infections	(57).	One	of	the	most	
striking	 features	 observed	 is	 that	 autoimmune	 diseases	with	 characteristic	 antibodies	 are	
generally	 associated	 with	 HLA	 class	 II	 alleles,	 whereas	 seronegative	 diseases	 most	 often	
associate	with	HLA	class	 I	 alleles,	 such	as	HLA-B27	 in	ankylosing	 spondylitis	 (AS)	 (58).	 The	
genetic	associations	between	HLA	and	autoimmune	diseases	have	been	reported	since	the	
early	1970s	(59).	Up	until	now,	it	has	been	confirmed	that	HLA	has	the	strongest	effect	size	in	
the	GWAS	of	autoimmune	diseases,	as	compared	to	any	other	non-HLA	loci.	However,	the	
molecular	mechanism	that	might	underpin	the	HLA-autoimmunity	association	has	remained	
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elusive	in	majority	of	the	diseases	and	the	presence	of	extensive	linkage	disequilibrium	(LD)	
in	this	region	poses	another	challenge	to	identifying	the	causative	genes.	One	good	example	
is	 the	 discovery	 of	 epistatic	 interaction	 between	HLA-B27	 and	HLA-B40	with	 endoplasmic	
reticulum	 aminopeptidase	 1	 (ERAP1)	 in	 AS	 (58,	 60).	 ERAP1	 has	 dual	 functions:	 it	 works	
together	with	endoplasmic	reticulum	aminopeptidase	2	(ERAP2)	in	endoplasmic	reticulum	to	
trim	and	present	peptides	on	HLA	class	 I	molecules	and	 it	 is	 involved	 in	cytokine	receptor	
shedding	 such	 as	 tumour	 necrosis	 factor	 receptor	 I,	 IL-1	 receptor	 2	 and	 IL-6Ra.	 This	
interaction	 supports	 the	 disease	 model	 where	 aberrant	 trimming	 of	 peptides	 or	 antigen	
presentation	by	ERAP1	are	 involved	in	the	pathogenesis	AS	together	with	abnormalities	 in	
cell	 surface	 receptor	 shedding	 which	 could	 affect	 the	 cellular	 responses	 to	 the	 relevant	
cytokines	(58,	61).		
	
The	human	HLA	is	divided	into	three	regions.	The	class	I	region	consists	of	the	classical	class	I	
genes	(HLA-A,	HLA-B	and	HLA-C)	and	two	clusters	of	non-classical	class	I	genes.	The	class	II	
region	 contains	 genes	 that	 have	 functions	 related	 to	 antigen	 processing	 (TAP,	 LMP)	 or	
presentation	(HLA-DR,	HLA-DQ	and	HLD-DP)	and	the	class	III	region	is	the	most	gene-dense	
region	in	the	human	genome	comprising	of	many	innate	immunity	related	genes	including	
cytokines	 tumour	 necrosis	 factor	 (TNF)	 and	 complement	 as	 well	 as	 non-immune	 related	
genes.	 The	 major	 differences	 between	 MHC	 class	 I	 and	 class	 II	 genes	 and	 functions	 are	
summarised	 in	 Table	 1.1	 (62,	 63).	 The	 International	 Immunogenetic	 Information	 system®	
(IMGT)	HLA	database	is	a	very	useful	resource	that	contains	a	compilation	of	sequences	of	
the	 human	HLA	 that	 are	 updated	 on	 a	 frequent	 basis	 as	well	 as	 tools	 for	 comparing	 and	
naming	HLA	alleles	and	proteins	(https://www.ebi.ac.uk/ipd/imgt/hla/).	Both	the	candidate	
gene	studies	and	GWAS	for	HLA	associations	in	AAV	are	summarised	in	Table	1.2	(64-78).	The	
strongest	evidence	of	HLA	association	in	AAV	is	HLA-DPB1.	This	association	was	first	reported	
in	a	cohort	of	150	German	GPA	patients	(HLA-DPB1*04:01,	p	=	1.51	x	10-10,	odds	ratio	(OR)	of	
3.91)	(67)	and	subsequently	replicated	in	an	independent	cohort	of	108	GPA	patients	with	a	
corrected	p-value,	pc	=	6.40	x	10-8	(66).	The	association	remained	significant	in	the	combined	
analysis	 with	 a	 pc	 =	 1.26	 x	 10-22	 and	 was	 later	 confirmed	 by	 the	 three	 GWAS;	 the	 most	
significant	single	nucleotide	polymorphism	(SNP)	in	the	HLA	region	from	the	EVGC	GWAS	was	
rs3117242,	encoding	HLA-DPB1	 (p	=	1.50	x	10-71,	OR	=	3.67)	(70)	and	subsequent	stepwise	
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logistic	regression	analysis	confirmed	that	there	was	one	independent	signal	in	this	region.	
Similar	HLA-DP	associations	were	also	replicated	in	both	GWAS	performed	by	VCRC	(71,	78).	
	
Table	1.1:	The	major	differences	between	HLA	class	I	and	class	II	genes	
	 HLA	Class	I	 HLA	Class	II	
Structure	 One	membrane-spanning	α	chain	(heavy	
chain)	produced	by	the	HLA	genes	and	
one	β	chain	(light	chain)	produced	by	the	
β2-microglobulin	gene	
Two	membrane-spanning	chains	(α	and	
β)	of	similar	size	and	produced	by	the	
HLA	genes	
Gene	regions	 HLA-A,	-B,	-C	 HLA-DR,	-DP,	-DQ	
Type	of	antigen	presenting	
cells	(APCs)	
Present	in	all	nucleated	cells	 Only	on	specialised	APCs	including	
macrophages,	dendritic	cells	and	B	cells	
Nature	of	antigen	presentation	 Endogenous	antigens	originate	from	
cytoplasm	
Exogenous	antigens	originate	
extracellularly	
Size	of	peptide	 8-10	amino	acid	peptides	 13-25	amino	acid	peptides	
Responsive	T	cells	 Present	antigen	to	cytotoxic	T	cells	
(CD8+)	
Present	antigen	to	helper	T	cells	(CD4+)	
Co-receptor	responsible	 Bind	with	CD8	co-receptors	on	cytotoxic	
T	cells	
Bind	with	CD4	co-receptors	on	helper	T	
cells	
Source	of	protein	antigens	 Cytosolic	proteins,	mainly	synthesised	in	
the	cell	
Endosomal/lysosomal	proteins,	mostly	
internalised	from	extracellular	
environment	
Enzyme	responsible	for	
peptide	generation	
Cytosolic	proteasome	 Endosomal	and	lysosomal	proteases	
Site	of	peptide	loading	on	HLA	 ER	 Specialised	vesicular	compartment	
Molecules	involved	in	
transport	of	peptides	and	
loading	on	HLA	
Chaperones,	TAP	in	ER	 Chaperones	in	ER,	invariant	chain	in	ER	
(li),	Golgi	and	HLA	class	II	compartment	
Final	outcome	 Target	cells	for	destruction	 Regulation	of	effector	cells	e.g.	induces	
antibody	production	and	attracts	other	
immune	cells	to	area	of	infection	
	
APC,	antigen	presenting	cells;	CD,	cluster	of	differentiation;	ER,	endoplasmic	reticulum;	HLA,	
human	leukocyte	antigen;	TAP,	transporter	associated	with	antigen	processing	protein	(62,	
63).	
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Table	1.2:	Previous	candidate	gene	studies	and	GWAS	on	HLA	associations	in	AAV	
Study,	Year	 Population	 HLA	 Cases/Controls	 OR	 P-value	
Spencer,	1992	 British	 HLA-DQw7	 34	GPA	&	25	MPA/1,103	 2.90	 <2.50	x	10-3	
HLA-DR3	 0.31	 <1.00	x	10-2	
Papiha,	1992	 British	 HLA-DR1	 27	GPA/105	 2.30	 4.00	x	10-2	
Hagen,	1995	 Dutch	 HLA-DR6	 224	AAV/2,443	 0.43	 <4.00	x	10-3	
HLA-DR13	 0.32	 <2.00	x	10-3	
Gencik,	1999	 German	 HLA-DRB1*13	 76	PR3/na	 0.40	 <5.00	x	10-2	
HLA-DQB1*06:03	 0.20	 <5.00	x	10-3	
Tsuchiya,	2003	 Japanese	 HLA-DRB1*09:01	 64	MPO/na	 2.44	 1.40	x	10-3	
Jagiello,	2004	 German	 HLA-DPB1*04:01	 150	PR3/100	 3.91	 1.51	x	10-10	
HLA-DPB1*04:01/	
RXRB03	
6.41	 7.13	x	10-17	
Tsuchiya,	2006	 Japanese	 HLA-DQB1*03:03	 50	MPA/77	 2.11	 1.70	x	10-2	
HLA-DRB1*09:01-	
HLA-DQB1*03:03	
2.36	 2.30	x	10-2	
Heckmann,	2007	 German	 HLA-DPB1*04:01	 282	GPA/380	 3.01	 2.31	x	10-21	
Stassen,	2009	 Dutch	 HLA-DR6	 304	AAV/9,872	 0.30	 <1.00	x	10-4	
HLA-DR4	 1.70	 <1.00	x	10-4	
Luo,	2011	 Chinese	 HLA-DRB1*14:54	 152	AAV/200	 0.02	 1.70	x	10-2	
HLA-DRB1*11:01	 107	MPA/200	 2.53	 2.30	x	10-2	
†Lyons,	2012	 European	 HLA-DP	(rs3117242)	 1,521	PR3/6,858	 7.03	 6.20	x	10-89	
HLA-DQ	(rs5000634)	 556	MPO/6,858	 0.65	 2.10	x	10-8	
†Xie,	2013	 North	
American	
HLA-DPB1	(rs9277554)	 750	GPA/1,820	 0.24	 1.92	x	10-50	
Wu,	2015	 Chinese	 HLA-DPB1	(rs3117242)	 100	GPA/485	 2.09	 6.24	x	10-5	
Kawasaki,	2016	 Japanese	 HLA-DRB1*09:01	 377	MPO/596	 1.57	 2.10	x	10-4	
HLA-DRB1*13:02	 0.42	 2.30	x	10-5	
†Merkel,	2016	 North	
American	
HLA-DPB1	(rs141530233)	 1,361	PR3/4,723	 6.19	 1.33	x	10-106	
HLA-DQA2	(rs7454108)	 378	MPO/4,723	 2.73	 5.03	x	10-25	
	
AAV,	ANCA-associated	vasculitis;	GPA,	granulomatosis	with	polyangiitis;	HLA,	human	leukocyte	antigen;	MPA,	
microscopic	polyangiitis;	MPO,	myeloperoxidase;	na,	not	applicable;	OR,	odds	ratio;	PR3,	proteinase	3.		
†SNPs	showing	the	most	significant	association	in	the	GWAS.		
Apart	from	the	GWAS,	the	patient	cohort	might	not	be	completely	independent	from	each	other	for	those	from	
the	same	ancestry	background	(64-78).	
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Strikingly,	the	sub-analysis	of	the	EVGC	GWAS	demonstrated	that	there	was	a	clear	distinction	
in	the	genetic	associations	between	GPA	and	MPA	where	patients	were	classified	according	
to	the	EMEA	algorithm.	More	importantly,	the	HLA-DP	association	was	stronger	in	the	PR3-
ANCA	positive	subgroup	(p	=	6.20	x	10-89),	independent	of	the	clinical	diagnosis,	while	this	was	
not	 observed	 in	 the	MPO-ANCA	 positive	 subgroup.	 In	 the	 latter	 group,	 a	 further	 analysis	
discovered	an	association	 in	the	HLA-DQ	 region	(p	=	2.10	x	10-8)	which	had	probably	been	
masked	in	the	primary	analysis	given	the	small	number	of	MPO-ANCA	positive	patients.	This	
finding	was	replicated	in	an	independent	cohort	of	Italian	patients	as	well	as	in	VCRC	GWAS.		
	
Comparably	in	the	Han	Chinese	cohort,	rs3117242	(HLA-DPB1)	conferred	an	increased	risk	for	
GPA	with	an	OR	of	2.09,	95%	CI	1.51-2.88	(77).	While	 in	the	Japanese	MPO-AAV	cohort,	a	
significant	association	was	detected	with	HLA-DRB1*09:01	where	the	carrier	frequency	was	
increased	in	MPO-AAV	patients	as	compared	to	healthy	Japanese	controls	(68,	75,	76).	HLA-
DRB1*09:01	is	one	of	the	most	common	HLA-DRB1	alleles	in	Asians	but	is	rare	in	Caucasian	
populations.	Interestingly,	it	has	also	been	shown	to	be	associated	with	multiple	autoimmune	
diseases,	 including	 type	 1	 diabetes	 (T1D),	 rheumatoid	 arthritis	 (RA)	 and	 systemic	 lupus	
erythematosus	 (SLE)	 (79).	 Therefore,	HLA-DRB1*09:01	 haplotype	 appears	 to	 be	 an	 Asian-
specific	genetic	factor	for	multiple	autoimmune	diseases.	
	
1.4.2 Non-HLA	associations	
SERPINA1	
α1-antitrypsin	(A1AT)	is	encoded	by	the	SERPINA1	(serpin	family	A	member	1)	gene.	It	is	an	
acute	phase	protein	 that	belongs	 to	 the	serine	protease	 inhibitor	 family	with	capability	of	
inactivating	many	different	proteases	including	PR3.	Deficiency	of	A1AT	as	a	result	of	carriage	
of	pathogenic	alleles	of	Pi-gene	(protease	inhibitor)	causes	chronic	uninhibited	breakdown	of	
lung	tissues	and	eventually	leads	to	characteristic	manifestation	of	pulmonary	emphysema.	
The	most	common	and	normally	 functioning	allelic	 form	is	PiM	and	so	the	healthy	human	
phenotype	is	designated	as	PiMM.	There	are	more	than	100	genetic	A1AT	variants,	among	
which	 PiZ	 and	 PiS	 are	 the	most	 common	 and	 clinically	 significant	 alleles.	 A1AT	 deficiency	
clinically	manifests	in	individuals	carrying	mutations	of	both	gene	Pi	alleles,	especially	in	the	
PiZZ	 variant,	whereas	 in	 the	 heterozygous	 state,	 the	 defect	 is	 partly	 compensated	 by	 the	
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normal	allele	that	is	found	in	individuals	with	PiMZ	and	PiMS	phenotypes.	A	list	of	the	previous	
candidate	gene	approach	studies	and	GWAS	of	SERPINA1	association	in	AAV	is	summarised	
in	Table	1.3	(70,	71,	78,	80-83).		
	
The	balance	of	A1AT	and	PR3	has	been	suggested	to	play	a	critical	role	in	GPA	pathogenesis.	
In	the	normal	physiological	state,	A1AT	binds	to	PR3	and	antagonises	its	pro-inflammatory	
activity.	However,	when	there	 is	an	excessive	amount	of	PR3	 in	the	blood	serum	due	to	a	
defect	of	the	SERPINA1	gene	or	inherited	predisposition	for	an	enhanced	expression	of	the	
PRTN3	 gene,	 this	may	 trigger	 the	 synthesis	of	 anti-PR3	ANCA	and	promote	PR3-mediated	
proteolytic	vessel	damage.	Interestingly,	it	has	been	reported	that	an	elderly	individual	with	
GPA	was	successfully	treated	with	A1AT	replacement	therapy	and	steroids	with	regression	of	
skin	lesions	and	normalization	of	renal	function	(84).		
	
Table	1.3:	Previous	candidate	gene	studies	and	GWAS	of	SERPINA1	association	in	AAV	
Study,	Year	 Population	 SERPINA1	 No.	of	Cases	 OR	 P-value	
Elzouki,	1994	 Swedish	 PiZ	allele	 88	AAV	(66	GPA)	 6.00	 1.00	x	10-4	
Borgmann,	2001	 German	 PiZ	allele	 79	GPA	 3.50	 <1.00	x	10-4	
Mahr,	2010	 German	 PiZ	and	PiS	alleles	 433	GPA	 14.58	 2.00	x	10-3	
†Lyons,	2012	 European	 §rs7151526	 1,521	PR3	 0.53	 5.60	x	10
-12	
†Xie,	2013	 North	American	 rs1956707	 987	GPA	 na	 9.00	x	10-3	
Pervakova,	2016	 Russian	 PiZ	and	PiF	alleles	 38	GPA	 9.68	 3.42	x	10-2	
†Merkel,	2016	 North	American	 §rs28929474	 1,361	PR3	 2.43	 1.29	x	10
-13	
	
AAV,	 ANCA-associated	 vasculitis;	 GPA,	 granulomatosis	 with	 polyangiitis;	 GWAS,	 genome-wide	 association	
studies;	na,	not	applicable;	OR,	odds	ratio;	PR3,	proteinase	3.	
†SNPs	showing	the	most	significant	association	in	the	GWAS.	
§These	associations	were	stronger	when	PR3-AAV	was	compared	with	healthy	controls,	rather	than	by	clinical	
syndrome	 (i.e.	 GPA).	 In	 contrast,	 no	 association	was	 observed	when	MPO-AAV	was	 compared	with	 healthy	
controls.	
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CTLA4	
CTLA4	 encodes	 for	 cytotoxic	 T-lymphocyte	 associated	 protein	 4,	 which	 is	 also	 known	 as	
cluster	of	differentiation	152	(CD152).	It	is	a	transmembrane	protein	of	the	immunoglobulin	
gene	superfamily	with	a	single	variable	domain	and	it	shares	76%	sequence	homology	with	
CD28,	which	is	an	important	co-stimulator	of	T	cells	and	it	binds	to	the	same	ligands,	CD80	
(B7-1)	and	CD86	(B7-2)	(85).	CTLA4	is	expressed	by	T	lymphocytes	following	activation	and	it	
is	known	to	bind	 to	CD80	and	CD86	with	markedly	higher	affinity	 than	CD28.	However,	 it	
functions	 as	 a	 CD28	 antagonist	 and	 has	 an	 essential	 inhibitory	 role	 in	 the	 regulation	 of	
immune	 responses.	 Hence,	 the	 B7-CD28/CTLA-4	 pathway	 is	 crucial	 in	 regulating	 T-cell	
activation	 and	 tolerance.	 This	 is	 most	 clearly	 demonstrated	 by	 the	 phenotype	 of	 CTLA4	
deficient	mice,	which	die	at	a	young	age	from	the	consequences	of	profound	uninhibited	T-
cell	proliferation,	leading	to	lymphocytic	infiltration	and	destruction	of	major	organs	(86).	In	
addition,	Ipilimumab	(CTLA-4	blockade)	which	is	now	used	in	mainstream	Oncology	practice,	
has	 demonstrated	 promising	 results	 in	 improving	 survival	 of	melanoma	 through	 tumour-
specific	 immune	 attack,	 but	 has	 also	 been	 associated	 with	 autoimmune	 related	 adverse	
events	affecting	multiple	organs	of	the	body	including	the	gastrointestinal	tract,	skin,	lungs,	
kidneys,	joints,	liver,	endocrine	system	and	central	nervous	system	(87).		
	
The	CTLA4	gene	locus	is	polymorphic	in	the	human	population	and	has	been	identified	to	be	
associated	with	several	autoimmune	diseases,	e.g.	RA	(88-90),	T1D	(91-93),	Graves’	disease	
and	 Hashimoto’s	 thyroiditis	 (93-96),	 coeliac	 disease	 (97),	 alopecia	 (98),	 Crohn’s	 disease,	
ulcerative	colitis	(UC),	primary	sclerosing	cholangitis	(PSC),	psoriasis	and	AS	(99).	A	list	of	the	
previous	 candidate	 gene	 approach	 studies	 and	 GWAS	 of	 CTLA4	 association	 in	 AAV	 is	
summarised	in	Table	1.4	(70,	76,	78,	100-108).	The	published	results	are	conflicting,	which	is	
perhaps	not	surprising	given	the	small	number	of	patients	included	in	each	cohort.	This	locus	
also	did	not	achieve	genome-wide	significance	(p	<	5.0	x	10-8)	 in	both	the	EVGC	and	VCRC	
GWAS.	 Interestingly,	 Steiner	 et	 al	 previously	 demonstrated	 that	 CTLA4	 was	 more	 highly	
expressed	by	unstimulated	peripheral	blood	CD4+	T	cells	from	GPA	patients	than	the	healthy	
control	group.	However,	upon	mitogen	stimulation,	T	cells	from	GPA	patients	were	defective	
in	their	expression	of	CTLA4,	similar	to	findings	observed	in	human	immunodeficiency	virus	
infection,	suggestive	of	underlying	T-cell	function	impairment	(109).	
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Table	1.4:	Candidate	gene	studies	and	GWAS	of	CTLA4	association	in	AAV	
Study,	Year	 Population	 CTLA4	 Cases/Controls	 OR	 P-value	
Huang,	2000	 Swedish	 CTLA4	(AT)	86	repeat	 32	GPA/109	 na	 <1.60	x	10-3	
Giscombe,	2002	 Swedish	 rs5742909	 32	GPA/122	 2.04	 2.59	x	10-2	
Tsuchiya,	2003	 Japanese	 na	 69	AAV/na	 na	 ns	
Zhou,	2004	 North	
American	
CTLA4	(AT)	86	repeat	 117	GPA/123	 0.38	 1.00	x	10-3	
Spriewald,	2005	 German	 rs231775	 32	GPA/91	 na	 ns	
rs5742909	
Slot,	2008	 Dutch	 rs231775	 102	AAV/188	 1.53	 1.00	x	10-2	
rs733618	 na	 ns	
rs4553808	
rs5742909	
Kamesh,	2009	 British	 rs231775	 222	AAV/629	 1.32	 1.00	x	10-2	
rs3087243	 0.67	 1.00	x	10-4	
Carr,	2009	 British	 rs3087243	 575	AAV/9,040	 0.84	 6.40	x	10-3	
†Lyons,	2012	 European	 rs16840252	 2,267	AAV/6,858	 0.87	 1.28	x	10-5	
Chung,	2012	 North	
American	
rs231775	 880	GPA/1,969	 0.82	 §1.00	x	10-3	
rs3087243	 0.79	 §9.83	x	10-5	
†Xie,	2013	 North	
American	
rs231726	 987	GPA/2,731	 na	 3.00	x	10-3	
rs3096851	 na	 3.00	x	10-3	
Wu,	2017	 Chinese	 rs231775	 176	AAV/485	 1.04	 ns	
rs5742909	 1.02	 ns	
	
AAV,	 ANCA-associated	 vasculitis;	 GPA,	 granulomatosis	 with	 polyangiitis;	 GWAS,	 genome-wide	 association	
studies;	na,	not	applicable;	ns,	not	significant;	OR,	odds	ratio.	
†SNPs	showing	the	most	significant	level	of	association	in	the	GWAS.	
§A	set	of	384	SNPs	was	analysed	in	this	study	and	the	p-values	had	not	been	adjusted	for	multiple	testing.	
	
PRTN3	
PR3	is	encoded	by	PRTN3	gene.	It	is	a	serine	protease	located	in	the	azurophilic	granules	of	
the	neutrophils.	In	the	normal	physiological	state,	PR3	is	mainly	inhibited	by	A1AT.	There	are	
two	alternative	transcripts	of	PRTN3	–	canonical	 (PRTN3-201)	and	alternative	(PRTN3-202)	
which	 initiates	transcription	at	the	 intron	1	promoter.	The	canonical	 isoform	is	 involved	in	
anti-bacterial	 activity	 (110)	while	 the	 alternative	 isoform	 encodes	 a	 24	 kD	 protein	with	 a	
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sequence	similar	to	that	previously	described	for	myeloblastin	(111),	which	is	involved	in	the	
proliferation	and	differentiation	of	neutrophils	(112).	The	enzyme	PR3	is	translocated	to	the	
cell	membrane	upon	stimulation	with	a	low	dose	of	pro-inflammatory	cytokines	such	as	TNF	
(113,	114)	or	by	 isolation	procedure	 (115).	This	key	process	 is	 called	priming	and	 it	 is	 the	
membrane-bound	 form	 of	 the	 PR3	 that	 is	 able	 to	 interact	 with	 the	 ANCA,	 precipitating	
neutrophil	 activation	 and	 endothelial	 adhesion.	 Halbwachs-Mecarelli	 and	 colleagues	
previously	demonstrated	that	there	is	a	bimodal	distribution	of	membrane	PR3	expression	
(mPR3+/-)	 and	 the	 proportion	 of	 mPR3+	 and	 mPR3-	 cells	 remains	 highly	 stable	 despite	
priming	 and	 over	 prolonged	 periods	 of	 time	 in	 a	 given	 individual	 (116).	 This	 finding	 was	
subsequently	replicated	(117)	and	more	importantly,	the	authors	also	reported	that	a	high	
concordance	of	mPR3+	percentage	exists	 in	monozygotic	 twins	but	not	 in	dizygotic	 twins,	
which	strongly	suggests	that	the	membrane	expression	of	PR3	is	genetically	determined.		
	
Over	the	last	two	decades,	several	observations	linking	PR3	to	AAV	have	been	made	and	these	
include	(i)	circulating	leukocytes	from	patients	with	AAV	displayed	an	increased	transcription	
of	the	PRTN3	gene	(118,	119),	(ii)	AAV	patients	had	increased	levels	of	circulating	PR3	in	the	
plasma	 (120),	 (iii)	 the	proportion	of	neutrophils	with	high	membrane	PR3	expression	was	
increased	in	AAV	patients	(115),	(iv)	deficiency	of	A1AT	seems	to	predispose	to	development	
of	PR3-AAV	and	(v)	a	SNP	in	the	promotor	region	of	the	PRTN3	gene	(-564A/G	or	rs62132295)	
was	found	to	be	associated	with	GPA	(121)	and	this	was	further	replicated	in	two	GWAS	(70,	
71).	 In	 addition,	 rs62132293	which	 is	 in	high	 LD	with	 rs62132295	 (r2	=	 0.92,	D’	 =	1.0)	has	
recently	been	reported	to	be	an	expression	quantitative	trait	loci	(eQTL)	in	neutrophils	where	
the	PR3-AAV	risk	allele	(G)	homozygotes	had	a	higher	expression	of	PRTN3	than	individuals	
with	CC	or	CG	genotypes	(71).		
	
In	contrast	 to	 the	aforementioned	 findings,	Pieters	K	et	al	 interrogated	whether	 -564	A/G	
polymorphism	caused	quantitative	differences	in	PR3	expression	using	a	luciferase	reporter	
assay.	They	transfected	four	different	cell	 lines	(promyelocytic	HL60,	NB-4	cells,	monocytic	
U937	cells	and	HeLa)	with	three	variants	of	the	PRTN3	promoter	(-564A/G,	-621	A/G	and	wild-
type)	 which	 were	 cloned	 into	 a	 luciferase	 reporter	 vector.	 They	 demonstrated	 a	 good	
correlation	between	endogenous	PR3	messenger	ribonucleic	acid	(mRNA)	expression	and	the	
promoter	activity,	but	no	significant	difference	 in	activity	observed	between	the	wild-type	
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and	polymorphic	variants	which	argued	against	the	-564	A/G	polymorphism	being	responsible	
for	the	increased	expression	levels	of	PRTN3	seen	in	myeloid	cells	from	GPA	patients	(122).	
Abdgawad	M	 and	 colleagues	 also	 reported	 similar	 findings	 involving	 a	 cohort	 of	 63	 AAV	
patients	 and	 107	 healthy	 controls.	 They	 found	 that	 AAV	 patients	 had	 increased	 plasma	
concentrations	of	PR3	as	well	as	mPR3-positive	neutrophils	compared	to	healthy	controls,	but	
found	 no	 skewed	 distribution	 of	 the	 -564	 A/G	 polymorphism	 in	 the	 PRTN3	 gene.	 They	
concluded	that	increased	plasma	PR3	and	high	expression	of	mPR3	are	associated	with	AAV,	
but	not	as	a	consequence	of	the	-564	A/G	polymorphism	of	the	PRTN3	gene	promoter	(123).	
	
PTPN22	
Protein	 tyrosine	 phosphatase,	 non-receptor	 type	 22,	 also	 known	 as	 lymphocyte	 tyrosine	
phosphatase,	is	a	protein	that	is	encoded	by	the	PTPN22	gene	and	is	primarily	expressed	in	
lymphoid	tissues.	The	important	role	of	PTPN22	as	a	risk	factor	for	autoimmunity	was	first	
recognized	with	 the	association	of	a	missense	SNP	 (1858C>T;	 rs2476601;	R620W)	with	an	
increased	risk	of	T1D	(91-93,	124,	125)	and	it	encodes	an	arginine	to	tryptophan	substitution	
at	 amino	 acid	 620	 (Arg620Trp)	 in	 the	 first	 proline-rich	motif	 of	 the	 PTPN22	 protein.	 This	
susceptibility	 locus	 has	 subsequently	 been	 found	 to	 be	 associated	 with	 numerous	
autoimmune	diseases	including	RA	(90,	126,	127),	SLE	(128,	129),	juvenile	idiopathic	arthritis	
(JIA)	(130),	autoimmune	thyroid	diseases	(93,	96)	and	Crohn’s	disease	(131).	The	frequency	
of	the	PTPN22	1858T	allele	varies	among	different	populations	where	it	is	most	commonly	
found	in	Northern	and	Eastern	Europe	(>10%)	and	is	encountered	less	frequently	in	Southern	
Europe	(2-3%	of	the	populations).	The	frequency	in	the	US,	Australia	and	New	Zealand	white	
populations	mirrors	those	of	the	Northern	Europeans	(6-10%).	However,	it	is	rare	in	Native	
American	(<1%),	African	(<1%),	Middle	Eastern	(0-3%)	and	Asian	populations	(<1%)	(132).	The	
published	genetic	association	results	for	PTPN22	in	AAV	are	summarised	in	Table	1.5	(48,	70,	
71,	78,	100,	133-135).		
	
PTPN22	has	an	N-terminal	catalytic	domain,	an	interdomain	region	and	a	C-terminal	domain	
with	 four	 proline-rich	 regions	 facilitating	 interaction	 with	 other	 proteins.	 In	 the	 adaptive	
immune	 system,	 it	 functions	 as	 a	 regulator	 of	 tyrosine	 phosphorylation-based	 cell	 signal	
transduction	by	removing	phosphate	groups	from	tyrosine	residues	on	intracellular	protein,	
which	is	the	natural	counterpart	of	protein	tyrosine	kinases	and	inhibit	T-cell	activation	(136).	
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While	 in	 the	 innate	 immune	 system,	 PTPN22	 selectively	 promote	 type	 I	 interferon	 (IFN)	
production	by	enhancing	the	downstream	signalling	of	pattern	recognition	receptors	(137).	
T-cell	activation	via	the	engagement	of	T-cell	receptor	(TCR)	initiates	a	cascade	of	signalling	
events	which	induces	proliferation,	mobilisation	and	differentiation	of	T	cells.	This	involves	a	
sequence	of	tyrosine-based	phosphorylation	events	mediated	by	kinases	of	the	Src	family	(Lck	
and	Fyn)	and	the	Syk	family	(ZAP-70),	which	cause	phosphorylation	of	the	immunoreceptor	
tyrosine-based	 activation	 motifs	 (ITAMs)	 of	 the	 TCR-associated	 CD3z-chain	 and	 trigger	
multiple	intracellular	signalling	pathways	(138).	The	binding	of	C-terminal	Src	kinase	(Csk)	to	
the	proline	rich	region	of	PTPN22	is	thought	to	further	augment	the	inhibitory	tuning	of	Src	
family	kinases	and	reduce	TCR	signal	transduction	(139).	However,	the	negative	effect	of	this	
interaction	has	been	challenged	as	other	studies	have	found	that	the	PTPN22/Csk	complex	
could	limit	the	activity	of	PTPN22	via	promoting	phosphorylation	of	an	inhibitory	residue	on	
PTPN22	(140)	or	by	altering	its	localisation	within	cell	membrane	lipid	rafts	(141).	
	
A	 series	 of	 approaches	 including	 transfected	 cell	 lines,	 primary	 human	 lymphocytes	 and	
animal	models	 have	 been	 employed	 to	 understand	 how	 the	 genetic	 risk	 variant	 (PTPN22	
Arg620Trp)	 contributes	 to	 development	 of	 autoimmunity.	 In	 Jurkat	 T	 cells	 lines,	 co-
transfection	 of	 the	 autoimmune-predisposing	 allele	 (PTPN22	 Trp620)	with	 Csk	 resulted	 in	
reduced	interaction	with	Csk	as	compared	to	wild-type	(124)	and	an	increase	in	TCR	responses	
(142).	On	the	contrary,	when	PTPN22	Trp620	was	transfected	without	the	addition	of	Csk,	a	
blunting	of	the	TCR	signal	was	observed	(143).	These	differences	with	respect	to	the	impact	
on	TCR	signalling	have	raised	questions	as	to	whether	PTPN22	Trp620	is	a	gain	or	a	loss	of	
function	allele.	Rawlings	and	Buckner	speculated	that	the	differences	in	signalling	analyses	
could	be	due	 to	 the	 relative	expression	 levels	of	PTPN22	and	Csk,	where	 in	 the	setting	of	
limiting	Csk,	the	localisation	of	PTPN22	to	the	cell	membrane	may	be	enhanced	and	therefore	
resulting	 in	 increased	 inhibitory	 activity	 while	 in	 cell	 lines	 where	 PTPN22	 and	 Csk	 are	
expressed	to	a	comparable	level,	the	loss	of	interaction	between	the	PTPN22	Trp620		and	Csk	
may	emphasise	its	loss	of	function	in	inhibition	of	TCR	signalling	(144).	
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Table	1.5:	Candidate	gene	studies	and	GWAS	of	PTPN22	association	in	AAV	
Study,	Year	 Population	 PTPN22	 Cases/Controls	 OR	 P-value	
Jagiello,	2005	 German	 rs2476601	[A]	 199	GPA/399	 1.75	 2.00	x	10-3	
Carr,	2009	 British	 rs2476601	[A]	 641	AAV/9,115	 1.40	 1.40	x	10-4	
Martorana,	2012	 Italian	 rs2476601	[A]	 143	GPA/945	 1.92	 5.00	x	10-3	
102	MPA/945	 1.59	 1.07	x	10-1	
99	EGPA/945	 0.52	 1.51	x	10-1	
Cao,	2012	 North	
American	
rs2476601	[A]	 230	AAV/1,178	 1.45	 3.68	x	10-2	
Chung,	2012	 North	
American	
rs2476601	[A]	 895	GPA/1,976	 1.35	 2.00	x	10-3	
†Lyons,	2012	 European	 rs6679677	[A]	 1,353	AAV/1,599	 0.80	 2.60	x	10-1	
†Xie,	2013	 North	
American	
rs2476601	[T]	 750	GPA/1,820	 na	 6.00	x	10-3	
†Merkel,	2016	 North	
American	
rs2476601	[A]	 1,986	AAV/4,723	 1.36	 1.86	x	10-7	
1,361	PR3/4,723	 1.33	 3.19	x	10-5	
378	MPO/4,723	 1.64	 5.85	x	10-6	
rs6679677	[A]	 1,986	AAV/4,723	 1.40	 1.88	x	10-8	
1,361	PR3/4,723	 1.36	 7.89	x	10-6	
378	MPO/4,723	 1.71	 8.83	x	10-7	
	
AAV,	ANCA-associated	vasculitis;	EGPA,	eosinophilic	granulomatosis	with	polyangiitis;	GPA,	granulomatosis	with	
polyangiitis;	GWAS,	genome-wide	association	studies;	MPA,	microscopic	polyangiitis;	MPO,	myeloperoxidase;	
na,	not	applicable;	OR,	odds	ratio;	PR3,	proteinase	3.	
†SNPs	showing	the	most	significant	level	of	association	in	the	GWAS.	
	
In	human	lymphocytes,	several	important	observations	have	been	made	regarding	the	role	
of	 PTPN22	 Trp620	 in	 immune	 responses.	 Vang	 et	 al	 demonstrated	 that	 T	 cells	 from	 T1D	
patients	carrying	PTPN22	Trp620	produce	less	interleukin-2	(IL-2)	upon	TCR	stimulation	(143)	
and	 this	 was	 subsequently	 confirmed	 in	 a	 larger	 cohort	 (145).	 A	 consistent	 finding	 was	
demonstrated	 in	 healthy	 controls	 where	 T	 cells	 from	 individuals	 carrying	 the	 risk	 allele	
(PTPN22	Trp620)	were	found	to	have	blunted	Ca2+	flux,	IL-2	and	IL-10	production	following	
anti-CD3	 stimulation	 and	 the	 effects	 were	 most	 pronounced	 in	 the	 memory	 T	 cell	
compartment	 (146).	 Other	 downstream	 effects	 of	 PTPN22	 Trp620	 on	 T	 cell	 maturation	
include	the	expansion	of	CD4	memory	T	cell	compartment	(146)	and	favouring	Th1	responses	
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(147).	More	recently,	Ferreira	et	al	reported	the	association	of	PTPN22	Trp620	with	increased	
frequencies	of	 thymically-derived	Tregs	 in	 the	peripheral	blood	of	SLE	patients,	 as	well	 as	
increased	PD-1	expression	on	both	Tregs	and	effector	T	cells	 (148).	 In	addition,	 studies	of	
normal	 human	 B	 cells	 indicate	 that	 PTPN22	 Trp620	 might	 directly	 contribute	 to	 the	
development	of	autoantibodies	and	autoimmunity	through	its	influence	on	BCR	signalling	and	
B	cell	development	(149,	150).							
	
The	 murine	 ortholog	 of	 PTPN22	 encodes	 the	 protein	 PEST	 domain-enriched	 tyrosine	
phosphatase	(PEP).	An	early	study	from	Zikherman	J	et	al	demonstrated	that	the	PEP-/-	mice	
have	increased	memory	and	effector	T	cells	and	spontaneous	germinal	center	production	but	
do	not	develop	systemic	autoimmunity.	However,	crossbreeding	of	the	PEP-/-	mice	with	non-
autoimmune	background	mice	 (C56BL/6)	 that	express	an	activating	mutation	within	CD45	
results	in	a	SLE-like	syndrome	(142).	Recently,	Zhang	et	al	generated	knock-in	mice	expressing	
PEP	R619W	(a	mutant	analogous	to	PTPN22	R620W)	and	they	developed	enlargement	of	the	
thymus	 and	 spleen,	 accompanied	 by	 expanded	 memory/effector	 T	 cell	 populations	 and	
hyperresponsiveness	 in	 both	 lymphocyte	 and	 dendritic	 cells,	 consistent	 with	 a	 loss-of-
function	effect	(151).	Similarly,	Dai	and	colleagues	also	generated	knock-in	mice	expressing	
PEP	R619W	which	displayed	T-cell	expansion,	transitional,	germinal	center	and	age-related	B-
cell	 expansion,	 accompanied	 by	 autoantibody	 production	 and	 development	 of	 systemic	
autoimmunity	(152).		
	
Overall,	both	individuals	with	PTPN22	Trp620	and	knock-in	animals	exhibit	an	expansion	of	
effector	memory	 T	 cells.	 However,	 the	 discordant	 response	 to	 antigen-receptor	 triggered	
signalling	 between	 human	 and	murine	 studies	where	 human	memory	 T	 and	 B	 cells	 from	
individuals	 carrying	 the	 risk	 variant	 exhibit	 significantly	 blunted	 signals	 upon	 intracellular	
calcium	 flux	 and	 the	 induction	 of	 tyrosine-phosphorylated	 signalling	 effectors	 while	
exaggerated	signals	are	observed	in	thymocytes,	naïve	T	cells	and	effector	T	cells	derived	from	
knock-in	mice,	still	require	further	investigation.	Furthermore,	the	role	of	PTPN22	Trp620	in	
shaping	the	B	cell	repertoire	and	B	cell	selection	has	yet	to	be	elucidated.					
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IRF5	
Interferon	regulatory	factor	5	(IRF5)	is	a	regulator	of	type	1	IFN	gene	expression,	involved	in	
the	production	of	type	1	IFN	and	pro-inflammatory	cytokines	such	as	IL-6,	IL-12,	IL-17,	IL-23,	
TNF,	 IFN-gamma-inducible	protein	10,	MCP-1	and	RANTES	 in	response	to	toll-like	receptor	
(TLR)	 ligands	 such	as	 lipopolysaccharide	 (LPS)	or	unmethylated	DNA	 (153,	 154).	 Increased	
expression	of	type	1	IFN	and	IFN-related	genes	have	been	reported	in	SLE	(155-157),	and	are	
considered	to	have	a	significant	role	in	the	pathogenesis	of	the	disease.	In	addition,	genetic	
variants	in	IRF5	have	been	strongly	linked	to	SLE	in	multiple	independent	case-control	cohorts	
from	different	ancestry	backgrounds	(129,	158-161).	It	is	also	implicated	in	other	autoimmune	
diseases	such	as	RA	(127),	primary	biliary	cirrhosis	(PBC)	(162,	163),	systemic	sclerosis	(164,	
165),	Sjogren’s	syndrome	(166)	and	UC	(167).	
	
Graham	 et	 al	 reported	 a	 haplotype	 of	 the	 IRF5	 gene	 to	 be	 a	 risk	 factor	 for	 SLE.	 More	
interestingly,	this	haplotype	was	shown	to	be	functionally	relevant.	Firstly,	rs2004640	T	allele	
alters	 a	 consensus	 splice	 donor	 site	 leading	 to	 expression	 of	 IRF5	 isoforms	 bearing	 an	
alternative	exon	1	 -	 exon	1B	 (168).	Another	 independent	 cis-variant,	 rs10954213	which	 is	
located	in	the	3’	UTR	region,	alters	the	polyadenylation	of	IRF5	mRNA	and	hence	its	stability.	
Lastly,	rs60344245	(30-bp-	in-frame	indel)	which	is	located	in	a	proline-,	glutamic	acid-,	serine-	
and	threonine-rich	region	known	to	affect	the	stability	and	function	of	protein,	might	have	an	
impact	on	the	transcription	initiating	effect	of	IRF5	on	its	target	genes,	while	rs2070197	is	a	
further	surrogate	marker	of	common	haplotypes	formed	by	the	other	three	polymorphisms	
(169).	This	haplotype	(combinations	of	the	three	functional	polymorphisms)	provides	a	good	
mechanistic	 explanation	 of	 higher	 expression	 of	 IRF5,	 feeding	 forward	 to	 the	 type	 1	 IFN	
pathway	and	contributing	to	the	pathogenesis	of	SLE,	although	it	has	yet	to	be	determined	
whether	this	is	mediated	in	an	additive	or	epistatic	manner.	
	
Two	 previous	 studies	 investigated	 polymorphisms	 within	 IRF5	 in	 AVV	 patients	 with	
contradictory	 results.	 In	 a	 German	 cohort	 consisting	 of	 601	 GPA	 cases	 and	 827	 controls,	
Wieczorek	et	al	identified	a	four	SNP	haplotype	of	IRF5	as	described	earlier,	which	conferred	
a	 protective	 effect	 in	 GPA	 patients	 (rs2004640/rs60344245/rs2070197/rs10954213;	
G/ins/T/G;	OR	=	0.73,	pc	=	0.0012,	CI	0.62-0.85)	a	similar	trend	to	that	observed	in	SLE	(170).	
On	 the	 other	 hand,	 Kawasaki	 et	 al	 found	 that	 the	 frequency	 of	 rs10954213	 G	 allele	was	
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increased	 in	MPO-ANCA	AAV	(n	=	232)	as	compared	to	healthy	controls	 (n	=	710,	additive	
model,	p	=	0.023,	OR	=	1.27)	(171).	This	locus	did	not	achieve	genome-wide	significance	in	all	
three	GWAS	of	AAV.	
	
FCRG3B	
Copy	number	variations	 (CNVs)	are	defined	as	 the	presence	of	variable	copies	of	genomic	
regions	as	a	result	of	deletion	or	duplication,	with	size	ranging	from	kilobases	to	megabases	
in	different	individuals.	CNVs	have	been	estimated	to	account	for	about	13%	of	the	human	
genome	and	 it	 can	be	 inherited	or	 sporadic	 (172).	CNVs	can	alter	 the	gene	dosage	of	 the	
affected	region	and	therefore	influence	the	risk	of	developing	a	range	of	diseases.	Association	
between	FCGR3B	CNV	and	a	number	of	autoimmune	diseases	(e.g.	SLE	(173)	and	RA	(174))	
have	been	reported	in	the	European	population.	
	
FcgRIIIb	is	a	member	of	a	family	of	low-affinity	Fcg	receptors	for	IgG	immune	complexes	where	
its	expression	is	largely	restricted	to	neutrophils	and	is	anchored	to	the	outer	layer	of	plasma	
membrane	via	a	phosphatidylinositol	 linkage	(175).	FcgRIIIb	can	also	be	shed	from	the	cell	
surface	 upon	 activation.	 FcgR	 plays	 crucial	 role	 in	 initiation	 and	 regulation	 of	 antibody-
mediated	 immune	 response	 as	 well	 as	 recognition	 and	 clearance	 of	 immune	 complexes.	
There	are	two	isoforms	of	FcgRIIIb:	FcgRIIIb-HNA1a	(NA1)	which	has	been	associated	with	SLE	
(176)	and	FcgRIIIb-HNA1b	(NA2)	which	has	been	associated	with	AAV	(177).	Wilcocks	et	al	
previously	demonstrated	that	a	higher	FCGR3B	copy	number	was	observed	in	AAV	patients	
but	a	lower	copy	number	in	SLE	patients	as	compared	to	healthy	controls	(178).	This	finding	
is	aligned	with	the	pathophysiology	of	the	disease	given	that	ANCA	mediates	its	pathogenic	
effect	by	activating	neutrophils	via	the	Fcg	receptor	and	should	therefore	be	worsened	by	a	
higher	FCGR3B	copy	number.	
	
TLR9	
Toll-like	receptor	9	(TLR9)	is	a	member	of	the	TLR	family,	also	known	as	pattern	recognition	
receptors	(PRRs)	which	recognise	molecular	structures	that	are	broadly	conserved	among	the	
pathogens,	 known	 as	 pathogen	 associated	 molecular	 patterns	 (PAMPs).	 The	 interaction	
between	TLRs	and	PAMPs	triggers	intracellular	signals	and	promotes	inflammatory	response	
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such	 as	 via	 type	 1	 IFN	 and	 pro-inflammatory	 cytokine	 production	 (179).	 Husmann	 et	 al	
previously	 investigated	 the	 associations	 of	 four	 SNPs	 (rs352162,	 rs352140,	 rs352139	 and	
rs5743836)	within	TLR9	in	AAV	patients	comprising	of	646	GPA,	164	EGPA	and	53	MPA.	They	
found	 that	 all	 four	 SNPs	 were	 strongly	 associated	 with	 GPA	 and	 interestingly,	 significant	
associations	were	also	identified	in	MPA	but	each	with	the	contrary	allele.	A	much	stronger	
association	 was	 observed	when	 they	 compared	 cases	 to	 controls	 according	 to	 the	 ANCA	
status	 and	 again	 a	 reciprocal	 effect	 was	 seen	 in	 MPO-AAV	 (180).	 These	 findings	 were	
replicated	in	a	cohort	of	426	Dutch	and	British	cases.	The	authors	provided	yet	another	piece	
of	evidence	that	PR3-AAV	differs	from	MPO-AAV	genetically	and	that	TLR9	signalling	might	
be	involved	in	disease	pathogenesis,	in	favour	of	an	infection	model	triggering	autoimmunity.	
	
MPO	
A	common	MPO	promoter	polymorphism	(-463G/A,	also	known	as	rs2333227)	was	previously	
identified	to	be	linked	to	Alzheimer’s	disease	(181,	182),	lupus	nephritis	(183)	and	a	range	of	
cancers	(184,	185).	The	-463	G/A	polymorphism	is	within	an	Alu-encoded	hormone	response	
element,	which	includes	overlapping	binding	sites	for	SP1	transcription	factor,	retinoic	acid	
receptor	and	thyroid	hormone	receptor.	 -463G	 is	within	 the	SP1	binding	site,	while	 -463A	
largely	inhibits	SP1	binding,	creating	a	binding	site	for	oestrogen	receptor	alpha.	In	myeloid	
leukemia	cells,	the	GG	genotype	was	associated	with	two	to	three-fold	higher	levels	of	MPO	
mRNA	and	protein	expression	than	in	the	GA	or	AA	genotypes	(186).	Moreover,	-463G	was	
associated	with	stronger	promoter	activity	than	-463A	in	cellular	transfection	assays.	
	
Reynolds	 and	his	 colleagues	previously	 looked	at	 patients	with	different	 types	of	AAV	 for	
clinical	associations	with	-463G/A	SNP.	They	demonstrated	that	GG	genotype	was	associated	
with	 an	 increased	 incidence	 of	 vasculitis	 in	 female	 MPO-AAV	 only	 while	 there	 was	 an	
association	of	the	GA/AA	genotypes	with	an	increased	relapse	rate	in	patients	with	MPO-AAV	
(187).	 The	authors	 suggested	 that	 the	G	and	A	alleles	might	be	differentially	 regulated	 in	
males	 and	 females	 given	 that	 the	 association	was	 only	 observed	 in	 females	 and	 this	was	
supported	by	a	Japanese	study	which	demonstrated	that	the	MPO	activity	was	2-fold	higher	
in	females	than	males	(188),	may	be	due	to	oestrogen	receptor	binding	to	the	MPO	promoter.		
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CD18	
The	b2	 integrin	 (CD18)	 is	a	protein	 that	 is	encoded	by	 the	 ITGB2	gene	which	 is	 located	at	
chromosome	 21q22.3.	 It	 is	 the	 common	 b-subunit	 of	 several	 different	 heterodimers:	
lymphocyte	 function-associated	antigen	1	 (LFA-1),	macrophage-1	antigen	 (Mac-1),	 integrin	
alphaXbeta2	and	integrin	alphaDbeta2.	Integrins	are	known	to	participate	in	cell	adhesion	as	
well	 as	 cell-surface	mediated	 signalling.	Mutations	 in	 ITGB2	 results	 in	 leukocyte	 adhesion	
deficiency	type	1	(LAD-1)	where	individuals	present	in	early	infancy	with	failure	of	umbilical	
cord	 separation,	 cutaneous,	 respiratory	 and	 gingival	 infections	 due	 to	 impairment	 of	
neutrophil	and	monocyte	cell	migration	and	phagocytosis	(189).	Gencik	et	al	first	reported	a	
variant	in	the	exon	11	of	ITGB2,	thymidine	to	cytosine	transversion	affecting	the	restriction	
enzyme	AvaII	recognition	sequence	which	confers	a	higher	risk	of	MPO-AAV	(190).	This	was	
followed	by	a	second	study	from	the	same	group	where	they	screened	the	entire	coding	and	
regulatory	regions	of	the	ITGB2	gene	to	identify	the	potential	causal	variants	that	are	involved	
in	 the	 pathogenesis	 of	 AAV.	 A	 total	 of	 10	 SNPs	 were	 identified,	 of	 which	 four	 showed	
significant	associations	with	MPO-AAV	including	the	former	one	(191).	One	of	these	SNPs	is	
located	in	the	alternative	transcription	start	site	which	could	influence	the	expression	of	the	
gene.		
	
Others	
A	list	of	other	polymorphisms	that	have	been	reported	in	small	series	to	play	a	role	in	AAV	is	
summarised	 in	Table	1.6	 (72,	100,	106,	192-202).	Most	of	 the	variants	are	 involved	 in	 the	
innate	and	adaptive	 immune	systems.	However,	none	of	 them	had	been	replicated	 in	 the	
GWAS.	
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Table	1.6:	A	summary	of	the	genetic	associations	that	were	reported	in	AAV	
Study,	Year	 Population	 Gene	(variant)	 Cases	/	Controls	 OR	 P-value	
Papiha,	1992	 British	 Complement	C4B	 27	GPA/163	 2.56	 4.00	x	10-2	
Finn,	1994	 British	 Complement	C3F	 63	AAV/na	 2.60	 <2.5	x	10-2	
Persson	U,	1999	 Swedish	 Complement	C3F	 37	PR3/101	 1.88	 <5.00	x	10-2	
Murakozy,	2001	 German	 IL-10-1082	 39	GPA/72	 0.72	 <5.00	x	10-2	
Zhou,	2002	 Swedish	 IL-10	promoter	microsatellite	 32	GPA/109	 na	 <5.00	x	10-2	
Spriewald,	2005	 German	 IL-10-1082,	-819,	-592	haplotype	 32	GPA/91	 na	 ns	
IFNG	+874	(A/T)	 3.14	 §2.7	x	10-2	
TNF	promoter	-238	(G/A)	 5.01	 §2.9	x	10-2	
Miyashita,	2006	 Japanese	 KIR2DS3	 43	MPA/239	 0.24	 3.8	x	10-2	
Mamegano,	
2008	
Japanese	 LILRA2	(rs2241524)	 50	MPA/284	 2.52	 4.9	x	10-2	
Wieczorek,	
2009	
German	 CD226	 642	GPA/1,226	 1.23	 3.1	x	10-3	
Carr,	2009	 British	 CD226	(rs763361)	 641	AAV/9,115	 0.90	 2.1	x	10-1	
IL-2RA	(rs41295061)	 675	AAV/8,936	 0.77	 1.22	x	10-2	
Wieczorek,	
2010	
German	 LEPR	(rs8179183)	 460	GPA/878	 0.72	 3.40	x	10-3	
GHSR	haplotype		
(rs519384,	rs572169,	rs509035)	
1.30	 6.70	x	10-3	
Zhou,	2012	 Chinese	 DEFB4	CNV	 112	AAV/523	 na	 9.00	x	10-3	
Wu,	2014	 Chinese	 TLR2	(rs3804100)	 76	MPA/501	 na	 1.80	x	10-2	
	
AAV,	ANCA-associated	 vasculitis;	CD226,	 cluster	 of	 differentiation	 226;	 CNV,	 copy	number	 variation;	DEFB4,	
defensin	beta	4A;	GHSR,	growth	hormone	secretagogue	receptor;	GPA,	granulomatosis	with	polyangiitis;	IFNG,	
interferon	 gamma;	 IL2RA,	 interleukin-2	 receptor	 alpha	 chain;	 IL-10,	 interleukin-10;	 KIR2DS3,	 killer	 cell	
immunoglobulin-like	 receptor,	 two	 Ig	 domains	 and	 short	 cytoplasmic	 tail	 3;	 LEPR,	 leptin	 receptor;	 LILRA2,	
leukocyte	 immunoglobulin-like	 receptor	 A2;	 MPA,	 microscopic	 polyangiitis;	 na,	 not	 applicable;	 ns,	 not	
significant;	OR,	odds	ratio;	PR3,	proteinase	3;	TLR2,	toll-like	receptor	2;	TNF,	tumour	necrosis	factor.	
	
§These	p-values	had	not	been	subjected	to	multiple	testing	correction.	
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1.5 The	role	of	ANCA	in	the	pathogenesis	of	AAV	
Since	the	first	description	of	ANCA	by	Davies	et	al	in	1982	(9),	followed	by	the	identification	
of	 MPO	 and	 PR3	 as	 the	 antigenic	 targets	 which	 paved	 the	 foundation	 of	 our	 current	
understanding	 of	 AAV,	 ANCA	 has	 become	 an	 important	 diagnostic	 marker	 and	 in	 most	
laboratories,	screening	for	ANCA	is	done	by	an	indirect	immunofluorescence	technique	using	
human	 buffy	 coat	 cells	 as	 substrate.	 Sera	 positive	 for	 ANCA	 are	 further	 tested	 by	 direct	
enzyme	 immunoassay	 (EIA)	 to	 reveal	 their	 specificity	 for	 either	purified	PR3	or	MPO	as	 a	
target	 antigen,	 both	 of	 which	 can	 give	 rise	 to	 a	 c-ANCA	 or	 p-ANCA	 staining	 pattern	
respectively	(203).	There	is	a	significant	overlap	of	the	ANCA	patterns	between	GPA	and	MPA.	
PR3-ANCA	are	detected	in	70-80%	of	the	GPA	patients,	whereas	about	10%	of	GPA	present	
MPO-ANCA,	which	are	more	characteristic	of	MPA.	In	addition,	approximately	10%	of	patients	
have	 no	 detectable	 ANCA	 (204).	 The	 cause	 of	 injury	 in	 ANCA-negative	 patients	 remains	
uncertain	 and	 whether	 this	 could	 be	 due	 to	 antibodies	 which	 cannot	 be	 detected	 using	
currently	available	immunoassays	or	epitope	specificity	remains	unknown	(205,	206).	Several	
other	possibilities	have	been	raised	including	inhibition	of	assays	for	anti-MPO	antibodies	by	
caeruloplasmin	 fragments	 in	 serum	 (207),	 podocyte	 specific	 non-immune	 triggers	 (e.g.	
epidermal	growth	factor	receptor	and	VHL/HIF	oxygen-sensing	pathway)	 leading	to	rapidly	
progressive	glomerulonephritis	which	have	been	demonstrated	in	animal	models	(208,	209)	
and	autoantibodies	against	human	LAMP-2	(hLAMP-2),	which	was	discovered	by	Kain	et	al	in	
the	 late	 90s.	 The	 autoantibodies	 against	 hLAMP-2	were	 found	 in	 untreated	 AAV	 patients	
presenting	 with	 pauci-immune	 necrotising	 crescentic	 glomerulonephritis	 (NCGN),	 both	
ANCA-positive	and	ANCA-negative	(43,	210).	However,	the	role	of	this	autoantibody	in	AAV	is	
not	fully	understood	and	further	discussion	is	elaborated	in	section	1.6.2.	
	
AAV	predominantly	 affects	 the	 small	 vessels	 in	 the	body	 (arteries,	 arterioles,	 venules	 and	
veins).	 In	 the	 acute	 phase,	 AAV	 is	 characterised	 a	 necrotizing	 vasculitis	 with	 infiltrating	
neutrophils	 and	 monocytes.	 Within	 days,	 the	 neutrophils	 undergo	 leukocytoclasis	 and	
disappear,	to	be	replaced	by	mononuclear	leukocytes	including	macrophages,	monocytes	and	
T	 lymphocytes.	 Histologically,	 AAV	 is	 characterised	 by	 the	 absence	 of	 immunoglobulin	
deposition	in	vessel	walls,	which	indicates	that	the	pathogenesis	of	AAV	is	different	from	the	
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pathogenesis	of	other	vasculitides	that	are	associated	with	extensive	vessel	wall	deposition	
of	 immunoglobulin,	 indicative	 of	 immune	 complex	 vasculitis	 or	 anti-glomerular	 basement	
disease.	Therefore,	ANCA	was	originally	thought	to	be	an	epiphenomenon,	accompanying	but	
not	driving	the	disease,	although	this	paradigm	has	been	gradually	overturned	in	recent	years	
following	the	emergence	of	evidence	supporting	ANCA	as	the	key	player	in	AAV	pathogenesis.	
	
1.5.1 Clinical	evidence	supporting	the	pathogenicity	of	ANCA	
AAV	is	characterised	by	vascular	inflammation	that	is	highly	correlated	with	the	presence	of	
circulating	ANCA.	In	general,	high	levels	of	ANCA	are	present	in	patients	with	active	disease	
and	the	titres	fall	during	therapy.	Nevertheless,	this	is	not	an	absolute	correlation	using	the	
current	clinical	assays	for	ANCA	and	there	is	insufficient	data	to	support	its	use	as	a	biomarker	
for	disease	activity	as	rising	titres	have	been	observed	in	up	to	40%	of	stable	AAV	patients	
(211).	 Bansal	 and	 Tobin	 reported	 a	 case	 of	 transplacental	 transfer	 of	MPO-ANCA	 from	 a	
mother	to	a	33-week	gestational	age	neonate	resulting	in	neonatal	pulmonary	haemorrhage	
and	 renal	 involvement	 that	 was	 successfully	 treated	 with	 high-dose	 steroid	 therapy	 and	
plasma	exchange	(212).	This	case	report	is	frequently	cited	as	the	most	direct	clinical	evidence	
for	the	pathogenicity	of	MPO-ANCA	in	humans;	though	no	further	similar	cases	have	been	
reported	and	the	delivery	of	a	healthy	newborn	despite	transplacental	transfer	of	high	level	
of	 MPO-ANCA	 from	 a	 mother	 with	MPA	 was	 previously	 described	 (213).	 The	 latter	 case	
suggested	that	anti-MPO	alone	might	not	be	sufficient	to	exert	the	pathogenic	effect	and	an	
inflammatory	stimulus	or	tissue	injury	is	required	for	the	development	of	clinical	vasculitis.	
	
Another	observation	in	humans	that	supports	a	pathogenic	role	of	ANCA	is	the	association	of	
AAV	 development	 with	 specific	 drugs,	 such	 as	 propylthiouracil,	 minocycline,	 pimagedine,	
hydralazine,	allopurinol,	D-penicillamine,	phenytoin,	isotretinoin	and	lemivasole-adulterated	
cocaine	 (214).	 The	 clinical	 manifestations	 can	 range	 from	 cutaneous	 and	 mild	 systemic	
symptoms	to	invasive	involvement	of	several	organs	and	it	is	often	associated	with	anti-MPO	
and	p-ANCA	rather	than	anti-PR3	and	c-ANCA.	Although	there	is	no	standardised	approach	to	
the	treatment	of	drug-induced	vasculitis,	complete	clinical	resolution	typically	occurs	after	
drug	withdrawal,	immunosuppressive	treatment	and	is	usually	followed	by	a	decline	in	ANCA	
titres.		
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Lastly,	the	effectiveness	of	B-cell	targeting	therapy	(e.g.	Rituximab)	for	remission	induction	
strongly	supports	a	pathogenic	role	for	ANCA.	In	the	RAVE	trial,	Rituximab	was	shown	to	be	
noninferior	to	daily	cyclophosphamide	(CYC)	regimen	for	induction	of	remission	in	severe	AAV	
and	superior	to	CYC	in	relapsing	patients	(215).	Similarly,	in	the	RITUXVAS	trial,	Rituximab	in	
combination	with	two	pulses	of	CYC	was	as	effective	as	a	standard	CYC	regimen	in	inducing	
remission	in	newly	diagnosed	AAV	patients	with	severe	renal	involvement	(216).	
	
1.5.2 Experimental	data	supporting	the	pathogenicity	of	ANCA	
The	 spontaneous	 crescentic	 glomerulonephritis-Kinjoh	 (SCG-Kinjoh)	 mice	 develop	 a	 high	
degree	of	glomerular	crescents	and	high	titres	of	anti-MPO	antibodies	(217).	However,	this	
autoimmune-prone	strain	also	produces	other	antibodies	that	might	contribute	to	pathology	
combined	with	significant	immune	deposits	found	in	the	kidneys,	rendering	it	not	ideal	as	a	
model	of	tissue	injury	in	AAV	that	is	pauci-immune	by	definition.	A	pivotal	breakthrough	in	
this	field	was	the	demonstration	of	passively	transferred	anti-MPO	immunoglobulin	G	(IgG)	
causing	focal	pauci-immune	NCGN	in	wild-type	mice	over	the	duration	of	a	week	by	Xiao	et	al	
(218),	suggesting	that	antibodies	alone	are	sufficient	to	induce	crescentic	glomerulonephritis	
in	 the	 absence	 of	 contribution	 from	 the	 cellular	 immune	 response,	 supporting	 the	
pathogenicity	of	MPO-ANCA.	Although	the	degree	of	disease	observed	was	mild,	this	model	
was	 further	 refined	 by	 Huugen	 et	 al	 by	 the	 administration	 of	 LPS	 (219),	 simulating	 the	
synergistic	effect	of	infection	in	exacerbating	autoimmune	phenomena	where	the	effect	was	
primarily	driven	by	TNF.	Another	autoimmune	model	has	been	developed	using	Wistar-Kyoto	
(WKY)	rats	by	Little	et	al	(220).	By	immunising	the	WKY	rats	with	human	MPO	(hMPO),	without	
further	 intervention,	 they	 developed	 antibodies	 specific	 for	 hMPO	within	 two	weeks	 and	
cross-reacted	with	rat	MPO,	resulting	in	vasculitis	and	pauci-immune	NCGN	by	6-8	weeks.		
	
Interestingly,	no	spontaneous	models	of	glomerulonephritis	or	vasculitis	associated	with	anti-
PR3	 antibodies	 have	 been	 reported.	 Furthermore,	 similar	 approaches	 as	 described	 were	
employed	 to	 generate	 an	 animal	 model	 for	 PR3-AAV	 but	 proved	 unsuccessful	 in	 initial	
attempts,	 which	 have	 primarily	 been	 attributed	 to	 the	 differences	 in	 the	 structure	 and	
expression	pattern	of	PR3	in	humans	and	rodents	as	well	as	the	absence	of	PR3	on	the	surface	
of	mouse	neutrophils	(221).	It	was	later	demonstrated	by	van	der	Geld	et	al	that	immunisation	
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of	mice	and	rats	with	chimeric	human/mouse	PR3	induced	high	titres	of	anti-PR3	antibodies,	
but	not	disease	(222).	It	was	not	until	recently	that	Little	and	colleagues	generated	humanised	
immunodeficient,	non-obese	diabetic	(NOD)/severe	combined	immune	deficient	(SCID),	IL-2	
receptor	knockout	mice,	which	 received	human	haemopoietic	 stem	cells	and	developed	a	
human-mouse	chimeric	immune	system.	Upon	passive	transfer	of	PR3-ANCA	containing	IgG	
derived	 from	 patients	 with	 severe	 systemic	 vasculitis,	 these	 mice	 developed	 mild	
glomerulonephritis	 and	 lung	haemorrhage	which	 supports	 the	pathogenicity	of	PR3-ANCA	
(223).		
	
Another	interesting	observation	was	made	by	Primo	et	al	where	the	transfer	of	splenocytes	
from	the	autoimmune-prone	NOD	mouse	following	immunisation	with	recombinant	murine	
PR3	 (rmPR3)	 led	 to	 NCGN	 in	 immunodeficient	 NOD-SCID	 recipients,	 but	 no	 disease	 was	
observed	 in	 NOD-SCID	mice	which	 received	 splenocytes	 from	 rmPR3-immunised	 C57BL/6	
control	mice	(224),	suggesting	a	susceptible	genetic	background	might	be	required	for	the	
development	of	disease	 in	addition	to	the	presence	of	ANCA.	Recent	developments	 in	the	
generation	of	animal	models	for	AAV	have	been	successful,	although	none	can	explain	why	
the	immune	tolerance	to	self-antigens	is	broken	in	the	first	instance,	these	models	are	a	useful	
tool	 for	 investigating	 the	molecular	mechanisms	of	downstream	events	once	 the	 immune	
tolerance	is	broken.	
	
Both	MPO	and	PR3	are	 typically	 found	 in	 the	cytoplasmic	azurophilic	neutrophil	 granules.	
Several	 in	 vitro	 studies	 showed	 that	 ANCA	 can	 activate	 neutrophils	 and	 mononuclear	
phagocytes	by	binding	to	 their	cognate	antigen	on	the	cell	 surface	after	priming	with	TNF	
(113,	 225),	 causing	 an	 oxidative	 burst	 with	 release	 of	 reactive	 oxygen	 species	 (ROS),	
degranulation	 with	 release	 of	 MPO,	 elastase	 and	 PR3	 (113,	 223,	 225),	 secretion	 of	 pro-
inflammatory	cytokines	(226)	and	upregulation	of	cell	adhesion	molecules,	which	promotes	
attachment	 of	 neutrophils	 to	 vascular	 endothelial	 cells	 (227,	 228),	 contributing	 to	 acute	
vascular	injury.	Therefore,	a	pathogenic	model	has	been	proposed	where	neutrophils	might	
be	activated	by	circulating	ANCA	to	cause	endothelial	damage	and	organ	dysfunction	in	the	
presence	of	pro-inflammatory	signals.	
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1.5.3 Genetic	studies	supporting	the	pathogenicity	of	ANCA	
Recent	GWAS	 identified	 strong	associations	of	AAV	with	SNPs	 located	at	 the	MHC	class	 II	
region,	SERPINA1	and	PRTN3	 (70,	71,	78).	These	SNPs	were	more	strongly	associated	with	
GPA	than	MPA	patients,	and	interestingly,	the	associations	were	even	more	significant	with	
anti-PR3	positive	vasculitis	than	anti-MPO.	In	the	subgroup	analysis,	PR3-AAV	was	associated	
with	 HLA-DP	 while	 MPO-AAV	 was	 associated	 with	 HLA-DQ	 (70).	 These	 findings	 strongly	
support	a	pathogenic	model	for	PR3-AAV	in	which	an	altered	availability	of	PR3	autoantigen	
(as	recently	demonstrated	by	Merkel	et	al	where	the	PR3-AAV	risk	allele	(rs62132293:G)	is	
associated	with	a	higher	expression	of	PRTN3	 in	neutrophils)	 (71),	 together	with	 impaired	
functional	suppression	by	A1AT	which	is	a	natural	physiological	inhibitor	of	PR3,	prompt	the	
generation	 of	 anti-PR3	 antibodies	 through	 permissive	 HLA	 presentation	 and	 eventually	
leading	to	AAV	development.	However,	the	genetic	evidence	for	MPO-AAV	is	still	lacking.	
	
1.6 The	possible	mechanisms	of	ANCA	emergence	
As	with	most	 autoimmune	diseases,	 the	 exact	 aetiologies	 of	AAV	are	not	 known,	 but	 are	
undoubtedly	 multifactorial	 with	 a	 combination	 of	 genetic	 predisposition,	 environmental	
exposure	 and	 characteristics	 of	 the	 immune	 system	 likely	 responsible.	 There	 is	 increasing	
evidence	 to	 support	 the	 role	 of	 bacterial	 infection	 as	 the	 trigger	 that	 breaks	 tolerance,	
resulting	in	autoimmunity.	The	three	main	hypotheses	that	dominate	the	field	are	discussed	
below.	
	
1.6.1 Complementary	PR3	(cPR3)	and	anti-idiotype	antibodies	
Complementary	protein	is	a	protein	that	results	from	transcription	of	the	anti-sense	strand	
of	the	gene	encoding	for	the	original	protein	while	anti-idiotype	response	is	defined	by	the	
presence	of	an	antibody	that	recognises	the	complementarity-determining	region	of	another	
antibody,	generating	circulating	immune	complexes	which	lead	to	abolishment	of	self-nonself	
distinction	 and	 eventually,	 autoimmune	 processes	 (229).	 In	 2004,	 Falk	 and	 colleagues	
inadvertently	identified	antibodies	that	could	react	with	cPR3	peptide	in	the	serum	of	GPA	
patients	(230)	and	immunisation	of	mice	with	cPR3	peptides	could	induce	production	of	both	
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anti-cPR3	and	anti-PR3	antibodies.	They	demonstrated	that	antibodies	to	PR3	and	cPR3	were	
bound	to	each	other	in	both	human	and	mice,	supporting	an	idiotypic	relationship.	Another	
observation	made	by	the	former	group	was	that	the	immunodominant	part	of	cPR3	showed	
partial	homology	with	various	microbial	peptides,	including	S.	aureus.	This	could	explain	the	
relationship	observed	between	chronic	S.	aureus	colonisation	and	increased	relapse	rates	in	
AAV	 (42)	 and	 the	 reduction	 in	 relapse	 following	 treatment	 with	 co-trimoxazole	 (231).	
However,	these	findings	have	not	been	confirmed	by	another	group	(232)	and	immunisation	
of	Wistar	rats	with	S.	aureus	did	not	induce	vasculitis	or	NCGN	(233).	Though	intriguingly,	the	
rats	 in	 the	 control	 arm	 that	 were	 immunised	 with	 Escherichia	 coli	 (E.	 coli)	 did	 develop	
vasculitis	and	c-ANCA.	
	
1.6.2 Anti-LAMP-2	and	molecular	mimicry	
LAMP-2	is	a	heavily	glycosylated	membrane	protein	expressed	in	lysosomes	and	on	the	cell	
surface.	 It	 plays	 important	 roles	 in	 transporting	 intracellular	 proteins,	maintaining	 cellular	
homeostasis	and	response	to	stress	(234).	Anti-hLAMP-2	has	been	described	as	a	sensitive	
marker	for	AAV	with	pauci-immune	NCGN.	Kain	et	al	reported	that	circulating	anti-hLAMP-2	
antibodies	were	present	in	80-90%	of	patients	with	AAV,	including	ANCA-negative	patients	
and	were	absent	 in	the	sera	of	healthy	controls	(43,	235,	236).	The	autoantibodies	rapidly	
become	undetectable	following	immunosuppressive	treatment	and	during	remission	phase,	
suggesting	a	potential	role	as	a	biomarker	for	active	disease.	More	importantly,	they	showed	
that	passive	transfer	of	rabbit	anti-hLAMP-2	IgG	could	induce	glomerulonephritis	in	WKY	rats	
by	cross-reacting	with	rat	LAMP-2	(43).	LAMP-2	IgG	could	activate	primed	neutrophils	and	
induce	 apoptosis	 in	 endothelial	 cells	 in	 a	 similar	 fashion	 to	 ANCA	 MPO	 and	 PR3	 IgG.	
Furthermore,	they	characterised	two	epitopes	that	were	recognised	by	the	autoantibodies	to	
hLAMP-2	 and	one	of	which	 (LAMP-2	 epitope	P41-49)	 has	 complete	homology	with	 FimH,	 a	
bacterial	 adhesion	 molecule.	 Rats	 immunized	 with	 FimH	 produced	 antibodies	 to	 rat	 and	
human	 LAMP-2	 and	 developed	 pauci-immune	 NCGN.	 Considering	 all	 available	 findings,	
infection	with	fimbriated	bacteria	bearing	FimH,	such	as	E.	coli	and	Klebsiella	pneumoniae,	
might	trigger	cross-reactive	autoimmune	responses	to	LAMP-2	and	cause	AAV.	The	clinical	
significance	of	anti-LAMP-2	has	yet	to	be	confirmed	as	the	majority	of	the	data	originate	from	
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a	single	group	and	Roth	et	al	recently	reported	a	much	lower	prevalence	of	autoantibodies	to	
LAMP-2	in	AAV	patients	at	21%	(237).	
	
1.6.3 NETosis	
Neutrophil	extracellular	traps	(NETs)	are	released	by	neutrophils	upon	activation,	consisting	
of	granule	proteins	and	chromatin	combined	together	to	form	an	extracellular	structure	to	
enhance	their	antimicrobial	properties,	serving	as	a	physical	barrier	to	trap	invading	microbes	
and	 keeping	 potentially	 noxious	 proteins	 like	 proteases	 from	diffusing	 away	 and	 inducing	
adjacent	tissues	damage	(238).	Kessenbrock	and	colleagues	demonstrated	that	even	in	the	
absence	of	microbial	infection,	NETs	formation	was	observed	in	neutrophils	incubated	with	
purified	IgG	from	AAV	patients	but	not	in	those	incubated	with	sera	for	healthy	controls.	Both	
antigenic	targets,	PR3	and	MPO,	were	identified	in	the	fibrous	DNA	deposits	(239).	Moreover,	
components	 of	 NETs	 were	 found	 in	 the	 vicinity	 of	 neutrophil	 infiltrates	 in	 the	 affected	
glomeruli	and	interstitium	of	AAV	patients.	Therefore,	it	has	been	suggested	that	NETs	might	
play	a	role	 in	the	development	of	autoimmune	diseases	due	to	the	persistent	exposure	of	
antigen-chromatin	 complexes	 to	 the	 immune	 system	and	 that	 this	 could	 be	 enhanced	 by	
bacterial	infection	such	as	S.	aureus,	which	has	been	shown	to	strongly	induce	NETs	formation	
(240).		
	
1.7 Immune	cells	and	pathways	involved	in	the	pathogenesis	of	AAV	
Both	the	innate	and	adaptive	immune	systems	play	important	roles	in	the	pathogenesis	of	
AAV.	 As	 discussed	 in	 section	 1.5.2,	 neutrophils	 represent	 both	 the	 target	 cells	 of	 the	
autoimmune	response	and	key	effector	cells	triggering	endothelial	cell	damage.	Mice	lacking	
circulating	neutrophils	have	been	shown	to	be	protected	from	anti-MPO	IgG-induced	NCGN	
(241),	while	 all	 control	mice	developed	NCGN.	 In	 addition,	patients	with	active	GPA	were	
found	to	have	elevated	serum	B	lymphocyte	stimulator	(BLyS,	a.k.a.	B-cell	activating	factor)	
levels	(242),	which	is	a	member	of	the	TNF	ligand	superfamily	cytokines	that	is	known	to	be	
essential	 for	B-cell	differentiation,	proliferation	and	 immunoglobulin	production.	Although	
the	authors	did	not	further	investigate	the	mechanisms	and	the	cell	types	responsible	for	this	
elevation,	 it	 has	 been	 speculated	 that	 ANCA-activated	 neutrophils	 could	 be	 an	 important	
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source	of	BLyS	 (243).	This	 is	 further	 supported	by	an	 in	vitro	 study	by	Holden	et	al	which	
demonstrated	 ANCA	 induced	 production	 and	 release	 of	 BLyS	 from	 activated	 neutrophils,	
promoting	B-cell	survival	(244).	
	
There	has	 also	been	growing	 interest	 in	 recent	 years	of	 the	 role	of	 T	 cells	 in	AAV,	where	
evidence	 has	 emerged	 supporting	 its	 role	 in	 the	 pathogenesis	 of	 AAV.	 Firstly,	 ANCA	
production	is	T-cell	dependent	where	B	cells	require	stimulation	from	antigen-specific	CD4+	
T	 cells	 to	 generate	 high	 affinity	 class-switched	 antibodies	 (245).	 Secondly,	 in	 addition	 to	
granulomas,	extensive	T-cell	infiltration	in	different	renal	compartments	are	commonly	found	
in	 renal	 biopsies	 of	 acute	 AAV	 patients,	 suggesting	 a	 pathogenic	 contribution	 of	 T-cell	
mediated	immune	response	(246-248).	Furthermore,	T-cell	activation	markers	such	as	soluble	
IL-2	receptor	and	soluble	CD30	have	been	shown	to	be	increased	in	the	plasma	of	PR3-AAV	
patients	as	compared	to	healthy	controls	and	the	levels	of	these	markers	correlated	strongly	
with	 disease	 activity	 (249).	 McKinney	 et	 al	 recently	 identified	 and	 validated	 a	 novel	
transcriptional	signature	in	CD8+	T	cells	with	prognostic	and	clinical	relevance	in	AAV	patients	
and	 that	 was	 enriched	 for	 genes	within	 the	 IL-7	 and	 TCR	 signalling	 pathways	 (250,	 251).	
Furthermore,	several	studies	have	consistently	demonstrated	defective	regulatory	T	cell	(Treg)	
suppressive	function	in	AAV	patients	despite	conflicting	results	regarding	the	number	of	Treg	
in	 the	 peripheral	 blood	 (252-254).	 Lastly,	 in	 the	MPO-induced	 glomerulonephritis	murine	
model,	the	severity	of	NCGN	was	attenuated	in	the	absence	of	CD8+	T	cells	(255)	and	CD4+	T	
cells	(256).	
	
The	importance	of	B	cells	in	the	development	of	AAV	is	supported	by	the	clinical	benefit	of	B-
cell	targeting	therapy	(section	1.5.1).	The	anti-CD20	monoclonal	antibody	rituximab	has	been	
widely	used	in	AAV	patients.	It	rapidly	depletes	CD20+	B	lymphocytes,	presumably	resulting	
in	the	interruption	of	the	pathological	cell		lineage	responsible	for	autoantibodies	production	
and	possibly	abrogation	of	cytokine	production	and	antigen	presentation	by	B	cells	(257).	In	
contrast,	 a	 distinct	 B	 cell	 subset	 with	 immunoregulatory	 properties	 has	 been	 termed	
regulatory	 B	 cells	 (Breg).	 They	 are	 characterised	 by	 high	 CD5	 surface	 expression	 and	 IL-10	
production	(258),	which	promote	the	development	of	Treg	and	inhibit	the	differentiation	of	
naïve	 T	 cells	 into	 Th1	 or	 Th17	 cells	 (259).	 Several	 studies	 have	 demonstrated	 a	 lower	
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frequency	 of	 Breg	 in	 the	 peripheral	 blood	 of	 active	 AAV	 patients,	 without	 functional	
impairment,	when	compared	with	patients	who	were	in	remission	and	healthy	controls	(260-
262),	suggesting	that	Breg	might	fail	to	prevent	autoreactive	responses	and	eventually	result	
in	autoimmunity.	
	
Given	the	histopathological	feature	of	pauci-immune	glomerulonephritis	and	the	absence	of	
hypocomplementaemia,	the	complement	system	was	originally	thought	not	to	be	involved	in	
AAV	pathogenesis.	However,	there	is	emerging	compelling	evidence	to	support	the	role	of	
alternative	complement	pathway	activation	in	the	development	of	AAV,	where	C5	and	factor	
B	deficient	mice	were	protected	from	NCGN	in	the	MPO-AAV	murine	model,	whereas	both	
wild-type	and	C4	deficient	mice	developed	AAV	(263).	Additionally,	treatment	with	an	anti-
C5	monoclonal	antibody	prior	to	the	administration	of	anti-MPO	IgG	in	mice	ameliorated	the	
development	of	NCGN	(264).	The	importance	of	the	complement	anaphylatoxin	C5a,	which	
is	 a	potent	neutrophil	 chemoattractant,	 has	been	demonstrated	by	 Schreiber	 et	 al	where	
ANCA-stimulated	 neutrophils	 released	 C5a,	 acting	 on	 C5a	 receptor	 (C5aR),	 which	 in	 turn	
recruited	and	primed	more	neutrophils,	resulting	in	an	amplification	loop	(265).	Importantly,	
the	 oral	 administration	 of	 a	 small	 molecule	 C5aR	 antagonist	 (CCX168,	 a.k.a	 Avacopan)	
prevented	the	development	of	NCGN	induced	by	anti-MPO	antibodies	in	the	murine	model	
of	AAV	(266).	In	humans,	C5aR	inhibition	with	Avacopan	was	shown	in	a	randomised,	placebo-
controlled	trial	(CLEAR	trial;	https://clinicaltrials.gov/ct2/show/record/NCT01363388)	to	be	
an	effective	replacement	for	high	dose	glucocorticoids	in	AAV	patients	(267).	
		
1.8 A	comparison	of	PR3-AAV	and	MPO-AAV	
Although	patients	with	GPA	and	MPA	have	historically	been	considered	as	a	single	disease	
entity	when	it	comes	to	treatment	strategies	and	enrolment	into	clinical	trials,	GPA	and	MPA	
diverge	in	several	important	aspects	as	highlighted	by	Franssen	et	al	almost	two	decades	ago	
(268),	such	as	in	the	extent	of	their	association	with	PR3	reactive	ANCAs	compared	to	MPO	
reactive	ANCAs,	 the	 association	 of	GPA	with	 granulomatous	 inflammation	 and	 the	 risk	 of	
relapse.	There	 is	 a	growing	debate	as	 to	whether	 they	are	 in	 fact	part	of	a	 single	disease	
spectrum	or	represent	distinct	clinical	entities.	Recent	GWAS	have	clearly	demonstrated	a	
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genetic	component	in	the	pathogenesis	of	AAV	and	suggested	a	distinction	between	PR3-AAV	
and	MPO-AAV,	which	questions	whether	AAV	patients	should	be	stratified	based	on	ANCA	
serotype	rather	than	by	clinical	syndrome.	That	might	not	only	help	to	reduce	selection	bias	
in	recruiting	patients	 into	clinical	 trials,	but	may	also	be	prognostically	and	therapeutically	
relevant.	 The	 major	 similarities	 and	 differences	 between	 PR3-AAV	 and	 MPO-AAV	 are	
summarised	in	Table	1.7	(269,	270).	
	
Table	1.7:	Similarities	and	differences	between	PR3-AAV	and	MPO-AAV	
Feature	 PR3-AAV	 MPO-AAV	
Epidemiology	 Northwestern	Europe	
North	America	
Southern	Europe	
Asia	
Age	at	diagnosis	 45-55	years	 60-65	years	
Pathology	 Granuloma	 Fibrosis	
Organ	involvement	 Upper	airways	
Lung	nodules	
Higher	number	of	organs	involved	
Renal	
Pulmonary	fibrosis	
Prognosis	 Higher	risk	of	relapse	 Higher	rate	of	initial	treatment	failure	
Increased	long-term	risk	of	ESKD	
Response	to	therapy	 Rituximab	>	CYC	 Rituximab	=	CYC	
Aetiology	 Staphylococcus	aureus	
Low	vitamin	D	level	
Silica	exposure	
Genetics	 HLA-DPB1,	PRTN3,	SERPINA1	 HLA-DQ	
Pathophysiology	 	 	
In	 vitro	 interaction	 of	
ANCA	with	neutrophils	
Not	different	
	
Endothelial	cells	
	
PR3	 induces	 apoptosis	 of	 endothelial	
cells	
	
MPO	 induces	 production	 of	
intracellular	oxidants	
Monocytes	 PR3-ANCA	induces	release	of	sFlt1	 MPO-ANCA	does	not	induce	release	of	
sFlt1	
	
AAV,	ANCA-associated	vasculitis;	ANCA,	anti-neutrophil	cytoplasmic	antibody;	CYC,	cyclophosphamide;	ESKD,	
end-stage	kidney	disease;	MPO,	myeloperoxidase;	PR3,	proteinase	3;	sFlt1,	soluble	fms-like	tyrosine	kinase-1.	
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1.9 Complex	genetic	diseases	and	GWAS	
Both	 genetic	 and	 environmental	 factors	 are	 thought	 to	 play	 important	 roles	 in	 the	
development	and	progression	of	autoimmunity.	A	better	understanding	of	the	genetic	basis	
of	autoimmune	diseases	has	the	potential	to	improve	therapeutic	strategies	and	prevention.	
In	the	1970s,	twin	and	family	studies	successfully	identified	the	most	important	genetic	risk	
of	autoimmune	diseases	–	the	HLA	region	(59,	271-274).	In	the	later	decades,	candidate	gene	
approach	 studies	 led	 to	 the	discovery	of	 several	 other	 significant	 risk	 loci	 in	 autoimmune	
diseases	 such	 as	NOD2	 (275,	 276),	 IL2RA	 (277,	 278),	 PTPN22	 (144)	 and	CTLA4	 (279).	 The	
genetic	landscape	subsequently	changed	tremendously	following	the	emergence	of	GWAS	in	
2006	 where	 hundreds	 and	 thousands	 of	 risk	 loci	 were	 discovered	 over	 the	 last	 decade,	
revealing	the	polygenetic	basis	of	common	diseases	and	implicating	that	both	adaptive	and	
innate	immune	systems	play	a	major	role	in	the	pathogenesis	of	many	autoimmune	diseases,	
which	 translates	 into	 new	 therapeutic	 possibilities.	 For	 example,	 GWAS	 discoveries	 have	
sparked	 drug	 repurposing	 of	 biological	 medications	 targeting	 components	 of	 the	 IL-23	
pathways	 which	 have	 now	 become	 the	 mainstay	 of	 treatments	 for	 psoriasis,	 psoriatic	
arthritis,	AS	and	inflammatory	bowel	disease	(280).	
	
1.9.1 The	GWAS	Era	
GWAS	 is	a	powerful	 tool	which	utilises	hypothesis-free	and	 rigorous	 statistical	 association	
mapping	 approaches	 to	 identify	 genetic	 variants	 that	 are	 strongly	 associated	with	 human	
traits,	predominantly	SNPs.	The	primary	goal	of	GWAS	is	to	better	understand	the	biology	of	
disease.	Advances	in	technology	have	facilitated	researchers	to	conduct	high-throughput	SNP	
analyses	in	very	large	case-control	populations	at	lower	cost.	Briefly,	a	GWAS	is	performed	by	
genotyping	a	 set	of	 tagging	SNPs	using	commercially	available	microarrays,	generally	over	
500K	SNPs	which	are	 carefully	 selected	 to	 capture	a	 sufficient	proportion	of	 the	 common	
variations	 in	 the	 genome,	 enabling	 the	 identification	 of	 loci	 associated	 with	 disease.	
Moreover,	GWAS	of	different	cohorts	can	be	combined	 into	a	meta-analysis	despite	being	
genotyped	 on	 different	 platforms,	 where	 a	 homogenous	 dataset	 can	 be	 derived	 using	
imputation	methods	such	as	IMPUTE2	(281),	MACH	(282)	or	Beagle	(283),	allowing	estimation	
of	unobserved	genotypes	using	haplotype	structures	provided	by	the	reference	panels	such	
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as	HapMap	or	the	1000	Genomes	Project	(284).	Imputation	can	thus	provide	more	uniform	
coverage	 of	 genetic	 variation	 across	 the	 genome	 without	 the	 need	 for	 resequencing	 or	
genotyping,	but	 is	 restricted	 to	 the	variants	 that	are	available	 in	 the	 reference	panel.	The	
HapMap	 reference	 set	 contains	 samples	 that	 have	 been	 genotyped	 on	 two	 different	
platforms,	the	Perlegen-Affymetrix	Human	SNP	Array	6.0	and	the	Illumina	Human	1M-single	
BeadChip.	The	data	set	consists	of	1,184	samples	from	11	populations	typed	up	to	2.5	million	
SNPs.	 In	 the	 1000	Genomes	 Project	 (phase	 3),	 the	 genomes	 of	 2,504	 individuals	 from	26	
populations	have	been	reconstructed	using	a	combination	of	 low-coverage	whole-genome	
sequencing,	deep	exome	 sequencing	and	dense	microarray	genotyping	 (285).	Overall,	 the	
existing	HapMap	and	1000	Genomes	Project	reference	panels	are	characterised	by	a	relatively	
small	sample	size	and	for	low-frequency	variants,	a	given	genotype	may	not	be	represented	
adequately	 in	 the	 reference	 data	 set.	 More	 recently,	 a	 new	 reference	 panel	 from	 the	
Haplotype	Reference	Consortium	(HRC)	has	become	available,	consisting	of	64,976	human	
haplotypes	 at	 39,235,157	 SNPs	 constructed	 using	 whole-genome	 sequence	 data	 from	 20	
studies	with	a	total	of	32,488	individuals	of	predominantly	European	ancestry.	This	permits	
more	accurate	genotype	imputation	at	minor	allele	frequencies	as	low	as	0.1%	(see	Figure	
1.2)	and	enriched	GWAS	coverage,	allowing	the	discovery	and	refinement	of	causal	loci	(286).		
	
	
Figure	1.2:	The	performance	of	imputation	using	difference	reference	panels.	
The	x-axis	shows	the	non-reference	allele	frequency	of	the	SNP	being	imputed	on	a	log	scale	while	the	y-axis	
shows	the	imputation	accuracy	measured	by	aggregate	R2	values	when	imputing	SNP	genotypes	into	ten	CEU	
(Northern	Europeans	from	Utah)	samples.	This	figure	was	adapted	from	McCarthy	et	al	(286).	
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1.9.2 The	problem	of	missing	heritability	in	GWAS	
The	heterogeneity	of	human	traits	and	diseases	in	a	population	is	the	result	of	interactions	
between	environmental	influences	and	the	associated	genetic	components.	Heritability	in	a	
broad	 sense	 refers	 to	 the	proportion	of	 the	phenotypic	 variance	due	 to	 genetic	 variance,	
which	can	be	further	divided	into	three	components:	additive	(average	effect	of	substituting	
one	allele	 for	 the	other),	dominance	 (interactions	between	alleles	at	 the	 same	 locus)	and	
epistatic	(interactions	between	alleles	at	different	loci)	genetic	effects.	Heritability	in	a	narrow	
sense	(h2)	is	defined	as	phenotypic	variance	due	to	additive	genetic	effects	(287).	Total	h2	is	
traditionally	estimated	using	offspring	and	parental	phenotypes,	siblings	or	monozygotic	and	
dizygotic	 twins.	Despite	 the	 success	 in	 identifying	SNPs	 that	affect	 the	variation	 in	human	
complex	 traits	 and	 diseases,	 GWAS	 has	 its	 own	 fundamental	 limitations	 and	 it	 has	 been	
criticised	for	being	able	to	explain	only	a	small	fraction	of	the	heritability	for	most	complex	
traits	and	diseases.	
	
Several	hypotheses	have	been	put	forward	to	explain	the	reasons	for	the	missing	heritability	
and	to	challenge	the	“common	disease,	common	variant”	hypothesis	 (288)	 that	 forms	the	
initial	basis	of	GWAS,	predicting	that	the	genetic	component	of	complex	diseases	is	the	sum	
of	the	effects	of	common	or	frequent	genetic	variants.	Much	of	the	speculation	has	focused	
on	 the	 “common	 disease,	 rare	 variant”	 hypothesis,	 which	 argues	 that	 rare	 variants	 with	
relatively	 high	 penetrance	 (289)	 are	 the	 major	 contributors	 of	 the	 genetic	 component	
explaining	the	observed	phenotypic	variation	in	the	population.	The	strongest	argument	in	
favour	 of	 the	 rare	 allele	model	 comes	 from	 evolutionary	 theory	 where	 variants	 that	 are	
deleterious	 to	 fitness	 should	 be	 selected	 against	 and	 therefore	 should	 not	 be	 common.	
Pritchard	argued	 that	 the	 selection	processes	 such	as	mutation,	 random	genetic	drift	 and	
purifying	 selection	 against	 susceptibility	 mutations	 have	 acted	 on	 the	 human	 population	
during	 its	expansion	over	the	 last	few	centuries	and	have	led	to	multiple,	very	recent	rare	
variations	 contributing	 to	 disease	 that	 are	 mildly	 deleterious	 but	 not	 subjected	 to	 overt	
negative	selection	for	a	long	time,	hence	reaching	an	appreciable	frequency	and	exhibiting	
extensive	allelic	heterogeneity	(290).	Furthermore,	several	rare	structural	variants	have	been	
identified	 to	 confer	 a	 substantial	 risk	 to	 autism,	 mental	 retardation,	 epilepsy	 and	
schizophrenia	 (172).	On	 the	 contrary,	Hunt	 et	 al	 performed	deep	exon	 sequencing	 for	 25	
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GWAS	 risk	 genes	 in	 over	 40,000	 individuals	 comprising	 of	 24,892	 patients	 with	 six	
autoimmune	diseases	and	found	that	rare	variants	within	the	coding	regions	have	negligible	
effect	in	autoimmune	disease	susceptibility	(291).	
	
Another	proposed	model	is	the	“infinitesimal	model”	where	a	large	number	of	small	effect	
common	 variants	 across	 the	 entire	 allele	 frequency	 spectrum	 contribute	 to	 the	 genetic	
component	 (287,	 292).	 A	 software	 tool	 known	 as	 GCTA	 (Genome-wide	 Complex	 Trait	
Analysis),	has	recently	been	developed	by	Yang	et	al	 to	estimate	additive	genetic	variance	
(h2SNP)	explained	by	all	the	SNPs	simultaneously	over	the	whole	genome	between	unrelated	
individuals,	fitting	them	as	random	effects	in	a	mixed	linear	model,	without	needing	to	test	
for	 association	 for	 every	 individual	 SNP	 with	 the	 trait	 (293).	 It	 consists	 of	 two	 steps:	 (i)	
generating	the	genetic	relationship	matrix	(GRM)	between	individuals,	and	(ii)	estimating	the	
variance	explained	by	all	SNPs	by	a	Restricted	Maximum	Likelihood	(REML)	analysis	of	the	
phenotypes	with	the	GRM	(294).	However,	h2SNP	is	not	the	same	as	h2	because	not	all	the	SNPs	
are	causal	variants	and	common	SNPs	in	the	genotyping	arrays	are	unlikely	to	tag	all	causal	
variants	perfectly	for	a	trait.	This	method	was	applied	to	a	number	of	traits	such	as	height	
(293),	body	mass	index	(295),	cognitive	ability	(296,	297)	and	schizophrenia	(298)	and	indeed	
a	large	proportion	of	heritability	can	be	explained	by	all	the	common	SNPs,	suggesting	that	
most	heritability	is	hidden	rather	than	missing	(299)	where	the	effects	of	these	hidden	SNPs		
are	too	small	to	reach	the	stringent	GWAS	p-value	threshold	and	hence	escape	identification	
(293).		
	
Other	proposed	models	include	the	“broad	sense	heritability	model”	which	supports	genetic	
variation	 being	 the	 result	 of	 the	 combination	 of	 genotype-by-genotype	 interactions	
(epistasis),	genotype-by-environment	interactions	and	epigenetic	effects	(300,	301)	and	the	
“threshold	dependent	model”	which	posits	 that	 complex	disease	 is	more	 likely	 to	arise	 in	
individuals	who	have	extreme	values	of	multiple	intermediate	phenotypes	that	are	involved	
in	 the	 disease	 pathogenesis	 and	 often,	 each	 of	 these	 intermediate	 phenotypes	 has	 a	
component	 of	 genetic	 inheritance	 that	might	 not	 be	 detectable	 at	 the	 level	 of	 the	main	
complex	trait	(302).	The	missing	heritability	could	be	at	least	partly	attributed	to	the	sum	of	
the	 heritability	 of	 each	 of	 these	 intermediate	 phenotypes.	 The	 concept	 of	 “mediated	
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pleiotropy”	was	then	coined	by	Solovieff	et	al	to	describe	a	genetic	variant	that	is	linked	to	a	
complex	 phenotype	 because	 the	 genetic	 variant	 is	 associated	 with	 an	 intermediate	
phenotype	that	in	turn	is	causally	related	with	the	outcome	complex	phenotype	(303).	This	is	
different	from	the	concept	of	“biological	pleiotropy”	where	one	or	more	genetic	variants	are	
associated	with	two	unrelated	phenotypes.	In	recent	years,	a	new	statistical	strategy	known	
as	Mendelian	randomisation	(MR)	has	been	developed	to	 identify	causal	association	of	an	
intermediate	 phenotype	 with	 an	 outcome,	 by	 using	 the	 SNPs	 associated	 with	 the	
intermediate	phenotype.	An	example	of	successful	application	of	MR	analysis	in	autoimmune	
diseases	 is	 the	 link	 between	 vitamin	 D	 and	 multiple	 sclerosis	 (MS),	 with	 two	 studies	
demonstrating	that	decreased	levels	of	vitamin	D	are	causally	associated	with	an	increased	
risk	of	MS,	supporting	the	epidemiological	observation	(304,	305).	
	
Ultimately,	the	components	of	missing	heritability	remain	unknown	and	might	probably	be	
attributed	to	a	combination	effect	of	all	the	proposed	explanations	as	discussed	above	(306).	
	
1.9.3 The	challenge	from	GWAS	to	biology	
Since	a	majority	of	the	identified	SNPs	do	not	affect	protein	coding	sequences	of	genes,	one	
major	 obstacle	 in	 the	 post-GWAS	 era	 is	 to	 identify	 the	 causal	 gene(s)	 or	 non-coding	
ribonucleic	acids	(RNAs)	in	an	unbiased	and	structured	manner	as	well	as	the	pathways	via	
which	the	causal	variants	exerting	their	biological	effects	on	altering	the	disease	risk.	There	is	
temptation	to	label	the	gene	nearest	to	the	variant	with	the	smallest	p-value	(the	lead	“SNP”)	
as	 the	 most	 likely	 causal	 gene	 but	 the	 physical	 distance	 of	 a	 variant	 to	 a	 gene	 is	 not	 a	
compelling	evidence	of	causality.	With	the	availability	of	big	data	derived	from	large	consortia	
and	 cohorts,	 advanced	 molecular	 technologies	 including	 single-cell	 genomics	 and	 new	
computational	 and	 statistical	 methods,	 a	 transformative	 era	 has	 begun	 to	 provide	
opportunities	to	bridge	this	existing	knowledge	gap.	This	process	can	be	broadly	divided	into	
two	main	stages:	(i)	fine	mapping	of	candidate	causal	variants	and	(ii)	 linking	the	potential	
variants	 to	 likely	 genes	 whose	 perturbation	 leads	 to	 altered	 disease	 susceptibility	 by	
functional	annotation	(Figure	1.3).	
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Figure	1.3:	A	generalised	fine-mapping	pipeline.	
This	figure	depicts	the	common	steps	to	progress	from	the	discovery	of	associated	variants	to	the	identification	
of	the	potential	causal	genes	and	pathways.	This	figure	was	adapted	from	Spain	et	al	(307).		
	
Several	statistical	methods	have	been	developed	for	the	prioritization	of	causal	variants	to	
explain	association	signals.	One	crucial	assumption	when	evaluating	the	relative	evidence	of	
each	associated	SNPs	being	the	causal	is	that	the	true	causal	SNP	is	being	considered	too.	A	
simple	 approach	 is	 to	 consider	 all	 SNPs	with	 a	 p-value	 less	 than	 a	 certain	 threshold	 (e.g.	
standard	genome-wide	significant	threshold	of	5	x	10-8),	as	candidates	for	causality.	This	is	
hardly	sensible	as	p-values	are	influenced	by	study-specific	factors	such	as	power,	which	is	in	
turn	 determined	 by	 sample	 size	 and	 locus-specific	 factors	 such	 as	minor	 allele	 frequency	
(MAF)	and	effect	size.	Therefore,	such	a	threshold	is	not	directly	comparable	between	studies.	
A	 slightly	 more	 sophisticated	 method	 involves	 considering	 all	 SNPs	 above	 a	 certain	 LD	
threshold	with	the	lead	SNP	as	potential	causal.	Although	this	is	less	arbitrary	than	p-value	
thresholds,	 it	 still	 ignores	 the	 properties	 of	 the	 dataset.	 An	 alternative	 approach	 is	 the	
Bayesian	method	that	 takes	account	of	 the	power	of	 the	dataset	at	 the	cost	of	additional	
modelling	assumptions	and	assigns	posterior	probabilities	of	causality	to	each	SNP	that	are	
comparable	across	different	studies	(308).	The	resolution	of	fine	mapping	at	a	locus	can	then	
be	assessed	by	constructing	a	“credible	set’	of	variants	that	are	most	likely	to	be	causal	and	
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be	prioritised	for	further	investigation	and	functional	validation.	A	further	refinement	of	the	
resolution	of	fine	mapping	could	be	achieved	by	performing	trans-ethnic	meta-analysis	which	
harnesses	 the	 different	 LD	 structures	 from	 ethnically	 diverse	 populations.	 For	 example,	 a	
genome-wide	trans-ancestry	meta-analysis	was	performed	using	MANTRA	in	type	2	diabetes	
comprising	 of	 26,488	 cases	 and	 83,964	 controls	 from	 European,	 east	 Asian,	 south	 Asian,	
Mexican	 and	 Mexican	 American	 ancestry,	 demonstrating	 considerable	 improvements	 in	
refining	 the	 association	 signals	 in	 several	 susceptibility	 loci	 –	 the	 greatest	 change	 was	
observed	at	 the	 JAZF1	 locus	where	 the	credible	set	was	reduced	to	only	 four	SNPs	with	a	
genomic	interval	of	16kb	(309).	
	
Although	protein	coding	variants	are	easier	 to	build	a	case	 for	prioritisation	and	to	design	
experiments	to	investigate	the	functional	consequences,	they	only	account	for	a	very	small	
fraction	 of	 GWAS	 hits.	 Several	 large	 efforts	 such	 as	 the	 ENCODE	 (Encyclopedia	 of	 DNA	
Elements)	 (310),	 BLUEPRINT	 (311),	 ROADMAP	 (312)	 and	 FANTOM	 (313)	 consortia	 have	
greatly	 transformed	 our	 understanding	 of	 the	 roles	 of	 the	 noncoding	 genome	 and	 the	
mechanisms	underpinning	variation	in	gene	expression	in	various	cell	types,	by	facilitating	the	
functional	 annotation	 of	 the	 genome	 including	 mapping	 of	 post-translational	 histone	
modifications,	 transcription	 factor	 binding	 sites,	 CpG	 methylation	 and	 areas	 of	 open	
chromatin.	 A	 landmark	 study	 by	 Maurano	 et	 al	 demonstrated	 that	 there	 is	 a	 significant	
enrichment	of	disease-	and	traits-associated	noncoding	genome-wide	significant	variants	in	
the	regulatory	DNA	region	marked	by	deoxyribonuclease	I	hypersensitive	sites,	that	can	alter	
chromatin	accessibility	and	transcription	factor	recognition	sequences	which	may	explain	the	
phenotype	associations	(314).	Subsequent	studies	identified	the	enrichment	of	autoimmune	
disease	 associated	 SNP	 in	 the	 super-enhancers,	 which	 are	 defined	 by	 large	 clusters	 of	
transcriptional	 enhancers	 that	 regulate	 spatiotemporal	 gene	 expression	 and	 define	 cell	
identity	 (315,	 316).	 Other	 public	 data	 resources	 such	 as	 the	 Genotype-Tissue	 Expression	
(GTEx)	project	(317)	and	whole	blood	analyses	(http://www.eqtlgen.org/cis-eqtls.html)	have	
been	 extremely	 useful	 in	 generating	 and	 compiling	 the	 expression	 quantitative	 trait	 loci	
(eQTL)	 data	 for	 a	 large	 of	 cohort	 of	 individuals	 in	 multiple	 tissues	 under	 many	 different	
conditions	(318).	However,	the	challenge	remains	in	autoimmune	diseases	whereby	there	is	
paucity	 of	 eQTL	 studies	 in	 purified	 immune	 cell	 types.	 Recent	 advances	 in	 proteomic	
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technologies	 has	 offered	 another	 wealth	 of	 genetic	 associations	 with	 plasma	 protein	
abundance	data	(pQTLs)	(319).	In	addition,	the	development	of	chromosome-conformation-
capture	techniques	to	determine	the	3-dimensional	structure	of	chromatin	has	facilitated	the	
identification	of	long-range	interactions	between	the	regulatory	elements	containing	disease	
associated	 SNPs	 and	 the	 promoters	 of	 target	 genes,	 thus	 activating	 or	 repressing	
transcription,	 depending	 on	 the	 nature	 of	 the	 regulatory	 elements	 such	 as	 enhancers,	
insulators	or	silencers	(Figure	1.4)	(320).	The	important	role	of	distal	enhancer	in	regulating	
lineage-specific	gene	expression	has	been	confirmed	by	Javierre	and	colleagues	through	the	
identification	of	networks	of	interaction	in	17	human	primary	haematopoietic	cell	types	(321).	
Data	 obtained	with	 these	 technologies	 have	markedly	 improved	our	 knowledge	of	 the	 3-
dimensional	architecture	of	the	genome	and	their	implications	on	human	disease.		
	
	
Figure	1.4:	The	3-dimensional	structure	of	chromatin.	
The	formation	of	DNA	loops	mediated	by	genome	organising	complexes	(as	indicated	in	purple)	can	modulate	
gene	expression.	(A)	A	regulatory	element	(RE),	such	as	an	enhancer,	 interacts	with	the	promoter	of	gene	Y,	
resulting	in	an	increased	expression	of	gene	Y	following	the	binding	of	transcription	factors	while	in	(B)	the	RE	
confers	a	repressive	activity,	either	by	DNA	methylation	of	the	promoter	of	gene	Y	as	indicated	by	yellow	circles	
or	chromatin	remodelling	proteins	that	promote	repressive	histone	modifications	as	indicated	by	red	hexagons.	
This	figure	was	adapted	from	Ray	G	et	al	(322).	
	
Taken	 all	 together,	 these	 approaches	 complement	 the	 statistical	 methods.	 Each	 disease-
related	region	in	the	genome	can	be	fine	mapped	to	obtain	a	credible	set	of	causal	variants.	
The	most	 likely	cell	 type	driving	the	association	can	be	 identified	by	determining	which	of	
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these	SNPs	lie	in	the	functional	region	of	a	particular	cell	type	and	the	most	likely	genes	that	
are	 being	 regulated	 can	 then	 be	 determined	 through	 eQTL	 and	 3-dimensional	 chromatin	
contact.	Ultimately,	a	better	understanding	of	the	genetic	basis	of	the	biological	pathways	
and	processes	underlying	the	aetiology	of	autoimmune	diseases	has	the	potential	to	improve	
the	success	rate	and	safety	of	medical	therapies	development.		
	
1.10 Aim	and	objectives	
Previous	GWAS	have	provided	evidence	that	PR3-AAV	and	MPO-AAV	are	genetically	distinct	
autoimmune	syndromes,	although	not	conclusive	as	only	three	loci	specific	to	PR3-AAV	(HLA-
DP,	SERPINA1	and	PRTN3)	and	one	to	MPO-AAV	(HLA-DQ)	were	identified.	The	aim	of	this	
study	was	to	perform	a	larger	GWAS	to	uncover	more	disease	specific	genetic	susceptibility	
loci	associated	with	AAV.	Specifically,	the	objectives	were	as	follows:	
	
I. To	perform	a	larger	GWAS	powered	to	examine	PR3-AAV	independently;		
	
II. To	perform	a	larger	GWAS	powered	to	examine	MPO-AAV	independently;	
	
III. To	validate	the	top	hit(s)	by	performing	a	meta-analysis	of	combined	samples;	
	
IV. To	investigate	the	genetic	relationship	between	PR3-AAV	and	MPO-AAV;	
	
V. To	elucidate	the	possible	functional	underpinnings	of	the	validated	top	hit(s).	
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2 Materials	and	Methods	
2.1 Genome-wide	association	study	
2.1.1 Contributions	
The	 study	 design	was	 conceived	 by	 the	 European	 Vasculitis	 Genetics	 Consortium	 (EVGC).	
Cases	 and	 controls	 were	 ascertained	 through	 the	 EVGC,	 Wellcome	 Trust	 Case	 Control	
Consortium	 (WTCCC)	 and	 the	 European	 Prospective	 Investigation	 of	 Cancer	 Consortium,	
Norfolk	(EPIC).	Genotyping	was	performed	at	various	centres	described	in	section	2.1.4.	The	
genotype	calling	and	quality	control	(QC)	were	performed	by	Drs	Tim	F	Rayner	and	Richard	
Coulson.	The	HLA	imputation	was	performed	by	Dr	Stephen	Leslie	(University	of	Melbourne,	
Australia).	All	other	analyses	were	performed	by	myself.	
	
2.1.2 Inclusion	criteria	and	study	subjects	
Case	patients	had	a	clinical	diagnosis	of	either	GPA	or	MPA	according	to	the	EMEA	algorithm,	
supported	by	either	a	positive	ANCA	assay	or	a	diagnostic	biopsy	with	c-ANCA	or	p-ANCA.	The	
important	issue	of	diagnostic	criteria	was	previously	discussed	in	the	supplementary	note	of	
Lyons	et	al	(70).		
	
I	 included	subjects	 from	two	European	ancestry	cohorts	as	described	 in	Table	2.1.	Briefly,	
GWAS1	was	the	discovery	cohort	from	Lyons	et	al	with	control	data	from	the	WTCCC.	The	
summary	 of	 patient	 demographics,	 clinical	 data	 and	 QC	 outcomes	 has	 been	 previously	
described	(Table	S4,	Lyons	et	al)	(70).	GWAS2	was	a	newly	recruited	cohort	consisting	of	1,763	
cases	from	66	centres	in	12	different	European	countries.	Following	QC,	1,738	remained	and	
of	these,	606	(34.9%)	were	MPO-ANCA	positive	and	1,132	(65.1%)	were	PR3-ANCA	positive.	
Genotype	data	for	6,000	UK	controls	was	obtained	from	the	EPIC	consortium	(323).	A	total	of	
5,465	 individuals	 remained	 following	QC.	We	also	 recruited	and	genotyped	1,223	controls	
from	6	European	countries.	The	breakdown	of	the	GWAS2	cohort	is	shown	in	Table	2.2.	Lastly,	
for	rs6679677	(PTPN22),	another	cohort	was	included	where	the	genotyping	was	previously	
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performed	 using	 the	 Sequenom	 MassARRAY	 platform.	 The	 study	 was	 approved	 by	 the	
institutional	 review	 board	 from	 each	 participating	 centre	 respectively	 and	 all	 individuals	
provided	written	informed	consent.	
	
Table	2.1:	Description	of	the	cohorts	included	in	the	meta-analysis		
Meta-analysis	 Cohort	 Genotyping	platform	 ‡Cases	 ‡Controls	
Stage	1	 †GWAS1	 Affymetrix	SNP6	 914	 5,259	
§GWAS2	 UK	Biobank	Axiom	array	 1,738	 6,688	
Stage	2	 *rs6679677	 Sequenom	MassARRAY	 1,550	 1,531	
	
†GWAS1	was	the	discovery	cohort	from	Lyons	et	al	(70),	of	which	478	were	PR3+,	278	were	MPO+	and	the	ANCA	
status	for	the	remaining	cases	were	unknown.	
§GWAS2	was	the	newly	recruited	cohort,	consisting	of	1,132	PR3+	and	606	MPO+	cases.		
*The	genotyping	for	rs6679677	was	performed	using	iPLEX	assays	on	the	Sequenom	MassARRAY	platform.	This	
cohort	was	part	of	the	replication	cohort	used	in	the	Lyons	et	al,	of	which	1,122	were	PR3+,	347	were	MPO+	and	
the	ANCA	status	for	the	remaining	cases	were	unknown.	
‡The	number	of	cases	and	controls	provided	here	were	those	post	QC.	
	
Table	2.2:	Breakdown	of	1,738	cases	and	6,688	controls	by	country	for	GWAS2	
Country	 Cases	 Controls	
Australia	 46	 0	
Austria	 40	 0	
Czech	Republic	 134	 130	
Denmark	 76	 0	
France	 228	 0	
Germany	 140	 273	
Italy	 145	 266	
Poland	 60	 118	
Spain	 10	 93	
Sweden	 261	 343	
United	Kingdom	and	Republic	of	Ireland	 598	 5,465	(EPIC)	
Total	 1,738	 6,688	
	
EPIC,	the	European	Prospective	Investigation	into	Cancer	consortium	(323).	
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2.1.3 Power	calculation	
Based	 on	 the	 sample	 size	 described	 in	 Table	 2.1,	 power	 calculation	was	 performed	 using	
Quanto	(software	by	USC	Biostats).	For	a	MAF	of	0.05,	we	had ≥ 80%	power	to	detect	genome-
wide	significant	(p	<	5	x	10-8)	SNPs	with	expected	ORs	of	≥	1.60	for	PR3-AAV	(see	Figure	2.1A).	
However,	we	had	less	power	to	detect	genome-wide	significant	SNPs	with	MAF	of	0.01,	where	
the	expected	OR	was	increased	to	≥	2.45.	Similarly,	we	had	≥	80%	power	to	detect	genome-
wide	significant	SNPs	with	expected	ORs	≥	1.83	and	3.0	 for	SNPs	with	MAF	0.05	and	0.01	
respectively	for	MPO-AAV	(see	Figure	2.1B).	
	
	
Figure	2.1:	Power	curves	for	the	individual	subset	analyses.	
Power	curves	are	shown	for	both	(A)	PR3-AAV	and	(B)	MPO-AAV	cohorts.	Power	was	calculated	for	various	effect	
sizes	assuming	a	minor	allele	frequency	of	1%	and	5%	with	an	alpha	value	of	5	x	10-8.	
	
2.1.4 Genotyping	and	quality	control	of	genotype	data	
Briefly,	for	GWAS1,	the	genotyping,	calling	and	data	QC	were	described	in	the	supplementary	
appendix	by	Lyons	et	al	(70).	The	genotyping	was	performed	by	AROS	Applied	Biotechnology	
(Aarhus,	Denmark)	using	the	Affymetrix	SNP6	platform,	consisting	of	934,968	SNPs,	of	which	
612,676	 passed	 QC	 analysis.	 In	 addition,	 four	 SNPs	 were	 genotyped	 using	 TaqMan	 SNP	
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genotyping	 assays	 (Applied	 Biosystems)	 and	 these	 included	 rs28929474	 and	 rs17580	
(SERPINA1),	rs5000634	(HLA-DQ)	and	rs62132296	(PRTN3).	
	
For	GWAS2,	genomic	DNA	was	extracted	from	whole	blood	using	magnetic	bead	technologies	
at	the	Centre	for	Integrated	Genomic	Medical	Research	(Manchester,	UK)	according	to	the	
manufacturer’s	instructions.	Both	cases	and	controls	were	genotyped	using	the	Affymetrix	UK	
Biobank	Axiom	array	according	to	the	manufacturer’s	protocol.	Genotyping	of	cases	and	non-
UK	 controls	was	 performed	 by	 AROS	Applied	 Biotechnology	 (Aarhus,	 Denmark)	while	 the	
genotyping	of	UK	controls	was	performed	by	 the	EPIC-Norfolk	consortium	using	 the	same	
array.	
	
The	UK	Biobank	Affymetrix	Axiom	array	is	a	customised	genotyping	array	comprising	820,967	
SNPs	and	short	insertions/deletions.	The	array	includes	the	“exome”	component,	which	were	
designed	to	capture	variants	likely	to	have	transcriptional	consequences	including	missense,	
splice	altering	and	truncating	and	a	good	genome-wide	coverage	in	European	populations	to	
ensure	 downstream	 good	 quality	 genome-wide	 imputation	 of	 variants	 that	 are	 common	
(MAF	>	5%)	or	low-frequency	(MAF	=	1-5%).	The	exome	component	includes	over	130,000	
predominantly	rare	variants	and	was	designed	using	data	from	three	large	exome	sequencing	
projects:	 the	 NHLBI	 Exome	 Sequencing	 Project	 (ESP)	 (324),	 the	 Exome	 Aggregation	
Consortium	(ExAC)	(325)	and	the	UK10K	non-Finnish	project	(326).	Additional	rare	variants	
were	included	in	cardiac	disease	and	cancer	predisposition	genes,	as	well	as	other	variants	
from	 the	 Human	 Gene	 Mutation	 Database	 (HGMD)	 (327).	 The	 genome-wide	 imputation	
scaffold	was	designed	by	selecting	tagging	variants	from	Affymetrix	databases	using	a	custom	
algorithm	(328).	The	mean	R2	between	observed	and	imputed	genotypes	for	common	variants	
was	estimated	to	be	0.92,	while	for	low-frequency	variants	was	0.79.	The	remaining	content	
on	 the	 array	 includes	 markers	 that	 are	 disease	 specific,	 including	 markers	 related	 to	
Alzheimer’s,	 autoimmune	 and	 inflammatory,	 blood	phenotypes,	 cancers,	 cardiometabolic,	
neurological	disease	as	well	as	dense	coverage	of	selected	genomic	regions	such	as	ApoE,	
HLA,	killer-cell	immunoglobulin-like	receptor,	Y	chromosome	and	mitochondria.	Of	particular	
relevance	 to	 this	 study,	 the	 array	 includes	 258	 variants	 related	 to	 autoimmune	 and	
inflammatory	diseases	and	2,545	variants	related	to	blood	phenotypes.	
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For	 GWAS2,	 genotype	 calling	 was	 performed	 using	 the	 Affymetrix	 Powertools	 software.	
Calling	was	performed	in	batches	of	contemporaneously	run	plates	as	per	the	manufacturer’s	
protocol.	After	genotype	calling,	 SNP	data	was	processed	 in	 the	 following	 sequence	using	
PLINK	v1.9	(329).	Samples	with	proportion	of	missing	SNPs	>	5%,	sex	mismatch	or	abnormal	
heterozygosity	were	removed.	SNPs	with	a	genotyping	call	rate	<	98%,	deviation	from	Hardy-
Weinberg	Equilibrium	 (p	<	1	 x	10-6)	or	monomorphic	were	 removed.	The	QC	process	was	
performed	 separately	 for	 each	 batch.	 The	 post-QC	 genotype	 data	 from	 each	 batch	 was	
subsequently	merged.	Duplicated	or	related	samples	(identified	using	Identity	by	State)	were	
removed	and	the	SNP	QC	was	performed	again	so	that	SNPs	with	a	genotype	call	rate	<	98%	
or	 deviation	 from	 Hardy-Weinberg	 Equilibrium	 (p	 <	 1	 x	 10-6)	 in	 the	 combined	 data	 were	
excluded.	SNPs	that	showed	significant	differential	missingness	(p	<	1.0	x	10-5)	between	cases	
and	 controls	 were	 removed.	 Finally,	 principal	 component	 analysis	 (PCA)	 of	 the	 post-QC	
genotype	calls	together	with	the	1000	Genome	individuals	was	performed.	The	means	and	
standard	deviations	of	PC1	and	PC2	were	calculated	for	the	EUR	subset	of	the	1000	Genomes	
samples.	Cases	or	controls	which	were	outside	of	±	3	standard	deviations	from	the	mean	on	
either	PC1	or	PC2	were	removed.	Following	these	QC	steps,	1,738	cases	and	6,688	controls	
remained	with	a	total	of	557,075	autosomal	SNPs	(see	Figure	2.2).	
	
	
Figure	2.2:	Principal	component	analysis	(PCA)	of	genotype	data.	
PCA	plots	show	ancestry	of	AAV	cases	and	controls	in	(A)	GWAS1	and	(B)	GWAS2	in	relation	to	the	1000	Genomes	
Project	individuals.	The	legend	details	the	ethnic	origin	of	samples	included	in	the	PCA.	AFR,	African;	AMR,	ad	
mixed	African;	EAS,	East	Asian;	SAS,	South	East	Asian	and	EUR,	European.	
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2.1.5 Association	testing	on	the	directly	genotyped	data	
Case-control	association	testing	on	the	directly	genotyped	autosomal	SNPs	was	performed	
using	logistic	regression	with	PLINK	v1.9.	Principal	components	(PCs)	were	calculated	using	
plink	 --pca	 containing	 both	 cases	 and	 controls	 and	 included	 as	 covariates	 to	 adjust	 for	
potential	 confounding	 and	 population	 substructures.	 Although	 this	 traditional	 genomic	
control	approach	(330)	carries	a	small	risk	of	masking	true	disease	associations,	it	is	a	more	
appropriate	 test	 given	 (i)	 the	 UK	 controls	 were	 genotyped	 in	 a	 different	 facility	 thereby	
potentially	 leading	 to	 confounding	 from	 a	 batch	 effect	 and	 (ii)	 French	 controls	 were	 not	
included	in	GWAS2.	I	also	tested	the	effect	of	using	increasing	numbers	of	PCs	as	covariates	
on	the	genomic	inflation	factor	(lambda,	λ)	which	is	the	ratio	of	the	median	of	the	observed	
chi-squared	 statistics	 to	 the	median	 of	 the	 expected	 chi-squared	 statistics	 under	 the	 null	
hypothesis.	There	was	minimal	inflation	with	a	lambda	of	1.03	for	GWAS1,	with	no	benefit	of	
including	further	PCs.	In	GWAS2,	the	lambda	was	reduced	from	1.31	to	1.15	using	the	first	20	
PCs	as	covariates.	
	
2.1.6 Association	testing	using	a	linear	mixed	model	
As	an	alternative	analysis	approach,	a	linear	mixed	model	(LMM)	was	employed	to	perform	
case-control	association	testing.	This	method	compares	the	deviation	of	each	individual	from	
the	population	mean	at	each	variant	 in	 the	data	set	and	compares	 individuals	pairwise	 to	
establish	 a	 value	 for	 overall	 genetic	 similarity.	 This	 value	 will	 then	 be	 used	 as	 a	 random	
variable	in	a	mixed	linear	regression	which	could	capture	population	variance	at	a	finer	scale	
level	than	principal	component	analysis	(331).	The	association	testing	was	carried	out	using	
the	BOLT-LMM	software	v2.3.2	(332,	333).	Although	the	mathematical	derivations	underlying	
BOLT-LMM	are	based	on	a	quantitative	trait	model,	it	can	be	applied	to	analyse	case-control	
traits	 simply	by	 treating	 the	binary	 trait	 as	a	quantitative	 trait	with	 the	 caveat	 that	 it	 can	
become	miscalibrated	for	unbalanced	case-control	traits	resulting	in	false	positive	association	
at	 rare	 SNPs.	 Moreover,	 a	 transformation	 of	 the	 effect	 size	 estimates	 (beta,	 b)	 on	 a	
quantitative	 scale	 to	 traditional	ORs	 is	 required,	using	 the	 formula	 log	OR	=	b	 /	 (µ*(1-µ)),	
where	µ	=	case	fraction.	Similarly,	the	standard	error	(SE)	of	SNP	effect	sizes	should	also	be	
divided	by	(µ*(1-µ))	when	applying	the	transformation	to	obtain	log	ORs.	
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2.1.7 Pre-phasing	and	imputation	
Pre-phasing	is	a	process	of	identifying	alleles	colocalised	on	the	same	strand	and	estimating	
the	haplotypes	of	GWAS	samples.	The	current	recommendation	is	that	GWAS	samples	should	
first	 be	 pre-phased	 using	 the	most	 accurate	methods	 available	 such	 that	 the	 subsequent	
imputation	step,	which	involves	imputing	alleles	from	one	set	of	haplotypes	into	another	set,	
will	be	more	accurate	and	computationally	efficient.	As	new	haplotype	reference	sets	become	
available,	imputation	can	be	repeated	more	rapidly	(281).	Imputation	was	performed	on	the	
Michigan	 Imputation	Server	v1.0.3	 that	 facilitates	access	 to	the	HRC	reference	panel	 (HRC	
release	 version	 1.1	 April	 2016,	 consisting	 of	 64,940	 haplotypes,	 32,470	 samples	 of	
predominantly	European	ancestry)	(286,	334).	Several	steps	were	executed	including	variant	
call	format	(VCF)	file	check,	QC	(where	population	EUR	was	selected	for	the	allele	frequency	
check),	pre-phasing	using	Eagle2	(335)	and	lastly	imputation	was	performed	using	minimac3.	
	
2.1.8 Post-imputation	quality	control	
Over	39	million	variants	were	generated	following	imputation	and	therefore	QC	is	paramount	
to	create	high	quality	data	for	downstream	analyses.	QC	was	performed	with	BCFtools	version	
1.2	using	HTSlib	1.2.1,	which	is	a	program	for	variant	calling	and	manipulating	VCF	files.	SNPs	
with	MAF	<	0.01	(1	in	100),	R2	<	0.3	or	which	were	monomorphic	were	removed	(336).	R2	is	a	
variance	 ratio,	being	 calculated	as	 the	proportion	of	 the	observed	dosage	variance	 to	 the	
expected	dosage	variance,	given	observed	allele	frequency.	Higher	values	of	R2	indicate	more	
accurate	genotype	imputation.	Table	2.3	shows	the	total	counts	of	SNPs	at	each	chromosome	
after	applying	the	imputation	quality	and	variant	frequency	filters	for	both	the	GWAS1	and	
GWAS2	datasets.	
	
2.1.9 Association	testing	following	imputation	
Association	testing	on	the	imputed	data	was	carried	out	using	the	SNPTEST	v2.5.2	software	
with	an	additive	genetic	model	(option	‘--frequentist	1’),	with	the	first	20	PCs	as	covariates	to	
adjust	 for	 population	 stratification.	Uncertainty	 in	 the	 imputed	 genotypes	was	 taken	 into	
account	in	the	association	testing	by	using	a	missing	data	likelihood	score	test.	In	addition,	
association	testing	was	performed	using	a	LMM	with	the	BOLT-LMM	software	(332,	333).	
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Table	2.3:	SNP	summary	for	samples	from	GWAS1	and	GWAS2	
	 GWAS1	 GWAS2	
Chromosome	 Imputation	output	 Filter	at	R2	0.3	 Imputation	output	 Filter	at	R2	0.3	
1	 3,069,931	 587,094	 3,069,931	 593,584	
2	 3,392,237	 644,689	 3,392,237	 650,354	
3	 2,821,894	 548,655	 2,821,894	 551,007	
4	 2,787,581	 559,243	 2,787,581	 563,826	
5	 2,588,168	 500,249	 2,588,168	 502,202	
6	 2,460,111	 510,367	 2,460,111	 515,160	
7	 2,289,305	 447,339	 2,289,305	 453,673	
8	 2,242,705	 428,952	 2,242,705	 432,423	
9	 1,675,898	 328,463	 1,686,471	 333,220	
10	 1,927,503	 390,344	 1,927,503	 393,635	
11	 1,936,990	 381,881	 1,936,990	 385,876	
12	 1,848,117	 369,942	 1,848,117	 372,997	
13	 1,385,433	 286,914	 1,385,433	 288,391	
14	 1,266,536	 251,658	 1,270,436	 255,973	
15	 1,139,215	 218,634	 1,139,215	 220,353	
16	 1,281,297	 233,729	 1,281,297	 239,615	
17	 1,090,072	 199,069	 1,090,072	 204,325	
18	 1,104,755	 222,763	 1,104,755	 223,483	
19	 868,554	 160,528	 868,554	 174,381	
20	 884,983	 174,108	 884,983	 175,283	
21	 531,276	 106,992	 531,276	 108,140	
22	 524,544	 104,963	 524,544	 106,633	
Totals	 39,117,105	 7,656,576	 39,131,578	 7,744,534	
	
“Imputation	output”	 lists	number	of	SNPs	as	result	of	 imputation	and	“Filter	at	R2	0.3”	 lists	number	of	SNPs	
passing	the	filtering	criteria:	MAF	³	0.01	and	R2	³	0.3.	
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2.1.10 Meta-analysis	
The	results	of	the	two	cohorts	(GWAS1	and	GWAS2)	were	meta-analysed	using	the	META	v1.7	
software	with	an	inverse-variance	method	based	on	a	fixed-effects	model	(option	‘--method	
1’).	Figure	2.3	provides	an	overview	of	the	study	design	for	GWAS	of	AAV.	
	
	
Figure	2.3:	An	overview	of	the	study	design	for	GWAS	of	AAV.	
The	phenotypes	and	their	classification	based	on	ANCA	serotype,	the	study	sample	size	and	a	summary	of	the	
data	analysis	methods	employed	to	identify	the	disease-associated	risk	loci.	
	
2.1.11 HLA	imputation	and	association	analysis	
The	HLA	imputation	was	performed	in	the	GWAS2	dataset.	Two	thousand	seven	hundred	and	
seventy-seven	SNPs,	343	classical	HLA	alleles	to	2-	or	4-	digit	resolution	and	1,092	amino	acid	
variants	were	imputed	at	8	HLA	loci	(HLA-A,	HLA-B,	HLA-C,	HLA-DRB1,	HLA-DQA1,	HLA-DQB1,	
HLA-DPA1	 and	 HLA-DPB1)	 from	 phased	 genotype	 data	 using	 the	 HLA*IMP:03	 software	
(https://www.biorxiv.org/content/10.1101/091009v1)	 (337).	 Association	 testing	 for	 HLA	
variants	was	performed	using	a	LMM	with	the	BOLT-LMM	software	to	adjust	for	population	
structure.	
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2.1.12 Heritability	explained	
A	LMM	method	was	applied	for	estimating	the	whole-genome	SNP-based	heritability	(h2SNP)	
using	both	common	and	low-frequency	variants,	which	is	implemented	in	the	GCTA	software	
(294).	The	top	20	ancestry	PCs	derived	from	the	GRM	across	the	same	data	set	obtained	using	
GCTA	 (option	 ‘--pca	 20’)	 were	 included	 as	 covariates	 in	 the	 model	 when	 estimating	 the	
genetic	variance	explained	by	all	the	SNPs	on	the	observed	scale.	As	the	studied	phenotypes	
were	 dichotomous	 traits,	 these	 results	 were	 transformed	 to	 the	 liability	 scale	 based	 on	
approximately	observed	disease	prevalence	from	the	literature	(assuming	disease	prevalence	
of	130/million	for	GPA	and	50/million	for	MPA)	(338).	Note	that	only	data	from	cases	and	
controls	that	were	unrelated	in	the	classical	sense	(‘--grm-cutoff	0.05’,	that	is	relatedness	<	
0.05,	equivalent	to	about	second-cousins)	were	included	in	the	analysis.	Therefore,	the	total	
control	 sample	 size	utilised	varied	 slightly	 from	 the	association	 testing.	Given	 that	 the	UK	
Axiom	Biobank	array	has	a	more	comprehensive	genome	coverage	than	the	SNP6	platform	
(especially	for	SNPs	with	MAF	range	from	0.01	to	0.10)	and	thus	better	at	tagging	the	causal	
variants,	the	SNP	heritability	analysis	was	carried	out	using	the	GWAS2	genotype	data.	Note,	
GCTA	implicitly	assumes	all	classes	of	SNPs	(rare,	low-frequency	or	common)	have	the	same	
effect	on	average.	However,	 rare	and	newer	variants	 tend	 to	have	a	 larger	effect	 as	 they	
represent	mutation	load	being	purged	by	negative	selection.	Rare	variants	(MAF	<	0.01)	were	
not	included	in	the	heritability	estimation	and	hence	this	might	bias	GCTA	estimates	towards	
underestimating	heritability.	
	
2.1.13 Genetic	correlation	between	PR3-AAV	and	MPO-AAV	
The	proportion	of	genetic	variation	as	tagged	by	common	genome-wide	SNPs	that	is	shared	
between	 PR3-AAV	 and	 MPO-AAV	 was	 estimated	 using	 the	 bivariate	 linear	 mixed-effects	
model	implemented	in	GCTA	(339).	This	method	uses	genome-wide	SNPs	to	estimate	genetic	
similarities	 between	 pairs	 of	 individuals,	 and	 uses	 bivariate	 REML	 to	 estimate	 covariance	
components	(rG)	of	the	linear	mixed	model.	The	genetic	correlation	analysis	was	performed	
using	the	GWAS2	genotype	data	for	the	reasons	as	discussed	in	section	2.1.12.	Given	that	the	
control	samples	were	completely	overlapped	between	PR3-AAV	and	MPO-AAV,	the	control	
samples	were	randomly	allocated	to	each	group	in	1:1	ratio	and	the	first	20	PCs	were	fitted	
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as	covariates.	The	random	allocation	process	was	repeated	for	n	=	100	and	the	median	rG	was	
obtained.	
	
2.1.14 Haplotype	block	estimation	
Millions	 of	 genetic	 variants	 were	 available	 following	 genotype	 and	 imputation	 and	 each	
variant	was	tested	to	see	whether	an	individual’s	genotype	is	predictive	of	the	phenotype.	A	
single	genetic	variant	with	a	causal	effect	on	the	phenotype	could	therefore	lead	to	multiple	
statistical	but	non-causal	associations	at	the	nearby	variants	due	to	LD	in	the	genome.	It	is	
important	to	count	the	number	of	independent	signals	in	the	genome	while	accounting	for	
LD.	 There	 are	 few	 ways	 to	 define	 approximately	 independent	 LD	 blocks	 including	 non-
overlapping	 segments	 of	 1	megabase	 (340)	 and	 non-overlapping	 segments	 of	 5000	 SNPs	
(341).	The	breakpoints	of	these	segments	sometimes	fall	in	regions	of	strong	LD	and	therefore	
lead	to	over-counting	of	the	number	of	associated	variants.	A	better	approximation	could	be	
obtained	by	considering	an	empirical	LD	pattern	in	a	reference	panel.	For	the	fine-mapping	
analysis,	I	employed	the	approximately	independent	LD	block	generated	by	Berisa	and	Pickrell	
using	r2	metric,	of	which	two	sets	of	SNPs	were	defined	as	“approximately	independent”	if	
the	 pairwise	 r2	 between	 SNPs	 in	 different	 sets	 is	 close	 to	 zero.	 The	 data	 is	 available	 at	
http://bitbucket.org.nygcresearch/ldetect-data	(342).	
	
2.1.15 Fine-mapping	
A	Bayesian	approach	was	employed	to	generate	the	credible	sets	of	causal	variants.	Credible	
set	construction	relies	on	two	underlying	assumptions:	(i)	the	causal	variant	has	been	tested	
for	association	and	 (ii)	 there	 is	 a	 single	 causal	 variant	at	 a	 locus.	Variants	are	 first	 ranked	
according	to	their	Bayes’	factor	in	favour	of	association	(from	largest	to	smallest).	Variants	
are	then	added	to	the	99%	credible	set,	by	moving	down	the	ranking,	until	the	cumulative	
posterior	probability	of	association	exceeds	0.99	(343).	The	approximate	Bayes	factor	for	each	
variant	was	computed	using	the	Wakefield	approximation	(344),	with	a	prior	parameter	W	=	
0.09,	indicating	the	prior	expectation	of	true	effect	sizes	(relative	risks)	exceed	2	only	1%	of	
the	time.	The	code	is	available	at	https://github.com/chr1swallace/lyons-et-al.	
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2.1.16 Colocalisation	
Hundreds	and	thousands	of	risk	loci	have	been	identified	by	GWAS	affecting	different	diseases	
and	traits.	The	integration	of	multiple	association	studies	could	improve	our	understanding	
of	the	molecular	basis	of	the	association	signals.	Visual	comparison	of	overlaps	of	association	
signals	are	insufficient	to	make	inferences	about	causality.	A	Bayesian	test	for	colocalisation	
between	pairs	of	genetic	association	studies	has	been	developed	by	using	summary	statistics	
to	assess	whether	two	association	signals	are	consistent	with	a	shared	causal	variant	(345).	
Colocalisation	 analysis	 was	 performed	 using	 the	 ‘coloc’	 R	 package	 to	 evaluate	 whether	
intermediate	cellular	phenotypes	(e.g.	eosinophil,	neutrophil	and	monocyte	counts)	and	AAV	
share	 the	 same	 causal	 variant	 at	BCL2L11	 locus.	 Summary	 statistics	were	obtained	 for	 all	
variants	within	the	LD-defined	haplotype	region	for	peripheral	blood	eosinophil,	neutrophil	
and	monocyte	counts	 in	a	population	 study	by	Astle	et	al	 (346).	A	 total	of	5,505	of	 these	
variants	 was	 available	 in	 the	 AAV	 dataset.	 The	 posterior	 probabilities	 of	 different	 causal	
variant	configurations	were	calculated	under	 the	assumption	of	a	single	causal	variant	 for	
each	 trait,	 including	H0	 (no	causal	 variant),	H1	 (causal	 variant	 for	 trait	1	only),	H2	 (causal	
variant	for	trait	2	only),	H3	(two	independent	causal	variants)	and	H4	(one	common	causal	
variant).	The	results	of	colocalisation	analysis	include	five	posterior	probabilities	(PP0,	PP1,	
PP2,	PP3	and	PP4)	where	a	large	posterior	probability	for	hypothesis	4	(PP4)	would	indicate	
that	a	single	variant	affects	both	traits.	
	
2.1.17 Mendelian	Randomisation	
Mendelian	randomisation	(MR)	is	an	analytic	approach	that	utilises	genetic	variants	that	are	
robustly	associated	with	a	modifiable	exposure	or	risk	factor	to	infer	a	more	reliable	causal	
relationship	with	a	clinically	relevant	outcome.	It	is	an	alternative	strategy,	especially	when	
randomised	 controlled	 trials	 to	 examine	 the	 causality	 are	 not	 feasible	 and	 observational	
studies	provide	biased	associations	because	of	confounding	or	reverse	causality.	MR	analysis	
is	an	alternative	of	randomised	trial,	exploiting	the	random	allocation	of	alleles	at	birth	to	
allow	 causal	 inference.	 The	 choice	 of	 a	 genetic	 instrumental	 variable	 is	 essential	 to	 a	
successful	MR	study.	In	order	to	achieve	an	unbiased	estimation	of	the	causal	effect	of	the	
exposure	 on	 the	 outcome,	 a	 valid	 genetic	 instrumental	 variable	 must	 fulfil	 three	 core	
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assumptions:	(i)	it	must	be	reproducibly	and	strongly	associated	with	the	exposure,	(ii)	it	must	
not	 be	 associated	 with	 confounders	 between	 exposure	 and	 outcome	 and	 (iii)	 it	 is	 only	
associated	with	the	outcome	through	the	exposure	(347).		
	
“Two-sample”	MR	was	performed	to	assess	whether	there	 is	a	causal	effect	of	eosinophil,	
neutrophil	or	monocyte	counts	(the	exposures)	on	PR3-AAV	and	MPO-AAV	(the	outcome).	
MR	 analysis	 was	 performed	 using	 the	 ‘MendelianRandomization’	 R	 package.	 Summary	
statistics	including	beta	coefficient	and	standard	error	of	the	variants	were	obtained	from	a	
population-based	 study	 by	 Astle	 et	 al	 (346),	 consisting	 of	 209,	 152	 and	 248	 conditionally	
independent	variants	associated	with	peripheral	blood	eosinophil,	neutrophil	and	monocyte	
counts	respectively.	After	excluding	the	HLA	region,	147	(eosinophil	count),	101	(neutrophil	
count)	and	169	(monocyte	count)	variants	were	available	in	the	AAV	dataset	for	MR	analysis	
(see	Figure	2.4).	 The	primary	analysis	was	 conducted	using	 the	 inverse-variance	weighted	
(IVW)	method	and	additional	analyses	were	performed	using	alternative	methods	including	
simple	median,	median-weighted	and	MR-Egger	to	test	the	robustness	of	our	results.	
	
	
Figure	2.4:	Venn	diagram	depicting	the	number	of	SNPs	used	in	MR	analysis.	
There	is	a	total	of	147,	101	and	169	conditionally	independent	variants	associated	with	eosinophil,	neutrophil	
and	monocyte	counts	respectively	that	are	in	common	in	the	AAV	dataset.	There	is	minimal	overlap	between	
significant	SNPs	in	eosinophil,	neutrophil	and	monocyte	counts.	
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2.1.18 Promoter	and	DNA	regulatory	elements	interaction	
It	 is	 well	 established	 that	 DNA	 regulatory	 elements	 such	 as	 enhancers	 or	 insulators	 can	
regulate	 gene	 transcription	 by	 physically	 interacting	with	 their	 target	 gene	 promoters	 via	
looping	 of	 DNA,	 which	 are	 both	 cell-type	 and	 stimulus	 specific.	 Long-range	 interactions	
between	genetic	 variants	 associated	with	AAV	and	gene	promoter	and	 regulatory	 regions	
were	identified	using	the	promoter	capture	Hi-C	datasets	from	a	wide	range	of	primary	cell	
types	 such	 as	 naïve	 CD4,	 activated	 CD4,	 naïve	 CD8,	 naïve	 B,	 monocytes,	 macrophages,	
neutrophils,	megakaryocytes	and	endothelial	precursors	(321)	as	well	as	cell	lines	including	
CD34	and	GM12878	(348)	on	the	CHiCP	browser	(349).	
	
2.1.19 Functional	annotation	and	data	mining	
Other	 diseases	 and	 traits	 associated	 with	 AAV-associated	 loci	 were	 identified	 using	
PhenoScanner	 v2	 (350).	 PhenoScanner	 is	 a	 curated	 database	 containing	 over	 65	 billion	
association	results	from	multiple	sources	including	the	NHGRI-EBI	(National	Human	Genome	
Research	 Institute-European	 Bioinformatics	 Institute)	 GWAS	 Catalog	 and	 NHLBI	 GRASP	
(Genome-Wide	Repository	of	Associations	Between	SNPs	and	Phenotype)	Catalog.	It	accounts	
for	LD	between	the	queried	SNPs	and	those	 in	the	catalog	of	trait-associated	variants.	For	
each	locus	associated	with	AAV,	trait-associated	SNPs	in	LD	(r2	≥	0.6)	with	the	lead	AAV	SNP	
and	a	p-value	of	≤	1	x	10-5	or	in	proximity	to	the	candidate	genes	were	identified.	eQTLs	at	
AAV-associated	loci	were	identified	from	the	eQTLGen	Consortium	(318).	It	incorporates	37	
datasets	 including	 the	 GTEx	 and	 BIOS	 Consortium,	 with	 a	 total	 of	 31,684	 individuals.	
Functional	annotation	was	performed	using	FUMA	(351)	–	an	integrative	web-based	platform	
that	 facilitates	 functional	 annotation	 of	 GWAS	 results,	 gene	 prioritisation	 and	 interactive	
visualisation	 using	 information	 from	 18	 biological	 resources	 comprising	 of	 functional	
annotations	of	SNPs	(CADD	v1.3,	RegulomeDB,	15-core	chromatin	state	and	GWAS	catalog),	
eQTLs	 (GTEx	 v6,	 Blood	 eQTL	 Browser	 and	 BIOS	 QTL	 browser),	 HiC,	 regulatory	 elements	
(Roadmap	epigenomics	project),	gene	score	and	gene	sets	(MsigDB	v5.2	and	WikiPathways).	
Regional	visualisation	of	genome-wide	association	results	for	each	AAV-associated	locus	was	
plotted	using	either	LocusZoom	or	Gviz	package.	
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2.2 Functional	validation	of	significant	association	signals	
2.2.1 Contributions	
Patient	recruitment	to	gene	expression	studies	was	coordinated	by	Professor	Ken	Smith,	Dr	
Paul	Lyons	and	Dr	David	Jayne	as	part	of	a	larger	immunophenotyping	study	and	physically	
undertaken	by	several	clinicians	and	study	research	nurses,	Sister	Jane	Hollis,	Sister	Valeria	
Morrison	and	Sister	Cecilia	Matara.	The	recruitment	of	the	ESKD	cohort	was	undertaken	by	
Dr	 Elaine	 Jolly.	 The	 initial	 sample	 processing	 was	 performed	 at	 the	 Smith	 Laboratory	 by	
several	clinicians	and	lab	assistants	depending	on	availability	and	resources.	I	was	primarily	
involved	 in	 DNA/RNA	 extraction	 and	 processing	 RNA	 samples	 for	 Affymetrix	 whole	
transcriptome	 microarray	 analysis	 as	 well	 as	 RNA	 sequencing	 for	 the	 ESKD	 cohort.	
Recruitment	 for	 the	 allele-specific	 expression	 (ASE)	 study	 and	 eosinophil	 apoptosis	 study	
together	with	all	the	transcriptomic	analysis	were	performed	by	myself.	
	
2.2.2 Patient	recruitment	to	gene	expression	studies	
2.2.2.1 Cambridge	–	AAV	patients	
Patients	with	AAV	were	recruited	through	the	Addenbrooke’s	Vasculitis	Service,	a	quaternary	
referral	centre	based	in	Cambridge,	UK	between	2004	and	2015	to	an	ongoing,	prospective	
observational	 study	 of	 gene	 expression	 patterns	 in	 autoimmune	 disease.	 Inpatients	 and	
outpatients	fulfilling	the	criteria	according	to	the	EMEA	or	CHCC	nomenclature	were	referred	
by	 clinicians	 of	 the	 service	 and	 enrolled	 prior	 to	 receiving	 induction	 immunosuppression.	
Initial	 ethical	 approval	 for	 recruitment	 and	 its	 extension	were	 obtained	 by	 Professor	 Ken	
Smith	 from	 the	National	 Research	 Ethics	 Service	 Committee	 East	 of	 England	 -	 Cambridge	
Central	 (ref:	 08/H0308/176	 and	 08/H306/21).	 Patients	 provided	 60-100	 ml	 of	 peripheral	
venous	blood	through	a	21-gauge	needle	at	3	time	points:	(i)	flaring	disease:	at	recruitment,	
prior	to	induction	therapy;	(ii)	early	remission:	3	months	after	recruitment	usually	towards	
the	 end	 of	 induction	 therapy;	 (iii)	 late	 remission:	 12	 months	 after	 recruitment,	 when	
maintenance	therapy	was	usually	well	established.	
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2.2.2.2 Cambridge	–	ESKD	patients	
A	cohort	of	93	ESKD	patients	who	received	either	living	or	deceased	donor	kidney	transplants	
at	 Addenbrooke’s	 Hospital,	 Cambridge	 University	 Hospitals	 NHS	 Foundation	 Trust,	
Cambridge,	UK	were	recruited	between	March	2009	and	May	2011.	A	110	ml	venous	blood	
sample	was	taken	prior	to	renal	transplantation	and	at	3	months	following	transplantation.	
Ethical	approval	for	this	study	was	granted	by	the	National	Research	Ethics	Service	Committee	
East	of	England	-	Cambridge	Central	(ref:	08/H0304/121).	
	
2.2.3 Healthy	volunteer	recruitment	to	the	allele-specific	expression	study	
Eight	healthy	volunteers	who	are	heterozygous	for	the	variant	(rs13405741)	were	identified	
and	 recalled	 from	 the	 database	 of	 the	 ongoing,	 prospective	 observational	 study	 of	 gene	
expression	patterns	in	autoimmune	diseases.	A	total	of	100	ml	of	peripheral	venous	blood	
through	 a	 19-gauge	 needle	 was	 taken	 into	 a	 falcon	 tube	 containing	 3.8%	 sodium	 citrate	
(Martindale	Pharma)	for	neutrophil	ASE	study.	Ethical	approval	was	granted	by	the	National	
Research	Ethics	Service	Committee	East	of	England	-	Cambridge	Central	(ref:	08/H0308/176).	
	
2.2.4 Healthy	volunteer	recruitment	to	the	eosinophil	apoptosis	study	
Healthy	volunteers	with	the	desired	genotype	for	rs13405741	(i.e.	homozygous	major	and	
minor)	were	recalled	through	the	Cambridge	BioResource.	Blood	sampling	was	carried	out	at	
the	NIHR/Wellcome	Trust	Clinical	Research	Facility,	Level	5,	Addenbrooke’s	Centre	for	Clinical	
Investigation.	A	total	of	100	ml	whole	blood	was	collected	from	each	healthy	volunteer	into	
a	falcon	tube	containing	3.8%	sodium	citrate	using	a	19-gauge	needle.	Blood	samples	were	
processed	immediately	after	collection	and	handled	very	gently	at	all	times	to	avoid	immune	
cell	 activation.	 Ethical	 approval	 was	 granted	 by	 the	 National	 Research	 Ethics	 Service	
Committee	East	of	England	-	Cambridge	Central	(ref:	08/H0308/176).	A	total	of	16	individuals	
were	 recruited	 and	 matched	 pair	 experiments	 were	 carried	 out	 to	 reduce	 possible	
confounding	 factors.	One	participant	 from	each	of	 the	 two	genotype	groups	was	 recalled	
simultaneously	and	were	matched	for	age	and	gender.		
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2.2.5 Sample	processing	
2.2.5.1 Leukocyte	separation	using	immunomagnetic	beads	
Blood	 samples	 were	 processed	 immediately	 to	 prevent	 any	 transcriptional	 alterations,	
especially	 in	 cells	 from	 the	myeloid	 lineage.	 Individual	 leukocyte	 subsets	were	purified	 as	
described	 (352).	 The	 purity	 of	 the	 populations	 obtained	 was	 assessed	 using	 the	 BD	
FACSCaliburä	flow	cytometer.	The	positively	selected	cell	subsets	were	resuspended	in	RLT	
buffer	with	1%	b-mercaptoethanol	and	stored	at	-80°C	for	future	RNA	extraction.	
	
2.2.5.2 Neutrophil	isolation	
Human	 peripheral	 blood	 neutrophils	 were	 purified	 from	 peripheral	 blood	 using	 Percoll	
gradient	as	previously	described	(353).	Briefly,	the	collected	blood	was	centrifuged	at	300	g	
for	20	min,	acceleration	9,	brake	3	at	24°C.	Post-centrifugation,	two	layers	were	formed:	a	
pellet	 at	 the	bottom	consisting	of	white	 and	 red	 cells	 and	platelet	 rich	plasma	 (PRP)	 as	 a	
supernatant.	The	PRP	was	removed	using	a	Pasteur	pipette	into	a	fresh	50	ml	falcon	tube.	To	
make	autologous	serum,	10	ml	of	PRP	was	added	into	a	sterile	glass	vial	and	followed	by	220	
µl	of	10	mM	CaCl2.	The	glass	vial	was	incubated	for	60	min	in	a	CO2	incubator	with	the	lid	of	
vial	 loose	prior	to	storing	at	4°C.	The	remaining	PRP	was	centrifuged	at	1400	g	for	20	min,	
acceleration	9,	brake	9	at	24°C.	The	supernatant	was	removed	into	a	fresh	50	ml	falcon	tube	
and	labelled	as	platelet	poor	plasma	(PPP).	
	
For	the	remaining	pellet,	6%	of	dextran	solution	was	added	(2.5	ml	dextran	solution	per	10	
ml	of	cell	pellet)	and	followed	by	warm	0.9%	sodium	chloride	to	make	up	a	final	volume	of	50	
ml.	The	tube	was	gently	rolled	several	times	to	resuspend	cells	and	left	with	cap	loosely	on	at	
room	temperature	for	25-40	min	until	a	separation	of	a	pellet	at	the	bottom	(red	cell)	and	a	
supernatant	 (myeloid	 cells	 enriched)	was	 observed.	 The	myeloid	 cells	 enriched	 layer	was	
removed	into	a	fresh	50	ml	falcon	tube	and	centrifuged	at	260	g	for	5	min,	acceleration	9,	
brake	 9	 at	 24°C	 while	 the	 bottom	 red	 cell	 pellet	 was	 discarded.	 Post-centrifugation,	 the	
supernatant	was	discarded	and	the	cell	pellet	was	resuspended	by	tapping	the	tube	gently.	
PPP	was	added	to	the	cell	to	make	up	a	final	volume	of	2	ml	and	transferred	into	a	15	ml	
falcon	tube.	42%	and	51%	Percoll	gradients	were	made	by	diluting	90%	Percoll	in	PPP	for	a	
final	volume	of	2	ml.	Subsequently,	2	ml	of	42%	Percoll	was	laid	under	the	cells	and	followed	
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by	51%	Percoll.	The	resulting	gradient	was	centrifuged	at	150	g	for	14	min,	acceleration	1,	
brake	0,	at	24°C.	The	resulting	bands:	top	(peripheral	blood	mononuclear	cells	(PBMCs)	at	PPP	
and	42%	interface)	and	bottom	(polymorphonuclear	cells	(PMNs)	at	42%	and	51%	interface).	
PMNs	were	collected	into	a	fresh	50	ml	falcon	tube	containing	PPP	and	centrifuged	at	256	g	
for	5	min,	acceleration	9,	brake	9	at	24°C.	The	supernatant	was	discarded.	The	cells	were	
consecutively	washed	twice	in	50	ml	of	phosphate	buffered	saline	(PBS),	without	Ca2+,	Mg2+	
and	followed	by	PBS	with	Ca2+	and	Mg2+,	centrifuged	at	256	g	for	5	min,	acceleration	9,	brake	
9	at	24°C.		
	
Freshly	isolated	neutrophils	were	suspended	in	Iscove	modified	Dulbecco	medium	(IMDM)	at	
5	 x	 106	 cells/ml	 supplemented	with	 10%	 autologous	 serum,	 100	 U/mL	 penicillin	 and	 100	
µg/mL	streptomycin	and	cultured	in	a	humidified	5%	CO2	atmosphere	at	37°C	in	the	presence	
and	absence	of	predetermined	optimal	concentrations	of	granulocyte-macrophage	colony-
stimulating	 factor	 (GM-CSF,	 10	 ng/ml)	 for	 6	 hr	 and	 20	 hr.	 Neutrophils	were	 harvested	 at	
different	time	points	and	resuspended	in	RLT	buffer	with	1%	b-mercaptoethanol	and	stored	
at	 -80°C	 for	 future	 RNA	 extraction.	 Cell	 purities	 were	 assessed	 by	 using	 air-dried	
cytocentrifuge	 preparations	 fixed	 in	 methanol	 and	 stained	 with	 May-Grünwald-Giemsa	
(Merck	Ltd,	Lutterworth,	Leicestershire,	UK)	where	at	least	300	cells	per	slide	were	counted	
(Figure	2.5A).	
	
2.2.5.3 Eosinophil	isolation	
Human	peripheral	blood	eosinophils	were	purified	using	 the	RoboSepä	 cell	 separation	kit	
(EasySepä	 Human	 Eosinophil	 Enrichment	 Kit	 and	 Fully	 Automated	 Cell	 Separator,	
STEMCELLä	Technologies;	catalogue	number	17956)	which	is	designed	to	isolate	eosinophils	
from	a	polymorphonuclear	cell-rich	fraction	of	peripheral	blood	by	negative	selection.	Briefly,	
8	ml	of	HES	6%	solution	(hydroxyethyl	starch,	Grifols)	was	added	into	every	40	ml	of	blood	
collected.	The	tubes	were	gently	mixed	and	left	standing	at	room	temperature	for	at	least	30	
min	to	allow	sedimentation	of	the	red	blood	cells.	Next,	all	the	top	layer	was	removed	and	
made	up	to	50	ml	with	RoboSep™	buffer	containing	Dulbecco’s	PBS,	2%	fetal	bovine	serum	
and	1	mM	EDTA.	This	was	centrifuged	at	250	g	for	10	min,	acceleration	9,	brake	9	at	24°C.	
Post-centrifugation,	 the	 supernatant	 was	 discarded	 and	 the	 cell	 pellet	 at	 the	 bottom	
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consisting	of	PMNs	and	some	red	cells.	The	cell	pellet	was	resuspended	in	50	ml	of	RoboSepä	
buffer.	
	
For	pre-RoboSep	cell	counting,	20	µl	of	3%	acetic	acid	in	PBS	was	mixed	with	20	µl	of	the	cell	
mixture.	 Cell	 counting	 was	 performed	 using	 a	 haemocytometer	 (red	 blood	 cells	 were	
excluded	from	the	counting).	The	cell	mixture	was	centrifuged	again	for	10	min,	acceleration	
9,	brake	9	at	24°C.	 The	 cell	 pellet	was	 then	 resuspended	 in	RoboSepä	 buffer	 at	50	 x	106	
cells/ml.	 Finally,	 the	 sample	 was	 placed	 in	 RoboSepä	 Automated	 Cell	 Separator	 and	 the	
separation	took	approximately	30-40	min.	Post-RoboSep,	cell	counting	was	performed.	The	
cell	 mixture	 was	 centrifuged	 at	 250	 g	 for	 10	 min,	 acceleration	 9,	 brake	 9	 at	 24°C.	 Post-
centrifugation,	the	supernatant	was	discarded	and	the	cell	pellet	was	resuspended	in	RPMI	
supplemented	with	100	U/ml	streptomycin	and	100	U/ml	penicillin	at	1	x	106	cells/ml	and	
cultured	for	24	hr	(“serum	withdrawal	induced	apoptosis”)	(354).	Cell	purities	were	assessed	
by	 cytospin	 preparations	 using	 May-Grünwald-Giemsa	 staining	 (Figure	 2.5B).	 Isolated	
eosinophils	were	resuspended	in	RLT	buffer	with	1%	b-mercaptoethanol	and	stored	at	-80°C	
for	future	RNA	extraction.	
	
	
Figure	2.5:	Light	micrographs	(40X)	of	freshly	isolated	neutrophils	and	eosinophils.	
(A)	Human	neutrophils	were	purified	using	Percoll	 gradient	while	 (B)	human	eosinophils	were	purified	 from	
mixed	 leukocytes	using	a	Robosepä	negative	selection	strategy.	White	arrow	head	 indicates	multi-lobulated	
nucleus	in	neutrophil,	red	arrow	indicates	bi-lobed	nucleus	in	eosinophil	and	black	arrow	indicates	eosinophilic	
granules.	Both	of	these	isolation	methods	have	been	previously	demonstrated	to	induce	minimal	cell	priming	
and	activation	(355,	356).	
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2.2.5.4 Cell	culture	
THP-1	and	MCF	cells	were	cultured	in	RPMI-1640	supplemented	with	10%	fetal	bovine	serum,	
1	mM	L-glutamine	and	1	mM	sodium	pyruvate.	THP-1	is	a	human	leukaemia	monocytic	cell	
line,	which	expresses	both	PRTN3	isoforms	while	MCF-7	is	a	breast	cancer	cell	line	that	only	
expresses	the	alternate	isoform	(PRTN3-202).	
	
2.2.6 Eosinophil	apoptosis	assay	
Eosinophils	 were	 cultured	 in	 a	 final	 volume	 of	 150	 µl	 in	 flat-bottomed	 96-well,	 ultralow	
attachment	plates	(Costar,	Hycombe,	Bucks,	UK)	for	24	hours.	Following	resuspension,	the	
cells	 were	 aspirated,	 cytocentrifuged,	 fixed	 and	 stained	 as	 described	 in	 section	 2.2.5.3.	
Morphologic	 analysis	 of	 eosinophil	 apoptosis	 was	 assessed	 under	 oil	 immersion	 light	
microscopy	with	the	observer	masked	to	the	experimental	conditions.	Apoptotic	eosinophils	
were	defined	as	cells	with	darkly	stained,	condensed	nuclei	 (Figure	2.6).	A	more	objective	
assessment	 of	 apoptosis	 was	 performed	 using	 Annexin	 V/propidium	 iodide	 (PI)	 flow	
cytometry	(Dead	Cell	Apoptosis	Kit	with	Annexin	V	FITC	and	PI,	Invitrogenä).	Eosinophils	were	
aspirated	and	centrifuged	at	256	g	for	5	min	at	4°C.	The	cell	pellet	was	resuspended	in	100	µl	
master	mix	containing	98	µl	of	1X	Annexin-binding	buffer,	1	µl	of	FITC	Annexin	V	and	1	µl	of	
the	100	µg/ml	PI.	Samples	were	incubated	for	20	minutes	at	4°C	in	the	dark	and	the	volume	
was	increased	to	500	µl	with	flow	cytometry	staining	buffer	(FACS	buffer)	immediately	before	
analysis	using	the	BD	FACSCantoä	II	flow	cytometry.	
	
	
Figure	2.6:	Apoptotic	eosinophils.	
Representative	image	of	apoptotic	eosinophils	from	a	healthy	volunteer	cultured	in	medium	with	no	serum	for	
24	hours.	The	black	arrows	indicate	darkly	stained,	condensed	nuclei.	
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2.2.7 gDNA	and	RNA	extraction,	quantification	and	quality	assurance	
Prior	to	mid-2010,	RNA	was	extracted	from	thawed	lysates	using	the	RNeasy	mini	kit	(Qiagen,	
cat	74104)	according	to	the	manufacturer’s	instructions.	Since	then,	RNA	was	extracted	using	
the	AllPrep	mini	kit	(Qiagen,	cat	80204)	which	also	yielded	cell	subset	specific	genomic	DNA	
(gDNA).	For	the	eosinophil	apoptosis	study,	RNA	was	extracted	using	the	RNEasy	micro	kit	
(Qiagen,	cat	74004)	given	the	lower	cell	numbers.	The	RNA	yield	and	quality	were	assessed	
using	both	an	Agilentâ	ND-1000	spectrophotometer	and	Agilentâ	2100	Bioanalyser	(Agilent	
RNA	6000	Nano	kit	or	Agilent	RNA	6000	Pico	Kit),	depending	on	the	RNA	input.	
	
2.2.8 SNP	Genotyping	analysis	
SNP	 genotyping	 was	 performed	 using	 TaqManâ	 SNP	 Genotyping	 Assays	 (Thermo	 Fisher	
Scientific)	according	to	the	manufacturer’s	instructions.	Wet	DNA	delivery	method	was	used.	
Briefly,	a	2.75	µl	reaction	mix	consisting	of	2X	TaqManâ	Genotyping	Master	Mix	(2.5	µl	per	
sample)	and	20X	SNP	Genotyping	Assay	Mix	(0.25	µl	per	sample,	Table	2.4)	was	aliquoted	to	
a	384-well	MicroAmpä	optical	reaction	plate.	Next,	2.25	µl	(5-10	ng)	of	purified	gDNA	was	
delivered	to	the	final	reaction	mix	including	a	No-Template-Control	(NTC).	The	reaction	plate	
was	sealed	with	MicroAmpä	optical	adhesive	film	and	centrifuged	briefly	to	spin	down	the	
contents	 and	 to	 eliminate	 any	 air	 bubbles.	 The	 reaction	 plate	 was	 then	 transferred	 to	
LightCyclerâ480	Real-Time	PCR	Instrument	for	polymerase	chain	reaction	(PCR).	The	thermal	
cycling	condition	was	as	follows:	10	min	at	95°C	(hold),	15	s	at	92°C	(denature),	1	min	at	60°C	
(annealing	and	extension),	repeated	for	a	total	of	35-40	cycles.	After	PCR	amplification,	an	
endpoint	plate	read	was	performed	to	plot	fluorescence	(Rn)	values	based	on	the	signals	from	
each	well.	Automatic	allele	calls	were	generated,	reviewed	and	converted	to	genotypes.	
	
Table	2.4:	A	list	of	the	TaqManâ	SNP	Genotyping	Assays	
SNP	ID	(gene)	 Assay	ID	 Context	sequence	[VICä	dye/FAMä	dye]	
rs62132279	(PRTN3)	 C_89462672_10	 TTGAGATGTCCTTCACACACACCAA[A/G]CAATTCACCCACTTAACAATTCGGT	
rs62132296	(PRTN3)	 C_25654080_10	 TGAGCCACGTGCCCATCCATCCAGC[C/T]TCCAGGCCCCGGTGGATTGTGGGGA	
rs13405741	(BCL2L11)	 C_30929894_10	 TTGGGTGGGAGTCTTGACCATGGGC[C/T]GGGGCTGCAGTCAGAAGCCCTTAGA	
	
The	SNP	alleles	are	included	in	the	square	brackets	and	highlighted	in	blue.	The	reporter	dye	information	is	represented	in	
the	assay	context	sequence	which	is	provided	in	the	(+)	genome	strand	orientation	relative	to	the	NCBI	reference	genome.	
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2.2.9 cDNA	synthesis	and	gene	expression	analysis	
Complementary	DNA	(cDNA)	was	generated	using	the	SuperScriptä	VILOä	cDNA	Synthesis	
Kit	(Cat	no:	11754050)	according	to	the	manufacturer’s	 instructions.	Briefly,	20	µl	reaction	
mix	consisting	of	5X	VILO	reaction	mix	(4	µl	per	sample),	10X	SuperScript	enzyme	(2	µl	per	
sample)	and	RNA	input	amounts	ranging	from	5	ng	to	150	ng	(16	µl	per	sample)	was	aliquoted	
to	a	0.2	ml	8-Strip	PCR	tube	and	gently	mixed.	The	PCR	tube	was	transferred	to	Eppendorf	
Mastercyclerâ	 Nexus	 for	 reverse	 transcription	 (RT)	 with	 the	 following	 thermal	 cycling	
condition:	 10	min	 at	 25°C,	 60	min	 at	 42°C	 and	 5	min	 at	 85°C.	 cDNA	was	 diluted	 prior	 to	
quantitative	PCR	(qPCR).	
	
qPCR	was	carried	out	using	TaqManâ	Gene	Expression	Assays	(Thermo	Fisher	Scientific,	see	
Table	2.5)	according	to	the	manufacturer’s	instructions.	Briefly,	a	20	µl	reaction	mix	consisting	
of	20X	TaqMan	Gene	Expression	Assay	(1	µl	per	sample),	2X	Master	mix	(10	µl	per	sample),	
RNase-free	 water	 (5	 µl	 per	 sample)	 and	 diluted	 cDNA	 template	 (4	 µl	 per	 sample)	 was	
aliquoted	to	a	384-well	MicroAmpä	optical	reaction	plate.	The	reaction	plate	was	sealed	with	
MicroAmpä	optical	adhesive	film	and	centrifuged	briefly	to	spin	down	the	contents	and	to	
eliminate	any	air	bubbles.	The	reaction	plate	was	then	transferred	to	LightCycler®480	Real-
Time	PCR	Instrument	for	PCR.	The	thermal	cycling	condition	was	as	follows:	2	min	at	50°C	
(hold),	10	min	at	95°C	(hold),	15	s	at	95°C	and	1	min	at	60°C	(PCR)	repeated	for	a	total	of	40	
cycles.	 The	 amplification	 plots	 for	 the	 entire	 plate	 was	 viewed	 and	 comparative	 cycle	
threshold	(CT)	values	were	generated	for	relative	quantification	of	gene	expression	analysis,	
which	was	performed	using	the	DCT	method	using	a	reference	gene	(see	formula	below).	This	
is	a	variation	of	the	Livak	method	that	is	simpler	to	perform	(357)	and	gives	essentially	the	
same	 results	 as	 those	 obtained	with	 the	 2-DDCT	method.	 This	method	 uses	 the	 difference	
between	reference	and	target	CT	values	for	each	sample.		
	
Ratio	(reference/target)	=	2CT(reference)	–	CT(target)	
	
In	order	to	detect	the	expression	of	PRTN3-001	mRNA	versus	PRTN3-002	mRNA,	I	designed	
two	 primer	 sets	 (Table	 2.6)	 for	 PCR,	which	was	 carried	 out	 using	 the	 Applied	 Biosystems	
AmpliTaq	Gold	DNA	polymerases	protocol	with	the	following	thermocycler	conditions:	95°C	
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3	min	(holding	stage),	35	cycles	of	PCR	–	denaturation	95°C	15	s,	annealing	58°C	30	s	and	
extension	72°C	1	min	and	final	holding	stage	72°C	7	min	(final	extension).	After	agarose	gel	
electrophoresis	of	the	resulting	PCR	products,	the	desired	amplicons	were	gel-purified	and	
sequenced	using	the	Sanger	method	to	confirm	their	sequences.	
	
	
Table	2.5:	A	list	of	the	TaqManâ	Gene	Expression	Assays	
Gene	 Assay	ID	 Details	(amplicon	length)	
PRTN3	 Hs00160521_m1		 Assay	probe	spans	exon	1-2,	detect	only	PRTN3-201	isoform	(100bp)	
PRTN3	 Hs01553330_m1	 Assay	probe	spans	exon	3-4,	detect	both	PRTN3-201	and	PRTN3-202	
isoforms	(72bp)	
BCL2L11	 Hs01076940_m1	 Assay	probe	spans	exon	1-2	(68bp)	
MIR4435-2HG	 Hs03680374_m1	 Assay	probe	spans	exon	1-2	(75bp)	
B2M	 Hs00984230_m1	 Assay	probe	spans	exons	3-4	(81bp)	
18S	 Hs99999901_s1	 Both	primers	and	probe	map	within	exon	1	(187bp)	
ACTB	 Hs99999903_m1	 The	probe	and	one	of	the	primers	sit	within	exon	1	(171bp)	
	
18S,	Eukaryotic	18S	rRNA;	ACTB,	Actin,	Beta,	cytoplasmic;	B2M,	Beta-2-microglobulin;	BCL2L11,	BCL2	Like	11	
(a.k.a	BIM);	bp,	base	pairs;	MIR4435-2HG,	MIR4435-2	Host	Gene	(a.k.a	MORRBID);	PRTN3,	proteinase	3.	
	
	
Table	2.6:	A	description	of	the	primer	sets	used	to	detect	different	PRTN3	isoforms	
Primer	Name	 Sequence	(amplicon	length)	
PRTN3-201	 FOR	5’-TGC	TGC	TGG	CCT	TGC	TGC	TGA	G-3’	
REV	5’-CCG	AGA	AGT	GCT	GCT	GGG	TGG	G-3’	(267	bp)	
PRTN3-202	 FOR	5’-GGG	AGA	CGG	AGG	CTC	GGA	GAG	G-3’	
REV	5’-AGA	AGT	GCT	GCT	GGG	TGG	GCT	C-3’	(337	bp)	
ACTB	
	
FOR	5’-GAG	CAT	CCC	CCA	AAG	TTC	A-3’	
REV	5’-AGA	GAA	GTG	GGG	TGG	CTT	TT-3’	(133	bp)	
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2.2.10 Western	blot	of	eosinophil	lysates	
1	x	105	isolated	eosinophils	aliquots	were	lysed	in	15	µl	1X	LDS	buffer	(Invitrogen™)	containing	
10%	b-mercaptoethanol.	Samples	were	boiled	at	70°C	for	10	min	before	loading	into	pre-cast	
NuPAGE	Novex	4-12%	Bis-Tris	protein	gels	(Invitrogen™).	Spectra™	Multicolour	Broad	Range	
Protein	 ladder	 (Invitrogen™)	 was	 used	 as	 a	 size	 ladder	 for	 each	 gel.	 Proteins	 were	
electrophoresed	in	electrode	buffer	(1X	MOPS	-	SDS	Running	Buffer,	FORMEDIUM™)	at	100	
V.	Proteins	were	electrotransferred	onto	PVDF	transfer	membrane	(Millipore)	at	350	mA	for	
1	hour.	Non-specific	binding	sites	on	the	membranes	were	blocked	with	5%	non-fat	dry	milk	
power	(Marvel,	UK)	dissolved	in	TBST	buffer	(1X	Tris	buffered	saline	with	0.1%	(vol/vol)	Tween	
20)	at	room	temperature	for	1	hour.	Membranes	were	then	incubated	with	diluted	primary	
antibodies	overnight	at	4°C	(anti-BCL2L11	from	Cell	Signaling	Technology®	at	1:1,000	dilution	
and	anti-beta	Actin	from	Abcam	at	1:3,000	dilution).	Following	primary	antibody	incubation,	
membranes	were	washed	3	times	 in	TBST	for	10	min	on	a	rocker	prior	 to	 incubation	with	
species-specific	HRP-conjugated	secondary	antibody	(Cell	Signaling	Technology®)	at	1:10,000	
dilution	for	45	min	at	room	temperature.	Membranes	were	then	washed	again	for	3	times	in	
TBST	 and	 once	 in	 PBS	 before	 being	 developed	 with	 SuperSignal™	 West	 Pico	 PLUS	
Chemiluminescent	Substrate	or	SuperSignal™	West	Femto	Maximum	Sensitivity	Substrate	as	
per	manufacturer’s	protocol	 and	exposed	 to	photographic	 film.	 Semi-quantitative	analysis	
was	carried	out	using	the	Image	Lab	software.	
	
2.2.11 cDNA	synthesis	and	hybridisation	to	Affymetrix	arrays	
cDNA	was	 synthesized	 and	 amplified	 from	 total	 RNA	using	 the	Ambionâ	whole	 transcript	
expression	 kit	 (Applied	 Biosystems),	 fragmented	 and	 labelled	 using	 the	 Affymetrixâ	
GeneChipâ	whole	transcript	terminal	labelling	kit	before	hybridisation	to	Affymetrixâ	Gene	
ST	1.1	arrays	according	to	manufacturer’s	instructions.	Briefly,	200	ng	of	total	RNA	was	used	
to	synthesise	the	first-strand	cDNA	in	the	initial	RT	reaction.	The	whole	transcript	expression	
kit	uses	a	priming	method	that	specifically	primes	non-ribosomal	RNA,	including	both	poly(A)	
and	non-poly(A)	mRNA.	Second-strand	cDNA	was	then	synthesised	from	the	first-strand	cDNA	
using	DNA	polymerase	and	RNase	H	to	simultaneously	degrade	the	RNA,	followed	by	in	vitro	
transcription	to	generate	synthesise	anti-sense	cDNA.	A	purification	step	was	then	performed	
		
	67	
to	 improve	 the	stability	of	cDNA	prior	 to	second	cycle	RT	 to	generate	sense-strand	cDNA.	
During	this	reaction,	deoxyuridine	triphosphate	(dUTP)	was	incorporated	into	the	DNA,	which	
was	then	recognized	by	uracil	DNA	glycosylase	(UDG)	and	apurinic/apyrimidinic	endonuclease	
1	 (APE1)	that	cleaved	the	DNA	strand	at	these	sites,	a	process	known	as	“fragmentation”.	
Fragmented	 DNA	 was	 labelled	 by	 terminal	 deoxynucleotidyl	 transferase	 (TdT)	 covalently	
linked	 to	 biotin.	 The	 terminally	 labelled	 fragmented	 cDNA	 was	 then	 hybridised	 onto	
Affymetrix	Human	Gene	ST	1.1	arrays	and	finally	scanned	using	an	Affymetrix	GeneTitanTM	
multichannel	instrument.	
	
2.2.12 RNA-Seq	library	preparation	
To	investigate	the	differential	expression	of	different	isoforms	of	PRTN3,	RNA-Seq	libraries	
were	prepared	with	the	Illuminaâ	TruSeqâ	Stranded	Total	RNA	Sample	Preparation	kit	using	
150	ng	RNA	input	and	the	low	sample	protocol.	Briefly,	ribosomal	RNA	(rRNA)	was	removed	
using	 biotinylated,	 target-specific	 oligos	 combined	 with	 Ribo-Zero	 rRNA	 removal	 beads.	
Following	purification,	the	RNA	was	fragmented	into	small	pieces	using	divalent	cations	under	
elevated	temperature.	The	cleaved	RNA	fragments	were	copied	into	first	strand	cDNA	using	
reverse	transcriptase	and	random	primers,	followed	by	second	strand	cDNA	synthesis	using	
DNA	polymerase	I	and	RNase	H.	These	cDNA	fragments	had	the	addition	of	a	single	“A”	base	
for	subsequent	adapter	ligation.	The	products	were	purified	and	enriched	with	PCR	to	create	
the	final	cDNA	library.	Next,	samples	were	assessed	for	quality	and	fragment	size	using	the	
Bioanalyzer	DNA	high	sensitivity	kit	 (Agilent)	prior	 to	 library	quantification	using	the	KAPA	
Illumina	Sequencing	Library	qPCR	Quantification	kit.	All	19	 libraries	were	pooled	to	a	 final	
concentration	of	4nM.	Sequencing	of	the	prepared	libraries	was	conducted	at	the	Cambridge	
Genomic	 Services,	 Department	 of	 Pathology,	 University	 of	 Cambridge	 using	 the	 Illumina	
NextSeq	 550	 System	 paired-end	 75	 bp	 run.	 Raw	 data	 files	 were	 generated	 in	 the	 FASTQ	
format.	
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2.2.13 Allele-Specific	Expression	assay	
Gene	variants	that	contribute	to	common	disease	susceptibility	often	alter	gene	expression	
only	modestly.	Small	expression	changes	can	be	technically	challenging	to	measure	robustly,	
especially	since	biological	variation	usually	contributes	negatively	to	this	goal.	A	clone-based	
ASE	assay	which	enables	quantification	of	genotype-determined	expression	differences,	such	
as	those	where	the	susceptibility	allele	is	transcribed	2-fold	less	than	the	resistance	allele	as	
previously	shown	by	Rainbow	et	al	(358),	was	performed	to	analyse	BCL2L11	transcription	in	
neutrophils	 from	 heterozygous	 individuals	 (rs13405741;	 C/T).	 This	 facilitated	 a	 direct	
comparison	between	the	amount	of	BCL2L11	pre-mRNA	that	was	transcribed	from	each	allele	
or	haplotype	and	ensured	that	external	factors	affected	both	alleles	equally.	The	workflow	of	
a	cloned-based	ASE	assay	is	summarised	in	Figure	2.7.	
	
	
Figure	2.7:	Workflow	of	a	clone-based	allele-specific	expression	assay.		
	
Human	 neutrophils	 were	 purified	 from	 the	 peripheral	 blood	 of	 heterozygous	 healthy	
volunteers	 as	 described	 in	 sections	 2.2.5.2.	 Freshly	 isolated	 neutrophils	 were	 routinely	
suspended	 at	 5	 x	 106/mL	 in	 IMDM	supplemented	with	 10%	autologous	 serum,	 100	U/mL	
penicillin	 and	 100	 µg/mL	 streptomycin.	 They	 were	 cultured	 in	 a	 humidified	 5%	 CO2	
atmosphere	at	37°C.	To	examine	 the	effect	of	GM-CSF	on	 the	BCL2L11	 transcription,	cells	
were	incubated	in	the	presence	or	absence	of	predetermined	optimal	concentrations	of	GM-
CSF	(10	ng/mL).	Neutrophils	were	harvested	at	0,	6,	and	20	hours	respectively	and	lysed	with	
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RLT	 plus	 buffer.	 gDNA	 and	 RNA	 were	 extracted	 from	 the	 lysates	 using	 Qiagenâ	 AllPrep	
DNA/RNA	Mini	kit.	RNA	was	treated	with	TURBO™	DNase	(Thermo	Fisher	Scientific)	to	ensure	
complete	 removal	 of	 gDNA	 from	 the	 samples	 and	 reversed	 transcribed	 to	 cDNA	 using	
SuperScriptâ	 VILOä	 cDNA	 Synthesis	 Kit.	 A	 nested	 PCR	 using	 two	 sets	 of	 primers	 was	
performed	(see	Table	2.7)	with	Phusionâ	High-Fidelity	DNA	Polymerase	to	amplify	the	region	
of	interest	at	rs13405741	from	both	gDNA	and	cDNA.	
	
After	agarose	gel	electrophoresis	of	the	resulting	PCR	products,	the	desired	amplicons	(301	
bp)	 were	 gel-purified	 and	 sequenced	 using	 the	 Sanger	 method	 to	 confirm	 the	 sequence	
variant.	 The	 amplicons	 were	 then	 cloned	 into	 pCRä-Blunt	 II-TOPOÒ	 vectors	 containing	 a	
kanamycin-resistance	 cassette	 (Zero	 BluntÒ	 TOPOÒ	 PCR	 Cloning	 Kit,	 Invitrogenä)	 and	
transfected	into	chemically	competent	E.	Coli.	Two	different	volumes	(100	μl	and	200	μl)	of	
each	transformation	were	spread	on	a	pre-warmed	kanamycin-containing	Luria-Bertani	agar	
plates	and	incubated	overnight	at	37°C.	Next,	96	colonies	per	condition	per	individual	were	
picked	and	added	into	a	96-well	plate	containing	20	μl	nuclease	free	water,	further	diluted	
with	 80	 μl	 nuclease	 free	water	 and	 heated	 at	 85°C	 for	 10	minutes	 for	 thermal	 lysis.	 The	
reaction	plate	was	centrifuged	briefly	to	spin	down	the	contents	and	the	supernatant	was	
used	as	DNA	template	for	TaqMan	SNP	genotyping	assay	to	determine	the	frequency	of	each	
allele.	
	
Table	2.7:	Primers	and	thermocycler	conditions	for	ASE	assay	
Primer	set	 Detailed	PCR	protocol	
First	set	
FOR	5’-CCT	GAG	TGG	TGC	AGT	GTT	TG-3’		
REV	5’-TCA	CTG	TTT	CTT	GTG	ATC	AAA	CAA-3’	
	
Initial	denaturation	98°C	30	s	
Denaturation	 98°C	 10	 s,	 annealing	 66°C	 30	 s	 and	
extension	72°C	20	s	(x30	cycles)	
Final	extension	72°C	5	min	
Second	set	
FOR	5’-TGT	ACC	GGT	TCA	TCT	GCT	GG-3’		
REV	5’-TGG	AGT	GAC	TTG	AGC	TGG	AC-3’	
	
Initial	denaturation	98°C	30	s	
Denaturation	 98°C	 10	 s,	 annealing	 66°C	 30	 s	 and	
extension	72°C	20	s	(x30	cycles)	
Final	extension	72°C	5	min	
	
FOR,	forward;	min,	minute;	PCR,	polymerase	chain	reaction;	REV,	reverse;	s,	second.	
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2.2.14 Microarray	data	analysis	
The	output	.CEL	files	were	processed	and	analysed	using	the	R	statistical	software	(v	3.2.5).	
Raw	microarray	data	were	background	adjusted,	quantile	normalised	and	summarised	using	
the	 robust	 multichip	 average	 method.	 QC	 was	 performed	 using	 the	 arrayQualityMetrics	
package.	 The	 parameters	 that	 were	 assessed	 as	 part	 of	 this	 QC	 process	 included	 array	
intensity	 distributions,	 between	 array	 distance	 comparisons,	 individual	 array	 quality	 and	
standard	deviation	versus	rank	of	the	mean.	An	object	(“exprsFile”)	was	generated	containing	
QC	 and	 normalised	 microarray	 data	 of	 x	 number	 of	 patients.	 Following	 the	 initial	 pre-
processing	 steps,	 an	 ExpressionSet	 was	 created	 using	 the	 Biobase	 package,	 consisting	 of	
expression	data	 from	microarray	 experiments	 (assayData,	 a	matrix	 of	 “expression”	 values	
which	has	F	rows	and	S	columns,	where	F	is	the	number	of	features	on	the	chip	and	S	is	the	
number	 of	 samples),	 phenotypic	 data	 describing	 samples	 in	 the	 experiment	 (phenoData),	
annotations	 and	 meta-data	 about	 the	 features	 on	 the	 chip	 used	 for	 the	 experiment	
(featureData,	Affymetrix	 human	gene	1.1	 ST	 array	 annotations	which	 contain	 information	
such	as	gene	name,	symbol,	Entrez	ID	or	chromosomal	location).	The	ExpressionSet	class	is	
designed	 to	 combine	 several	 different	 sources	 of	 information	 into	 a	 single	 convenient	
structure	that	allows	easy	manipulation	of	data	for	downstream	analysis.	There	was	a	total	of	
19,783	probesets	remaining	after	filtering	out	the	control	probesets	and	those	that	did	not	
have	assigned	annotations.	
	
The	following	code	was	used	to	create	a	normalised	ExpressionSet:	
#	Loading	the	library		
>	library(hugene11sttranscriptcluster.db)	
>	library(Biobase)	
>	library(arrayQualityMetrics)	
>	library(oligo)	
>	library(annotate)	
	
#	Identify	microarray	CEL	files	and	read	in	the	CEL	files	in	the	directory	
>	cels	<-	list.files(pattern=".*.CEL")	
>	rawData	<-	read.celfiles(cels)	
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#	Normalise	the	data	and	perform	QC	
>	exprsFile	<-	rma(rawData)	
>	arrayQualityMetrics(exprsFile)	
	
#	Create	an	ExpressionSet	
>	phenoData	<-	new("AnnotatedDataFrame",	data=pData)	
>	phenoData(exprsFile)	=	phenoData	
>	ID=featureNames(exprsFile)	
>	Symbol=getSYMBOL(ID,"hugene11sttranscriptcluster.db")	
>	fData(exprsFile)=data.frame(Symbol=Symbol)	
>	eSet=exprsFile[!is.na(fData(exprsFile)),]	
	
#	Compute	principal	components	
>	prData=prcomp(t(exprs(eSet)))	
>	pdf("PCA	Batch	Effect.pdf",width=7,	height=7,	paper="special")	
>	factor	=	as.factor(eSet$info_batch_name)	
>	factors	=	sort(unique(factor))	
>	cols	=	rainbow(length(factors),	alpha	=	0.8)	
>	label	=	eSet$Study_ID	
>	plot(prData$x[,1],prData$x[,2],pch=21,bg=cols[match(factor,factors)],xlab='PCA1',			
ylab='PCA2',main='Principal	Components	Plot')	
>	text(prData$x,	labels	=	label,	cex=	0.5,adj=(-.3))	
>	legend("topright",legend=factors,pch=	21,bty="n",cex=0.9,title="",pt.bg=cols,pt.cex	=	1)	
>	dev.off()	
	
#	Batch	correction		
>	pheno	=	pData(eSet)	
>	edata	=	exprs(eSet)	
>	batch	=	eSet$info_batch_name	
>	mod	=	model.matrix(~as.factor(pheno$rejection_6mth)	+	as.factor(pheno$rejection)	+					
as.factor(pheno$infection)	+	as.factor(pheno$DGF)	+	as.factor(pheno$gender),	data=pheno)	
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>	combat_edata=ComBat(dat=edata,	batch=batch,	mod=mod,	par.prior=TRUE,	
prior.plots=FALSE)	
>	exprs(eSet)	<-	combat_edata	
	
2.2.15 RNA-Seq	data	analysis	
To	begin	with	raw	reads	that	are	stored	in	FASTQ	format,	the	overall	quality	of	the	sequenced	
reads	 was	 checked	 using	 FastQC	 software	 (Babraham	 Institute,	 Cambridge).	 For	 adapter	
trimming,	the	first	13	bp	of	Illumina	standard	adapters	(‘AGATCGGAAGAGC’)	were	removed	
using	Trim	Galore	with	the	following	specifications	--paired	--illumina	--phred	24	--length	20	-
-stringency	13.	Ribosomal	reads	were	removed	in	silico	using	BBSplit	prior	to	read	alignment	
with	 HISAT2	 using	 the	 Genome	 Reference	 Consortium	 Human	 Build	 38	 (GRCh38).	 QC	 of	
aligned	 reads	were	 carried	out	using	 the	Quality	 of	RNA-Seq	Toolset	 (QoRTs).	 In	order	 to	
achieve	approximately	30	million	reads	per	sample,	two	sequencing	runs	were	performed	and	
the	aligned	reads	were	then	merged	into	a	single	bam	file	for	each	sample.	A	summary	of	the	
mapped	sequencing	reads	to	genomic	features	was	obtained	using	featureCounts	(=	raw	read	
counts)	and	normalised	for	sequencing	depth	differences	with	edgeR.	The	read	counts	were	
then	 transformed	 to	 the	 log	 scale	 for	 downstream	 analyses.	 Quantitative	 visualisation	 of	
alternative	isoform	expression	was	performed	using	Sashimi	plot.	
	
	
Figure	2.8:	Workflow	for	RNA-Seq	data	analysis.	
The	most	 commonly	used	 file	 formats	 to	 store	 the	 results	 are	 indicated	 in	 smaller	 font	 sizes	with	 the	most	
commonly	used	tools	shown	on	the	right.	
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Figure	2.9:	Quality	control	and	data	processing	of	RNA-Seq	experiment.	
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(A)	Quality	control	summary	plots	generated	using	Quality	of	RNA-Seq	Toolset	(QoRTs).	
(B)	Library	size	per	sample.	Y-axis	represents	read	count.	
(C)	 RNA-Seq	 data	 normalisation	 using	 the	 edgeR	 package.	 Boxplots	 of	 log-RPKM	 (Reads	 Per	 Kilobase	 of	
transcript,	per	Million	mapped	reads)	values	showing	expression	distributions	for	unnormalised	data	(left)	and	
normalised	data	(right)	for	each	sample	in	the	CKD	datasets.	
	
2.2.16 General	statistical	analyses	
Analyses	were	performed	using	GraphPad	Prism	v6	(GraphPad	Software,	San	Diego,	CA)	and	
R	statistical	software.	Unless	otherwise	specified,	comparisons	of	a	single	parameter	across	
two	groups	were	performed	using	the	unpaired,	non-parametric,	two-tailed	Mann-Whitney	
test	for	continuous	variables.	Comparisons	of	a	single	parameter	across	more	than	two	groups	
were	 performed	 using	 the	 Kruskal-Wallis	 rank-sum	 test.	 Where	 the	 comparison	 was	
significant,	 pairwise	 two-sample	 Wilcoxon	 tests	 were	 performed	 to	 determine	 which	
individual	 comparisons	 contributed	 to	 the	 significant	 result.	 The	 resulting	 p-values	 were	
adjusted	for	the	number	of	comparisons	made	using	the	false	discovery	rate	method	unless	
otherwise	stated.	An	alpha	value	<	0.05	was	considered	significant.	Correlation	testing	was	
performed	with	either	Pearson	or	Spearmann	correlations,	depending	on	the	context.	
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Table	2.8:	Key	resources	table	
Resource	 Identifier	
Affymetrix	Hugene	
11	annotation	data	
https://bioconductor.org/packages/release/data/annotation/html/hugene11sttranscriptcluster.db.html	
Annotate	 https://www.bioconductor.org/packages/release/bioc/html/annotate.html	
ArrayQualityMetrics	 https://bioconductor.org/packages/release/bioc/html/arrayQualityMetrics.html	
BCFtools	 https://samtools.github.io/bcftools/bcftools.html/		
Biobase	 https://bioconductor.org/packages/release/bioc/html/Biobase.html	
BLUEPRINT	 http://blueprint-data.bsc.es/release_2016-08/#!/	
BOLT-LMM	 https://data.broadinstitute.org/alkesgroup/BOLT-LMM/		
CHiCP	 https://www.chicp.org/		
Colocalisation	 https://cran.r-project.org/web/packages/coloc/coloc.pdf		
edgeR	 https://www.bioconductor.org/packages/devel/bioc/vignettes/edgeR/inst/doc/edgeRUsersGuide.pdf		
eQTLgen		 http://www.eqtlgen.org/cis-eqtls.html	
FastQC	 https://www.bioinformatics.babraham.ac.uk/projects/fastqc/	
FUMA	 http://fuma.ctglab.nl/	
GCTA	 http://cnsgenomics.com/software/gcta	
ggplot2	 https://cran.r-project.org/web/packages/ggplot2/index.html	
GraphPad	 https://www.graphpad.com/scientific-software/prism/	
Gviz	 https://bioconductor.org/packages/release/bioc/html/Gviz.html	
Haplotype	block	 http://bitbucket.org.nygcresearch/ldetect-data	
HISAT2	 https://ccb.jhu.edu/software/hist2/	
Integrative	
Genomics	Viewer	
https://software.broadinstitute.org/software/igv/	
	
LocusZoom	 http://locuszoom.org/	
META	v1.7	 https://mathgen.stats.ox.ac.uk/genetics_software/meta/meta.html	
Michigan	Server	 https://imputationserver.sph.umich.edu/index.html#!	
MISO	 https://miso.readthedocs.io/en/fastmiso/sashimi.html		
oligo	 https://bioconductor.org/packages/release/bioc/html/oligo.html	
PhenoScanner	 http://www.phenoscanner.medschl.cam.ac.uk/	
PLINK	v1.9	 https://www.cog-genomics.org/plink/1.9/			
QoRTS	 https://hartleys.github.io/QoRTs/	
Quanto	 http://biostats.usc.edu/software.html/		
R	v3.4.4	 https://www.r-project.org/	
Rsubread	 https://bioconductor.org/packages/release/bioc/html/Rsubread.html	
SNPTEST	v2.5.2	 https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html	
TrimGalore	 https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/	
Two	sample	MR	 https://cran.r-project.org/web/packages/MendelianRandomization/MendelianRandomization.pdf		
UCSC	 https://genome.ucsc.edu/index.html	
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3 Discovery	of	PR3-AAV	risk	loci	
3.1 Introduction	
PR3-AAV	is	more	frequent	in	northwestern	Europe	and	North	America	than	southern	Europe	
and	is	uncommon	in	Asian	populations.	The	incidence	of	PR3-AAV	in	the	United	Kingdom	has	
been	reported	to	be	10.6	per	million	per	year	while	in	Spain,	the	incidence	is	approximately	
4.9	 per	million	 per	 year	 (32).	 PR3-AAV	 patients	 are	more	 likely	 to	 have	 upper	 and	 lower	
respiratory	tract	as	well	as	renal	involvement	as	opposed	to	vasculitis	limited	to	the	kidneys	
in	MPO-AAV.	The	nature	of	pulmonary	involvement	differs	between	ANCA	serotypes	where	
cavitating	 lung	 nodules	 are	 often	 observed	 in	 PR3-AAV	 while	 fibrosing	 lesions	 are	 more	
frequently	seen	in	MPO-AAV.	Furthermore,	the	clinical	outcome	differs	according	to	ANCA	
serotype	with	PR3-AAV	predisposing	to	disease	relapse	(hazard	ratio	1.6-3.2)	as	compared	to	
MPO-AAV	(359,	360).	
	
Over	and	above	the	strong	association	within	the	HLA	region	(HLA-DP),	previous	GWAS	have	
identified	 two	 genome-wide	 significant	 loci	 at	 SERPINA1	 (chr14q32.13)	 and	 PRTN3	
(chr19p13.3)	to	be	associated	with	PR3-AAV.	In	order	to	identify	additional	risk	loci	associated	
with	 PR3-AAV,	 a	 total	 of	 1,132	 PR3-AAV	 cases	 from	 Europe,	 along	with	 6,688	 population	
matched	 controls,	 were	 genotyped	 on	 the	UK	 Biobank	 Axiom	 array.	 A	meta-analysis	was	
subsequently	performed	with	the	recent	AAV	GWAS	by	Lyons	et	al	(70).	
	
In	 this	 chapter,	 I	 will	 discuss	 the	 identification	 of	 seven	 genome-wide	 significant	 loci	
associated	with	PR3-AAV	including	the	HLA	region,	four	of	which	are	implicated	in	PR3-AAV	
risk	for	the	first	time.	Within	the	HLA	region,	imputation	of	HLA	classical	alleles	revealed	four	
independent	associations	and	the	strongest	association	was	observed	at	HLA-DPB1*04:01.	
Furthermore,	I	performed	fine-mapping	of	the	newly	identified	loci	by	calculating	Bayesian	
posterior	probability	of	causality	for	all	variants	to	generate	the	99%	credible	sets	of	most	
likely	causal	SNPs,	followed	by	prioritisation	of	variants	using	functional	annotation	to	reduce	
the	size	of	the	associated	regions	and	the	number	of	plausible	target	genes.	
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3.2 Samples	and	genotype	data	
Following	sample	and	SNP	QC,	a	total	of	397,205	SNPs	from	GWAS1	and	558,875	SNPs	from	
GWAS	2	respectively	were	available	for	analysis.	The	breakdown	of	the	number	of	patients	
included	in	the	meta-analysis	of	PR3-AAV	is	summarised	in	Table	3.1.	
	
Table	3.1:	The	number	of	cases	and	controls	included	in	the	meta-analysis	of	PR3-AAV	
Cohort	 No	of	Controls	 No	of	Cases	
GWAS1	 5,259	 478	
GWAS2	 6,688	 1,132	
†Sequenom	Genotype	(rs6679677)	 1,531	 1,122	
Total	 13,478	 2,732	
	
†For	rs6679677,	a	further	cohort	was	available	for	meta-analysis	where	the	genotyping	was	performed	using	the	
Sequenom	MassARRAY	platform	in	the	replication	cohort	of	Lyons	et	al	2012.	
	
3.3 Association	testing	with	genotype	data	
I	performed	association	testing	of	 the	genotype	data	using	two	analytic	methods	-	 logistic	
regression	and	LMM	as	implemented	in	BOLT-LMM.	A	comparison	between	the	two	models	
is	highlighted	in	Table	3.2.	There	was	minimal	genomic	inflation	observed	in	GWAS1	(lambda	
gc, lgc	=	1.03)	as	all	the	cases	and	controls	were	from	the	UK.	In	contrast,	the	lgc	for	GWAS2	
remained	 over	 1.1	 despite	 fitting	 an	 increasing	 number	 of	 PCs	 as	 covariates	 in	 a	 linear	
regression	model.	 Not	 to	 our	 surprise,	 the	 LMM	method	 that	 has	 been	 shown	 to	 better	
control	for	population	stratification	than	correction	for	PCs,	reduced	the	lgc	from	1.308	to	
1.087,	supporting	that	population	stratification	in	GWAS2	was	well	controlled	(Figure	3.1).		
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Table	3.2:	A	comparison	of	logistic	regression	and	linear	mixed	model	analyses	
Genotyped	data	 Genomic	inflation	factor	(lambda,	l)	
GWAS1	 GWAS2	
No	covariates	 1.033	 1.308	
3	PCs	 1.034	 1.156	
6	PCs	 1.036	 1.148	
20	PCs	 1.039	 1.135	
BOLT-LMM	 1.031	 1.087	
*BOLT-LMM	(imputed	data)	 1.029	 1.065	
	
LMM,	linear	mixed	model;	PCs,	principal	components.		
Lambda,	λ	is	the	ratio	of	the	median	of	the	observed	chi-squared	statistics	to	the	median	of	the	expected	chi-
squared	statistics	under	the	null	hypothesis.	
*	indicates	genomic	inflation	factor	calculated	using	the	imputed	data.	
	
	
Figure	3.1:	Quantile-quantile	plots	and	genomic	inflation	factors.	
Association	 tests	 were	 performed	 on	 genotyped	 data	 and	 comparison	 between	 logistic	 regression	 with	 no	
covariates,	varying	numbers	of	principal	components	as	covariates	and	LMM	for	(A)	PR3-AAV	in	GWAS	1	and	(B)	
GWAS2	respectively.	The	HLA	region	and	SNPs	with	genome-wide	significant	associations	were	not	included	in	
the	QQ	plots.	The	black	line	is	y	=	x.	
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3.4 Association	testing	of	the	imputed	data	and	meta-analysis	
Following	QC	of	the	imputed	data,	a	total	of	7,656,576	and	7,744,534	autosomal	markers	in	
GWAS	1	and	GWAS2	respectively	with	r2	>	0.3	were	available	for	analysis.	Of	these,	7,460,066	
SNPs	were	in	common	to	both	cohorts	for	meta-analysis.	Case-control	association	testing	was	
performed	 using	 a	 LMM	 with	 BOLT-LMM	 software	 to	 minimise	 the	 effect	 of	 population	
stratification	and	meta-analysis	was	performed	using	an	inverse-variance	method	based	on	a	
fixed-effects	model.	
	
A	total	of	seven	PR3-AAV	susceptibility	loci	were	identified	(Table	3.3).	In	five	of	the	seven	
risk	loci	identified,	the	most	significant	SNP	within	each	locus	was	a	common	variant	(MAF	>	
0.05)	with	the	ORs	ranging	between	1.23-1.68,	except	for	the	HLA	region	where	the	OR	was	
2.58	(95%	CI	2.41-2.75)	with	the	strongest	association	(p	=	3.59	x	10-173).	The	most	significant	
associations	in	the	remaining	two	loci	were	low-frequency	variants	(MAF	=	0.01-0.05)	with	
ORs	of	2.39	and	3.43	respectively.	Stepwise	conditional	regression	analysis	within	each	non-
HLA	locus	did	not	identify	additional	independent	genome-wide	significant	signals.	
	
Two	 previously	 reported	 genome-wide	 significant	 non-HLA	 risk	 loci	 were	 replicated,	
rs112635299	at	chr14q32.13	(SERPINA1)	and	rs55952682	at	chr19p13.3	(PRTN3).	Although	
not	 the	 same	 lead	 SNP,	 they	 were	 in	 moderate-to-high	 LD	 with	 the	 lead	 SNPs	 from	 the	
previous	GWAS	including	rs7151526	(r2	=	0.44)	and	rs28929474	(r2	=	1.0)	at	SERPINA1	and	
rs62132295	(r2	=	0.66)	and	rs62132293	(r2	=	0.70)	at	PRTN3	(70,	71).	As	PRTN3	locus	was	not	
well	represented	on	the	Affymetrix	SNP	6.0	Platform,	the	quality	of	imputation	in	this	region	
was	very	poor	in	GWAS1	and	majority	of	the	SNPs	were	filtered	out	due	to	low	r2.	Therefore,	
only	the	p-value	of	GWAS2	was	reported	for	this	locus.	
	
3.5 Genetic	heritability	
To	quantify	the	genetic	influence	on	PR3-AAV,	the	total	SNP	heritability	(h2SNP)	was	estimated	
using	the	genome-wide	genotyped	variants	(MAF	≥	0.01)	and	additively	they	explained	46%	
of	 the	 total	 disease	 liability	 (se	 =	 0.03),	 for	 a	 population	 prevalence	 of	 130	 per	 million	
population	(338).
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Table	3.3:	HLA	and	non-HLA	associations	with	PR3-AAV	
§SNP	 ¶Chr	 ¶Position	 Gene(s)	
*Risk	
allele	
RAF	
GWAS1		
(478	cases	vs	5,259	controls)	
GWAS2		
(1,132	cases	vs	6,688	controls)	
Meta-analysis		
(1,610	cases	vs	11,947	controls)	
†OR	(95%	CI)	  yP	 †OR	(95%	CI)	 yP	 †OR	(95%	CI)	  DP	
rs115670873	 2p13.1	 74,171,061	 DGUOK,	TET3	 A	 0.93	 1.11	(0.70-1.78)	 6.50	X	10-1	 1.72	(1.48-2.00)	 8.60	X	10-12	 1.68	(1.44-1.97)	 1.22	X	10-10	
rs13405741	 2q13	 111,913,056	 BCL2L11,	
MIR4435-2HG	
C	 0.11	 1.55	(1.20-1.99)	 6.60	X	10-4	 1.34	(1.17-1.53)	 1.60	X	10-5	 1.40	(1.24-1.58)	 3.76	X	10-8	
rs3130216	 6p21.32	 33,077,271	 HLA-DP	 G	 0.48	 3.06	(2.68-3.49)	 1.50	X	10-61	 2.46	(2.28-2.65)	 4.30	X	10-114	 2.58	(2.41-2.75)	 3.59	X	10-173	
rs145007430	 10q26.3	 131,690,291	 EBF3,	MGMT	 A	 0.02	 4.75	(2.50-9.04)	 2.00	X	10-6	 1.77	(1.26-2.49)	 5.70	X	10-4	 2.39	(1.76-3.25)	 2.38	X	10-8	
rs112635299	 14q32.13	 94,838,142	 SERPINA1	 T	 0.02	 6.51	(4.21-10.07)	 4.20	X	10-17	 2.56	(1.99-3.30)	 8.90	X	10-13	 3.43	(2.75-4.27)	 2.37	X	10-28	
rs11845244	 14q32.33	 107,170,077	 IGHV1-69	 T	 0.37	 1.29	(1.12-1.49)	 4.70	X	10-4	 1.21	(1.11-1.32)	 2.00	X	10-5	 1.23	(1.15-1.33)	 2.16	X	10-8	
‡rs55952682	 19p13.3	 835,908	 PRTN3	 T	 0.26	 	 	 1.39	(1.26-1.54)	 1.90	X	10-11	 1.39	(1.26-1.54)	 1.90	X	10-11	
	
§	SNPs	showing	the	most	significant	level	of	association	after	meta-analysis	of	GWAS1	and	GWAS2.	
¶	Chr,	chromosome;	Genomic	coordinates	from	Genome	Reference	Consortium	Human	Build	37	(GRCh37/hg19).	
*	The	risk	allele	refers	to	the	effect	allele	in	the	overall	meta-analysis;	RAF,	risk	allele	frequency.	
†	The	odds	ratio	(OR)	is	with	respect	to	the	risk	allele;	CI,	confidence	interval.		
‡	The	SNP6	platform	that	was	used	in	the	GWAS1	has	a	poor	coverage	for	PRTN3	locus	and	imputed	SNPs	were	removed	due	to	poor	quality	(R2	<	0.3).	
y	The	p-values	were	calculated	using	a	linear	mixed	model	(BOLT-LMM).	
D	The	p-values	were	calculated	using	inverse-variance	method	based	on	a	fixed-effects	model.	
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3.6 Candidate	gene	prioritisation	(non-HLA	loci)	
To	prioritise	candidate	genes,	I	first	performed	fine	mapping	of	all	the	risk	loci	identified	using	
the	Bayesian	approach	to	generate	credible	sets	of	SNPs.	Next,	I	searched	for	nonsynonymous	
coding	and	known	eQTL	among	the	SNPs	in	high	LD	(r2	>	0.6)	with	the	most	associated	SNPs.	
Risk	loci	were	functionally	annotated	using	publicly	available	data	from	a	number	of	resources	
using	FUMA	while	long-range	interactions	between	the	PR3-AAV	associated	SNPs	and	gene	
promoters	and	regulatory	regions	were	identified	in	promoter	capture	Hi-C	datasets	using	the	
CHiCP	browser.	In	addition,	I	cross-referenced	the	lead	associated	variant	at	each	locus	with	
disease-associated	variants	that	are	in	high	LD	from	the	Phenoscanner.	I	also	sought	external	
evidence	 from	 experimental	 literature	 and	 other	 genomic	 databases	 to	 provide	 further	
evidence	 to	 implicate	 candidate	 genes	 in	 the	 pathogenesis	 of	 PR3-AAV.	 The	 results	 are	
summarised	in	Table	3.4.	
	
3.6.1 DGUOK/TET3	
The	top	variant	found	in	chr2p13.1,	rs115670873	(pmeta	=	1.22	x	10-10),	is	located	in	the	intron	
of	deoxyguanosine	kinase	(DGUOK).	It	is	an	imputed	SNP	with	info	scores	of	0.53	and	0.68	for	
GWAS1	and	GWAS2	respectively.	It	does	not	have	any	LD	buddies	(or	“proxy”	SNPs;	defined	
by	r2	³	0.4).	The	cluster	plots	of	the	genotyped	SNPs	in	this	region	(±	500	kb	from	the	lead	
variant)	were	satisfactory.	Although	this	SNP	has	not	been	reported	to	be	associated	with	any	
trait,	this	locus	has	been	reported	to	be	associated	with	SLE,	eosinophil	count,	seropositive	
RA	and	dialysis-related	mortality.	Promoter	capture	Hi-C	(PCHi-C)	data	showed	interactions	
of	this	SNP	with	the	promoter	region	of	ten-eleven	translocation	methylcytosine	dioxygenase	
3	 (TET3),	DGUOK	antisense	RNA	1	 (DGUOK-AS1)	and	signal	 transducing	adaptor	molecule-
binding	protein	(STAMBP)	in	primary	immune	cell	subsets	and	GM12878	cell	line.	Other	PCHi-
C	prioritised	plausible	candidate	genes	 in	this	region	are	summarised	 in	Table	3.4.	DGUOK	
encodes	a	protein	that	is	responsible	for	phosphorylation	of	purine	deoxyribonucleosides	in	
the	mitochrondrial	matrix	and	is	highly	expressed	in	common	lymphoid	progenitor,	common	
myeloid	 progenitor	 and	 haematopoietic	 stem	 cells	 (BLUEPRINT	 data	 release	 2016-08).	
Mutations	 in	 this	 gene	 has	 been	 associated	 with	 mitochondrial	 DNA	 (mtDNA)	 depletion	
syndrome	 (OMIM:251880)	where	affected	 individuals	 suffer	 from	progressive	 liver	 failure,	
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neurological	 abnormalities,	 hypoglycaemia	 and	 increased	 lactate	 in	 body	 fluids.	 However,	
immune	phenotypes	have	not	been	reported.	Affected	tissues	were	previously	shown	to	have	
decreased	activity	of	the	mtDNA-encoded	respiratory	chain	complexes	(I,	III,	IV,	V)	and	mtDNA	
depletion,	 suggesting	 that	 this	enzyme	might	be	 involved	 in	 the	maintenance	of	balanced	
mitochondrial	dNTPs	pools	(361).	
	
The	ten-eleven	translocation	(TET)	family	of	proteins	consisting	of	TET1,	TET2	and	TET3	can	
catalyse	the	oxidation	of	the	methyl	group	on	cytosine	and	thus	play	an	important	role	in	DNA	
demethylation.	They	have	been	shown	to	participate	in	numerous	developmental	processes	
including	haematopoiesis	(362).	TET2	plays	a	role	in	the	regulation	of	FoxP3	expression	and	
influences	the	differentiation	and	homeostasis	of	CD4+FoxP3+	regulatory	T	cells	(363)	while	in	
myeloid	cells,	TET2	is	involved	in	IL-6	production	(364).	TET3	is	ubiquitously	expressed,	but	is	
most	 abundantly	 in	 the	 myeloid	 and	 monocytic	 haematopoietic	 cells,	 and	 it	 has	 been	
suggested	that	 it	might	play	a	role	 in	the	development	of	these	 immune	cells	 (365).	More	
recently,	Xue	et	al	and	colleagues	investigated	the	role	of	TET3	in	the	production	of	type	I	IFN	
by	immune	cells	and	demonstrated	that	TET3	is	a	negative	regulator	of	IFN-b	in	response	to	
viral	infection	and	by	deleting	TET3,	the	expression	of	IFN-b	and	IFN-stimulated	genes	were	
increased	resulting	in	a	heightened	antiviral	response.	They	further	showed	that	this	effect	
was	 independent	 of	 DNA	 demethylation,	 instead	 TET3	 recruited	 histone	 deacetylase	 1	
(HDAC1)	 to	 the	 promoter	 of	 IFNB1	 (366).	 In	 addition,	 global	 hypomethylation	 has	 been	
observed	in	CD4+	T	cells	in	individuals	with	SLE	and	it	has	been	postulated	that	demethylation	
induced	by	TET3	might	play	a	 role	 in	 lymphocyte	development	and	 induction	of	 tolerance	
(367).	
	
STAMBP	plays	a	critical	role	in	cytokine-mediated	signalling	for	MYC	induction	and	cell	cycle	
progression.	It	binds	to	the	SH3	domain	of	the	signal-transducing	adaptor	molecule	in	the	JAK-
STAT	signalling	cascade.	 It	 is	most	highly	expressed	 in	the	common	 lymphoid	and	myeloid	
progenitor	cells.	 In	the	murine	model,	complete	knockout	of	STAMBP	 leads	to	preweaning	
lethality	while	heterozygous	mice	develop	an	abnormal	haematopoietic	system	affecting	the	
monocyte	and	lymphocyte	numbers.	A	recent	publication	by	Bednash	et	al	which	discovered	
the	 role	 of	 STAMBP	 in	 deubiquitinating	NALP7	 (NACHT,	 LRR	 and	 PYD	 domains-containing	
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protein	7)	which	 is	one	of	the	 inflammasome	constituents,	to	 impede	NALP7	trafficking	to	
lysosomes,	 leading	 to	 an	 increase	NALP7	 abundance	 and	 inflammasome-dependent	 IL-1b	
cleavage	 and	 release.	 A	 small-molecule	 inhibitor	 of	 STAMBP	 deubiquitinase	 activity,	
decreases	NALP7	protein	levels	and	suppressed	IL-1b	release	after	TLR	agonism,	suggesting	it	
could	 be	 a	 potential	 therapeutic	 target	 to	 reduce	 pro-inflammatory	 stress	 (368).	 These	
relevant	functional	associations	involving	the	immune	system	suggest	that	TET3,	DGUOK	and	
STAMBP	are	more	likely	to	be	the	causal	gene	at	this	locus	as	compared	to	other	candidate	
genes.	
	
	
Figure	3.2:	Genomic	feature	at	chr2p13.1	(DGUOK	region).	
Top	to	bottom	panels:	Genomic	positions	(hg19),	representative	RefSeq	genes,	promoter	capture	Hi-C	(PCHi-C)	
data	 from	 Javierre	et	 al	 (primary	 immune	 cell	 subsets),	 SNPs	association	with	PR3-AAV	with	 filled	 red	 circle	
indicates	the	 lead	SNP	(rs115670873),	causal	variant	mapping	expressed	as	posterior	probability	 (PP),	GWAS	
significant	hits	in	the	region	obtained	from	the	NHGRI-EBI	Catalog	of	published	GWAS	and	methylation	data.	
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Table	3.4:	Candidate	genes	at	PR3-AAV	associated	loci	
SNP	 Most	likely	
causal	gene(s)	
Type	of	
variants	
Diseases	or	traits	associated	with	the	lead	SNP	or	in	high	LD	
with	lead	SNP	(r2	>	0.6)	or	in	proximity	to	candidate	gene(s)	
*Cis-eQTL	
(blood/relevant	
tissues)	
‡Immune	
phenotype	in	
murine	model	
PCHi-C	prioritised	protein	
coding	gene(s)	
PCHi-C	
prioritised	
non-protein	
coding	
transcript(s)	
Disease	or	trait	(SNP)	 Relationship	
rs115670873	 DGUOK,	TET3	 Intronic	 SLE	(158,	369)	 In	proximity	 n/a	 STAMBP	 TET3,	BOLA3,	MOB1A,	
MTHFD2,	ACTG2,	
STAMBP,	ALMS1,	SEMA4F,	
M1AP,	INO80B,	WBP1,	
DCTN1,	SCL4A5	
DGUOK-AS1,		
BOLA-AS1,		
AC073046.1-
201,	
DCTN1-AS1	
	
Eosinophil	counts	(370)	
†Systemic	sclerosis	
†Seropositive	RA	
Dialysis-related	mortality	(371)		
†Crohn’s	disease	
rs13405741	 BCL2L11,	
MIR4435-2HG	
Intronic	 ¶mQTL	(cg04202892)	(372)	 Same	 BCL2L11	(blood),	
MIR4435-2HG	
(brain)	
	
BCL2L11,	
MIR4435-2HG	
BCL2L11,	ACOXL	 MIR4435-2HG	
EGPA	(rs72836352)	 r2	=	1.0	
Eosinophil	count,	neutrophil	%	of	granulocytes	
(rs17484848)	(346)	
r2	=	0.91	
PSC	(373),	†Asthma	(rs72837826)	 r2	=	0.89	
Monocyte	%	of	white	cells	(rs72836346)	(346)	 r2	=	0.65	
Vitiligo	(rs4308124)	(374)	 r2	=	0.17	
CLL	(375),	monocyte	count	(346),	atopic	
dermatitis	(376)	
In	proximity	
rs145007430	 EBF3,	MGMT	 Intronic	 Atopic	eczema,	psoriasis	(377)	 In	proximity	 n/a	 n/a	 MGMT,	PTPRE	 n/a	
†RA	
rs112635299	 SERPINA1	 Intergenic	 §pQTL	(SNAP25,	C1QTNF1)		 Same	 SERPINA1,	
IFI27L2,	IFI27L1,		
IFI27	(blood)	
SERPINA1	 SERPINA9,	SERPINA12,	
SERPINA4,	SERPINA5		
RP11-349I1.2,	
RP11-986E7.7	§pQTL	(MRPL33,	ZNF175,	ACP2,	NCF2,	WISP3,	
PIM1,	ARFIP2,	SLC14A2,	TXNDC5,	DNAJB9,	
GPC6)	(rs28929474)	
r2	=	1.0	
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SNP	 Most	likely	
causal	gene(s)	
Type	of	
variants	
Diseases	or	traits	associated	with	the	lead	SNP	or	in	high	LD	
with	lead	SNP	(r2>0.6)	or	in	proximity	to	candidate	gene(s)	
*Cis-eQTL	
(blood/relevant	
tissues)	
‡Immune	
phenotype	in	
murine	model	
PCHi-C	prioritised	protein	
coding	gene(s)	
PCHi-C	
prioritised	
non-protein	
coding	
transcript(s)	
Disease	or	trait	 Relationship	
rs11845244	 IGHV1-69	 Missense	 ¶mQTL	 Same	 IGHV1-69,	IGHV3-
66,	IGHV3-64,	
IGHV4-61,	IGHV4-
59,	IGHV3-53,	
IGHV4-39	(blood)	
n/a	 n/a	 n/a	
§pQTL	(DEF119,	LAP,	EPHB3)	 Same	
§pQTL	(ACP2)	(rs10139058)	 r2	=	0.79	
§pQTL	(STIM1)	(rs3814922)	 r2	=	0.78	
rs55952682	 PRTN3	 Intergenic	 §pQTL	(PRTN3)	 Same	 PRTN3,	CFD,	
MED16	
PRTN3,	ELANE,	
CFD,	KISS1R,	
ARID3A,	CNN2	
PRTN3,	ELANE,	CFD,	AZU1,	
PLPPR3,	PTBP1,	MISP,	
PALM,	PRSS57	
CTB-31O20.4,		
CTB-31O20.3,	
MIR1909,	
CTB-25B13.6,	
RPS15P9,	
CIRBP-AS1,	
AC004221.2	
¶mQTL,	Basophil	%	of	white	cells	(346)	 Same	
Monocyte	count	 Same	
Monocyte	%	of	white	cells	(rs138303849)	(346)	 r2	=	0.99	
White	blood	cell	count	(rs56757486)	(346)	 r2	=	0.99	
§pQTL	(PRTN3)	(rs7254911)	 r2	=	0.97	
	
CLL,	chronic	lymphocytic	leukaemia;	EGPA,	eosinophilic	granulomatosis	with	polyangiitis;	eQTL,	expression	quantitative	trait	loci;	mQTL,	methylation	quantitative	trait	loci;	PCHi-C,	promoter	capture	Hi-C;	
pQTL,	protein	quantitative	trait	loci;	PSC,	primary	sclerosing	cholangitis;	RA,	rheumatoid	arthritis;	SLE,	systemic	lupus	erythematosus;	%,	percentage.			
†Results	obtained	from	UK	Biobank	study	(378)	using	Phenoscanner	database	(http://www.phenoscanner.medschl.cam.ac.uk/).		 
*The	lead	SNP	or	SNPs	in	high	LD	with	the	lead	SNP	in	the	locus	that	are	known	eQTLs	(obtained	from	http://www.eqtlgen.org/index.html).		
§pQTL	was	obtained	Sun	et	al	from	NHGRI-EBI	GWAS	Catalog	(https://www.ebi.ac.uk/gwas/)	or	Phenoscanner	(319).	
‡The	immune	phenotype	designation	was	taken	from	http://www.informatics.jax.org/phenotypes.shtml.		
¶mQTL	was	obtained	from	mQTL	database	http://www.mqtldb.org/	(372).
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3.6.2 BCL2L11	
The	top	variant	found	in	chr2q13,	rs13405741	(pmeta	=	3.76	x	10-8),	is	located	in	the	intron	of	
Bcl-2-like	protein	11	(BCL2L11),	encoding	BIM	which	is	a	Bcl2	family	member	that	is	essential	
for	controlling	apoptosis	and	immune	homeostasis.	This	SNP	and	several	SNPs	in	strong	LD	
with	it	(r2	>	0.6)	have	been	reported	to	be	associated	with	PSC	(373),	EGPA	(Lyons	et	al	2018	
bioRxiv),	 eosinophil	 count,	 neutrophil	 percentage	 of	white	 cells,	monocyte	 percentage	 of	
white	cells	(346)	and	asthma	(378).	Specifically,	the	PR3-AAV	risk	allele	(rs13405741,	C	allele)	
is	associated	with	a	higher	eosinophil	count,	a	greater	eosinophil	percentage	of	white	cells,	a	
decreased	neutrophil	percentage	of	granulocytes,	a	higher	monocyte	percentage	of	white	
cells	(346)	and	an	increased	risk	of	PSC	(373).	This	locus	has	been	independently	(r2	<	0.1)	
reported	to	be	associated	with	CLL	 (375)	and	atopic	dermatitis	 (376).	PCHi-C	data	showed	
interactions	of	rs17484848	(in	high	LD	with	rs13405741,	r2	=	0.91)	with	the	putative	enhancer	
region	of	MIR4435-2HG	and	the	promoter	region	of	both	BCL2L11	and	Acyl-CoA	oxidase	like	
(ACOXL)	 (Figure	3.3).	Furthermore,	 rs13405741	 is	a	known	eQTL	 for	BCL2L11	 in	 the	whole	
blood	 with	 p-value	 of	 8.75	 x	 10-36,	 where	 the	minor	 allele	 (C,	 risk	 allele	 for	 PR3-AAV)	 is	
associated	with	a	higher	expression	of	BCL2L11,	supporting	that	the	SNP	might	play	a	role	in	
regulating	the	expression	of	BCL2L11	(318).	In	addition,	BCL2L11tm1.1Ast	knockout	mice	exhibit	
progressive	 systemic	 autoimmune	 diseases	with	 abnormal	 accumulation	 of	 lymphoid	 and	
myeloid	cells	(379).		
	
MIR4435-2HG	(a.k.a	Morrbid),	encodes	a	long	non-coding	RNA,	was	recently	discovered	to	
play	a	critical	role	in	the	regulation	of	BCL2L11	transcription	in	the	myeloid	cells	and	hence	
their	 lifespan,	by	promoting	 the	enrichment	of	 the	polycomb	repressive	complex	2	at	 the	
promoter	of	BCL2L11	to	keep	it	in	a	poised	state	(380).	Morrbid-deficient	mice	had	markedly	
reduced	number	of	eosinophils,	neutrophils	and	Ly6Chi	classical	monocytes	in	the	blood	and	
tissues	but	no	effects	were	observed	in	other	immune	cell	types.	Interestingly,	the	authors	
also	reported	an	overexpression	of	Morrbid	 in	the	eosinophils	of	patients	who	suffer	from	
hypereosinophilic	syndrome	(HES),	suggesting	its	potential	role	in	the	pathogenesis	of	HES.	
The	relevant	functional	associations	suggest	that	BCL2L11	and	Morrbid	are	more	likely	to	be	
the	causal	gene	at	this	locus	than	ACOXL,	of	which	its	function	is	not	well	defined	and	it	is	
highly	expressed	in	the	lung,	testis	and	prostate.	
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Figure	3.3:	Genomic	features	at	chr2q13	(BCL2L11	region).	
Top	 to	 bottom	panels:	Genomic	 positions	 (hg19),	 representative	RefSeq	 genes,	 PCHi-C	 data	 (Javierre	 et	 al	 -	
granulocytes	 subset),	 SNPs	 association	 with	 PR3-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	
(rs13405741),	causal	variant	mapping	expressed	as	posterior	probability	(PP),	GWAS	significant	hits	in	the	region	
obtained	from	the	NHGRI-EBI	Catalog	of	published	GWAS	and	methylation	data.	
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3.6.3 EBF3	
The	top	variant	found	in	chr10q26.3,	rs145007430	(pmeta	=	2.38x	10-8),	is	located	in	the	intron	
of	 early	 B-cell	 factor	 3	 (EBF3),	 encoding	 for	 a	member	 of	 the	 EBF	 family	 of	 DNA	 binding	
transcription	factors.	It	is	an	imputed	SNP	with	info	scores	of	0.63	and	0.83	for	GWAS1	and	
GWAS2	respectively.	It	does	not	have	any	strong	LD	buddies	(r2	³	0.4)	and	the	cluster	plots	
of	the	genotyped	SNPs	in	this	region	(±	500	kb	from	the	lead	variant)	were	satisfactory.	EBF	
proteins	are	involved	in	differentiation	and	maturation	of	several	cell	lineages,	including	B-
progenitors	 lymphoblasts,	 neuronal	 precursors	 and	 osteoblast	 progenitors	 (381).	 The	
encoded	protein	inhibits	cell	survival	through	the	regulation	of	genes	involved	in	cell	cycle	
arrest	and	apoptosis,	and	aberrant	methylation	or	deletion	of	this	gene	have	been	associated	
with	multiple	malignancies	such	as	acute	 lymphoblastic	 leukaemia	and	glioblastoma	(382).	
EBF3	is	expressed	in	the	common	lymphoid	progenitor	and	plasma	cells,	but	not	in	naïve	and	
memory	B	cells.	The	PCHi-C	dataset	showed	interactions	of	rs145007430	with	the	putative	
regulatory	 region	 and	 the	 promoter	 region	 of	 O-6-methylguanine-DNA	methyltransferase	
(MGMT)	 in	GM12878	 cell	 line,	which	 encodes	 a	 protein	 that	 catalyses	 transfer	 of	methyl	
groups	 from	 O(6)-alkylguanine	 and	 other	 methylated	 moieties	 of	 the	 DNA	 to	 its	 own	
molecule.	Mechanistically,	DNA	methylation	can	modulate	gene	expression	by	influencing	the	
binding	 affinities	 of	 transcription	 factors.	 It	 was	 demonstrated	 that	 patients	 with	
hypersensitivity	 pneumonitis	 had	 evidence	 of	 hypomethylation	 of	 EBF3	 as	 compared	 to	
healthy	controls	with	significantly	higher	expression	of	EBF3,	 IL-4	and	IL-10,	 indicating	that	
EBF3	hypomethylation	in	B	cells	might	play	a	role	in	the	conversion	of	Th1	dominant	to	Th2	
dominant	 response	 in	 patients	 who	 were	 in	 the	 chronic	 phase	 of	 the	 disease	 (383).	 In	
contrast,	 hypermethylation	 at	 CpG	 sites	 in	 the	 EBF3	 gene	 were	 observed	 in	 RA	 synovial	
fibroblasts	with	a	marked	decrease	 in	EBF3	expression	as	compared	with	OA	patients	and	
healthy	controls,	suggesting	its	potential	role	in	the	pathogenesis	of	RA	(384).	This	locus	has	
independently	been	reported	to	the	associated	with	 inflammatory	skin	disorders	 including	
psoriasis	and	eczema	(377).		
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Figure	3.4:	Genomic	features	at	chr10q26.3	(EBF3	region).	
Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	
GM12878	 cell	 line),	 SNPs	 association	 with	 PR3-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	
(rs145007430),	 causal	 variant	mapping	 expressed	 as	 posterior	 probability	 (PP),	 GWAS	 significant	 hits	 in	 the	
region	obtained	from	the	NHGRI-EBI	Catalog	of	published	GWAS	and	methylation	data.	
	
3.6.4 SERPINA1	
This	locus	has	been	identified	in	previous	GWAS	and	its	potential	role	in	the	pathogenesis	of	
PR3-AAV	is	discussed	in	section	1.4.2.	The	top	variant	identified	in	chr14q32.13,	rs112635299	
(pmeta	=	2.37	x	10-28),	is	located	in	the	intergenic	region	with	close	proximity	to	SERPINA1.	It	is	
a	known	eQTL	for	SERPINA1	and	IFI27	(interferon-alpha-inducible	protein	27).	In	addition,	it	
is	a	pQTL	for	two	proteins	including	synaptosomal	nerve-associated	protein	25	(SNAP-25)	and	
complement	 C1q	 tumour	 necrosis	 factor-related	 protein	 1	 (C1QTNF1).	 The	 second	 most	
significant	variant	in	this	locus	was	rs28929474	(pmeta	=	9.40	x	10-28)	and	it	is	in	complete	LD	
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with	rs112635299	(r2=	1.0).	It	is	a	missense	variant	that	leads	to	substitution	of	the	amino	
acid	glutamine	in	position	342	in	the	protein	for	a	lysine	amino	acid	and	is	also	known	as	the	
“Z”	 allele.	 The	 PCHi-C	 dataset	 showed	 interactions	 with	 the	 promoters	 of	 SERPINA5,	
SERPINA9,	SERPINA11	and	SERPINA12	in	GM12878	cell	line.	SERPINA5	encodes	for	protein	c	
inhibitor	 which	 interacts	 with	 lipid	 membrane	 leading	 to	 permeabilisation	 of	 bacterial	
pathogen	 to	 exert	 antimicrobial	 activity	 while	 SERPINA12	 encoding	 vaspin,	 has	 been	
previously	shown	to	reduce	expression	of	proinflammatory	factors,	improve	lipid	catabolism	
and	increase	insulin	sensitivity.	
	
	
Figure	3.5:	Genomic	features	at	chr14q32.13	(SERPINA1	region).	
Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	
GM12878	 cell	 line),	 SNPs	 association	 with	 PR3-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	
(rs112635299),	causal	variant	mapping	expressed	as	posterior	probability	(PP),	other	GWAS	significant	hits	in	
the	region	and	methylation	data.	
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3.6.5 IGHV1-69	
The	most	significant	association,	rs11845244	is	located	in	the	immunoglobulin	heavy	variable	
1-69	(IGHV1-69)	gene	(Figure	3.6).	It	is	a	missense	variant	that	results	in	a	change	of	amino	
acid	at	position	50	from	glycine	to	arginine	(G50R	based	on	Kabat	numbering	system),	which	
is	 the	 last	 amino	 acid	 in	 the	 framework	 region	 2	 and	 is	 immediately	 adjacent	 to	 the	
complementarity	determining	region	2	(CDR2)	as	demonstrated	 in	Figure	3.7.	 It	 is	a	trans-
pQTL	 for	defensin	beta	119	 (DEFB119),	 an	antimicrobial	peptide	 that	protects	 tissues	and	
organs	from	infection	by	a	variety	of	microorganisms.	
	
	
Figure	3.6:	Genomic	features	at	chr14q32.33	(IGHV1-69	gene).	
Top	to	bottoms	panels:	Genomic	positions	(hg19),	representative	RefSeq	genes,	SNPs	association	with	PR3-AAV	
where	the	filled	red	circle	indicates	the	lead	SNP	(rs11845244),	causal	variant	mapping	expressed	as	posterior	
probability	(PP),	other	GWAS	significant	hits	 in	the	region	obtained	from	the	NHGRI-EBI	Catalog	of	published	
GWAS	and	methylation	data	(H3k27ac,	H3k4me3	and	H3k27m3).	
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Figure	3.7:	IGHV1-69	germline	polymorphisms.		
(A)	This	schematic	representation	of	an	immunoglobulin	(Ig),	which	is	made	up	of	two	heavy	chains	(VH)	and	two	
light	 chains	 (VL).	 The	 variable	 region	 of	 Ig	 that	 binds	 to	 the	 antigen	 for	which	 the	 antibody	 is	 specific	 to	 is	
highlighted	 in	 a	 red	 dotted	 circle.	 Each	 heavy	 and	 light	 chain	 contains	 three	 complementarity-determining	
regions	(CDRs)	that	are	folded	together	to	form	the	antigen	binding	site,	which	determine	the	specificity	and	the	
affinity	of	binding.	rs11845244	is	a	missense	variant	that	results	in	a	change	of	amino	acid	at	position	50	from	
glycine	 to	 arginine	 (G50R),	which	 is	 located	 at	 the	 border	 of	 framework	 region	 2	 of	 the	 heavy	 chain	 and	 is	
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indicated	 by	 a	 filled	 red	 circle.	 The	 rearranged	 genomic	 VH1-69	 gene	 encoding	 the	 protein	 heavy	 chain	 is	
demonstrated.	
(B)	 The	 amino	 acid	 sequences	 of	 IGHV1-69	 alleles	 are	 aligned	 and	 grouped	 based	 on	 the	 occurrence	 of	
phenylalanine	or	leucine	at	position	54	(F54L).	The	black	boxes	highlight	the	location	of	CDR1,	CDR2	and	partial	
CDR3	based	on	the	 International	 Immunogenetics	 Information	System	(IMGT)	database.	Positions	where	the	
alleles	are	different	among	the	sequences	are	depicted	with	colored	amino	acids.		
(C)	The	genotype	frequency	differences	at	two	SNPs	in	IGHV1-69	that	have	been	shown	to	encode	functional	
residues	 that	 are	 critical	 for	 neutralizing	 antibodies	 against	 the	 influenza	 hemagglutinin	 stem	 region	
(rs55891010,	 where	 A/A	 encodes	 the	 functional	 critical	 F54	 residue)	 and	 NEAT2	 domain	 of	 S.	 aureus	
(rs11845244,	where	C/C	encodes	the	primary	G50	residue),	between	five	human	ethnic	groups	(Africans	(AFR);	
Central	and	South	Americans	(AMR);	Europeans	(EUR);	South	Asians	(SAS)	and	East	Asians	(EAS)),	published	by	
the	1000	Genomes	project	(285).			
	
Antibodies	 are	 key	 components	 of	 the	 adaptive	 immune	 response	 and	 can	 selectively	
recognise	and	mediate	immune	responses	to	foreign	antigens.	This	is	accomplished	through	
the	vast	diversity	of	the	B-cell	antibody	repertoire,	which	begins	in	the	bone	marrow	where	
B	lymphocytes	rearrange	their	immunoglobulin	(Ig)	variable	(V),	diversity	(D)	and	joining	(J)	
region	gene	segments	coding	for	the	B-cell	receptor	for	antigen.	This	specialised	process	is	
known	as	V(D)J	recombination	that	somatically	joins	various	V,	D	and	J	segments	at	Ig	heavy-
chain	locus	or	V	and	J	segments	at	Ig	Kappa	and	Ig	Lambda	chain	loci.	Ig	is	made	up	of	two	
heavy	chains	and	two	light	chains.	It	can	be	divided	into	two	fragments,	Fab	and	Fc	fragments.	
The	Fab	fragment	engages	antigen	while	the	Fc	fragment	mediates	effector	functions.	They	
differ	in	IgV	gene	composition	where	the	Fab	region	contains	the	antigen-binding	site,	being	
composed	predominantly	of	the	Ig	variable	region	gene	segments	(IGHV,	IGHD	and	IGHJ)	and	
the	 Fc	 region	 composed	 completely	 by	 an	 IGHC	 gene	 (385).	 Each	 heavy	 and	 light	 chain	
contains	 three	 CDRs	 that	 are	 folded	 together	 to	 form	 the	 antigen-binding	 site,	 which	
determine	the	specificity	and	the	affinity	of	binding.	Random	rearrangement	of	the	heavy-	
and	 light-chain	genes	 further	 increases	genetically	encoded	diversity	 to	ensure	 that	 it	will	
likely	 contain	 a	 naïve	 antibody	 with	 at	 least	 weak	 initial	 binding	 against	 a	 vast	 array	 of	
antigens.	This	diversity	will	then	be	augmented	following	antigen	stimulation	where	B	cells	
undergo	 somatic	 hypermutation,	 resulting	 in	 thousands	 of	 clonally	 derived	 affinity	
maturation	variants	of	the	initial	antibody	to	mount	a	highly	specific	antigen	response	(386).	
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Despite	 the	 importance	of	 the	unique	molecular	mechanisms	 in	 generating	highly	diverse	
functional	antibodies,	there	is	a	growing	appreciation	that	the	Ig	genes	exhibit	a	high	level	of	
allelic	polymorphism.	Recent	studies	have	demonstrated	that	 Ig	germline	variation	plays	a	
crucial	role	in	the	development	of	naïve	B	cell	repertoire	and	downstream	implications	in	the	
B	cell	memory	compartment	and	individual’s	ability	to	mount	antibody	response	to	specific	
epitopes	(387-390).	It	has	been	shown	in	several	studies	that	there	is	biased	use	of	the	heavy-
chain	 gene	 IGHV1-69	 in	 generating	 stem-directed	 broadly	 neutralising	 antibodies	 against	
influenza	hemagglutinin	(HA)	(391,	392).	More	importantly,	there	are	two	SNPs	in	IGHV1-69	
that	have	been	shown	to	encode	functional	residues	that	are	critical	for	broadly	neutralising	
antibodies	against	influenza	HA	(F54	and	L54	amino	acid-associated	alleles;	rs55891010)	(387,	
390,	393)	and	NEAr-iron	Transporter	2	(NEAT2)	domain	of	S.	aureus	(G50	and	R50	amino	acid-
associated	alleles;	rs11845244)	(394).	Yeung	and	colleagues	demonstrated	that	it	is	the	CDR-
H2	that	dominates	the	binding	interaction	between	neutralising	antibodies	and	NEAT2.	More	
importantly,	 using	 enzyme-linked	 immunosorbent	 assay,	 they	 also	 showed	 that	 allelic	
variation	at	position	50	(R50)	completely	abolished	NEAT2	binding,	presumably	due	to	steric	
hindrance	(394).	Both	rs55891010	and	rs11845244	are	in	high	LD	(r2	=	0.93)	and	therefore	
L54	and	R50	amino	acid	 tend	to	co-occur	 in	alleles	of	 IGHV1-69.	The	 frequencies	of	 these	
critical	alleles	vary	across	populations	where	the	L54	and	R50	amino	acids	are	most	commonly	
seen	 in	 South	 Asians	 and	 least	 frequently	 in	 Africans	 (Figure	 3.7).	 rs55891010	 was	 not	
available	in	our	imputed	data.	
	
3.6.6 PRTN3	
This	locus	has	been	identified	in	previous	GWAS	and	its	potential	role	in	the	pathogenesis	of	
PR3-AAV	is	discussed	in	section	1.4.2.	The	top	variant	identified	in	chr19p13.3,	rs55952682	
(pGWAS2	 =	 1.90	 x	 10-11),	 is	 located	 in	 the	 upstream	 region	 of	 PRTN3	 and	 downstream	 of	
azurocidin	1	(AZU1).	AZU1	encodes	a	protein	precursor	that	 is	proteolytically	processed	to	
generate	 a	 mature	 azurophil	 granule	 antibiotic	 protein	 with	 antimicrobial	 and	 monocyte	
chemotactic	activity.	AZU1,	neutrophil	elastase	2	(ELANE)	and	PRTN3	are	located	in	a	cluster.	
Their	mRNA	 expressions	 are	 coordinately	 controlled	 during	 neutrophil	 differentiation	 and	
their	protein	products	are	packaged	into	azurophil	granules.	The	lead	SNP	and	several	SNPs	
in	 strong	LD	with	 it	 (r2	>	0.6)	have	been	 reported	 to	be	associated	with	monocyte	count,	
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monocyte	percentage	of	white	cells,	white	blood	cell	count	and	basophil	percentage	of	white	
cells.	Furthermore,	it	is	a	known	eQTL	for	PRTN3,	complement	factor	D	(CFD)	and	mediator	
complex	 subunit	 16	 (MED16)	 in	 the	whole	blood,	where	 the	 risk	 allele	 for	 PR3-AAV	 (T)	 is	
associated	with	higher	expressions	of	PRTN3	(p	=	9.69	x	10-117)	and	CFD	(p	=	4.35	x	10-17)	but	
a	lower	expression	of	MED16	(p	=	1.394	x	10-5)	(318).	It	is	also	a	pQTL	where	the	PR3-AAV	risk	
allele	is	associated	with	an	increased	plasma	PR3	levels	(319).	There	are	four	independent	cis-
pQTL	association	signals	for	plasma	PR3	levels	in	this	locus	and	the	strongest	association	is	
rs10425544,	which	lies	in	the	promoter	region	of	PRTN3.	The	relationship	between	PR3-AAV	
associated	 variants	 and	PR3	pQTL	 variants	 are	 shown	 in	 Table	 3.5.	 Furthermore,	 a	 higher	
frequency	of	chromatin	interactions	was	observed	in	this	region	(see	Figure	3.8),	suggesting	
this	region	could	be	a	topologically	associating	domain	(TAD)	(395),	where	the	DNA	sequences	
physically	interact	with	each	other	more	often	than	with	sequences	outside	the	TAD,	which	
has	been	postulated	to	play	a	role	in	gene	regulation	and	its	disruption,	leading	to	disease.	
	
	
Figure	3.8:	Genomic	features	at	chr19p13.3	(PRTN3	region).	
Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	
GM12878	 cell	 line),	 SNPs	 association	 with	 PR3-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	
(rs55952682),	causal	variant	mapping	expressed	as	posterior	probability	(PP),	GWAS	significant	hits	in	the	region	
obtained	from	the	NHGRI-EBI	Catalog	of	published	GWAS	and	methylation	data.	
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Table	3.5:	LD	between	PR3-AAV	associated	variants	and	PR3	pQTL	variants.	
	 *Lead	pQTLs	 *Conditionally	independent	pQTLs	 Lyons	et	al	 Merkel	et	al	 Present	study	
rs10425544	 rs7254911	 rs351111	 rs6510982	 rs62132295	 rs62132293	 rs55952682	
rs7254911	
D’:	1.0	
r2:	0.0984	
-	 -	 -	 -	 -	 -	
rs351111	
D’:	0.86	
r2:	0.3079	
D’:	0.89	
r2:	0.1901	
-	 -	 -	 -	 -	
rs6510982	
D’:	0.97	
r2:	0.6068	
D’:	0.88	
r2:	0.0491	
D’:	1.0	
r2:	0.2692	
-	 -	 -	 -	
rs62132295	
D’:	0.70	
r2:	0.0620	
D’:	0.90	
r2:	0.6317	
D’:	0.91	
r2:	0.2523	
D’:	0.90	
r2:	0.0656	
-	 -	 -	
rs62132293	
D’:	0.72	
r2:	0.0709	
D’:	1.0	
r2:	0.7222	
D’:	0.88	
r2:	0.2533	
D’:	0.81	
r2:	0.0577	
D’:	1.0	
r2:	0.9202	
-	 -	
rs55952682	
D’:	1.0	
r2:	0.0952	
D’:	1.0	
r2:	0.9676	
D’:	0.89	
r2:	0.1828	
D’:	0.87	
r2:	0.0471	
D’:	0.93	
r2:	0.6562	
D’:	1.0	
r2:	0.0471	
-	
	
*pQTL	data	was	obtained	from	Sun	et	al	(319).		
LD	calculations	were	based	on	1000	Genomes	phase	3	European	ancestry	individuals	using	LDlink	(https://ldlink.nci.nih.gov/?tab=home).		
	
3.7 Fine-mapping	of	the	HLA	region	
The	HLA	region	contained	the	strongest	association	signals	in	the	PR3-AAV	GWAS,	including	
the	HLA-DQ	and	HLA-DP	loci.	The	most	significant	associated	variant	was	rs3130216	(HLA-DP;	
OR	=	2.58,	p	=	3.59	x	10-173)	following	a	meta-analysis	of	GWAS1	and	GWAS2.	Given	the	HLA	
region	is	known	to	show	extensive	linkage	disequilibrium,	I	performed	reciprocal	conditional	
association	analysis	to	dissect	the	independent	signals	in	this	region.	As	the	HLA	imputation	
was	performed	only	on	the	GWAS2	dataset,	I	focused	on	the	same.		
	
The	lead	SNP	in	the	HLA	region	for	GWAS2	PR3-AAV	was	rs1042169,	which	is	in	moderate	LD	
with	rs3130216	(r2	=	0.50)	and	was	reported	in	Merkel	et	al	as	one	of	the	top	hits	in	the	HLA-
DPB1	region	(71).	It	is	a	missense	variant	that	results	in	a	change	of	amino	acid	at	position	
113	from	glycine	to	aspartate	in	the	DP	beta	1	chain	precursor.	A	conditional	analysis	of	the	
top	variant	identified	two	additional	independent	variants,	rs9277569	(HLA-DPB1;	OR	=	2.49,	
conditional	p	=	8.20	x	10-39)	and	rs28407950	(HLA-DQ;	OR	=	1.50,	conditional	p	=	1.50	x	10-19)	
(Table	3.6).	Lastly,	conditioning	on	all	three	variants	accounted	for	the	entire	signal	seen	in	
the	HLA	region	(Figure	3.9).	
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Table	3.6:	Stepwise	conditional	analysis	of	the	HLA	region	for	PR3-AAV	(GWAS2)	
SNPs	
(*Chr:Position)	
Gene(s)	 Type	
 †Risk	
allele	
(RAF)	
Unconditioned	
‡p	value	
(OR)	
Conditioned	on	
rs1042169	 rs9277569	
rs1042169	
rs9277569	
rs1042169	
(6:33,048,686)	
HLA-DPB1	 Missense	
G	
(0.721)	
1.2	x	10-117	
(2.74)	
-	
6.2	x	10-140	
(3.08)	
-	
rs9277569	
(6:33,058,402)	
HLA-DPB1	 Intergenic	
C	
(0.892)	
1.6	x	10-14	
(1.69)	
8.2	x	10-39	
(2.49)	
-	 -	
rs28407950	
(6:32,626,348)	
HLA-DQ	
Regulatory	
region	
C	
(0.730)	
9.0	x	10-23	
(1.54)	
5.2	x	10-22	
(1.54)	
3.1	x	10-21	
(1.52)	
1.5	x	10-19	
(1.50)	
	
*	Genome	Reference	Consortium	Human	Build	37	(GRCh37).	
†	The	risk	allele	refers	to	the	effect	allele.	RAF,	risk	allele	frequency.	
‡	The	p-values	were	calculated	using	linear	mixed	model	(using	BOLT-LMM);	OR,	odds	ratio	with	respect	to	the	risk	allele.		
	
	
Figure	3.9:	The	HLA	associations	with	PR3-AAV	is	localised	to	the	Class	II	region.	
(A)	The	HLA	association	signals	in	PR3-AAV	(GWAS2)	and	the	genomic	coordinates	are	from	the	hg19	genome	
build.	The	HLA	association	signals	following	conditioning	on	(B)	rs1042169,	(C)	rs1042169	and	rs9277569	and	
(D)	rs1042169,	rs9277569	and	rs28407950	where	no	further	genome-wide	significant	signals	were	observed.	
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The	classical	HLA	alleles	at	2-	or	4-digit	resolution	and	amino	acid	variants	at	eight	HLA	loci	
were	 imputed.	 Univariate	 LMM	 analysis	 identified	 nine	 HLA	 alleles	 conferring	 either	
susceptibility	or	protection	to	PR3-AAV.	To	test	association	among	imputed	HLA	alleles	and	
amino	acid	variants,	I	used	a	forward	stepwise	strategy	to	establish	statistically	independent	
signals.	Within	each	variant	 type,	 I	 first	 identified	 the	most	significant	associated	signal	as	
defined	by	the	lowest	p-value	and	performed	forward	iterative	conditional	regression	analysis	
to	identify	other	independent	signals.		
	
I	identified	four	independent	HLA	signals	for	PR3-AAV,	three	of	which	conferred	risk	including	
HLA-DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	 and	 HLA-DPA1*	
01:03-HLA-DPB1*02:01	 while	 the	 remaining	 signal	 conferred	 protection	 by	 an	 extended	
haplotype	 encoding	 HLA-DRB1*01:01-HLA-DQA1*01:01-HLA-DQB1*05:01.	 The	 strongest	
independent	associations	with	disease	susceptibility	were	observed	at	HLA-DPB1*04:01	(OR	
=	2.52,	 p	 =	 4.60	 x	 10-116),	HLA-DPB1*04:02	 (OR	=	2.47,	 conditional	 p	 =	 5.90	 x	 10-38),	HLA-
DQA1*01:01	 (OR	 =	 0.71,	 conditional	 p	 =	 1.20	 x	 10-10)	 and	 HLA-DPB1*02:01	 (OR	 =	 1.41,	
conditional	p	=	3.50	x	10-7)	(Table	3.7	and	Figure	3.10).	In	addition,	HLA-DPB1*04:01	was	a	
stronger	signal	than	the	top	hit	SNP,	supporting	that	the	main	signal	in	the	region	is	indeed	
driven	by	the	HLA	allele.	
	
Individual	amino	acid	variants	in	HLA-DPB1,	HLA-DQB1	and	HLA-DRB1	were	associated	with	
disease.	Within	HLA-DPB1,	the	HLA	classical	alleles	had	stronger	associations	than	the	amino	
acid	variants.	There	were	significant	residual	effects	for	HLA-DPB1*04:01	(conditional	p	=	2.00	
x	10-7)	and	HLA-DPB1*02:01	(conditional	p	=	1.70	x	10-9)	after	conditioning	on	all	the	amino	
acid	associations	in	this	region.	Within	HLA-DQB1,	the	amino	acid	polymorphism	HLA-DQB1	
His30	(OR	=	0.64,	p	=	2.00	x	10-20),	which	is	located	in	the	peptide-binding	groove,	accounted	
for	 most	 of	 the	 HLA	 allele	 effects	 (HLA-DQB1*06:02,	 conditional	 p	 =	 0.00054	 and	 HLA-
DQB1*05:01,	 conditional	 p	 =	 0.23).	 Within	HLA-DRB1,	 there	 were	 no	 significant	 residual	
effects	for	HLA	classical	alleles	after	conditioning	on	the	most	significant	amino	acid	variants	
consisting	of	HLA-DRB1	Ala	or	Lys71	(OR	=	1.34,	p	=	1.10	x	10-11),	HLA-DRB1	Gly	or	Tyr13	(OR	
=	1.36,	conditional	p	=	5.50	x	10-9)	and	HLA-DRB1	Glu58	(OR	=	1.54,	conditional	p	=	2.30	x	10-
8)	-	all	of	which	are	part	of	the	peptide-binding	site	of	HLA-DRB1.	
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Table	3.7:	Association	of	classical	HLA	alleles	in	PR3-AAV	(GWAS2)	
MHC	allele	
	
Unconditioned	
Conditioned	on	
HLA-DPB1*04:01	 HLA-DPB1*04:01	
HLA-DPB1*04:02	
HLA-DPB1*04:01	
HLA-DPB1*04:02	
HLA-DQA1*01:01	
HLA-DPB1*04:01	
HLA-DPB1*04:02	
HLA-DQA1*01:01	
HLA-DPB1*02:01	
OR	 P	 OR	 P	 OR	 P	 OR	 P	 OR	 P	
HLA-DPB1*04:01	 2.52	 4.6	x	10-116	 -	 -	 -	 -	 -	 -	 -	 -	
HLA-DPA1*01:03	 2.36	 2.9	x	10-54	 1.58	 7.1	x	10-14	 1.25	 3.6	x	10-5	 1.27	 2.4	x	10-5	 1.12	 0.036	
HLA-DPA1*02:01	 0.42	 1.7	x	10-44	 0.65	 6.6	x	10-11	 0.82	 1.1	x	10-3	 0.82	 1.0	x	10-3	 0.93	 0.20	
HLA-DPB1*03:01	 0.43	 4.8	x	10-32	 0.66	 1.4	x	10-7	 0.83	 0.054	 0.83	 0.045	 0.94	 0.80	
HLA-DPB1*01:01	 0.44	 8.1	x	10-18	 0.69	 1.7	x	10-4	 0.86	 0.10	 0.83	 0.042	 0.93	 0.38	
HLA-DPB1*02:01	 0.60	 1.8	x	10-15	 1.02	 0.54	 1.40	 9.4	x	10-7	 1.41	 3.5	x	10-7	 -	 -	
HLA-DPA1*02:02	 0.49	 7.1	x	10-9	 0.71	 5.1	x	10-3	 0.84	 0.086	 0.82	 0.065	 0.90	 0.23	
HLA-DQA1*01:01	 0.74	 8.2	x	10-9	 0.76	 1.2	x	10-7	 0.71	 1.2	x	10-10	 -	 -	 -	 -	
HLA-DQB1*06:02	 1.37	 1.7	x	10-8	 1.04	 0.41	 -	 -	 -	 -	 -	 -	
HLA-DRB1*15:01	 1.34	 9.2	x	10-8	 1.01	 0.62	 -	 -	 -	 -	 -	 -	
HLA-DQB1*05:01	 0.74	 2.1	x	10-7	 0.77	 8.0	x	10-6	 0.71	 2.1	x	10-9	 0.92	 0.51	 -	 -	
HLA-DRB1*01:01	 0.75	 3.3x	10-6	 0.80	 1.6	x	10-4	 0.71	 4.0	x	10-8	 0.92	 0.36	 -	 -	
HLA-DPB1*04:02	 1.29	 3.3	x	10-4	 2.47	 5.9	x	10-38	 -	 -	 -	 -	 -	 -	
	
OR,	odds	ratio;	P,	p-values	were	calculated	using	a	linear	mixed	model	with	BOLT-LMM	software.
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Figure	3.10:	Associations	of	classical	alleles	with	PR3-AAV.			
Imputation	of	classical	alleles	identified	four	independent	signals	to	be	associated	with	PR3-AAV,	three	of	which	
conferred	susceptibility	while	one	was	protective.	
		
3.8 Discussion	
In	 this	 study,	 seven	 risk	 loci	 for	 PR3-AAV	were	 identified.	We	 replicated	 three	 previously	
identified	 genome-wide	 significant	 risk	 loci	 including	 HLA-DP,	 SERPINA1	 and	 PRTN3.	
Additional	four	risk	loci	were	implicated	in	PR3-AAV	for	the	first	time.	Within	the	classical	HLA	
alleles,	 three	 independent	 signals	 were	 identified	 to	 confer	 disease	 risk,	 including	 HLA-
DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	 and	 HLA-DPA1*01:03-
HLA-DPB1*02:01.	The	estimated	SNP	heritability	(h2SNP)	for	PR3-AAV	was	modest	(0.46	±	se	
0.03),	 indicating	 that	 46%	 of	 the	 variability	 in	 the	 trait	 in	 a	 population	 is	 due	 genetic	
differences	among	people.	This	estimate	 is	 largely	consistent	with	other	population-based	
heritability	estimates	such	as	Crohn’s	disease	(0.55),	type	2	diabetes	(0.42)	and	it	is	lower	than	
those	estimated	for	T1D	(0.80)	and	SLE	(0.66)	(396).	This	finding	supports	that	PR3-AAV	is	a	
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polygenic	disease	and	with	increasing	sample	sizes,	more	genetic	variants	are	expected	to	be	
identified.	
	
Among	the	potential	candidate	susceptibility	genes	identified,	PRTN3	is	well	studied	and	its	
potential	role	in	autoimmunity	is	supported	by	numerous	functional	studies	as	discussed	in	
section	 1.4.2.	 This	 locus	was	 reported	 in	 previous	 GWAS	 by	 EVGC	 and	 VCRC	 (albeit	 with	
different	 lead	 SNPs).	 The	 association	 was	 limited	 to	 the	 GPA	 and	more	 importantly,	 the	
association	 was	 stronger	 in	 the	 PR3-ANCA	 subset.	 Together	 with	 the	 eQTL	 and	 pQTL	
association	 signals	where	 the	 disease	 risk	 allele	 is	 associated	with	 a	 higher	 expression	 of	
PRTN3	and	a	higher	plasma	level	of	the	autoantigen	PR3,	these	findings	are	consistent	with	
the	pathophysiologic	relevance	of	PR3	serine	protease	to	the	phenotypes.	
	
In	addition,	the	second	most	significant	risk	allele	at	the	SERPINA1	locus	was	rs28929474:T	
(also	 known	 as	 the	 “Z”	 allele,	 which	 is	 in	 complete	 LD	with	 the	 lead	 SNP,	 rs112635299).	
rs28929474	 is	 a	 misssense	 variant	 (Glu342Lys)	 which	 results	 in	 defective	 secretion	 and	
intracellular	accumulation	of	A1AT,	leading	to	deficiency	of	circulating	A1AT	and	eventually	
leading	to	respiratory	complications	such	as	emphysema	and	liver	disease.	Recent	genome-
wide	plasma	proteomic	data	by	Sun	et	al	had	identified	that	the	Z	allele	was	associated	with	
lower	level	of	plasma	A1AT.	Despite	using	conservative	significance	threshold	(p	<	1.5	x	10-
11),	 it	was	 found	 to	 be	 associated	with	 13	 proteins	 (trans-pQTL),	 supporting	 that	 a	 single	
mutation	can	cause	perturbation	of	a	wide	range	of	downstream	proteins	(319).	Interestingly,	
one	 of	 these	 proteins	 was	 neutrophil	 cytosolic	 factor	 2	 (NCF2),	 which	 is	 involved	 in	 the	
neutrophil	oxidative	burst	reactions.	Mutations	in	NCF2	can	lead	to	chronic	granulomatous	
disease	which	 exhibits	 granulomatous	 inflammation,	 a	 pathognomonic	 pathological	 lesion	
with	 a	 predilection	 for	 the	 upper	 and	 lower	 respiratory	 tracts	 in	 patients	 with	 PR3-AAV.	
Furthermore,	 there	 were	 significant	 interactions	 between	 these	 SNPs	 (rs112635299	 and	
rs28929474)	and	the	promoters	of	several	candidate	target	genes,	some	of	which	are	involved	
in	 anti-bacterial	 (SERPINA5)	 and	 anti-inflammatory	 (SERPINA12)	 responses,	 altogether	
suggesting	 that	 there	 might	 be	 additional	 pathways	 contributing	 to	 the	 pathogenesis	 of	
disease.	
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These	data	show	that	the	PR3-AAV	risk	allele	at	PRTN3	increases	PRTN3	mRNA	expression	in	
the	 whole	 blood	 (318)	 and	 total	 PR3	 plasma	 levels	 while	 the	 SERPINA1	 Z-allele	 causes	 a	
reduction	in	circulating	A1AT	levels.	These	risk	alleles	 lead	to	an	altered	availability	of	PR3	
autoantigen,	 together	 with	HLA	 associated	 genetic	 predisposition	 (e.g.	HLA-DPB1*04:01),	
increase	 the	 susceptibility	 for	 breaking	 immune	 tolerance	 and	 the	production	of	 anti-PR3	
antibodies.	Apart	from	in	vitro	experiments	and	animal	models	as	well	as	clinical	studies,	the	
genetic	evidence	strongly	supports	that	anti-PR3	antibodies	are	pathogenic	rather	than	an	
epiphenomenon.	
	
Infection	has	long	been	suggested	as	a	trigger	for	induction	and	reactivation	of	different	forms	
of	vasculitides.	Large-vessel	vasculitis	has	been	associated	with	Mycobacterium	tuberculosis	
(Takayasu	arteritis)	and	Burkholderia	bacterium	(GCA)	while	hepatitis	B	and	C	viruses	have	
been	related	to	PAN,	which	have	a	different	clinical	phenotype	from	non-viral	PAN	(397).	The	
pathogenesis	of	GPA,	where	PR3-ANCA	is	the	predominant	serotype,	has	been	linked	to	S.	
aureus	which	is	a	Gram-positive,	commensal	bacterium.	It	has	consistently	been	shown	that	
about	60-70%	of	GPA	patients	are	chronic	nasal	carriers	of	S.	aureus	as	compared	to	only	20-
30%	of	general	population	(42,	398-400).	Moreover,	S.	aureus	nasal	carriage	is	associated	with	
an	 increased	 risk	of	 relapse	 in	GPA	patients	and	prophylactic	antimicrobial	 co-trimoxazole	
(trimethoprim/sulfamethoxazole)	treatment	reduces	the	risk	of	relapse	(42,	231).	A	recent	
nasal	microbiome	study	using	deep	sequencing	methods	in	GPA	patients	demonstrated	that	
GPA	was	associated	with	an	altered	microbial	composition,	at	both	the	bacterial	and	fungal	
levels	(401).	However,	the	authors	did	not	observe	a	difference	in	the	relative	abundance	of	
S.	aureus	between	GPA	patients	(n	=	60,	comprising	60%	PR3-ANCA	positive,	25%	MPO-ANCA	
positive	and	15%	ANCA	negative	 individuals)	 and	healthy	 controls	 (n	=	41),	of	which	 they	
attributed	the	discrepancy	with	prior	studies	to	the	differences	in	methodology	including	the	
location	within	 the	nasal	 cavity	where	 the	 swabbing	was	performed.	 In	 contrast,	 a	 recent	
abstract	by	Kronbichler	et	al,	where	they	investigated	the	changes	of	the	nasal	microbiome	
using	 culture,	 bacterial	 16S	 rRNA	profiling	 and	 shotgun	metagenomics	 sequencing	 in	GPA	
patients	(both	active	and	in	remission),	disease	controls	including	MPA	or	EGPA	patients	as	
well	as	healthy	controls,	observed	a	different	composition	of	Staphylococcus	spp.	between	
active	GPA	patients	versus	healthy	controls	and	disease	controls.	They	found	that	patients	
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with	active	GPA	had	a	higher	abundance	of	S.	aureus,	while	healthy	controls	had	a	higher	
abundance	of	S.	epidermidis	(402).	However,	the	exact	mechanism	by	which	the	pathogen	
triggers	vasculitis	remains	unclear.	
	
For	most	microorganisms,	iron	is	an	essential	nutrient	for	colonization	and	pathogenesis.	S.	
aureus	has	evolved	sophisticated	mechanisms	to	acquire	iron	from	the	host	organism,	known	
as	the	iron-regulated	surface	determinant	(Isd)	system,	which	is	activated	in	response	to	iron	
depletion.	 It	comprises	a	group	of	proteins	that	captures	(IsdH	and	IsdB),	transports	(IsdA,	
IsdC	 and	 transmembrane	 complex	 IsdEF-FhuD)	 and	 metabolises	 (IsdD	 and	 IsdI)	 heme	
molecules	to	extract	the	 iron	atom.	 IsdB,	which	 is	an	extracellular	receptor,	 functions	as	a	
central	 component	 of	 removing	 heme	 from	 haemoglobin	 (403,	 404).	 It	 contains	 two	
structurally	conserved	NEAr-iron	Transporter	(NEAT)	domains,	NEAT1	(Hb	binding)	and	NEAT2	
(heme	binding),	that	function	synergistically	(405).	The	NEAT	domains	are	also	found	in	other	
Gram-positive	 human	 pathogens	 such	 as	 Bacillus	 anthracis,	 Streptococcus	 pyogenes,	
Clostridium	perfringens	and	Listeria	monocytogenes	(406).	It	has	been	demonstrated	that	S.	
aureus	strains	lacking	IsdB	had	a	reduction	in	virulence	due	to	inability	to	bind	haemoglobin	
for	iron	acquisition	in	a	murine	model	of	abscess	formation	(407,	408).	A	recombinant	anti-
IsdB	was	isolated	from	the	Cambridge	Antibody	Technology	antibody	library	over	a	decade	
ago	and	it	was	shown	to	confer	protection	against	S.	aureus	infection	in	a	murine	lethal	sepsis	
model	when	dosed	prior	to	challenge	(409).	Importantly,	a	high	level	of	serum	titre	against	
IsdB	had	been	observed	in	patients	with	S.	aureus	infection	(410).		
	
Yeung	 and	 colleagues	 recently	 demonstrated	 that	 there	was	 a	 heavily	 biased	 use	 of	 two	
immunoglobulin	heavy	chain	germlines	generated	antibodies	that	neutralise	NEAT1	(IGHV4-
39)	 and	 NEAT2	 (IGHV1-69)	 domains	 respectively.	 Notably,	 they	 found	 that	 the	 antibody-
antigen	binding	mechanism	was	nearly	identical	despite	antibody	derivation	from	different	
donors.	Though	being	a	part	of	 the	adaptive	 immune	system,	 the	authors	postulated	that	
both	IGHV1-69	and	IGHV3-49	might	have	evolved	under	selection	pressure	to	encode	binding	
motifs	 that	 are	 capable	 of	 recognising	 and	 neutralising	 structurally	 conserved	 protein	
domains,	which	are	involved	in	iron	acquisition	across	different	pathogens.	More	importantly,	
the	authors	demonstrated	that	allelic	variation	at	position	50	 in	 IGHV1-69	 (G50R,	the	 lead	
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SNP	 in	 chr14q32.33	 locus)	 completely	 abolished	 NEAT2	 binding	 presumably	 from	 steric	
hindrance,	which	 led	 us	 to	 posit	 a	 potential	 host	 genetic	 factor	 in	 PR3-AAV	 patients	 that	
predisposes	them	to	chronic	S.	aureus	nasal	carriage,	where	the	risk	allele	results	in	a	change	
of	amino	acid	in	the	framework	region	2	of	the	heavy	chain	leading	to	a	reduction	in	their	
ability	to	neutralise	NEAT2-mediated	heme-iron	acquisition.	Furthermore,	rs55891010	(F54L)	
which	is	in	high	LD	with	the	lead	SNP	(r2	=	0.93)	was	previously	shown	to	encode	a	functionally	
critical	 residue	 for	broadly	neutralising	antibodies	against	 the	 influenza	HA	stem	 (HV1-69-
sBnAb)	where	the	L-allele	was	associated	with	a	weaker	binding	affinity	to	HA	(411,	412)	and	
individuals	carrying	L-alleles	had	consistently	been	shown	to	have	 lower	 levels	of	HV1-69-
sBnAbs	(387,	390,	393).	Several	case	reports	have	described	a	temporal	association	of	AAV	to	
influenza	 vaccination	 (413,	 414),	 which	 raises	 another	 possibility	 that	 influenza	 antigens	
might	serve	as	a	trigger	for	AAV	induction	in	genetically	predisposed	individuals.	Although	the	
roles	of	Ig	germ-line	polymorphisms	have	not	been	extensively	explored,	there	is	a	growing	
body	 of	 evidence	 to	 support	 that	 they	 can	 influence	 antibody	 repertoire	 and	 functional	
variation	in	protective	antibody	responses.	
	
3.9 Conclusions	
Through	meta-analysis	of	two	PR3-AAV	European	cohorts	comprising	13,557	individuals,	this	
study	provides	conclusive	evidence	 that	PR3-AAV	 is	a	polygenic	disease.	A	majority	of	 the	
candidate	genes	identified	are	involved	in	the	immune	pathway,	offering	new	leads	into	the	
pathogenesis	of	PR3-AAV.	Our	study	also	presents	a	plausible	host	genetic	factor	(IGHV1-69;	
rs11845244:C>T;	 G50R)	 in	 determining	 the	 susceptibility	 to	 infectious	 disease	 and	 as	 a	
potential	driver	of	PR3-AAV.	
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4 Genetic	relationship	of	MPO-AAV	and	PR3-AAV	
4.1 Introduction	
The	 epidemiological	 and	 clinical	 manifestations	 of	 AAV	 differ	 geographically.	 The	 overall	
annual	 incidence	 of	 AAV	 was	 similar	 between	 Japan	 and	 the	 UK	 (36).	 However,	 the	
predominant	subtype	observed	in	Japan	was	MPA,	accounting	for	83%	of	patients	and	more	
than	 80%	 were	MPO-ANCA	 positive.	 A	 similar	 pattern	 was	 observed	 in	 China	 (415,	 416)	
although	population-based	data	is	lacking.	Previous	GWAS	in	the	European	population	have	
only	 identified	 one	 genome-wide	 significant	 locus	 within	 the	 HLA	 region	 (HLA-DQ)	 to	 be	
associated	 with	 MPO-AAV	 (70,	 71)	 while	 genetic	 data	 from	 Asian	 countries	 are	 scarce,	
primarily	candidate	gene	analyses	and	most	genetic	variants	are	not	widely	confirmed	except	
the	 HLA	 alleles.	 The	 presence	 of	 HLA-DRB1*09:01	 and	 HLA-DRB1*11:01	 alleles	 were	
associated	with	MPO-AAV	in	both	Japanese	and	Chinese	populations	respectively	(68,	69).	
Although	there	is	a	substantial	overlap	in	the	clinicopathological	phenotypes	between	MPO-
AAV	and	PR3-AAV,	the	genetic	relationship	between	the	two	syndromes	has	not	previously	
been	defined.	
	
In	order	to	discover	additional	risk	loci	associated	with	MPO-AAV,	a	total	of	606	MPO-AAV	
cases	from	Europe,	along	with	6,688	population	matched	controls,	were	genotyped	on	the	
UK	Biobank	Axiom	array.	A	meta-analysis	was	then	performed	with	the	AAV	GWAS	by	Lyons	
et	al	(70).		
	
In	 this	 chapter,	 I	 will	 discuss	 the	 identification	 of	 five	 risk	 loci	 associated	with	MPO-AAV	
including	the	HLA	region.	Within	the	HLA	region,	two	independent	signals	were	identified	in	
a	region	encompassing	the	butyrophilin-like	protein	2	(BTNL2)	and	HLA-DQ.	Furthermore,	the	
genome-wide	genetic	correlation	(rG)	between	MPO-AAV	and	PR3-AAV	was	estimated	based	
on	common	variants	of	the	genotyped	data	using	a	bivariate	linear	mixed	model,	confirming	
a	high	similarity	in	the	genetic	architecture	between	the	two	syndromes.	
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4.2 Samples	and	genotype	data	
Following	sample	and	SNP	QC,	a	total	of	469,699	SNPs	from	GWAS1	and	558,830	SNPs	from	
GWAS2	respectively	were	available	for	analysis.	The	breakdown	of	the	number	of	patients	
included	in	the	meta-analysis	of	MPO-AAV	is	summarised	in	Table	4.1	.	
	
Table	4.1:	The	number	of	cases	and	controls	included	in	the	meta-analysis	of	MPO-AAV	
Cohort	 No	of	Controls	 No	of	Cases	
GWAS1	 5,259	 264	
GWAS2	 6,688	 606	
†Sequenom	Genotype	(rs6679677)	 1,531	 347	
Total	 13,478	 1,217	
	
†For	rs6679677,	a	further	cohort	was	available	for	meta-analysis	where	the	genotyping	was	performed	using	
the	Sequenom	MassARRAY	platform	in	the	replication	cohort	of	Lyons	et	al	2012.	
	
4.3 Association	testing	with	genotype	data	
I	performed	association	testing	of	the	genotype	data	using	two	analytic	methods	–	logistic	
regression	and	LMM	as	implemented	in	BOLT-LMM.	A	comparison	was	made	between	the	
two	methods	and	summarised	in	Table	4.2.	There	was	a	minimal	genomic	inflation	observed	
in	GWAS1	(lgc	=	1.01)	as	all	the	cases	and	controls	were	from	the	UK.	In	contrast,	the	lgc	for	
GWAS2	 was	 reduced	 from	 1.242	 to	 1.094	 after	 fitting	 20	 PCs	 as	 covariates	 in	 a	 linear	
regression	model.	 Similarly,	 the	 LMM	method	 reduced	 the	lgc	 to	 1.094,	 supporting	 that	
population	stratification	in	GWAS2	was	well	controlled	for	(Figure	4.1).	
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Table	4.2:	A	comparison	of	logistic	regression	and	linear	mixed	model	analyses	
Genotyped	data	
MPO-AAV	(lambda,	l)	
GWAS1	 GWAS2	
No	covariates	 1.014	 1.242	
3	PCs	 1.015	 1.121	
6	PCs	 1.014	 1.099	
20	PCs	 1.012	 1.094	
LMM	 0.999	 1.094	
*LMM	(imputed	data)	 0.999	 1.073	
	
LMM,	linear	mixed	model;	PCs,	principal	components.	
Lambda,	λ	is	the	ratio	of	the	median	of	the	observed	chi-squared	statistics	to	the	median	of	the	expected	chi-
squared	statistics	under	the	null	hypothesis.	
*	indicates	genomic	inflation	factor	calculated	using	imputed	data.	
	
	
	
Figure	4.1:	Quantile-quantile	plots	and	genomic	inflation	factors.		
Association	 tests	 were	 performed	 on	 genotyped	 data	 and	 comparison	 between	 logistic	 regression	 with	 no	
covariates,	varying	numbers	of	principal	components	(PCs)	as	covariates	and	LMM	for	MPO-AAV	in	(A)	GWAS1	
and	 (B)	GWAS2	 respectively.	 The	HLA	 region	 and	 SNPs	with	 genome-wide	 significant	 associations	were	 not	
included	in	the	QQ	plots.	The	black	line	is	y	=	x.	Additional	PCs	as	covariates	did	not	alter	the	genomic	inflation	
factors.	
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4.4 Association	testing	of	the	imputed	data	and	meta-analysis	
Following	QC	of	the	imputed	data,	a	total	of	7,656,576	and	7,744,534	autosomal	markers	in	
GWAS1	and	GWAS2	respectively	with	MAF	≥	0.01	and	r2	≥	0.3	were	available	for	downstream	
analyses.	Of	these,	7,576,565	SNPs	were	in	common	to	both	cohorts	for	meta-analysis.	Case-
control	association	testing	was	performed	using	the	LMM	model	to	minimise	the	effect	of	
population	stratification	and	meta-analysis	was	performed	using	an	inverse-variance	method	
based	on	a	fixed	effects	model.	
	
A	total	of	five	MPO-AAV	susceptibility	loci	were	identified	(Table	4.3).	In	three	of	the	five	risk	
loci	identified,	the	most	significant	SNP	within	each	locus	was	a	common	variant	(MAF	>	0.05)	
of	 modest	 effect	 where	 ORs	 ranged	 between	 1.37-1.82.	 The	 strongest	 association	 was	
observed	at	the	HLA	region	(rs116522341,	MAF	=	0.04)	where	the	OR	was	4.80	(95%	CI	3.67-
6.26,	pmeta	=	1.09	x	10-30).	The	lead	SNP	(rs79005509)	in	the	remaining	risk	locus	(chr6q15)	
was	a	low-	frequency	variant	(MAF	=	0.02)	with	an	OR	of	2.90	(95%	CI	2.00-4.20,	pmeta	=	1.90	
x10-8).	Subsequent	stepwise	conditional	regression	analyses	within	each	non-HLA	locus	did	
not	identify	additional	independent	genome-wide	significant	signals.	
	
For	PTPN22	(rs6679677),	a	further	replication	cohort	that	was	previously	genotyped	using	the	
Sequenom	MassARRAY	platform	was	included	for	combined	analysis,	consisting	of	347	MPO-
AAV	cases	and	1,531	controls.	Following	the	second-stage	meta-analysis,	rs6679677:A	was	
associated	with	an	increased	risk	of	MPO-AAV	with	an	OR	of	1.47	(95%	CI	1.29-1.67,	pmeta	=	
5.50	x	10-9).	
	
4.5 Genetic	heritability	
To	quantify	the	genetic	influence	on	MPO-AAV,	the	total	SNP	heritability	(h2SNP)	was	estimated	
using	the	genome-wide	genotyped	variants	(MAF	≥	0.01)	and	additively,	they	explained	33%	
of	 the	 total	 disease	 liability	 (se	 =	 0.02),	 for	 a	 population	 prevalence	 of	 50	 per	 million	
population	(338).	This	was	slightly	lower	than	PR3-AAV	(h2SNP	=	0.46,	se	=	0.03).	
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Table	4.3:	HLA	and	non-HLA	associations	with	MPO-AAV.	
§SNP	 ¶Chr	 ¶Position	 Gene(s)	
*Risk	
allele	
RAF	
GWAS1		
(264	cases	vs	5,259	controls)	
GWAS2		
(606	cases	vs	6,688	controls)	
Meta-analysis		
(870	cases	vs	11,947	controls)	
†OR	(95%	CI)	  yP	 †OR	(95%	CI)	 yP	 †OR	(95%	CI)	 ∆P	
‡rs2476601	 1p13.2	 114,377,568	 PTPN22	 A	 0.10	 1.52	(1.13-2.05)	 5.50	X	10-3	 1.52	(1.27-1.83)	 1.40	X	10-6	 1.49	(1.28-1.74)	 3.13	X	10-7	
‡rs6679677	 1p13.2	 114,303,808	 PTPN22	 A	 0.10	 1.50	(1.13-2.01)	 5.70	X	10-3	 1.52	(1.27-1.83)	 1.30	X	10-6	 1.48	(1.27-1.73)	 3.51	X	10-7	
rs115670873	 2p13.1	 74,171,061	 DGUOK,	TET3	 A	 0.93	 1.97	(1.05-3.68)	 3.50	x	10-2	 1.69	(1.38-2.08)	 8.50	x	10-7	 1.82	(1.46-2.27)	 7.60	x	10-8	
rs116522341	 6p21.32	 32,367,697	 BTNL2,	HLA-DQ	 G	 0.04	 4.80	(2.80-8.23)	 1.10	X	10-8	 5.11	(3.76-6.94)	 6.00	X	10-25	 4.80	(3.67-6.26)	 1.09	X	10-30	
rs79005509	 6q15	 90,850,730	 BACH2	 T	 0.02	 7.28	(3.21-16.52)	 2.00	X	10-6	 1.98	(1.33-2.95)	 8.90	X	10-4	 2.90	(2.00-4.20)	 1.90	X	10-8	
rs2965955	 16q24.3	 89,524,923	 ANKRD11,	SPG7	 C	 0.69	 1.40	(1.15-1.69)	 5.80	X	10-4	 1.39	(1.23-1.58)	 7.70	X	10-8	 1.37	(1.24-1.51)	 9.64	X	10-10	
	
§	SNPs	showing	the	most	significant	level	of	association	after	meta-analysis	of	GWAS1	and	GWAS2.		
¶	Genomic	coordinates	from	Genome	Reference	Consortium	Human	Build	37	(GRCh37/hg19);	Chr,	chromosome.		
*	The	risk	allele	refers	to	the	effect	in	the	overall	meta-analysis.	RAF,	risk	allele	frequency.	
†	The	odds	ratio	(OR)	is	with	respect	to	the	risk	allele.	CI,	confidence	interval.	
y	The	p-values	were	calculated	using	a	linear	mixed	model	(BOLT-LMM).	
∆	The	p-values	were	calculated	using	inverse-variance	method	based	on	a	fixed-effects	model.	
‡	rs2476601	and	rs6679677	are	the	lead	SNPs	at	chr1p13.2.	A	further	replication	cohort	was	available	for	rs6679677	for	second-stage	meta-analysis	consisting	of	347	MPO-
AAV	cases	and	1,531	controls,	resulting	in	a	final	pmeta	=	5.50	x	10-9.
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4.6 Candidate	gene	prioritisation	(non-HLA	loci)	
To	prioritise	candidate	genes,	I	first	performed	fine	mapping	of	all	the	risk	loci	identified	using	
the	Bayesian	approach	to	generate	credible	sets	of	SNPs.	I	then	searched	for	nonsynonymous	
coding	and	known	eQTL	among	the	lead	SNPs	or	SNPs	in	high	LD	with	them	(r2	>	0.6).	Risk	
loci	were	functionally	annotated	using	multiple	publicly	available	datasets,	similar	to	PR3-AAV	
(see	section	3.6).	The	results	are	summarised	in	Table	4.4.	
	
4.6.1 PTPN22	
The	two	most	significant	associations	that	were	observed	in	chr1p13.2	were	rs2476601	and	
rs6679677.	They	are	in	complete	LD	(r2	=	1.0)	and	as	expected,	the	effect	sizes	for	these	two	
variants	were	equivalent.	rs2476601	is	a	missense	variant	(R620W)	which	has	been	studied	
quite	extensively	over	the	last	two	decades.	Its	potential	role	in	autoimmunity	is	supported	
by	 several	 functional	 studies	 as	 discussed	 in	 section	 1.4.2.	 It	 has	 been	 reported	 to	 be	
associated	with	a	wide	range	of	autoimmune	diseases	including	RA	(90,	417),	T1D	(91-93),	
thyroid	diseases	(95,	96),	Crohn’s	disease	(131),	alopecia	areata	(418),	vitiligo	(374)	and	SLE	
(129).	 Importantly,	 this	 variant	 showed	 the	 same	 direction	 of	 effect	 (i.e.	 same	 allele	
associated	with	higher	risk	of	MPO-AAV	and	other	autoimmune	diseases).	It	was	also	reported	
in	 the	VCRC	GWAS	 (71),	although	 the	p-value	 for	 the	MPO-AAV	subset	 fell	 just	below	the	
genome-wide	significance	threshold.	Furthermore,	the	PCHi-C	data	showed	 interactions	of	
this	SNP	with	multiple	gene	promoters	in	total	B	cell,	CD4	and	CD8	T	cells	(see	Table	4.4	and	
Figure	 4.2)	 and	 notably,	 three	 of	 the	 new	 plausible	 candidate	 genes	 (TRIM33,	HIPK1	 and	
NRAS)	might	be	of	biological	relevance	to	the	pathogenesis	of	disease.		
	
TRIM33	(tripartite	motif-containing	33),	also	known	as	transcriptional	intermediary	factor	1-
g,	which	is	a	modulator	of	transforming	growth	factor-b	(TGF-b)	signalling	that	associates	with	
SMAD	family	member	2	 (SMAD2),	was	 recently	demonstrated	 to	play	a	critical	 role	 in	 the	
regulation	of	proinflammatory	function	of	Th17	cells.	TRIM33	deficient	T	cells	ameliorated	
autoimmune	phenotype	in	the	experimental	autoimmune	encephalomyelitis	mouse	model	
by	upregulating	the	expression	of	IL-10	and	suppressing	the	production	of	IL-17	(419).	Several	
studies	have	indicated	that	Th17	cells	might	play	a	role	in	AVV	pathogenesis.	Expansion	of	
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Th17	cells	was	 found	 in	both	active	and	quiescent	GPA	patients	 (420).	 In	addition,	higher	
serum	levels	of	IL-17A	and	IL-23	were	observed	in	acute	AAV	patients	as	compared	to	healthy	
controls,	and	levels	remained	elevated	in	a	proportion	of	patients	despite	disease	remission	
(421).	IL-17A	deficient	mice	also	displayed	substantially	less	renal	injury	in	the	experimental	
autoimmune	anti-MPO	vasculitis	model	(422).	
	
HIPK1	 (homeodomain-interacting	 protein	 kinase-1)	 is	 one	 of	 the	 four	 highly	 related	
serine/threonine	 kinases	 identified	 as	 corepressors	 for	 several	 homeodomain-containing	
transcription	 factors	 and	 TNF-mediated	 cellular	 apoptosis	 (423).	 HIPK1	 is	 ubiquitously	
expressed	 and	 relatively	 abundant	 in	 the	 naïve	 B	 cells,	 CD8	 T	 cells,	 neutrophils	 and	
monocytes.	 HIPK1	was	 shown	 to	 play	 an	 essential	 role	 in	 splenic	 B	 cell	 homeostasis	 and	
function	where	HIPK1-/-	mice	exhibited	a	reduction	of	total	B	cells	 in	the	spleen,	especially	
transitional-1	and	follicular	B	cell	populations	and	the	humoral	response	was	impaired	despite	
an	expansion	of	marginal	zone	B	cell	population	(424).		
	
NRAS	 (also	 known	 as	 NRAS	 proto-oncogene,	 GTPase)	 encodes	 N-Ras	which	 is	 involved	 in	
regulating	 cell	 division.	 Mutations	 in	 NRAS	 causes	 autoimmune	 lymphoproliferative	
syndrome,	 which	 is	 characterised	 by	 an	 expansion	 of	 non-malignant	 lymphocytes	 due	 to	
defective	 apoptosis,	 an	 increased	 risk	 of	 autoimmunity	 and	 haematological	 malignancies	
(425).	Similar	phenotypes	are	observed	in	the	mutant	mouse	strain	(obtained	from	mouse	
genome	informatics	http://www.informatics.jax.org).		
	
4.6.2 DGUOK/TET3	
The	lead	SNP	(rs115670873)	in	this	locus	was	the	same	as	PR3-AAV,	with	equivalent	effect	
size	 and	 direction,	 although	 its	 p-value	 was	 just	 below	 the	 threshold	 for	 genome-wide	
significance	(pmeta	=	7.60	x	10-8).	See	3.6.1	for	further	details	about	this	region.	
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Table	4.4:	Candidate	genes	at	MPO-AAV	associated	risk	loci	
SNP	 Most	likely	
causal	
gene(s)	
Type	of	
variants	
Diseases	or	traits	associated	with	the	lead	SNP	or	in	high	LD	
with	lead	SNP	(r2	>	0.6)	or	in	proximity	to	candidate	gene(s)	
*Cis-eQTL	(blood/relevant	tissues)	 ‡Immune	
phenotype	in	
murine	model	
PCHi-C	prioritised	
protein	coding	
gene(s)	
PCHi-C	prioritised	
non-protein	coding	
transcript(s)	Disease	or	trait	(SNP)	 Relationship	
rs2476601	 PTPN22	
(R620W)	
Missense	 RA,	RA	(ACPA-positive)	(90,	417)	 Same	 PTPN22,	DCLRE1B,	PHTF1,	AP4B1-AS1,	
AP4B1	
PTPN22,	NRAS	 PTPN22,	NRAS,	
CSDE1,	TRIM33,	
HIPK1,	AP4B1,	
DCLRE1B,	OLFML3,	
BCL2L15,	RHOC,	
RHOC	
RP5-1073O3.7,	
AP4B1-AS1	
T1D	(91-93)	
Hypothyroidism,	Grave’s	disease	(95,	96)	
Crohn’s	disease	(131)	
Alopecia	areata	(418),	vitiligo	(374)	
SLE	(129)	
JIA	(130),	AS	(99)	(rs6679677)	 r2	=	1.0	
rs79005509	 BACH2	 Intronic	 Eosinophil	counts	(346)	 In	proximity	 BACH2	 BACH2	 BACH2	 AL391559.1,	
snoU13	T1D	(426)	,	coeliac	disease	(97)	
Crohn’s	disease	(427)	
Vitiligo	(374),	SLE	(369)	
MS	(428)	
rs2965955	 ANKRD11	
SPG7	
Intronic	 Lymphocyte	count	(346)	 In	proximity	 ANKRD11,	RPL13,	MC1R,	SPG7,	SPATA2L,	
DBNDD1,	SPIRE2,	ZNF276,	FANCA,	
AC137932.6,	AC137932.5,	TRAPPC2L,	
VPS9D1,	TCF25,	CHMP1A	(whole	blood);	
†SPG7	(renal	tubule);	RP11-368I7.4	(testis);		
CPNE7	(prostate);	SPG7	(muscles);	CHMP1A	
(thyroid);	SPIRE2	(skin);	FANCA	(nerve)	
FANCA	 ANKRD11,	CDK10,	
SPG7,	PIEZO1,	MVD	
RP11-368I7.4	
CD4	cells	(%Th22)	(429)	
Multiple	myeloma	(IgH	translocation)	(430)	
	
ACPA,	anti-citrullinated	protein	antibody;	AS,	ankylosing	spondylitis;	eQTL,	expression	quantitative	trait	loci;	JIA,	juvenile	idiopathic	arthritis;	MS,	multiple	sclerosis;	PCHi-C,	promoter	capture	Hi-C	data;	
RA,	rheumatoid	arthritis;	SLE,	systemic	lupus	erythematosus;	T1D,	type	1	diabetes;	%,	percentage.			
*The	lead	SNPs	or	SNPs	in	high	LD	with	them	that	are	known	eQTLs	(obtained	from	GTEx	and	http://www.eqtlgen.org/index.html)	(317,	318).		
‡The	immune	phenotype	designation	was	taken	from	http://www.informatics.jax.org/phenotypes.shtml.	
†eQTL	in	renal	tubule	was	obtained	from	human	kidney	eQTL	atlas	(http://susztaklab.com/eqtl)	(431).
		
	113	
	
Figure	4.2:	Genomic	features	at	chr1p13.2	(PTPN22	region).	
Top	to	bottom	panels:	Genomic	position	(hg19),	representative	RefSeq	genes,	PCHi-C	data	(Javierre	et	al	–	total	
CD8),	 SNPs	association	with	MPO-AAV	where	 the	 filled	 red	circle	 indicates	 the	 lead	SNP	 (rs2476601),	 causal	
variant	mapping	expressed	as	posterior	probability	(PP),	GWAS	significant	hits	in	the	region	obtained	from	the	
NHGRI-EBI	catalog	of	published	GWAS	and	methylation	data.		
	
4.6.3 BACH2	
The	two	most	significant	associations	in	chr6q15,	rs79005509	and	rs78275221	(pmeta	=	1.90	x	
10-8	and	pmeta	=	7.87	x	10-8	respectively,	r2	=	0.88)	are	located	in	the	intron	of	BTB	domain	and	
CNC	homolog	2	(BACH2).	It	encodes	a	leucine	zipper	transcription	regulator.	Although	neither	
of	these	variants	has	been	reported	to	be	associated	with	any	trait	or	disease,	this	locus	has	
independently	 been	 linked	 to	multiple	 inflammatory	 diseases	 including	 T1D	 (426),	 coeliac	
disease	(97),	Crohn’s	disease	(427),	vitiligo	(374),	SLE	(369)	and	MS	(428).	In	addition,	both	
rs79005509	 and	 rs78275221	 are	 known	 eQTLs	 where	 the	 risk	 alleles	 for	 MPO-AAV	 are	
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associated	with	reduced	expression	of	BACH2	in	the	whole	blood	(p	=	2.59	x	10-21	and	Z-score	
=	-9.48	for	rs79005509;	p	=	4.44	x	10-24	and	Z-score	=	-10.12	for	rs78275221)	(318).	The	PCHi-
C	data	showed	significant	interactions	between	these	SNPs	with	the	promoter	of	BACH2	in	
CD4	and	CD8	T	cells	(Figure	4.3).		
	
BACH2	 is	 most	 abundantly	 expressed	 in	 the	 bone	marrow	 and	 immune	 system	with	 the	
highest	expression	found	in	germinal	centre	B	cells,	followed	by	naïve	B	cells,	CD4	T	cells,	class	
switched	memory	 B	 cells	 and	 CD8	 T	 cells	 (BLUEPRINT	 data	 release	 2016-08).	 It	 acts	 as	 a	
repressive	 transcription	 regulator,	 maintaining	 the	 balance	 of	 a	 network	 of	 all	 other	
transcription	factors	which	are	critical	for	B	and	T-cell	differentiation	and	maturation.	Its	role	
in	B-cell	development	has	been	studied	greatly	where	it	represses	the	expression	of	Blimp-1	
(a.k.a.	PR	domain	zinc	 finger	1)	 (432),	 to	decelerate	plasma	cell	differentiation	and	permit	
antibody	 class	 switch	 recombination	 (433-435).	 In	 T	 cells,	BACH2	 modulates	 networks	 of	
genes	that	control	T	cell	effector	lineages	(316),	balancing	differentiation	into	effector	cells	
and	development	of	FoxP3+	regulatory	T	cells	(Treg)	(436).	BACH2-/-	mice	exhibit	impaired	B-
cell	 differentiation	 in	 the	 marginal	 and	 follicular	 zones	 of	 the	 spleen,	 impaired	 somatic	
hypermutation	with	decreased	number	of	mature	B	cells	and	absence	of	germinal	center	B	
cells.	These	mice	also	have	low	number	Treg	cells	and	an	excess	number	of	effector	T	cells,	
leading	to	autoimmunity	and	death	prematurely	between	3-9	months	of	age	(436).	Afzali	et	
al	recently	described	a	syndrome	called	BACH2-related	immunodeficiency	and	autoimmunity	
(BRIDA)	resulting	from	BACH2	haploinsufficiency,	where	patients	displayed	reduced	Treg	cells,	
enhanced	 Th1	 differentiation,	 defective	 B-cell	 proliferation	 and	 maturation,	 leading	 to	
profound	Ig	deficiency	and	colitis	requiring	intravenous	Ig	treatment	(437).	
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Figure	4.3:	Genomic	feature	at	chr6q15	(BACH2	region).	
Top	to	bottom	panels:	Genomic	position	(hg19),	representative	RefSeq	genes,	PCHi-C	data	(Javierre	et	al	–	total	
CD4),	SNPs	association	with	MPO-AAV	where	the	filled	red	circle	indicates	the	lead	SNP	(rs79005509),	causal	
variant	mapping	expressed	as	posterior	probability	(PP),	GWAS	significant	hits	in	the	region	obtained	from	the	
NHGRI-EBI	catalog	of	published	GWAS	and	methylation	data.	
	
4.6.4 ANKRD11/SPG7	
The	top	association	signal	in	chr16q2.3,	rs2965955	(pmeta	=	9.64	x	10-10),	is	located	in	the	intron	
of	ankyrin	repeat	domain	11	(ANKRD11).	More	than	half	of	the	variants	within	the	credible	
set	 are	 located	 in	 the	 region	 with	 evidence	 of	 chromatin	 signatures	 of	 active	 enhancers	
(enrichment	for	histone	H3K27ac,	Figure	4.4).	None	of	these	variants	has	been	reported	to	be	
associated	 with	 other	 traits	 or	 diseases,	 but	 this	 locus	 has	 been	 linked	 to	 immune	 cell	
frequencies	including	lymphocyte	count	(346)	and	T	helper	type	22	cells	(429)	and	multiple	
myeloma	(430).	rs2965955	is	a	known	eQTL	for	16	genes	in	the	whole	blood	and	a	wide	range	
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of	other	tissue	types	including	renal	tubules,	muscle,	skin,	nerve,	testes,	prostate	and	thyroid	
(Table	4.4)	(317,	318,	431).	These	genes	are	enriched	for	different	immune	related	pathways	
(Figure	 4.5).	 The	 PCHi-C	 data	 showed	 evidence	 of	 interactions	 between	 these	 potential	
variants	with	promoters	of	several	candidate	genes	in	GM12878	cell	line.		
	
ANKRD11	 encodes	 a	 protein	 that	 contains	 multiple	 ankyrin	 domains,	 which	 allows	 its	
interaction	with	other	proteins	such	as	histone	deacetylases	(chromatin	modifying	enzymes)	
to	modulate	gene	expression.	For	example,	 it	has	been	shown	to	 inhibit	 ligand-dependent	
transactivation	 by	 recruiting	 histone	 deacetylases	 to	 p160	 coactivators/nuclear	 receptor	
complex	(438).	Its	critical	role	in	regulating	transcription	might	explain	the	high	number	of	
eQTLs	 observed	 in	 this	 region.	 It	 is	 ubiquitously	 expressed,	 being	 most	 abundant	 in	 the	
cerebral	cortex,	skin,	bone	marrow,	spleen,	testis	and	ovary.	Mutations	in	ANKRD11	causes	
KBG	and	16q24.3	microdeletion	syndromes	which	are	characterised	by	abnormal	craniofacial	
features	and	intellectual	disability	with	a	higher	incidence	of	autism	spectrum	disorders	in	the	
latter,	but	immune	related	phenotypes	have	not	been	reported	to	date.	
	
SPG7	encodes	for	paraplegin,	a	mitochondrial	metalloprotease	protein	that	is	a	member	of	
the	AAA	(ATPases	associated	with	diverse	cellular	activities)	protein	family,	which	regulates	
ribosome	assembly	and	degrades	misfolded	proteins	(439).	It	is	ubiquitously	expressed	and	
mutations	in	SPG7	causes	spastic	paraplegia,	a	neurodegenerative	disease	characterised	by	a	
slowly	 progressive	weakness	 and	 spasticity	 in	 the	 lower	 limbs.	Notably,	 the	 risk	 allele	 for	
MPO-AAV	(rs2965955:C)	has	opposing	directions	of	effect	on	SPG7	expression	in	whole	blood	
and	 renal	 tubules,	 where	 a	 higher	 expression	 is	 found	 in	 the	 former	 (318)	 and	 a	 lower	
expression	in	the	latter	(431).	This	observation	is	not	uncommon	and	eQTLs	with	contrasting	
effects	have	been	demonstrated	in	different	immune	cell	types	and	in	different	disease	states,	
and	is	postulated	to	have	complex	downstream	implications	on	immunity	(440).	Furthermore,	
SPG7	has	been	 inferred	to	be	associated	with	glomerulonephritis	and	nephrotic	syndrome	
with	moderately	high	confidence	scores,	using	the	DISEASES	database	from	the	University	of	
Copenhagen	(http://diseases.jensenlab.org).	
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Figure	4.4:	Genomic	features	at	chr16q24.3	(ANKRD11-SPG7	region).	
Top	 to	 bottom	 panels:	 Genomic	 position	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 –	
GM12878	 cell	 line),	 SNPs	 association	 with	 MPO-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	
(rs2965955),	causal	variant	mapping	expressed	as	posterior	probability	(PP),	GWAS	significant	hits	in	the	region	
obtained	from	the	NHGRI-EBI	catalog	of	published	GWAS	and	methylation	data.		
	
	
	
Figure	4.5:	Gene-set	enrichment	in	immune	related	pathways.	
The	lead	SNP	and	those	in	high	LD	with	it	are	known	eQTLs	for	large	number	of	genes,	which	are	significantly	
enriched	in	different	immune	related	pathways.	The	diagram	is	generated	using	FUMA.	
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4.7 Fine-mapping	of	the	HLA	region	
Following	 a	 meta-analysis	 of	 GWAS1	 and	 GWAS2,	 there	 were	 two	 peaks	 showing	 the	
strongest	 associations	 in	 the	 MHC	 region,	 spanning	 approximately	 300	 kb	 region	 and	
including	 BTNL2,	 HLA-DRA,	 HLA-DRB5,	 HLA-DRB6,	 HLA-DRB1,	 HLA-DQA1	 and	 HLA-DQB1	
(Figure	4.6).	The	most	significant	association	for	each	peak	was	rs116522341	and	rs9275319	
respectively.	rs116522341	is	an	intronic	SNP	at	butyrophilin-like	protein	2	(BTNL2)	that	is	part	
of	the	extended	region	of	HLA	class	III	and	it	has	a	stronger	signal	(pmeta	=	1.09	x	10-30).	BTNL2	
encodes	a	HLA,	class	II	associated,	type	1	transmembrane	protein	which	is	involved	in	immune	
surveillance,	acting	as	a	negative	T-cell	 regulator	by	 inhibiting	T	 cell	proliferation	and	TCR	
activation	(441).	This	variant	is	implicated	in	a	number	of	autoimmune	diseases	including	RA,	
UC,	PSC,	PBC	and	asthma	(350).	rs9275319	is	an	intergenic	SNP	at	the	HLA-DQ	 loci	(pmeta	=	
1.78	x	10-22),	which	is	consistent	with	the	previous	GWAS	finding	albeit	with	a	different	lead	
SNP.	
	
	
Figure	4.6:	Regional	plot	of	the	HLA	class	II/III	of	chromosome	6.	
Meta-analysis	 of	 the	 association	 analyses	 of	 GWAS1	 and	 GWAS2	 for	 MPO-AAV.	 Two	 separate	 peaks	 were	
observed	at	chr6p21.32	where	the	strongest	association	was	rs116522341,	indicated	by	the	purple	diamond	and	
the	lead	SNP	for	the	other	peak	region	was	rs9275319.	
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I	 performed	 a	 stepwise	 conditional	 association	 analysis	 in	 this	 region	 to	 confirm	 the	
independent	signals	and	since	the	HLA	imputation	was	performed	on	the	GWAS2	dataset,	I	
focused	 on	 the	 same.	 The	 lead	 SNP	 for	 the	 weaker	 cluster	 in	 GWAS2	 MPO-AAV	 was	
rs9275318,	 which	 is	 in	 complete	 LD	 with	 rs9275319	 (r2	 =	 1.0).	 Upon	 conditioning	 on	
rs116522341,	 there	 was	 indeed	 an	 additional	 genome-wide	 significant	 association	 –	
rs3104415	which	was	part	of	the	weaker	cluster	(OR	=	1.42,	conditional	p	=	1.80	x	10-8)	while	
rs9275318	did	not	achieve	significant	association	(OR	=	1.45,	conditional	p	=	8.00	x	10-5,	Table	
4.5).	Reciprocal	conditional	analysis	on	rs3104415	demonstrated	that	rs116522341	remained	
genome-wide	 significant,	 confirming	 that	 there	were	 two	 independent	 signals	 in	 the	HLA	
region	for	MPO-AAV	and	lastly,	conditioning	on	both	rs116522341	and	rs3104415	accounted	
for	the	entire	signal	seen	in	this	region.		
	
Table	4.5:	Stepwise	conditional	analysis	of	the	HLA	region	in	MPO-AAV	(GWAS2)		
SNPs	
(*Chr:Position)	
Gene(s)	 Type	
 †Risk	
allele	
(RAF)	
Unconditioned	
‡p	value	
(OR)	
Conditioned	on	
rs116522341	 rs3104415	
rs116522341	
rs3104415	
rs116522341	
(6:32,367,697)	
BTNL2	 Intronic	
G	
(0.037)	
6.00	x	10-25	
(5.11)	
-	
1.00	x	10-17	
(4.04)	
-	
rs9275318	
(6:32,666,173)	
HLA-DQ	 Intergenic	
G	
(0.137)	
6.60	x	10-17	
(2.04)	
8.00	x	10-5	
(1.45)	
6.50	x	10-7	
(1.64)	
0.14	
(1.17)	
rs3104415	
(6:32,582,577)	
HLA-DQ	
Regulatory	
region	
C	
(0.355)	
1.00	x	10-15	
(1.64)	
1.80	x	10-8	
(1.42)	
-	 -	
	
*	Genome	Reference	Consortium	Human	Build	37	(GRCh37).	
†	The	risk	allele	refers	to	the	effect	allele.	RAF,	risk	allele	frequency.	
‡	The	p-values	were	calculated	using	a	linear	mixed	model	with	BOLT-LMM.	OR,	odds	ratio	with	respect	to	the	risk	allele.		
	
The	classical	HLA	alleles	at	2-	or	4-digit	resolution	and	amino	acid	variants	at	eight	HLA	loci	
were	imputed.	Univariate	LMM	analysis	identified	three	HLA	alleles	conferring	susceptibility	
to	MPO-AAV.	Forward	stepwise	iterative	conditional	analysis	confirmed	one	signal	conferred	
by	 an	 extended	 haplotype	 encoding	 HLA-DRB1*04:04-HLA-DQA1*03:01-HLA-DQB1*03:02	
(Table	4.6),	where	the	strongest	independent	association	with	disease	risk	was	observed	at	
HLA-DRB1*04:04	(OR	=	4.79,	p	=	3.10	x	10-30).	Furthermore,	HLA-DRB1*04:04	was	a	stronger	
signal	than	the	top	hit	SNP,	supporting	that	the	main	signal	in	the	region	is	indeed	driven	by	
the	HLA	allele.	Individual	amino	acid	variants	in	HLA-DRB1,	HLA-DQA1	and	HLA-DQB1	were	
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associated	with	disease.	Conditioning	on	the	most	significant	amino	acid	variant	(absence	of	
Valine	at	position	180	in	HLA-DRB1;	OR	=	1.77,	p	=	2.20	x	10-16)	eliminated	most	of	the	effects	
at	all	other	amino	acid	variants	and	all	the	classical	HLA	alleles	except	HLA-DRB1*04:04	(OR	=	
3.79,	conditional	p	=	2.60	x	10-18).	Conditioning	on	HLA-DRB1*04:04	accounted	for	the	entire	
signal	observed	in	the	HLA	region	(Figure	4.7).	
		
Table	4.6:	Association	of	classical	HLA	alleles	with	MPO-AAV.	
MHC	Allele	
Unconditioned	
Conditioned	on	
HLA-DRB1*04:04	 HLA-DQB1*03:02	 HLA-DQA1*03:01	
OR	 P	 OR	 P	 OR	 p	 OR	 P	
HLA-DRB1*04:04	 4.79	 3.10	x	10-30	 -	 -	 4.00	 8.70	x	10-16	 3.99	 1.70	x	10-19	
HLA-DQB1*03:02	 2.14	 4.20	x	10-17	 1.26	 0.045	 -	 -	 1.74	 1.70	x	10-5	
HLA-DQA1*03:01	 1.71	 3.50	x	10-14	 1.26	 0.0036	 1.26	 0.019	 -	 -	
	
	
Figure	4.7:	Amino	acid	positions	in	HLA-DRB1,	HLA-DQA1	and	HLA-DQB1.	
Amino	acid	positions	in	(A)	HLA-DRB1,	(B)	HLA-DQA1	and	(C)	HLA-DQB1	associated	with	susceptibility	to	MPO-
AAV	(upper	panels)	and	following	conditioning	on	HLA-DRB1*04:04	(lower	panels).	
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4.8 The	genetic	relationship	between	MPO-AAV	and	PR3-AAV	
To	address	the	genetic	relationship	between	MPO-AAV	and	PR3-AAV,	I	performed	a	combined	
AAV	analysis,	including	both	MPO-AAV	and	PR3-AAV	cases	to	increase	the	power	to	detect	
potential	 shared	 susceptibility	 loci.	 Next,	 a	 comparison	 of	 the	 strength	 of	 the	 association	
signals	between	MPO-AAV	and	PR3-AAV	as	well	as	the	direction	of	effects	was	made.	A	signal	
that	appears	specific	to	one	group	might	reflect	lack	of	power	to	detect	it	in	the	other	and	to	
formally	address	this	issue,	I	used	a	Bayesian	test	of	colocalisation	to	identify	loci	with	strong	
evidence	of	either	shared	or	independent	causal	variants	between	MPO-AAV	and	PR3-AAV	
across	each	of	the	ten	non-HLA	risk	loci.	Furthermore,	I	compared	the	genotypes	of	MPO-AAV	
and	 PR3-AAV	 samples	 directly	 with	 one	 another	 independent	 of	 controls	 (“within-case”	
analysis)	 and	 computed	 p-values	 for	 the	 12	 SNPs	 that	 declared	 hits	 in	 the	 primary	meta-
analysis.	A	significant	difference	in	allelic	frequency	between	the	two	traits	at	a	given	SNP	
supports	a	ANCA	specific	effect	on	disease	susceptibility.	
	
4.8.1 Combined	AAV	meta-analysis	
The	number	of	patients	included	in	the	meta-analysis	of	AAV	is	summarised	in	Table	4.7.	
	
Table	4.7:	The	number	of	cases	and	controls	included	in	the	meta-analysis	of	AAV	
Cohort		 No	of	Controls	 No	of	Cases	
GWAS1	 5,259	 914	
GWAS2	 6,688	 1,738	
†Sequenom	Genotype	(rs6679677)	 1,531	 1,550	
Total	 13,478	 4,202	
	
†For	rs6679677,	a	further	cohort	was	available	for	meta-analysis	where	the	genotyping	was	performed	using	
the	Sequenom	MassARRAY	platform	in	the	replication	cohort	of	Lyons	et	al	(70).			
	
Following	QC	of	the	imputed	data,	over	7.4	million	SNPs	were	in	common	to	both	GWAS1	and	
GWAS2	for	meta-analysis.	Case-control	association	was	performed	using	a	LMM	to	account	
for	 population	 stratification	 and	 meta-analysis	 was	 performed	 using	 an	 inverse-variance	
method	based	on	a	fixed-effects	model.	An	additional	genome-wide	significant	association	
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was	 identified	 at	 chr2q33.2,	 rs1863800	 which	 is	 located	 at	 the	 upstream	 of	 CTLA4	 and	
downstream	of	CD28	(OR	1.19,	95%	CI	1.12-1.26	and	pmeta	=	1.39	x	10-9).	This	variant	and	those	
with	high	LD	it	(r2	>	0.6)	have	been	implicated	in	Graves’	disease,	RA,	T1D,	alopecia	areata	
and	coeliac	disease	(350).	Furthermore,	rs1863800	is	an	eQTL	where	the	risk	allele	for	AAV	is	
associated	with	a	lower	expression	of	CTLA4	(p	=	2.37	x	10-70	and	Z-score	=	-17.73)	but	a	higher	
expression	of	inducible	T-cell	costimulator	(ICOS)	(p	=	2.41	x	10-8	and	Z-score	=	5.58)	in	the	
whole	blood	(318).	Although	it	is	an	intergenic	variant,	the	PCHi-C	data	showed	evidence	of	
interactions	 between	 this	 SNP	 with	 CTLA4,	 CD28	 and	 RNU6-474P	 (Figure	 4.8).	 Genetic	
association	 of	 CTLA4	 with	 AAV	 was	 investigated	 extensively	 in	 the	 past	 using	 primarily	
candidate	gene	approach	with	conflicting	results.	We	report	for	the	first	time,	its	genome-
wide	significant	association	with	AAV	in	the	present	study.	Further	details	about	this	region	
are	discussed	in	section	1.4.2.	
	
	
Figure	4.8:	Genomic	features	at	chr2q33.2	(CTLA4	region).	
Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 gene,	 PCHi-C	 data	 (Mifsud	 et	 al	 –	
GM12878	cell	line),	SNPs	association	with	AAV	where	the	filled	red	circle	indicates	the	lead	SNP	(rs1863800),	
causal	 variant	 mapping	 expressed	 as	 posterior	 probability	 (PP),	 other	 GWAS	 significant	 hits	 in	 the	 region	
obtained	from	the	NHGRI-EBI	Catalog	of	published	GWAS	and	methylation	data.
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Table	4.8:	A	comparison	between	combined	AAV	meta-analysis	with	PR3-AAV	and	MPO-AAV	
 The	values	reported	for	rs6679677	included	a	further	replication	cohort,	comprising	1,531	controls,	347	MPO-AAV,	1,122	PR3-AAV	and	81	unknown	ANCA	status.	
*	The	risk	allele	refers	to	the	effect	in	the	overall	meta-analysis.	RAF,	risk	allele	frequency;	OR,	odds	ratio;	CI,	confidence	interval.	
§	The	nominal	p-value	for	PR3-AAV	versus	MPO-AAV	was	0.00417.	The	p-values	were	calculated	using	the	SNPTEST	v2.5.2	software	with	an	additive	genetic	model.	
¶	A	Bayesian	test	of	colocalisation	was	used	to	identify	loci	with	strong	evidence	of	either	shared	or	independent	causal	variants	between	PR3-AAV	and	MPO-AAV	across	each	of	the	10	non-HLA	susceptibility	loci,	
expressed	as	posterior	probability	in	percentage,	PP	(%).
SNP	
Candidate	
gene(s)	
Chr:	Position	
(hg19)	
*Risk	
allele	
(RAF)	
AAV	vs	Control	
(2,652	vs	11,947)	
PR3-AAV	vs	Control	
(1,610	vs	11,947)	
MPO-AAV	vs	Control	
(870	vs	11,947)	
PR3-AAV	vs	MPO-AAV	
(1,610	vs	870)	
¶Bayesian	test	of	
Colocalisation	
OR	
(95%	CI)	
 P	
OR	
(95%	CI)	
P	
OR	
(95%	CI)	
P	
OR	
(95%	CI)	
§P	
PP	(%)	
Shared	
PP	(%)	
MPO	
PP	(%)	
PR3	
‡rs6679677	 PTPN22	 1:114,303,808	 A	(0.10)	
1.27	
(1.18-1.38)	
1.25	x	10-9	
1.22	
(1.11-1.34)	
2.73	X	10-5	
1.47	
(1.29-1.67)	
5.50	X	10-9	
0.85		
(0.74-0.99)	
3.03	x	10-2	 75.20	 17.00	 0.74	
rs115670873	 DGUOK,	TET3	 2:74,171,061	 A	(0.94)	
1.68	
(1.48-1.91)	
7.35	x	10-16	
1.68	
(1.44-1.97)	
1.22	X	10-10	
1.82	
(1.46-2.27)	
7.60	X	10-8	
0.97	
(0.69-1.37)	
8.62	x	10-1	 99.80	 0.00	 0.03	
rs13405741	
BCL2L11,	
MIR4435-2HG	
2:111,913,056	 C	(0.11)	
1.25	
(1.13-1.37)	
7.36	x	10-6	
1.40	
(1.24-1.58)	
3.76	X	10-8	
1.09	
(0.92-1.29)	
3.10	X	10-1	
1.31	
(1.09-1.57)	
3.64	x	10-3	 3.99	 0.35	 62.40	
rs1863800	 CTLA4,	CD28	 2:204,702,660	 C	(0.58)	
1.19	
(1.12-1.26)	
1.39	x	10-9	
1.17	
(1.10-1.26)	
5.15	X	10-6	
1.19	
(1.09-1.31)	
2.33	X	10-4	
0.95	
(0.84-1.07)	
3.98	x	10-1	 71.80	 2.61	 8.34	
rs116522341	
BTNL2,		
HLA-DQ	
6:32,367,697	 G	(0.04)	
1.56	
(1.33-1.82)	
3.56	x	10-8	
0.83	
(0.68-1.02)	
6.94	X	10-2	
4.80	
(3.67-6.26)	
1.09	X	10-30	
0.23	
(0.17-0.31)	
8.55	x	10-23	 -	 -	 -	
rs3130216	 HLA-DPB	 6:33,077,271	 G	(0.49)	
1.90	
(1.80-2.00)	
2.50	x	10-119	
2.58	
(2.41-2.75)	
3.59	X	10-173	
1.08	
(0.98-1.19)	
1.10	X	10-1	
2.90	
(2.58-3.25)	
2.44	x	10-73	 -	 -	 -	
rs79005509	 BACH2	 6:90,850,730	 T	(0.02)	
1.50	
(1.21-1.86)	
1.85	x	10-4	
1.07	
(0.82-1.40)	
6.12	X	10-1	
2.90	
(2.00-4.20)	
1.90	X	10-8	
0.52	
(0.34-0.78)	
1.52	x	10-3	 3.13	 40.30	 9.35	
rs145007430	 EBF3,	MGMT	 10:131,690,291	 A	(0.02)	
1.75	
(1.37-2.24)	
8.36	x	10-6	
2.39	
(1.76-3.25)	
2.38	X	10-8	
1.23	
(0.79-1.90)	
3.57	X	10-1	
1.58	
(1.04-2.40)	
3.10	x	10-2	 1.95	 7.40	 45.10	
rs112635299	 SERPINA1	 14:94,838,142	 T	(0.02)	
2.21	
(1.85-2.64)	
3.09	x	10-18	
3.43	
(2.75-4.27)	
2.37	X	10-28	
1.13	
(0.81-1.57)	
4.77	X	10-1	
2.16	
(1.64-2.86)	
5.91x	10-8	 4.77	 0.00	 65.10	
rs11845244	 IGHV1-69	 14:107,170,077	 T	(0.37)	
1.13	
(1.06-1.20)	
6.49	x	10-5	
1.23	
(1.15-1.33)	
2.16	X	10-8	
0.99	
(0.89-1.09)	
8.01	X	10-1	
1.28	
(1.13-1.45)	
1.00	x	10-4	 4.18	 0.01	 88.00	
rs2965955	
ANKRD11,	
SPG7	
16:89,524,923	 C	(0.69)	
1.12	
(1.06-1.19)	
1.64	x	10-4	
1.03	
(0.96-1.11)	
3.97	X	10-1	
1.37	
(1.24-1.51)	
9.64	X	10-10	
0.70	
(0.61-0.80)	
1.04	x	10-7	 2.95	 83.50	 0.00	
rs55952682	 PRTN3	 19:835,908	 T	(0.26)	
1.22	
(1.12-1.32)	
2.40	x	10-5	
1.39	
(1.26-1.54)	
1.90	X	10-11	
0.96	
(0.84-1.11)	
5.60	X	10-1	
1.51	
(1.27-1.78)	
1.41	x	10-6	 2.75	 0.00	 66.10	
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A	comparison	of	 the	odds	ratios	between	combined	AAV	meta-analysis	with	PR3-AAV	and	
MPO-AAV	 is	 summarised	 in	Table	4.8.	 Three	of	 the	12	 loci	 associated	with	AAV	displayed	
strong	evidence	of	a	 shared	causal	variant	between	MPO-AAV	and	PR3-AAV	of	equivalent	
effect	size	in	the	same	direction	(CTLA4,	PTPN22,	DGUOK-TET3).	Although	rs1863800	(CTLA4)	
did	 not	 reach	 the	 genome-wide	 significance	 for	 both	MPO-AAV	 and	 PR3-AAV,	 rs6679677	
(PTPN22)	and	rs115670873	(DGUOK/TET3)	were	only	genome-wide	significant	in	MPO-AAV	
and	PR3-AAV	respectively,	these	SNPs	demonstrated	strong	evidence	for	colocalisation	with	
high	posterior	probability	scores	and	attained	genome-wide	significance	in	the	combined	AAV	
analysis	where	the	total	sample	size	was	larger	and	thus	better	powered	to	detect	weaker	
signals.	 Furthermore,	 in	 the	 within-case	 analysis,	 none	 of	 these	 SNPs	 achieved	 nominal	
significance,	supporting	that	the	signals	at	these	loci	are	not	subgroup	specific.	Notably,	the	
shared	 risk	 loci	 between	 MPO-AAV	 and	 PR3-AAV	 also	 shared	 commonalities	 with	 other	
immune-related	diseases	(Figure	4.9).	
	
The	remaining	nine	loci	displayed	strong	evidence	of	independent	causal	variant	for	either	
MPO-AAV	or	PR3-AAV.	Three	risk	 loci	were	MPO-AAV	specific	 (BTNL2-HLA-DQ,	BACH2	and	
ANKRD11-SPG7)	 while	 six	 risk	 loci	 were	 PR3-AAV	 specific	 (HLA-DP,	 PRTN3,	 SERPINA1,	
BCL2L11-MIR4435-2HG,	EBF3-MGMT	and	IGHV1-69)	(Figure	4.10).	In	the	within-case	analysis,	
all	 variants	 in	 these	 risk	 loci	 revealed	 nominally	 significant	 associations	 with	 appropriate	
direction	of	effects	except	rs145007430	(EBF3-MGMT),	which	could	be	due	to	lack	of	power	
or	less	likely	the	signal	at	this	locus	might	not	be	subgroup	specific.	
	
In	 summary,	 both	 colocalisation	 and	 within-case	 analysis	 provide	 robust	 evidence	 of	 a	
differential	genetic	basis	of	MPO-AAV	and	PR3-AAV	at	the	HLA	region	and	seven	non-HLA	loci	
including	BACH2,	ANKRD11-SPG7,	 PRTN3,	 SERPINA1,	BCL2L11-MIR4435-2HG,	 EBF3-MGMT	
and	IGHV1-69	as	well	as	common	susceptibility	loci	comprising	PTPN22,	CTLA4	and	DGUOK-
TET3.	
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Figure	4.9:	Shared	genetic	architecture	with	other	autoimmune	diseases.		
Three	 risk	 loci	 are	 shared	 between	MPO-AAV	 and	 PR3-AAV	 and	 their	 associations	 with	 other	 autoimmune	
diseases	 in	genome-wide	association	studies	obtained	from	the	Phenoscanner	and	the	NHGRI-EBI	Catalog	of	
published	 GWAS.	 The	 filled	 blue	 boxes	 indicate	 genome-wide	 significant	 associations	 for	 the	 autoimmune	
diseases	and	the	risk	loci.	
	
	
Figure	4.10:	Forest	plot	depicts	the	odds	ratios	for	MPO-	and	PR3-AAV	risk	loci.		
The	error	bars	represent	95%	confidence	intervals	and	the	x-axis	is	in	logarithmic	scale.	
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4.8.2 Genetic	correlation	using	GCTA	
Using	the	genome-wide	individual	level	genotype	data	(MAF	≥	0.05),	I	used	GCTA	to	estimate	
genome-wide	 genetic	 correlation	 (rG)	 between	 MPO-AAV	 and	 PR3-AAV	 using	 a	 bivariate	
LMM.	rG	ranges	from	-1	(negatively	correlated/genetically	unrelated)	to	1	(co-heritable).	The	
rG	between	MPO-AAV	and	PR3-AAV	was	0.69	±	se	0.09	(p	=	0.0000E+00).	This	estimate	of	
genetic	correlation	is	similar	to	that	observed	between	UC	and	Crohn’s	disease	(rG	=	0.62	±	
0.042)	(373,	442)	but	is	greater	than	that	between	type	2	diabetes	and	hypertension	(rG	=	0.31	
±	 0.14)	 (339).	 A	 comparison	 of	 bivariate	 estimates	 of	 genetic	 correlation	 across	 different	
diseases	including	those	from	the	paediatric	population	is	shown	in	Figure	4.11.	The	rG	was	
even	stronger	after	exclusion	of	the	MHC	region	(rG	=	0.84	±	se	0.12).	
	
	
Figure	4.11:	Bivariate	estimates	of	genetic	correlation	across	different	diseases.	
Genetic	correlation	(rG)	estimated	using	GCTA	across	different	diseases	in	paediatric	population	(indicated	by	
blue	bars)	–	type	1	diabetes	and	Crohn’s	disease	(CD),	common	variable	immunodeficiency	disorder	(CVID)	and	
juvenile	idiopathic	arthritis	(JIA),	ulcerative	colitis	(UC)	and	CD	(443);	adult	population	(indicated	by	yellow	bars)	
–	type	2	diabetes	and	hypertension	(339),	schizophrenia	(Schz)	with	depression	and	bipolar	disorder	(BPD)	(444),	
UC	and	CD	(442);	MPO-AAV	and	PR3-AAV	as	indicated	by	the	red	bar.	
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4.9 Discussion	
We	performed	the	largest	genome-wide	association	study	of	AAV	to	date,	which	was	powered	
to	examine	both	MPO-AAV	and	PR3-AAV	 independently.	Following	a	meta-analysis	of	 two	
European	cohorts,	a	total	of	12	regions	of	the	genome	were	identified	to	be	associated	with	
AAV,	 including	five	risk	 loci	from	previous	studies	(HLA-DP,	HLA-DQ,	SERPINA1,	PRTN3	and	
PTPN22).	Apart	 from	SERPINA1,	 the	 strongest	effect	 size	was	observed	 in	 the	HLA	 region.		
Three	 independent	HLA	signals	were	confirmed	to	confer	 susceptibility	 for	PR3-AAV	while	
there	was	one	for	MPO-AAV.	Of	these	12	loci,	three	displayed	strong	evidence	for	a	shared	
causal	variant	between	MPO-AAV	and	PR3-AAV	(PTPN22,	DGUOK-TET3	and	CTLA4),	which	are	
also	 implicated	 in	 a	 wide	 range	 of	 autoimmune	 diseases.	 Three	 risk	 loci	 were	MPO-AAV	
specific	and	these	include	BTNL2-HLA-DQ,	BACH2	and	ANKRD11-SPG7	while	six	risk	loci	were	
PR3-AAV	 specific	 consisting	 of	 HLA-DP,	 BCL2L11-MIR4435-2HG,	 EBF3-MGMT,	 SERPINA1,	
IGHV1-69	 and	 PRTN3.	 These	 findings	 have	 confirmed	 that	 AAV	 is	 a	 polygenic	 disease.	 In	
addition,	the	estimated	total	SNP	heritability	(h2SNP)	was	slightly	higher	in	PR3-AAV	than	MPO-
AAV,	in	a	similar	range	to	inflammatory	bowel	disease	but	was	lower	than	that	of	T1D	and	SLE	
(396,	442),	suggesting	that	environmental	factors	might	play	a	larger	role	in	AAV,	in	keeping	
with	 previous	 epidemiological	 and	 observational	 studies	 demonstrating	 infections,	 silica,	
solvent,	asbestos	and	drug	exposures	(42-45)	to	be	related	to	AAV	as	well	as	a	much	later	age	
of	diagnosis	as	compared	to	T1D,	which	is	commonly	diagnosed	by	or	before	23	years	of	age	
and	SLE,	which	is	classically	seen	in	women	of	childbearing	age.	
	
The	shared	genetic	risk	between	MPO-AAV	and	PR3-AAV	was	also	quantified	for	the	first	time.	
The	strength	of	genetic	correlation	between	these	two	syndromes	is	similar	to	those	observed	
between	UC	and	Crohn’s	disease	(373,	443),	suggesting	that	substantial	components	of	the	
genetic	architecture	are	shared	between	the	two	syndromes.	Although	only	three	common	
risk	loci	have	been	identified	so	far,	this	is	likely	due	to	the	limitation	of	a	small	sample	size.	
For	example,	in	UC	and	Crohn’s	disease	where	a	large	number	of	shared	risk	loci	have	been	
identified	(167),	the	sample	sizes	for	most	studies	were	ten	to	hundred	times	larger	than	that	
in	our	study.	Although	a	degree	of	the	co-heritability	observed	between	autoimmune	diseases	
could	 be	 due	 to	 common	 HLA	 alleles,	 Li	 and	 colleagues	 previously	 estimated	 genetic	
correlations	 across	 different	 paediatric	 autoimmune	 diseases	 with	 and	 without	 the	 HLA	
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region	and	they	did	not	observe	significant	difference	between	the	two	methods,	suggesting	
that	it	is	unlikely	that	genetic	sharing	of	HLA	haplotypes	can	explain	the	genetic	correlation	
observed	(443).	 In	contrary,	we	found	a	stronger	genetic	correlation	after	exclusion	of	the	
HLA	region,	which	is	not	too	surprising,	given	that	MPO-AAV	and	PR3-AAV	have	distinct	HLA	
associations	 and	 by	 far	 have	 the	 greatest	 genetic	 effect	 on	 the	 risk	 of	 developing	 AAV.	
Furthermore,	 in	 population-based	 studies,	 the	 estimate	 of	 genetic	 effect	 that	 is	 shared	
between	two	traits	 is	 inevitably	confounded	by	common	environmental	 factors	or	genetic	
environment	interactions,	and	therefore	the	genetic	correlation	between	MPO-AAV	and	PR3-
AAV	could	be	slightly	biased	to	overestimation.	
	
One	of	the	new	MPO-AAV	specific	risk	loci	is	BACH2	–	a	classical	example	of	a	super-enhancer	
regulated	gene	that	is	associated	with	many	autoimmune	diseases	(437).	Both	the	PCHi-C	and	
eQTL	data	support	 that	 the	 lead	variant	 (rs79005509:T),	which	 lies	 in	 the	distal	 regulatory	
region,	is	likely	to	regulate	the	expression	of	BACH2	through	an	interaction	with	its	promoter	
(321)	 in	CD4+	 and	CD8+	 T	 cells,	 potentially	 influencing	 the	binding	affinity	of	 transcription	
factors.	The	risks	allele	reduces	BACH2	mRNA	expression	(318)	and	might	consequently	lead	
to	 an	 imbalance	 of	 Treg	 cell	 formation	 and	 effector	 cell	 differentiation,	 thus	 promoting	
immunity	over	tolerance.	Treg	cells	are	an	important	subpopulation	of	T	cells	that	modulate	
immune	system	to	maintain	tolerance	to	self-antigens.	The	role	of	Treg	in	the	pathogenesis	of	
AAV	has	been	well	demonstrated	in	the	animal	models.	By	depleting	the	Treg	population	using	
anti-CD25	monoclonal	antibody,	Tan	et	al	showed	that	the	MPO-immunised	mice	developed	
more	severe	segmental	necrosis	and	glomerular	cellular	proliferation	as	compared	with	non-
Treg-depleted	MPO-immunised	mice	with	an	enhanced	autoimmune	B	cell	response	to	MPO	
(445).	Moreover,	 in	 the	experimental	 crescentic	 glomerulonephritis	model,	mice	 that	 lack	
CXCR3	in	Treg	which	is	essential	for	its	migration	to	site	of	inflammation,	were	found	to	have	
a	reduced	number	of	Treg	 in	the	kidneys	with	an	overwhelming	Th1	 immune	response	and	
developed	with	more	severe	renal	impairment	that	was	reversible	with	anti-IFNg	treatment	
(446).	Several	studies	have	also	showed	a	reduced	suppressor	function	of	Treg	in	AAV	patients	
as	compared	to	healthy	controls	(253,	254,	447).	Further	functional	studies	will	be	required	
to	elucidate	the	biological	mechanisms	by	which	the	causal	variant	increases	susceptibility	to	
disease.	
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We	also	confirmed	the	association	of	CTLA4	with	AAV	at	a	genome-wide	significance	level.	
CTLA-4	 is	an	 important	negative	 regulator	of	T-cell	 activation	and	 it	 is	 implicated	 in	many	
organ-specific	autoimmune	diseases.	The	lead	variant	in	this	locus	is	a	known	eQTL	where	the	
risk	 allele	 (rs1863800:C)	 is	 associated	 with	 a	 lower	 expression	 of	 CTLA4	 but	 a	 higher	
expression	 of	 ICOS	 in	 the	 whole	 blood	 (318).	 ICOS	 (a.k.a	 CD278)	 is	 a	 CD28-superfamily	
costimulatory	 molecule	 that	 is	 expressed	 on	 T	 cells	 upon	 activation.	 In	 addition,	 other	
reported	autoimmunity-susceptibility	variants	 in	this	region	 including	rs231775,	rs3087234	
and	 rs231806,	which	 are	 in	 high	 LD	with	 the	 lead	 SNP,	 have	 been	demonstrated	 to	 have	
functional	 effects	 on	CTLA4	 transcription	 (in	 both	 CD4+	 T	 cells	 and	 CD8+	 T	 cells),	 splicing,	
production	 of	 the	 soluble	 form	 of	 CTLA-4	 and	 post-translational	modifications	 (448-451).	
Taken	all	together,	individuals	carrying	the	risk	alleles	might	have	a	lower	activation	threshold	
of	 T	 cells	 and	 thus	 contribute	 to	 T-cell	 activation	 and	 autoimmune	 disease	 susceptibility.	
There	 is	an	ongoing	clinical	 trial	 (ABROGATE,	ClinicalTrials.gov	 Identifier:	NCT02108860)	to	
evaluate	 the	 efficacy	 of	 Abatacept	 to	 achieve	 sustained	 glucocorticoid-free	 remission	 in	
patients	with	relapsing	non-severe	GPA.	Abatacept	 is	a	 fusion	protein	composed	of	the	Fc	
region	of	IgG1	fused	with	the	extracellular	domain	of	CTLA-4,	and	it	binds	to	the	CD80	and	
CD86	molecules	to	prevent	T-cell	activation.		
	
4.10 Conclusion	
Both	MPO-AAV	and	PR3-AAV	are	polygenic	diseases	and	they	share	a	substantial	component	
of	their	genetic	architecture.	The	common	risk	loci	between	the	two	syndromes	also	share	
commonalities	with	other	immune-related	diseases.	Each	disease-related	region	can	be	fine-
mapped	to	obtain	the	most	likely	causal	variants.	Through	eQTL	and	chromatin	interaction	
datasets,	we	are	able	to	determine	the	genes	that	these	SNPs	most	probably	regulate	in	the	
disease	 relevant	 cell	 types.	 This	 will	 enable	 us	 to	 better	 understand	 the	 molecular	
mechanisms	underpinning	the	development	of	AAV	and	identify	novel	therapeutic	pathways	
for	drug	development.	
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5 Functional	follow-up	at	BCL2L11-MIR4435-2HG	
and	PRTN3	regions		
5.1 Prelude	
Statistical	and	computational	analyses	provide	important	information	on	which	SNPs	within	
a	trait	associated	LD	block	could	be	a	causal	variant.	However,	these	analyses	do	not	provide	
definite	proof	of	causality	but	rather	bring	forward	strong	candidates	to	undergo	functional	
validation.	In	addition,	cellular	or	 in	vivo	experiments	would	be	required	to	prove	that	the	
gene(s)	 regulated	 by	 a	 causal	 variant	 do	 indeed	 lead	 to	 disease	 relevant	 phenotypes	 if	
perturbed.	In	this	chapter,	I	will	discuss	the	post-GWAS	bioinformatics	analyses	and	functional	
follow-up	of	two	PR3-AAV	susceptibility	loci	including	BCL2L11-MIR4435-2HG	and	PRTN3,	to	
understand	how	the	causal	variants	exert	their	effects	in	contributing	to	the	pathogenesis	of	
PR3-AAV.	
	
5.2 BCL2L11-MIR4435-2HG	
5.2.1 Introduction	
As	described	in	Chapter	3,	one	of	the	newly	identified	PR3-AAV	specific	risk	loci	in	the	meta-
analysis	was	BCL2L11-MIR4435-2HG,	which	is	located	in	the	long	arm	of	chromosome	2.	The	
top	variant	was	rs13405741	(risk	allele:	C,	OR	=	1.40,	pmeta	=	3.76	x	10-8)	which	is	an	intronic	
variant	in	BCL2L11.	Furthermore,	PCHi-C	data	confirmed	interactions	between	the	SNPs	from	
the	credible	set	with	the	promoter	region	of	BCL2L11	and	the	putative	regulatory	region	of	
MIR4435-2HG	in	granulocytes.	BCL2L11	encodes	for	Bim,	which	is	part	of	the	Bcl2	family	and	
is	critical	in	regulating	cell	death	while	MIR4435-2HG	is	a	long,	non-coding	RNA	that	has	been	
discovered	recently	to	play	an	essential	role	 in	the	regulation	of	BCL2L11	 transcription.	To	
date,	no	functional	data	exists	to	explain	the	association	of	this	locus	with	disease.	
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There	 are	 two	major	mechanisms	 by	which	 cell	 death	 can	 occur	 –	 necrosis	 or	 apoptosis.	
Necrosis	is	a	pathological	process	that	occurs	when	cells	are	subjected	to	severe	physical	or	
chemical	stress.	In	contrast,	apoptosis	is	a	fundamental	physiological	process	of	cell	death	in	
multicellular	organisms	during	development	and	tissue	homoeostasis	(452).	It	is	also	known	
as	 programmed	 cell	 death	 and	 is	 characterised	 by	 cell	 shrinkage,	 nuclear	 and	 chromatin	
condensation,	DNA	fragmentation,	membrane	blebbing,	phosphatidylserine	externalisation	
and	 formation	 of	membrane-bound	 apoptotic	 bodies.	 These	 apoptotic	 bodies	 are	 rapidly	
phagocytosed	 by	 either	 macrophages	 or	 adjacent	 epithelial	 cells	 to	 avoid	 inflammatory	
response.	In	vitro,	the	apoptotic	bodies	and	the	remaining	cell	fragments	ultimately	swell	and	
lyse.	 This	process	 is	 also	 known	as	 secondary	necrosis.	 The	balance	between	 survival	 and	
apoptotic	signals	is	tightly	controlled	and	disruption	of	this	balance	leads	to	diseases	such	as	
cancer.	 In	AAV,	neutrophils	are	the	primary	effector	cells	 in	mediating	endothelial	cell	and	
vascular	damage.	Several	studies	have	demonstrated	that	apoptosis	of	infiltrating	neutrophils	
is	 disrupted	 by	 ANCA	 activation	 and	 removal	 of	 apoptotic	 neutrophils	 occurs	 in	 a	
proinflammatory	manner,	resulting	in	persistent	inflammation	(453,	454).	
	
There	are	many	players	that	are	known	to	regulate	apoptosis,	including	caspases,	cell	death	
receptors	of	the	TNF	family,	adaptor	proteins,	inhibitor	of	apoptosis	proteins	and	the	bcl-2	
family.	 The	Bcl-2	 family	 contains	 at	 least	 20	 related	 proteins.	 Each	member	 of	 the	 family	
shares	one	or	more	Bcl-2	homology	(BH)	domains	and	are	divided	into	two	groups	based	on	
whether	they	facilitate	or	inhibit	apoptosis.	Bim	is	a	BH3-only	containing	protein	and	was	first	
discovered	over	two	decades	ago	as	a	pro-apoptotic	protein	(455).	Three	isoforms	of	Bim	are	
generated	by	alternative	splicing	(BimEL	~33kDa,	BimL	~25kDa	and	BimS	~15kDa),	all	of	which	
induce	apoptosis	by	binding	to	and	antagonising	anti-apoptotic	members	of	the	Bcl-2	family	
that	 ultimately	 influence	 the	 insertion	 of	 Bax	 and	 Bax-like	 proteins	 into	 the	 outer	
mitochondrial	membrane,	leading	to	cytochrome	C	release	and	activation	of	caspase9/Apaf-
1	 (apoptotic	protease	activating	factor	1)	apoptosome.	Bims	 is	 the	most	potent	 inducer	of	
apoptosis.	 The	 lifespans	of	myeloid	and	 lymphoid	 cells	 are	 substantially	 increased	 in	Bim-
deficient	 mice,	 where	 the	 numbers	 of	 granulocytes,	 monocytes,	 B	 cells	 and	 T	 cells	 are	
increased	by	2-4	fold	(379).		
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Intriguingly,	 the	 transcription	 of	 BCL2L11	 was	 recently	 discovered	 to	 be	 regulated	 by	 its	
neighbouring	 long	non-coding	RNA	–	MIR4435-2HG	 (also	known	as	Morrbid,	myeloid	RNA	
regulator	of	Bim-induced	death),	specifically	in	myeloid	cells	and	in	a	cis	manner	by	promoting	
the	enrichment	of	the	polycomb	repressive	complex	2	at	BCL2L11	promoter,	maintaining	the	
gene	 in	a	poised	state	and	enabling	 rapid	control	of	apoptosis	 in	 response	 to	pro-survival	
cytokines	 (380).	MIR4435-2HG	 is	 highly	 conserved	 across	 species	 and	 is	 localised	 in	 the	
nucleus,	 predominantly	 chromatin	 bound.	 It	 is	most	 abundantly	 expressed	 in	 eosinophils,	
neutrophils	and	classical	monocytes	 in	both	human	and	mice.	These	three	cell	 types	were	
greatly	reduced	in	MIR4435-2HG-deficient	mice,	while	natural	killer	and	other	lymphoid	cells	
remained	unaffected.	Furthermore,	an	accelerated	apoptosis	was	observed	in	these	three	cell	
types	in	bone	marrow	cultured	ex	vivo	with	markedly	elevated	BCL2L11	mRNA	and	protein	
levels.	MIR4435-2HG-deficient	mice	were	more	prone	 to	bacterial	 infection	but	protected	
from	eosinophil-driven	 inflammatory	 lung	disease.	 Importantly,	 the	authors	demonstrated	
overexpression	of	MIR4435-2HG	in	eosinophils	isolated	from	patients	with	hypereosinophilic	
syndrome	as	compared	to	healthy	controls,	which	was	positively	correlated	with	plasma	IL-5	
levels,	supporting	the	important	role	of	MIR4435-2HG	in	eosinophil-mediated	inflammatory	
disorders	(380).	
	
rs13405741	 is	an	eQTL	for	BCL2L11	 in	the	whole	blood	(318).	To	establish	the	specific	cell	
types	that	this	variant	might	have	its	effect	on,	I	began	by	looking	into	the	existing	microarray	
whole-genome	gene	expression	datasets	for	a	number	of	leukocyte	lineages	in	patients	with	
chronic	kidney	disease	(CKD),	comprising	CD16+	neutrophils,	CD14+	monocytes,	CD8+	T	cells,	
CD4+	T	cells	and	CD19+	B	cells	that	were	generated	in	the	Smith	lab.	
	
5.2.2 The	effect	of	rs13405741	genotype	on	BCL2L11	expression	in	different	immune	cells	
Firstly,	the	genotype	of	each	individual	in	the	CKD	cohort	was	determined	using	the	TaqManâ	
SNP	genotyping	assay.	Following	QC	of	 the	gene	expression	datasets,	a	breakdown	of	 the	
number	of	patients	included	in	the	eQTL	analysis	for	each	immune	cell	subset	is	summarised	
in	Table	5.1.	The	allele	frequency	of	the	risk	allele	(rs13405741:C)	is	0.11	and	not	surprisingly,	
there	was	only	one	homozygous	minor	patient	in	the	CKD	cohort.	There	was	a	trend	towards	
higher	 expression	 of	 BCL2L11	 in	 association	 with	 the	 risk	 allele	 in	 neutrophils	 (one-way	
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analysis	of	variance	(ANOVA),	p	=	0.0921;	test	for	linear	trend,	p	=	0.0324)	but	not	in	other	
cell	 lineages	 (Figure	 5.1A).	 One	major	 limitation	 of	 this	 analysis	 was	 a	 small	 sample	 size,	
particularly	of	the	statistical	power	for	detecting	a	difference	in	minor	allele	homozygotes.	
	
Table	5.1:	The	number	of	CKD	patients	included	in	the	eQTL	analysis	
Immune	cell	subsets	
*rs13405741	genotype	
T/T	 T/C	 C/C	
CD16+	neutrophils	 55	 21	 1	
CD14+	monocytes	 40	 17	 0	
CD8+	T	cells	 56	 20	 1	
CD4+	T	cells	 22	 9	 1	
CD19+	B	cells	 47	 19	 1	
	
*rs13405741	(T/T:	homozygous	major;	T/C:	heterozygous;	C/C:	homozygous	minor).	
		
5.2.3 Allele-specific	expression	of	BCL2L11	in	neutrophils	
To	ascertain	whether	rs13405741:T>C	or	a	variant	in	strong	LD	with	it,	might	influence	gene	
expression,	 a	 clone-based	 allele-specific	 expression	 assay	 was	 used	 to	 analyse	 BCL2L11	
transcription	 in	 neutrophils	 from	 eight	 heterozygous	 healthy	 individuals.	 This	 technique	
facilitated	 a	 direct	 comparison	 between	 the	 amount	 of	 BCL2L11	 pre-mRNA	 that	 was	
transcribed	 from	 each	 allele	 and	 ensured	 that	 the	 external	 factors	 affected	 both	 alleles	
equally.	 Under	 basal	 conditions	 (unstimulated,	 time	 0	 hr),	 we	 observed	 allele-specific	
differences	 in	 transcription,	with	~0.3-fold	more	BCL2L11	being	 transcribed	 from	the	DNA	
strand	containing	the	minor	allele	(C,	the	risk	allele	for	PR3-AAV;	p	=	0.0078)	than	from	the	
strand	containing	the	major	allele	(T).	There	was	no	difference	observed	in	the	genomic	DNA	
which	was	inherently	in	a	1:1	ratio,	thereby	serving	as	an	internal	control.	At	time	6	hr,	the	
same	trend	was	seen	in	neutrophils	that	were	cultured	with	standard	medium	though	the	
effect	size	was	less	marked	as	compared	to	time	0	hr	(p	=	0.0391).	In	contrast,	the	ratio	of	
major	(T)	to	minor	(C)	alleles	in	BCL2L11	pre-mRNA	was	no	different	at	time	6	hr	when	the	
neutrophils	 were	 stimulated	 with	 GM-CSF,	 suggesting	 that	 the	 allele-specific	 expression	
might	be	abrogated	by	a	pro-survival	agent	(Figure	5.1	B).	
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Figure	5.1:	rs13405741:C	allele	is	associated	with	a	higher	expression	of	BCL2L11	in	
neutrophils.	
(A)	Microarray	whole-genome	 gene	 expression	 of	 different	 immune	 cell	 subsets	 for	 chronic	 kidney	 disease	
patients.	There	was	a	trend	of	higher	expression	of	BCL2L11	in	neutrophils	for	individuals	carrying	the	PR3-AAV	
risk	alleles	(rs13405741:C)	but	not	in	other	leukocyte	lineages.	In	box	plots,	each	box	extends	from	the	25th	to	
the	75th	percentile	with	a	line	represents	the	median	and	whiskers	extend	to	the	minimum	and	maximum	values.	
(B)	 Allele-specific	 expression	 assay	 showing	 the	 ratio	 of	 rs13405741	 alleles	 in	 genomic	 DNA	 (gDNA)	 and	
complementary	DNA	(cDNA;	synthesised	from	pre-mRNA)	from	neutrophils	of	heterozygous	individuals	(n	=	8).	
Ninety-six	colonies	were	genotyped	per	individuals	per	condition	(either	unstimulated	[unstim.]	or	stimulated	
[stim.]	with	GM-CSF).	Data	are	represented	as	mean	±	standard	error	of	mean	(SEM),	*p	<	0.05	and	**p	<	0.01	
(Wilcoxon	signed	rank	test).	
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5.2.4 PR3-AAV	shares	the	same	causal	variant	as	eosinophil	count	at	BCL2L11-MIR4435-
2HG	
Clinical	evidence	and	in	vitro	studies	support	the	notion	that	the	innate	immune	system	plays	
an	important	role	in	the	pathogenesis	of	AAV	(as	described	in	section	1.5.2).	Chromosome	
2q13	 has	 been	 reported	 to	 be	 associated	 with	 several	 haematological	 traits	 including	
eosinophil	count,	eosinophil	percentage	of	granulocytes,	neutrophil	percentage	of	white	cells	
and	monocyte	percentage	of	white	cells	in	a	population-based	study	(346).	Importantly,	the	
candidate	genes	in	this	locus	–	BCL2L11	and	MIR4435-2HG	are	involved	in	the	regulation	of	
myeloid	cell	 lifespan	and	henceforth,	cell	numbers.	A	natural	question	to	ask	was	whether	
these	 haematological	 traits	 shared	 the	 same	 causal	 variant	 as	 PR3-AAV	 at	 this	 locus	 and	
therefore,	also	potentially	share	the	same	causal	mechanism.	Visual	comparison	of	overlaps	
of	between	the	association	signals	from	different	traits	was	a	step	in	the	right	direction	but	
inadequate	to	make	inferences	about	causality.	The	Bayesian	statistical	test	for	colocalisation	
was	employed	to	address	this	question,	using	GWAS	summary	statistics	generated	by	Astle	et	
al	 (346)	 for	 three	 haematological	 traits	 comprising	 eosinophil,	 neutrophil	 and	 monocyte	
counts.	The	results	of	the	colocalisation	analysis	include	five	posterior	probabilities	(PP0,	PP1,	
PP2,	PP3	and	PP4)	where	a	large	posterior	probability	for	hypothesis	3	(PP3)	indicates	support	
for	two	independent	causal	variants	with	each	trait	while	a	large	PP4	supports	a	single	variant	
affecting	both	traits	(see	Section	2.1.16).	We	demonstrated	positive	(eosinophil	count,	PP4	=	
98%)	 and	 negative	 (neutrophil	 count,	 PP4	 <	 0.01%	 and	 monocyte	 count,	 PP4	 =	 0.07%)	
colocalisation	results	(Figure	5.2),	supporting	that	PR3-AAV	and	eosinophil	count	share	the	
same	causal	variant	at	BCL2L11-MIR4435-2HG.	
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Figure	5.2:	Illustration	of	the	colocalisation	results.	
(A)	The	2q13	region	containing	the	candidate	genes	BCL2L11	and	MIR4435-2HG.	Top	to	bottom	panels:	regional	
visualisation	of	genome-wide	association	results	for	PR3-AAV	(top	SNP,	rs13405741),	eosinophil	count	(top	SNP,	
rs17484848),	neutrophil	count	(top	SNP,	rs10171849)	and	monocyte	count	(top	SNP,	rs150449635).	Region	of	
interest	 is	highlighted	 in	orange.	(B)	Magnified	view	of	the	region	of	 interest	showing	positive	(PR3-AAV	and	
eosinophil	count,	PP4	=	98%)	and	negative	(PR3-AAV	and	neutrophil	count,	PP4	<	0.01%;	PR3-AAV	and	monocyte	
count,	PP4	=	0.07%)	colocalisation	results.	(C)	The	relationships	between	PR3-AAV	and	3	other	haematological	
traits	including	eosinophil,	neutrophil	and	monocyte	counts.	
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5.2.5 A	higher	eosinophil	count	is	associated	with	an	increased	risk	of	PR3-AAV		
Having	established	that	PR3-AAV	and	eosinophil	count	have	a	high	probability	of	sharing	the	
same	 causal	 variant	 at	BCL2L11-MIR4435-2HG	 region,	 we	 then	 asked	whether	 eosinophil	
count	was	causally	related	to	PR3-AAV.	To	address	this	question,	we	performed	Two-sample	
Mendelian	Randomisation	 analysis	 using	 the	 summary	 statistics	 from	GWAS	of	 eosinophil	
counts	 (346),	 consisting	 of	 209	 conditionally	 independent	 genome-wide	 significant	 SNPs.	
After	excluding	the	HLA	region,	147	of	these	variants	were	available	in	the	PR3-AAV	dataset	
for	 MR	 using	 the	 IVW	 method.	 We	 found	 that	 a	 higher	 eosinophil	 count	 was	 strongly	
associated	with	an	increased	likelihood	of	developing	PR3-AAV	(causal	estimate	=	0.249,	p	=	
0.028).	 The	 results	were	 similar	when	different	MR	methods	were	 used,	 including	 simple	
median	MR	(causal	estimate	=	0.593,	p	=	0.000)	and	penalised	IVW	MR	(causal	estimate	=	
0.299,	p	=	0.002),	except	for	MR-Egger	approach	where	the	causal	estimate	was	attenuated	
(causal	estimate	=	0.086,	p	=	0.75).	The	MR-Egger	intercept	was	close	to	zero,	indicating	that	
there	was	no	evidence	of	pleiotropy	(Table	5.2).	MR-Egger	is	a	sensitivity	analysis	which	it	is	
generally	used	to	correct	for	potential	violations	of	assumptions	by	quantifying	the	amount	
of	directional	pleiotropy.	However,	its	power	to	detect	a	causal	effect	is	greatly	reduced	as	
compared	to	the	traditional	MR	methods.	In	this	instance,	although	MR-Egger	analysis	did	not	
provide	additional	evidence	 for	a	 causal	effect,	 it	did	not	 contradict	evidence	 for	a	 causal	
effect	from	the	conventional	MR	analysis	methods	either.	
	
Table	5.2:	Estimates	from	various	Mendelian	randomisation	methods	for	the	association	
between	eosinophil	count	and	PR3-AAV	
Method	 Causal	Estimate	 95%	CI	 P-value	
Simple	median	MR	 0.593	 0.318	–	0.868	 0.000***	
Weight	median	MR	 0.243	 -0.040	–	0.525	 0.092	
Penalised	weighted	median	MR	 0.245	 -0.038	–	0.528	 0.090	
IVW	MR	 0.249	 0.028	–	0.470	 0.028*	
Penalised	IVW	MR	 0.299	 0.111	–	0.486	 0.002**	
Robust	IVW	MR	 0.263	 0.061	–	0.465	 0.011*	
Penalised	robust	IVW	MR	 0.304	 0.117	–	0.491	 0.001***	
MR	Egger	estimate	 0.086	 -0.441	–	0.613	 0.750	
MR	Egger	intercept	 0.007	 -0.015	–	0.030	 0.504	
	
IVW,	 inverse	 variance	 weighted;	 MR,	 Mendelian	 randomisation;	 *Significant	 at	 the	 0.05	 probability	 level;	
**Significant	at	the	0.01	probability	level;	***	Significant	at	the	0.001	probability	level.	
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Summary	statistics	were	also	obtained	for	152	and	248	conditionally	 independent	variants	
associated	with	peripheral	blood	neutrophil	and	monocyte	counts	respectively	(346).	After	
excluding	the	HLA	region,	101	(neutrophil	count)	and	169	(monocyte	count)	variants	were	
available	 in	 the	 PR3-AAV	 dataset	 for	 MR	 analysis.	 We	 did	 not	 identify	 evidence	 of	 any	
association	between	neutrophil	or	monocyte	counts	with	susceptibility	to	PR3-AAV	(Figure	
5.3).	
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Figure	5.3:	A	higher	eosinophil	count	is	associated	with	an	increased	risk	of	PR3-AAV.		
Scatter	plots	showing	correlation	of	genetic	associations	of	(A)	eosinophil	count,	(B)	neutrophil	count	and	(C)	
monocyte	count	with	genetic	associations	of	PR3-AAV.	Points	represent	genome-wide	significant	conditionally	
independent	variants	associated	with	each	haematological	trait	in	the	GWAS	by	Astle	et	al	and	coloured	lines	
represent	the	slopes	(equivalent	to	the	estimated	causal	effects)	of	the	different	MR	regression	analyses.	IVW,	
inverse-variance	weighted.	
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5.2.6 Genetic	variation	at	rs13405741	modulates	the	lifespan	of	eosinophil	
Taking	all	the	findings	so	far	and	the	relevant	functional	associations	of	the	candidate	genes	
in	this	region,	we	next	considered	whether	rs13405741,	or	a	variant	in	strong	LD	with	it,	might	
influence	gene	expression	 in	eosinophils	 and	 consequently	alter	eosinophil	 count	 through	
prolongation	 of	 cell	 survival.	We	 recruited	 eight	 pairs	 of	 healthy	 individuals	 via	 the	NIHR	
BioResource	Centre	Cambridge,	who	were	homozygous	for	either	the	major	or	minor	allele	
at	 rs13405741,	 and	 were	 matched	 for	 age	 and	 gender.	 Eosinophils	 were	 isolated	 from	
polymorphonuclear	 cell-rich	 fraction	 of	 peripheral	 blood	 by	 negative	 immunomagnetic	
selection.	 Eosinophils	 represent	 a	minor	 population	 of	 leukocytes	 in	 the	 peripheral	 blood	
(typically	between	2-5%)	and	therefore	cell	yield	following	isolation	varied	among	samples.	
We	first	examined	the	expression	of	BCL2L11	and	MIR4435-2HG	to	determine	whether	these	
differed	 by	 genotype.	 We	 found	 that	 eosinophils	 from	 minor	 (C)	 allele	 homozygotes	
expressed	more	MIR4435-2HG	compared	to	those	from	major	(T)	allele	homozygotes	at	time	
0	hr	(p	=	0.080)	and	24	hr	(p	=	0.029)	following	culture	in	the	absence	of	serum.	However,	we	
did	not	detect	any	genotype-specific	differences	in	the	transcription	of	BCL2L11	at	both	time	
points	 (Figure	 5.4A).	We	 then	 investigated	how	differences	 in	MIR4435-2HG	 transcription	
might	 affect	 the	 production	 of	 Bim,	 by	 performing	 Western	 blot	 of	 eosinophil	 lysates	
recognising	the	limitations	that	only	three	samples	from	each	genotype	group	had	adequate	
cell	yields	for	this	experiment	and	therefore	no	finite	conclusion	could	be	made.	Nevertheless,	
there	was	a	trend	for	lower	Bim	production	by	eosinophils	from	minor	allele	homozygotes	
(Figure	5.4C).	To	determine	whether	differences	in	MIR4435-2HG	transcription	might	have	an	
implication	on	eosinophil	survival,	we	measured	the	apoptosis	rate	in	eosinophils	following	
24	hr	culture	without	serum	using	flow	cytometry	(Annexin	V	and	PI)	and	observed	that	lower	
apoptosis	 occurred	 in	minor	 allele	 homozygotes	 (p	 =	 0.0156),	 consistent	 with	 the	 earlier	
discovery	of	higher	MIR4435-2HG	transcription	and	lower	Bim	production	in	this	genotype	
(Figure	5.4D	and	E).	
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Figure	5.4:	rs13405741:C	allele	is	associated	with	a	lower	apoptosis	rate	in	eosinophils.	
(A)	 Representative	 photomicrographs	 of	 eosinophils	 at	 time	 0	 hr	 (top)	 and	 24	 hr	 (bottom)	 after	 incubation	
without	serum	depicting	the	morphological	features	of	apoptosis	including	DNA	fragmentation,	cell	shrinkage,	
nuclear	 and	 chromatin	 condensation	 and	membrane	 blebbing.	 Cytospin	 preparations	 using	May-Grünwald-
Giemsa	staining,	original	magnification	40X.	
(B)		Evidence	of	eQTL	for	MIR4435-2HG.	Expression	of	BCL2L11	and	MIR4435-2HG	were	assessed	using	qPCR	at	
time	0	hr	and	24	hr,	assayed	in	triplicate,	n	=	8	per	group	except	for	major	allele	homozygotes	(T/T)	at	time	24	
hr	consisting	of	7	per	group.	Mann-Whitney	test	was	performed.	Data	are	represented	as	mean	±	SEM,	*p	<	
0.05.	
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(C)	Representative	western	blot	images	of	purified	eosinophils	 lysed	in	loading	buffer	following	24	hr	culture	
and	blotted	for	expression	of	3	different	isoforms	of	Bim	(BimEL,	BimL	and	BimS).	b-Actin	was	used	as	a	loading	
control.	 Shown	on	 the	 right	 are	 the	densitometries	 calculated	using	 ImageLab	 software	and	expression	was	
normalised	to	b-Actin	(n	=	3	per	group).	
(D)	Representative	flow	cytometry	of	Annexin	V/Propidium	iodide-stained	eosinophils.	Eosinophil	apoptosis	was	
measured	following	24	hr	culture	in	the	RPMI	medium	in	the	absence	of	serum	supplement.	
(E)	 Eosinophil	 apoptosis	 rate	was	 lower	 in	 the	minor	 allele	 homozygotes.	Matched-pairs	 experiments	were	
carried	out	and	assayed	in	triplicate.	Wilcoxon	matched-pairs	signed-rank	test	(*p	<	0.05),	n	=	7	per	group	was	
performed	and	dotted	lines	link	paired	samples.		
	
5.3 PRTN3	
5.3.1 Introduction	
PRTN3	encodes	PR3	which	is	a	major	antigenic	target	for	AVV.	It	is	most	abundantly	expressed	
in	the	most	immature	myeloid	precursors	(myeloblasts	and	promyelocytes)	and	subsequently	
diminishes	 during	 granulopoiesis,	 reaching	 an	 almost	 undetectable	 level	 in	 the	 circulating	
mature	neutrophils	(Figure	5.5A,	RNA-seq	data	obtained	from	BLUEPRINT	datasets).	This	gene	
has	 two	 transcripts	 –	 canonical	 isoform	 (PRTN3-201)	 and	alternative	 isoform	 (PRTN3-202)	
which	 initiates	 transcription	 at	 a	 different	 promoter	 located	 in	 the	 intron	 1.	 Alternative	
splicing	was	first	reported	by	Chow	et	al	in	1977	(456).	It	is	an	important	biological	process	
that	 contributes	 to	 the	 diversity	 of	 protein	 isoforms	 of	 subtle	 functional	 differences,	 yet	
translating	 into	 significant	 biological	 consequences.	 It	 has	 also	 been	 implicated	 in	 a	wide	
range	of	diseases,	for	example	in	coeliac	disease,	where	patients	were	found	to	express	high	
levels	of	the	alternatively	spliced	FoxP3∆2	isoform	which	lacks	exon	2,	rather	than	the	full-
length	FoxP3	in	the	intestinal	cells,	resulting	in	failure	to	achieve	adequate	downregulation	of	
immune	response	(457).		
	
As	discussed	in	section	1.4.2,	a	higher	expression	of	PRTN3	transcript	was	demonstrated	in	
AAV	 patients	 as	 compared	 to	 healthy	 controls	 (118,	 119).	 Furthermore,	 McInnis	 and	
colleagues	recently	detected	the	alternative	PRTN3	transcript	(PRTN3-202)	 in	AAV	patients	
(111),	where	its	expression	correlated	with	disease	activity.	Notably,	its	predicted	amino	acid	
sequence	is	identical	to	that	previously	reported	for	myeloblastin	(112),	which	lacks	the	
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peptide	sequence,	dipeptide	(alanine-glutamate)	and	14	amino	acids	coded	by	exon	2	with	a	
predicted	 size	 of	 24	 kDa	 (Figure	 5.5B).	 Myeloblastin	 was	 originally	 discovered	 in	 human	
leukemic	cells	and	is	involved	in	the	proliferation	and	differentiation	of	leukaemic	cells	(112).	
However,	it	remains	to	be	confirmed	whether	is	PRTN3-202	transcript	coding	for	myeloblastin	
despite	identical	protein	sequence	as	the	published	cDNA	sequence	for	myeloblastin	differs	
from	the	sequence	for	PRTN3-202	message.	Furthermore,	the	potential	role	of	the	alternative	
isoform	of	PRTN3	in	the	pathogenesis	of	AAV	is	yet	to	be	elucidated.	
	
Three	different	lead	variants	at	the	PRTN3	locus	that	have	been	reported	in	previous	GWAS	
(rs62132295	and	rs62132293)	and	in	the	present	study	(rs55952682)	are	known	eQTLs	in	the	
whole	blood	where	the	risk	alleles	for	PR3-AAV	are	associated	with	a	higher	expression	of	
PRTN3	 (318).	 In	 terms	 of	 disease-relevant	 cell	 type,	 there	were	 two	 studies	 investigating	
whether	 these	 variants	 had	 an	 influence	 on	 PRTN3	 expression	 in	 neutrophils	 with	
contradictory	 results	 (71,	 123),	 while	 another	 study	 failed	 to	 detect	 any	 quantitative	
difference	in	PRTN3	expression	between	wild-type	and	polymorphic	variant	(122)	using	the	
luciferase	reporter	assay.	
	
To	 investigate	 how	 genetic	 variation	 at	 this	 locus	 might	 influence	 PRTN3	 expression	 in	
neutrophils,	we	first	examined	whether	rs62132296	(availability	of	individual	level	genotype	
data)	was	an	eQTL	using	the	existing	microarray	gene	expression	datasets	for	AAV	and	CKD	
cohorts	in	the	Smith	lab.	Furthermore,	we	aimed	to	determine	whether	there	was	evidence	
of	differential	expression	at	the	isoform	level.	See	Table	5.3	for	LD	between	rs62132296	with	
other	previously	identified	lead	variants	at	this	locus.	
	
Table	5.3:	Relationship	of	rs62132296	with	previously	reported	lead	variants	at	PRTN3	
SNP	 LD	with	rs62132296	
rs62132295	(Lyons	et	al)	 1.0	
rs62132293	(Merkel	et	al)	 0.9202	
rs55952682	(present	study)	 0.6562	
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Figure	5.5:	PRTN3	expression	in	different	stages	of	granulopoiesis.	
(A)	Left:	There	are	two	PRTN3	transcripts	(PRTN3-201	and	PRTN3-202).	PRTN3	gene	expression	by	RNA-seq	in	
different	stages	of	granulopoiesis	(BLUEPRINT	datasets,	auto-scale	to	the	level	of	expression	as	depicted	on	the	
left	 axis).	 Right:	 The	 stages	 of	 granulopoiesis	 from	myeloblast	 to	 the	mature	 circulating	 neutrophil.	 During	
neutrophil	maturation,	 granulocytic	 cells	 change	 shape,	 acquire	 primary	 and	 specific	 granules	 and	 undergo	
nuclear	condensation	(Images	were	obtained	from	https://imagebank.hematology.org/).	
(B)	 *In	 silico	 translation	 of	 PRTN3-202	 transcript	 indicates	 that	 it	 has	 an	 identical	 amino	 acid	 sequence	 as	
myeloblastin,	which	lacks	the	signal	peptide	sequence	that	is	present	in	PR3.	Signal	peptide	is	critical	in	directing	
newly	synthesised	protein	to	the	Golgi	for	post-translational	glycosylation.	Adapted	and	modified	from	McInnis	
et	al.	
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5.3.2 rs62132296:T	allele	is	associated	with	a	higher	expression	of	PRTN3	in	neutrophils	
Firstly,	the	genotype	of	each	individual	in	the	CKD	and	AAV	cohort	was	determined	using	the	
TaqManâ	 SNP	 genotyping	 assay.	 Following	 QC	 of	 the	 CD16+	 neutrophil	 gene	 expression	
datasets,	the	number	of	patients	included	in	the	eQTL	analysis	is	summarised	in	Table	5.4.	To	
evaluate	for	allelic	effects	of	rs62312296:	C	>	T	on	PRTN3	expression,	I	first	performed	whole	
transcript	 analysis	 and	 showed	 that	 in	 the	 CKD	 cohort,	 PRTN3	 transcript	 levels	 were	
significantly	higher	in	minor	(T)	allele	homozygotes	(risk	allele	for	PR3-AAV)	than	in	patients	
with	CC	or	CT	genotypes,	with	evidence	of	allelic	transcripts	dosage	effect	(ANOVA,	p	<	0.001;	
test	 for	 linear	 trend,	p	<	0.0001;	 Figure	5.6A).	 In	 contrast,	 I	 did	not	detect	 any	genotype-
specific	differences	in	PRTN3	expression	in	the	AAV	cohort,	which	could	possibly	be	attributed	
to	(i)	a	small	sample	size	or	(ii)	PRTN3	expression	reaching	the	saturation	limit	in	the	setting	
of	active	disease	(Figure	5.6B).		
	
To	investigate	differential	isoform	transcripts	expression,	I	performed	exon-level	analysis	of	
the	same	CKD	cohort.	There	are	seven	probes	targeting	PRTN3	on	the	Affymetrix	GeneChip®	
microarray	–	 two	probes	 for	exons	1	and	5	 respectively	and	one	probe	 for	 the	 remaining	
exons.	 I	detected	 significantly	higher	expressions	of	exons	3	 (ANOVA,	p	=	0.0362;	 test	 for	
linear	 trend,	 p	 =	 0.0229),	 4	 (ANOVA,	 p	 =	 0.0042;	 test	 for	 linear	 trend,	 p	 =	 0.0010)	 and	 5	
(ANOVA,	p	=	0.0002;	test	for	linear	trend,	p	<	0.0001	and	ANOVA,	p	=	0.0286;	test	for	linear	
trend,	p	=	0.0272	for	each	respective	probe)	in	the	minor	allele	homozygotes	than	those	from	
the	major	allele	homozygotes.	These	exons	are	common	to	both	isoforms.	However,	there	
were	no	differences	observed	in	exons	1	and	2,	therefore	it	was	not	possible	to	detect	any	
evidence	of	differential	isoform	transcripts	expression	(Figure	5.6C).	
	
Table	5.4:	Number	of	patients	included	in	the	eQTL	analysis	
Cohort	 rs62132296:	C	>	T	
C/C	 C/T	 T/T	
CKD	 38	 35	 4	
AAV	 7	 17	 5	
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Figure	5.6:	PRTN3	expression	in	neutrophils	
(A)	rs62132296	is	an	eQTL	for	PRTN3.	In	the	CKD	cohort,	the	expression	of	PRTN3	was	significantly	associated	
with	the	genotype	at	rs62132296	by	standard	ANOVA	(p	<	0.0001)	and	post-test	for	linear	trend	(p	<	0.0001).	
(B)	The	expression	of	PRTN3	in	the	active	AAV	cohort	was	not	associated	with	genotype	at	rs62132296.	
(C)	Exon-level	expression	analysis	showing	significant	differential	expressions	of	exons	3,	4	and	5	by	genotype	
but	not	exons	1	and	2.	The	p-values	represent	test	for	linear	trend.		
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5.3.3 Detection	of	alternative	PRTN3	transcript	(PRTN3-202)	
To	confirm	the	expression	of	PRTN3-202	transcript,	I	performed	PCR	with	RNA	from	isolated	
PMN	 and	 CD16+	 neutrophils	 (see	 Table	 2.6	 for	 PCR	 primer	 sets)	 and	 data	 indicated	 that	
healthy	controls,	 active	AAV	and	CKD	patients	expressed	both	PRTN3-201	 and	PRTN3-202	
transcripts.				
	
	
Figure	5.7:	Detection	of	PRTN3-202	transcript	in	PMN	and	CD16+	neutrophils	
THP-1	cells	express	both	PRTN3-201	(267	bp)	and	PRTN3-202	(337	bp)	while	MCF	cells	express	only	PRTN3-202.	
They	were	 used	 as	 the	 positive	 controls.	 AAV,	 ANCA-associated	 vasculitis;	 CKD,	 chronic	 kidney	 disease;	 HC,	
healthy	controls;	NTC,	no	template	control;	PMN,	polymorphonuclear	cells.	The	target	PCR	bands	were	purified	
prior	to	Sanger	sequencing	to	confirm	the	cDNA	sequence.	The	upper	bands	(~400bp)	in	the	middle	panel	were	
non-specific	bands.	
	
5.3.4 rs62132296:T	 allele	 is	 associated	 with	 a	 higher	 expression	 of	 PRTN3-201	 in	
neutrophils	
To	determine	which	isoform	of	PRTN3	was	aberrantly	expressed,	I	performed	qPCR	with	RNA	
from	isolated	CD16+	neutrophils	 from	CKD	patients.	Two	TaqMan®	gene	expression	assays	
were	used	including	Hs00160521_m1	where	the	probe	spans	exons	1	and	2,	detecting	only	
PRTN3-201	isoform	and	Hs01553330_m1	where	the	probe	spans	exons	3	and	4,	allowing	the	
detection	both	PRTN3-201	and	PRTN3-202	isoforms.	These	assays	validated	the	microarray	
findings	 (section	 5.3.2)	 where	 genotype	 at	 rs62132296	 had	 an	 allelic	 effect	 on	 PRTN3	
expression	in	neutrophils.	qPCR	analysis	using	the	former	probe	showed	the	cellular	PRTN3-
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201	transcript	level	to	be	significantly	higher	in	risk	allele	(T)	homozygotes	than	in	individuals	
with	CC	or	CT	genotypes	 (ANOVA,	p	=	0.0005;	 test	 for	 linear	 trend,	p	=	0.0005).	A	 similar	
observation	was	noted	with	the	latter	probe	(ANOVA,	p	=	0.0001;	test	for	linear	trend,	p	<	
0.0001;	Figure	5.8A).	However,	 it	was	not	possible	to	determine	the	relative	expression	of	
PRTN3-202	by	deducting	the	CT	of	these	two	probes	due	to	different	PCR	efficiency.	The	data	
imply	that	the	risk	allele	is	associated	with	a	higher	expression	of	PRTN3-201,	but	we	could	
not	conclude	whether	rs62132296	has	an	allelic	effect	on	PRTN3-202.	There	is	a	possibility	
that	the	differences	that	we	observed	using	the	latter	probe	could	be	purely	driven	by	PRTN3-
201	rather	than	both	PRTN3-201	and	PRTN3-202.	
	
To	further	pursue	the	question	of	whether	rs62132296	or	the	causal	variant	in	high	LD	with	it	
had	an	allelic	 effect	on	PRTN3-202,	 I	 generated	RNA-Seq	gene	expression	data	with	 good	
quality	RNA	from	isolated	CD16+	neutrophils	of	CKD	patients,	comprising	eight	major	allele	
homozygotes,	seven	heterozygotes	and	four	minor	allele	homozygotes.	Following	QC	of	the	
raw	data,	an	average	of	28.7	million	reads	were	obtained	per	 library	and	gene	expression	
levels	 were	 evaluated	 by	 counting	 the	 number	 of	 transcripts	 per	 kilobase	million	 (TPM).	
Despite	having	a	smaller	sample	size,	a	differential	PRTN3	expression	was	validated	(ANOVA,	
p	=	0.0625;	test	for	linear	trend,	p	=	0.0249;	Figure	5.8B)	and	the	results	were	comparable	
with	those	obtained	using	microarray	and	qPCR	analyses.		
	
I	then	made	Sashimi	plots,	a	quantitative	visualisation	of	aligned	RNA-seq	reads	that	allows	
comparison	of	exon	usage	across	all	samples	using	the	Broad	Institute	Integrative	Genomics	
Viewer,	 enabling	 rapid	 differential	 isoform	 usage	 analysis.	 Each	 splice	 junction	 track	
represents	one	sample	and	it	calls	a	splicing	event	when	at	least	a	single	read	splits	across	
two	exons	in	the	alignment	track	and	each	splice	junction	is	represented	by	an	arc	from	the	
beginning	to	the	end	of	the	junction	(Figure	5.8C).	Despite	relatively	high	sequencing	depth,	
no	splicing	events	between	exons	1	and	2	were	detected	for	all	except	one	sample	and	the	
overall	numbers	of	reads	spliced	across	any	of	the	other	splice	junctions	were	low.	These	read	
counts	were	not	able	to	capture	differential	isoform	usage.	
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Figure	5.8:	rs62132296:T	is	associated	with	a	higher	expression	of	PRTN3-201.	
(A)	 qPCR	 using	 the	 TaqMan	 genotyping	 assays	 with	 probes	 targeting	 different	 exons	 showing	 differential	
expression	 of	PRTN3-201	 by	 genotype	 at	 rs62132296	 (left:	 test	 for	 linear	 trend,	 p	 =	 0.0005)	 and	 combined	
expression	of	PRTN3-201	and	PRTN3-202	(right:	test	for	linear	trend,	p	<	0.0001).	
(B)	 PRTN3	 expression	 quantification	 at	 gene	 level	 using	 the	 RNA-seq	 data	 of	 CD16+	 neutrophils	 showing	
comparable	 findings	 as	 microarray	 and	 qPCR	 analyses	 where	 higher	 expression	 of	 PRTN3	 was	 observed	 in	
patients	bearing	homozygous	risk	genotype	at	rs62132296	(test	for	linear	trend,	p	=	0.0249).		
(C)	 Representative	 Sashimi	 plot	 consisting	 7	 samples	 for	 PRTN3	 region	 generated	 using	 Broad	 Institute	
Integrative	Genomics	Viewer.	Genomic	coordinates	are	plotted	on	x-axis	and	read	density	on	y-axis.	The	raw	
junction	read	counts	are	shown	on	top	of	each	junction	arch.	
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5.4 Discussion	
Understanding	 the	 fundamental	 mechanisms	 of	 how	 genetic	 variants	 might	 exert	 their	
pathogenic	 effects	 is	 essential	 for	 the	 development	 of	 novel	 diagnostic	 and	 treatment	
avenues.	 Translating	 GWAS	 results	 into	 biologically	 relevant	 effects	 remains	 a	 major	
challenge,	although	 these	barriers	have	been	gradually	overcome	with	 recent	advances	 in	
technology,	statistical	and	bioinformatics	approaches,	along	with	publicly	available	genomic	
databases	 generated	 by	 large	 consortia.	 We	 demonstrated	 that	 PR3-AAV	 and	 eosinophil	
count	shared	the	same	causal	variant	at	BCL2L11-MIR4435-2HG	 locus.	Importantly,	for	the	
first	time,	we	established	a	causal	association	between	higher	eosinophil	count	and	increased	
risk	of	PR3-AAV.	We	further	explored	the	functional	implication	of	rs13405741	(or	the	causal	
variant	in	high	LD	with	it)	in	eosinophils	by	recalling	healthy	volunteers	by	genotype	and	found	
that	the	risk	allele	homozygotes	expressed	higher	levels	of	MIR4435-2HG	transcript	with	an	
appropriately	lower	eosinophil	apoptosis	rate,	supporting	our	hypothesis	that	the	risk	variant	
is	 associated	 with	 a	 higher	 expression	 of	MIR4435-2HG	 in	 eosinophils,	 which	 results	 in	
downregulation	of	BCL2L11	transcription	and	eventually,	reduced	apoptosis.	Prolongation	of	
cell	survival	leads	to	a	higher	eosinophil	count	which	underpins	the	pathogenesis	of	PR3-AAV.	
Although	we	 did	 not	 detect	 any	 differences	 in	BCL2L11	 mRNA	 levels	 by	 genotype	 in	 our	
experiments,	it	does	not	exclude	a	possible	role	of	BCL2L11	for	this	biological	process	as	the	
negative	 results	 might	 be	 attributed	 to	 (i)	 the	 complex	 regulatory	 network	 for	 BCL2L11	
expression,	(ii)	suboptimal	harvest	time	of	samples	to	detect	a	significant	difference	if	 it	 is	
present	and	(iii)	insufficient	power	to	detect	a	small	effect	size.	
	
According	to	the	1990	ACR	classification	criteria,	eosinophilia	(more	than	10%	of	peripheral	
white	blood	cells)	and	extravascular	eosinophilia	are	two	of	the	six	criteria	used	to	distinguish	
EGPA	from	other	vasculitis	(458).	However,	these	two	features	are	not	specific	to	EGPA	and	
have	been	observed	in	other	types	of	small	and	medium-vessel	vasculitis,	most	notably	GPA	
(459).	Yousem	and	Lombard	were	the	first	to	coin	the	term	“eosinophilic	variant	of	GPA”	in	
1988	when	they	described	four	cases	of	atypical	histological	variant	of	GPA	(460)	and	several	
studies	of	similar	description	have	been	reported	in	the	literature	where	tissue	eosinophilic	
infiltration	was	universally	observed	in	all	cases,	primarily	involving	the	lungs,	nasal,	orbital	
and	mastoid	regions,	with	evidence	of	PR3-ANCA	(those	who	had	their	ANCA	status	tested)	
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and	absence	of	allergy	and	asthma	except	for	one	patient	(460-467).	Furthermore,	Balding	
and	colleagues	demonstrated	a	Th2	dominant	cytokine	millieu	within	the	nasal	mucosa	of	
GPA	patients	as	compared	to	healthy	and	disease	controls,	where	higher	levels	of	CD3+	T	cells	
and	eosinophils,	along	with	the	observation	of	higher	IL-4	but	lower	IL-2	expression	in	GPA	
patients	 (468).	 Schnabel	 et	 al	 found	 higher	 eosinophil	 cationic	 protein	 levels	 in	 the	
bronchoalveolar	lavage	fluid	from	GPA	patients	but	below	the	detection	limit	in	patients	with	
sarcoidosis,	which	 is	 a	 granulomatous	 disease	without	 vasculitis	 involvement	 and	 healthy	
controls,	 suggestive	 of	 eosinophil	 activation	 and	 degranulation	 (469).	 Nonetheless,	 it	 is	
difficult	to	ascertain	the	precise	role	of	eosinophils	in	disease	pathogenesis	as	these	studies	
are	predominantly	based	on	case	reports.	With	the	application	of	MR	methodology,	our	study	
provides	a	 clear	genetic	evidence	 to	 support	 the	causal	 role	of	higher	eosinophil	 count	 in	
increasing	the	risk	of	PR3-AAV.	
	
Eosinophils	were	first	described	by	Paul	Ehrlich	in	1879	due	to	high	affinity	of	its	secondary	
granules	 for	 red	 dye	 eosin	 (470)	 and	more	 than	 90%	of	 eosinophils	 reside	 in	 the	 tissues,	
particularly	bone	marrow,	gastrointestinal	 tract,	 thymus	and	the	endometrial	 lining	of	 the	
uterus	(471).	Eosinophil	differentiation	and	expansion	occur	in	the	bone	marrow	under	the	
influence	 of	 a	 number	 of	 transcription	 factors	 (GATA-binding	 factor	 1,	 PU.1	 and	 CCAAT-
enhancer-binding	 proteins)	 and	 several	 cytokines	 (IL-3,	 IL-5	 and	 GM-CSF)	 (459).	 The	
secondary	 granules	 contain	 cationic	 proteins	 including	 major	 basic	 protein,	 eosinophilic	
cationic	protein,	eosinophil	peroxidase	and	eosinophil	derived	neurotoxin	that	mediate	cell	
death,	as	well	as	a	vast	range	of	preformed	proinflammatory	cytokines,	growth	factors	and	
enzymes,	which	are	released	upon	cell	activation.	Well	known	for	their	important	roles	in	host	
defence	 against	 helminths	 and	 allergic	 inflammation	 such	 as	 asthma,	 Lee	 and	 colleagues	
recently	hypothesised	that	resident	tissue	eosinophils	might	be	essential	for	local	immunity,	
remodelling	and	 repair	 in	both	health	and	disease	 (471),	as	accumulating	data	 supporting	
their	 immunomodulatory	 abilities	 through	 expression	 of	 cytokines	 and	 growth	 factors	
characterised	 as	 Th1/Th17,	 Th2	 as	 well	 as	 acute	 phase	 pro-inflammatory	 and	 anti-
inflammatory	(472).	In	addition,	eosinophils	are	critical	in	maintaining	the	plasma	cell	survival	
by	secreting	APRIL	(A	PRoliferation-Inducing	Ligand)	and	IL-6.	Low	plasma	cell	numbers	had	
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been	 observed	 in	 eosinophil-deficient	mice	 both	 at	 steady	 state	 and	 after	 immunisation,	
which	improved	momentarily	following	eosinophil	reconstitution	(473).	
	
The	 pathogenic	 role	 of	 eosinophils	 in	 vasculitis	 is	 best	 characterised	 in	 EGPA,	 primarily	
inferred	from	clinical	studies	given	the	lack	of	widely	accepted	animal	model	of	eosinophilic	
vasculitis.	Its	role	remains	underexplored	in	other	forms	of	vasculitis	as	peripheral	and	tissue	
eosinophilia	are	not	frequently	present	in	these	conditions.	Hellmark	and	colleagues	recently	
investigated	 the	 functional	and	activation	 status	of	eosinophils	 in	a	 cohort	of	120	healthy	
controls	 and	 98	 GPA/MPA	 patients,	 of	 whom	 88%	 were	 on	 active	 treatment	 with	
immunosuppression	and	78%	in	disease	remission.	The	authors	reported	a	lower	percentage	
of	eosinophils	in	the	peripheral	blood	of	AAV	patients	with	altered	expression	of	cell	surface	
markers	 including	 CD16,	 CD64,	 CCR3,	 CD35,	 CD11c	 and	 CD62L	 as	 compared	 to	 healthy	
controls.	Although	the	production	of	ROS	was	noted	to	be	lower	in	the	AAV	eosinophils,	they	
demonstrated	an	increased	in	eosinophil	extracellular	DNA	traps	(EETs)	formation	following	
ANCA	stimulation,	postulating	that	it	could	lead	to	deposition	of	intact	eosinophilic	granules	
in	 tissues	 and	 contribute	 to	 inflammation	 (474).	 However,	 one	 must	 be	 cautious	 in	
interpreting	 the	 results	 as	 they	 could	 potentially	 be	 confounded	 by	 immunosuppressive	
treatment	particularly	glucocorticoids,	which	are	known	to	 induce	eosinophil	apoptosis	by	
inhibiting	survival	prolonging	signals	and	influence	the	levels	of	NADPH	oxidase	subunits	and	
ROS	 (475,	 476).	 Notably,	 eosinophils	 have	 been	 shown	 to	 coexpress	 eosinophil	 specific	
granule	proteins	and	neutrophil	primary	granule	proteins	including	cathepsin	G,	azurocidin,	
lysozyme,	neutrophil	elastase,	MPO	and	PR3	during	early	differentiation	stages	in	the	bone	
marrow,	which	diminish	before	full	maturation	(477).	PRTN3	transcript	is	also	detectable	in	
mature	eosinophils	(BLUEPRINT	datasets).	Future	studies	are	required	to	establish	the	role	of	
eosinophils	in	the	pathogenesis	of	PR3-AAV	though	it	is	tempting	to	speculate	that	eosinophil	
infiltration	of	inflamed	mucosal	tissue	may	support	a	Th2-mediated	inflammatory	process	and	
provide	a	specific	microenvironment	to	prolong	plasma	cell	survival,	further	enhancing	the	
autoreactive	immune	response.	In	addition,	eosinophils	could	increase	the	availability	of	PR3	
autoantigen	 via	 EETs.	 Eosinophil	 directed	 therapy	 might	 be	 a	 new	 potential	 therapeutic	
approach	in	AAV,	especially	in	those	resistant	to	currently	available	treatment	regimens	along	
with	histopathological	evidence	of	tissue	eosinophilic	infiltration.	
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Moreover,	we	investigated	the	functional	implication	of	the	causal	variant	at	PRTN3	locus.	As	
we	 were	 conducting	 experiments	 to	 assess	 whether	 the	 identified	 variant	 exerted	 its	
influence	 by	 modulating	 gene	 expression	 of	 PRTN3,	 Merkel	 and	 colleagues	 reported	 a	
neutrophil-specific	eQTL	for	PRTN3	(71)	at	rs62132293:	C	>	G	and	demonstrated	that	cellular	
PRTN3	transcript	levels	were	higher	in	those	homozygous	for	the	risk	(G)	allele	than	in	donors	
with	CC	or	CG	genotypes.	Not	only	did	our	findings	confirm	this	observation,	but	we	were	also	
able	to	demonstrate	that	the	canonical	transcript	(PRTN3-201)	was	differentially	expressed	
by	 genotype	 at	 rs62132296	 in	 neutrophils.	 These	 data	 agree	with	 the	 proteomic	 analysis	
where	higher	plasma	levels	of	PR3	were	observed	in	individuals	carrying	the	risk	alleles	(319).	
Although	we	detected	 the	expression	of	 the	alternative	 transcript	 (PRTN3-202)	 in	PMN	of	
healthy	 controls	 and	 AAV	 patients,	 we	 were	 not	 able	 to	 determine	 differential	 isoform	
expression	due	to	 low	read	counts	for	PRTN3	 in	mature	neutrophils.	PRTN3-202	 transcript	
has	been	demonstrated	to	correlate	with	disease	activity	 in	AAV	patients	 (111)	and	might	
potentially	be	antigenic.	Further	investigation	will	be	necessary	to	confirm	its	role	in	disease	
pathogenesis	and	to	address	whether	the	causal	variant	has	an	impact	on	its	expression,	one	
will	 have	 to	 consider	 using	 bone	 marrow	 samples,	 of	 which	 the	 expression	 of	 PRTN3	 in	
neutrophil	precursors	can	be	100-1000	times	higher	than	in	mature	neutrophils,	facilitating	
differential	isoform	analysis.	
	
5.5 Conclusion	
This	is	the	first	demonstration	of	genetic	evidence	supporting	a	causal	role	eosinophil	number	
in	PR3-AAV	and	this	effect	might	partly	be	due	to	dysregulation	of	MIR4435-2HG,	 thereby	
prolonging	 eosinophil	 survival.	 The	 current	 paradigm	 of	 the	 pathogenesis	 of	 AAV	 focuses	
primarily	on	neutrophils,	monocytes	and	lymphocyte-dependent	mechanisms.	This	study	is	
an	 important	 step	 towards	 understanding	 the	 role	 of	 eosinophils	 in	 vasculitis	 other	 than	
EGPA.	 We	 also	 validated	 that	 the	 genetic	 variant	 at	 PRTN3	 locus	 is	 associated	 with	
dysregulation	of	autoantigen	expression.	
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6 GENERAL	DISCUSSION	
6.1 Summary	and	implication	of	findings	
AAV	 is	 a	 rare	 autoimmune	 disorder	 that	 is	 associated	 with	 substantial	 morbidity	 and	
mortality.	The	aim	of	this	study	was	to	unravel	the	genetic	basis	of	PR3-AAV	and	MPO-AAV	
independently	in	order	to	improve	our	understanding	about	the	pathogenesis	of	disease	and	
to	pave	 the	way	 for	 the	development	of	new	diagnostic	 and	 therapeutic	 approaches.	We	
conducted	a	meta-analysis	of	two	AAV	GWAS	datasets,	comprising	2,652	cases	and	11,947	
controls	of	European	ancestry.	We	replicated	previously	identified	genome-wide	significant	
risk	loci	and	discovered	seven	additional	risk	loci	(Figure	6.1).	In	addition,	fine-mapping	of	the	
classical	HLA	alleles	identified	three	independent	signals	conferring	disease	susceptibility	for	
PR3-AAV,	 including	 HLA-DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	
and	HLA-DPA1*01:03-HLA-DPB1*02:01,	which	were	distinct	from	MPO-AAV,	conferred	by	an	
extended	 haplotype	 encoding	 HLA-DRB1*04:04-HLA-DQA1*03:01-HLA-DQB1*03:02.	 Using	
Bayesian	methods	to	define	credible	sets	from	the	GWAS	results,	together	with	integration	
of	 multi-sourced	 genomic	 datasets	 consisting	 of	 functional	 annotation,	 gene	 expression,	
methylation	 and	 PCHi-C	 data,	 we	 were	 able	 to	 identify	 candidate	 genes	 that	 provide	
potentially	important	biological	insights	into	disease	pathogenesis.	
	
Further	 analyses	 based	 on	 genotyped	 common	 variants	 suggested	 a	 significant	 positive	
genetic	correlation	between	PR3-AAV	and	MPO-AAV,	comparable	to	that	observed	between	
UC	and	Crohn’s	disease,	supporting	that	both	conditions	share	a	strong	genetic	architecture.	
The	 three	 risk	 loci	 that	are	common	to	both	PR3-AAV	and	MPO-AAV	 (PTPN22,	CTLA4	 and	
DGUOK-TET3)	also	share	commonalities	with	a	range	of	other	autoimmune	diseases	and	have	
been	 implicated	 in	 several	 key	 immunological	pathways.	 This	 led	us	 to	 speculate	 that	 the	
clinical	similarities	between	PR3-AAV	and	MPO-AAV	could	be	explained	by	common	genetic	
predisposition	in	addition	to	ANCA	itself,	which,	through	targeting	the	neutrophil	albeit	via	
different	granules	antigens,	drives	a	similar	pathology.	
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Figure	6.1:	The	relationship	between	MPO-AAV	and	PR3-AAV.		
	
By	performing	colocalisation	analysis,	we	 found	 that	PR3-AAV	and	eosinophil	 count	had	a	
greater	than	98%	probability	of	sharing	the	same	causal	variant	at	the	BCL2L11-MIR4435-2HG	
locus.	Several	studies	have	consistently	reported	an	atypical	histological	variant	of	PR3-AAV	
associated	with	tissue	eosinophilia,	however	disentangling	causality	is	challenging	as	neither	
eosinophilia	 nor	 extravascular	 eosinophilia	 are	 universal	 clinical	 features	 of	 PR3-AAV.	We	
confirmed	a	causal	association	between	higher	eosinophil	numbers	and	increased	risk	of	PR3-
AAV	 but	 not	 MPO-AAV,	 using	 two-sample	 MR	 and	 publicly	 available	 GWAS	 summary	
statistics.	This	effect	could	partly	be	modulated	by	MIR4435-2HG	 through	prolongation	of	
eosinophil	survival.	Very	little	is	known	about	the	role	of	eosinophils	in	the	pathogenesis	of	
PR3-AAV.	This	 is	an	area	worthy	of	 further	 research	efforts	with	potential	 for	becoming	a	
target	for	new	therapeutics.	
	
Finally,	 we	 identified	 an	 association	 between	 a	 missense	 variant	 at	 the	 IGHV1-69	 locus	
(rs11845244)	with	PR3-AAV.	This	single	point	of	mutation	in	the	V	gene	results	in	a	change	of	
amino	acid	in	the	framework	region	2	(immediately	adjacent	to	the	CDR2)	of	the	heavy	chain	
that	has	previously	been	shown	to	completely	abolish	NEAT2	domain	binding	which	is	critical	
for	iron	acquisition	in	S.	aureus	during	infection.	Our	study	presents	a	plausible	host	genetic	
factor	to	support	the	association	between	chronic	S.	aureus	nasal	carriage	and	PR3-AAV.	
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6.2 Lessons	learnt	
The	strengths	of	the	current	study	include	the	following	aspects.	This	is	the	largest	GWAS	of	
AAV	 to	 date	 and	 the	 samples	 were	 well	 phenotyped.	 We	 utilised	 the	 latest	 imputation	
software	and	a	large	imputation	reference	panel,	which	led	to	better	imputation	accuracy,	
thereby	facilitating	further	discoveries	that	would	have	otherwise	been	challenging	to	detect.	
As	we	recruited	patients	and	controls	from	a	number	of	European	countries,	we	employed	
the	 LMM	 model	 for	 genetic	 association	 testing,	 which	 has	 been	 shown	 to	 be	 better	 in	
accounting	 for	 population	 substructure	 than	 traditional	 genomic	 control	 using	 principal	
component	analysis	to	reduce	false	positive	signals.	Through	this	project,	I	have	developed	
skills	and	proficiency	in	running	imputation,	genome-wide	association	tests,	visualisation	of	
the	GWAS	summary	statistics	and	work-flow	for	loci	prioritisation.	With	the	support	from	the	
NIHR	BioResource	Centre	Cambridge,	we	were	able	to	recall	age	and	gender-matched	healthy	
volunteers	 by	 genotype	 to	 perform	 functional	 experiments	 to	 uncover	 the	 potential	
mechanisms	by	which	the	genetic	variants	exert	their	effects.	
		
However,	there	are	some	limitations	in	this	study	that	are	worth	noting.	Firstly,	the	sample	
size	was	still	relatively	limited	given	the	rare	nature	of	AAV	and	it	was	not	adequately	powered	
to	capture	 low-frequency	and	rare	variants	with	small	effects	sizes.	Nonetheless,	we	have	
discovered	common	and	a	few	low-frequency	variants	with	high	penetrance,	the	majority	of	
which	are	ANCA	status	specific.	Having	discovered	that	both	PR3-AAV	and	MPO-AAV	share	a	
strong	genetic	architecture,	a	larger	sample	size	would	enable	discovery	of	more	variants	that	
are	 common	 to	 both.	 Secondly,	 the	 overall	 eosinophil	 yield	 was	 low	 during	 in	 vitro	
experiments	despite	the	use	of	the	immunomagnetic	purification	procedure,	which	is	a	highly	
reproducible	method	for	 isolating	eosinophils.	Therefore,	 I	did	not	have	adequate	cells	for	
time-course	 experiments	 to	 investigate	 time-dependent	 transcriptional	 responses	 under	
different	 conditions.	 As	 eosinophils	 represent	 only	 a	minority	 of	 the	 circulating	 leukocyte	
population,	 this	problem	could	be	addressed	by	 sampling	a	 larger	volume	of	whole	blood	
from	healthy	volunteers.	Thirdly,	we	did	not	detect	differential	PRTN3	 isoform	expression	
using	RNA-Seq	due	to	low	read	counts	despite	acquiring	approximately	30	million	reads	per	
sample.	 This	 is	 unsurprising	 as	 mature	 neutrophils	 are	 generally	 considered	 to	 be	
transcriptionally	inactive.	Bone	marrow	samples	will	be	an	ideal	research	substrate	to	resolve	
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this	question	as	PRTN3	is	highly	expressed	in	the	myeloid	precursor	cells.	However,	it	will	be	
immensely	challenging	to	recruit	sufficient	research	participants.	
	
6.3 Future	research	in	the	field	
GWAS	have	been	tremendously	successful	in	deciphering	the	genetic	component	of	common	
complex	diseases.	Advances	in	genomic	technologies,	larger	sample	sizes	and	collaborative	
research	 generating	 multi-omics	 datasets	 have	 driven	 the	 evolution	 of	 bioinformatics,	
bridging	 the	 gap	 between	 genetic	 association	 and	 biological	 function	 and	 eventually,	
translating	 toward	 new	 therapeutics.	 The	 data	 presented	 here	 highlight	 several	 areas	 for	
further	research.	
		
6.3.1 Discovering	additional	genetic	variants	
The	first	step	is	to	increase	the	number	of	individuals	within	a	sample	because	a	larger	sample	
size	will	provide	the	greatest	effect	gain	on	power.	Although	replacing	high	density	SNP	chips	
with	whole	genome	sequencing	will	tag	low-frequency	loci,	this	alone	will	not	be	sufficient	to	
capture	effects	of	rare	variants	as	these	variants	will	be	present	at	such	low	numbers	that	
very	large	datasets	will	be	required	for	their	detection.	Given	the	rarity	of	the	disease,	it	is	
unlikely	 that	we	will	 reach	a	 sufficiently	 large	power,	 contrary	 to	other	 common	complex	
diseases	such	as	hypertension	and	type	2	diabetes,	to	allow	low-frequency	and	rare	variants	
to	be	dissected	to	a	far	greater	extent.	An	alternative	approach	is	to	perform	whole	genome	
sequencing	 in	densely	affected	 families,	which	will	 enable	 identification	of	additional	 rare	
variants	 that	 can	 subsequently	 be	 validated	 with	 a	 combination	 of	 genotyping	 and	 deep	
sequencing	of	variants	in	large	number	of	cases	and	controls.	
	
The	differences	in	the	geographical	and	ethnic	distribution	of	AAV	are	well	reported.	To	date,	
GWAS	in	AAV	have	only	focused	on	populations	of	European	ancestry.	Notably,	some	of	the	
identified	risk	variants	are	monomorphic	in	the	East	Asian	populations.	Therefore,	conducting	
GWAS	 in	 different	 ethnic	 groups	 will	 provide	 valuable	 information	 including	 identifying	
genetic	determinants	that	are	shared	between	racial	groups	or	specific	to	a	subpopulation	
and	 localisation	 of	 functional	 variant	 (or	 variants)	 by	 harnessing	 different	 LD	 patterns	 in	
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different	ethnic	groups.	In	addition,	alternative	approach	(e.g.	conditional	false	discovery	rate	
(cFDR))	 could	 be	 employed	 to	 address	 the	 question	 of	 genetic	 overlap	 as	 this	 statistical	
framework	 increases	 the	power	 for	discovery	of	 risk	 loci	by	 leveraging	overlapping	signals	
across	GWAS.	
	
6.3.2 From	association	to	function	
Individual	effect	sizes	at	common	loci	are	modest	and	each	risk	allele	only	explains	a	small	
fraction	of	the	phenotypic	variance	of	a	trait.	Computational	approaches	help	to	pinpoint	the	
causal	variant	underlying	an	association	signal	but	do	not	provide	definitive	proof	of	causality.	
Rather,	 it	brings	 forward	a	reasonable	number	of	strong	candidates	to	undergo	functional	
validation	 and	 exploratory	 experiments	 in	 primary	 cells	 or	 animal	 models	 to	 reveal	 the	
underlying	 biological	 basis	 of	 a	 GWAS	 signal.	 This	 can	 be	 facilitated	 by	 cutting-edge	
experimental	 techniques	 such	 as	 massively	 parallel	 reporter	 assays	 (MPRA)	 and	 various	
genome-editing	tools.	
	
Reporter	 assays	 such	 as	 luciferase	 are	widely	 used	 as	 a	 tool	 to	 study	 gene	 expression	 at	
transcriptional	level.	A	DNA	region	of	interest	(containing	SNP	or	SNPs)	can	be	cloned	either	
upstream	or	downstream	of	a	promoter	reporter	gene	cassette	in	a	plasmid,	which	is	then	
transfected	into	a	cell	type	of	interest.	The	protein	product	of	the	reporter	gene	is	measured	
to	 determine	 allelic	 effects	 of	 SNP	 on	 gene	 regulation.	 However,	 this	 is	 not	 an	 efficient	
method	to	screen	a	large	number	of	candidate	causal	variants.	MPRA	is	a	high-throughput	
platform	that	allows	the	interrogation	of	the	transcriptional	regulatory	activity	of	hundreds	
of	sequences	simultaneously,	by	synthesising	a	large	number	of	oligonucleotides	containing	
a	short	genomic	DNA	sequence	of	interest	in	parallel.	Briefly,	each	oligonucleotide	is	coupled	
to	a	unique	barcode	tag	and	subcloned	into	a	fixed	reporter	plasmid	backbone.	The	pool	of	
reporter	plasmids	is	then	introduced	into	cells	or	tissues	and	incubated	for	a	sufficient	period	
of	 time	 to	 allow	 the	 reporters	 to	 be	 fully	 expressed,	 followed	 by	 high-throughput	 RNA	
sequencing	and	counting	of	the	barcode	tags	to	determine	the	relative	regulatory	activities	
of	all	the	genomic	DNA	sequences	(478).	Similar	to	the	individual	reporter	assay	experiments,	
MPRA	lacks	the	complete	chromatin	structure	of	endogenous	genomic	DNA	and	is	therefore	
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unable	to	capture	short-range	or	long-range	chromatin	interactions	that	might	significantly	
influence	gene	expression.		
	
Advances	 in	 genome	 editing	 technologies	 have	 greatly	 facilitated	 research	 progress	 in	
studying	the	biological	mechanisms	in	health	and	disease.	One	good	example	is	the	clustered	
regularly	interspaced	short	palindromic	repeats	(CRISPR)-CRISPR-associated	protein	9	(Cas9)	
system	that	has	become	widely	applied	in	basic	science	research	due	its	efficacy	and	ease	of	
use,	allowing	investigators	to	introduce,	remove	or	alter	specific	DNA	sequences	with	a	high	
degree	of	target	specificity	within	a	controlled	genetic	background.	The	CRISPR-Cas9	system	
was	adapted	from	naturally	occurring	bacterial	adaptive	immune	systems,	comprising	both	
protein	and	RNA	components	 to	destroy	 invading	viral	and	plasmids	DNA	by	generating	a	
double-strand	break	 in	the	DNA	(479).	To	explore	the	direct	effect	of	genotype	on	cellular	
phenotype,	one	could	use	CRISPR-Cas9	system	to	knock	in	alternate	SNP	alleles	into	cellular	
or	animal	models	to	generate	variant	and	wild-type	models	that	are	isogenic.	This	method,	
however	can	be	very	inefficient	and	an	alternative	approach	is	to	knock	out	the	SNP	site.	It	is	
important	to	note	that	any	differences	between	the	wild-type	and	variant	models	cannot	be	
attributed	 to	 the	 SNP	 itself,	 rather	 the	 sequence	 containing	 the	 SNP	 allele.	 Furthermore,	
CRISPR-Cas9	technology	has	been	adapted	to	study	transcriptional	regulation	where	the	Cas9	
protein	is	altered	to	be	catalytically	dead	but	still	forming	a	protein	RNA-DNA	complex	with	
specifically	 engineered	 guide	 RNAs	 and	 an	 additional	 transcriptional	 activator	 (CRISPR	
activation)	 (480)	or	 repressor	 (CRISPR	 interference)	 (481)	domain	 to	alter	 the	 target	 gene	
expression.	For	example,	by	positioning	Cas9	at	the	site	of	a	SNP	with	or	without	additional	
domain,	the	regulatory	activity	can	be	inhibited	by	steric	interference	due	to	reduced	binding	
sites	for	endogenous	regulatory	factors.	These	latest	technologies	hold	promise	in	expediting	
future	efforts	to	understand	the	genetic	basis	of	human	disease	and	clinical	translation.		
	
6.3.3 The	role	of	eosinophils	in	disease	pathogenesis	of	PR3-AAV	
Our	 data	 support	 a	 causal	 role	 of	 eosinophil	 count	 in	 the	 development	 of	 PR3-AAV.	
Eosinophils	 have	 long	 been	 perceived	 as	 non-specific	 destructive	 and	 cytotoxic	 cells	with	
prominent	 roles	 in	 asthmatic	 lung	 disease	 and	 host	 defences	 against	 helminth	 infections.	
However,	there	is	emerging	evidence	to	support	their	diverse	functions,	including	the	ability	
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to	 polarise	 T-cell	 function	 (through	 expression	 of	 Th1/2	 cytokines),	 to	modulate	 humoral	
response	 and	 to	 promote	 immunosuppressive	 activity	 as	 well	 as	 tissue	 remodelling	 and	
repair,	all	of	which	have	been	underappreciated	in	health	and	disease	(482).	The	functional	
role	of	eosinophils	in	PR3-AAV	is	a	largely	unexplored	area	and	greater	research	endeavours	
in	this	area	may	provide	further	insight	into	new	therapeutic	opportunities.	Newer	techniques	
such	as	single	cell	RNA-Seq	and	mass	cytometry	by	time	of	flight	(CyTOF)	have	the	ability	to	
profile	individual	cells	of	a	heterogeneous	population	and	measure	more	than	40	cell	surface	
markers	 on	 individual	 cells,	 allowing	 interrogation	 of	 cellular	 phenotype,	 function	 and	
signalling	 status	 simultaneously.	 Furthermore,	 the	development	of	monoclonal	 antibodies	
recognising	anti-eosinophil	peroxidase	has	enabled	the	detection	and	quantification	of	tissue	
infiltrating	eosinophils,	as	well	as	evidence	of	degranulation,	which	is	far	more	specific	and	
rigorous	than	conventional	evaluation	using	haematoxylin	and	eosin-stained	slides	and	assays	
detecting	eosinophil	cationic	protein	or	eosinophil-derived	neurotoxin	which	are	also	present	
in	other	leukocytes	such	as	neutrophils	(483).	
	
We	further	explored	the	functional	implication	of	the	risk	locus	at	chr2p13	and	three	genes	
including	ACOXL,	BCL2L11	and	MIR4435-2HG	were	found	to	interact	with	credible	SNPs	in	the	
granulocyte	PCHi-C	data.	We	demonstrated	that	the	genotype	at	rs13405741	was	associated	
with	 dysregulation	 of	 MIR4435-2HG	 which	 led	 to	 prolongation	 of	 eosinophil	 survival.	
Although	no	difference	in	BCL2L11	expression	between	groups	was	present,	our	results	have	
been	encouraging	 to	merit	 further	 investigation	 to	understand	how	the	most	 likely	causal	
variant	and	potentially,	DNA	elements	within	this	locus	regulate	the	expression	of	MIR4435-
2HG	and	BCL2L11.	
	
In	conclusion,	the	aims	of	this	thesis	have	been	achieved.	We	have	established	a	robust	set	of	
causal	variants	 in	AAV	and	have	 laid	 the	groundwork	 for	 future	 research	 to	 relate	genetic	
variation	to	the	aetiopathogenesis	of	AAV.			
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